



**Military Allergy Program** 

**0001 26<sup>th</sup> Annual Harold S. Nelson Allergy/Immunology Symposium**

7:20 am to 5:00 pm  
 Programmed by the Military Allergy/Immunology Assembly of the AAAAI. Funded through an education grant from Teva Respiratory.

**Convention Center, S230AB, Level II**

Pre-registration and ticket required. No fee. Continental breakfast and box lunch included.

Credit: 8.00 CME / 9.60 CE

Moderator: *Mark H. Tucker, MD*

**8:00 Morning Address: AERD and Aspirin Desensitization**

*Andrew A. White, MD FAAAAI*

**9:00 Break**

**9:15 Fellow Research and Clinical Case Presentations**

**11:30 Lunch and Bruton Lecture: Application of Flow Cytometry in Diagnosing and Understanding Primary Immune Deficiencies**

*Thomas A. Fleisher, MD FAAAAI*

**1:15 Research and Clinical Case Presentations**

**2:15 Break**

**2:30 Vaccine Healthcare Center Update**

*Renata J.M. Engler, MD FAAAAI*

**3:00 Military Aeroallergen Extract Laboratory Updates**

*Susan E. Kosisky, MA*

**Consultants to the Surgeons General Updates**

**3:30 Air Force**

*Stephen E. Scranton, MD*

**3:45 Army**

*Michael R. Nelson, MD PhD FAAAAI*

**4:00 Navy**

*Mark H. Tucker, MD*

**4:15 Business Meeting and Award Presentations**

Upon completion of this session, participants should be able to: Describe the purpose of aspirin desensitization in AERD; Identify the different types of hypersensitivity; Discuss the role for challenge/desensitization in all types of aspirin reactions; Explain to a colleague the mechanics of how desensitization can safely be performed; Identify the appropriate flow cytometry tests that clarify specific PIDD diagnoses; Define the principles of intracellular flow cytometry in screening for specific PIDD; Outline the approach to evaluate immunologic functions using flow cytometry methods.

**Fellows-in-Training Program** 
**1011 FIT Symposium**

7:00 am to 2:00 pm

**Peabody, Windermere Ballroom W, Convention Level**

Pre-registration and ticket required. No fee. Continental breakfast and box lunch included.

Credit: No CME / No CE

**7:00 From FITs to Faculty: Meet Your Future Breakfast: Networking with Prominent A/I Professors and Researchers**
**Tales from Academia***Moderator: Lawrence B. Schwartz, MD PhD FAAAAI*
**7:30 Introduction to the Program Directors Assembly**
*Lawrence B. Schwartz, MD PhD FAAAAI*
**7:40 Tales from Academia**
*Hugh A. Sampson, MD FAAAAI**Andrew Saxon, MD FAAAAI**Moderator: Martha K. Elias, MD*
**8:30 Welcome and Opening Remarks**
*Martha K. Elias, MD*
**8:35 Climate Change and its Effect on Aerobiology**
*Richard W. Weber, MD FAAAAI*
**9:05 Allergic and Non-Allergic Mechanisms Contributing to Upper Airway Inflammation**
*Robert P. Schleimer, PhD FAAAAI*
**9:35 Welcome from the President**
*Dennis K. Ledford, MD FAAAAI*
**9:45 Difficult Clinical Cases in Allergy: A Master Clinician's Perspective**
*Dennis K. Ledford, MD FAAAAI*
**10:15 Break**
**10:30 Immunomodulation with Immunotherapy**
*Harold S. Nelson, MD FAAAAI*
**11:00 Accelerated Immunotherapy Approaches for Aeroallergens**
*David A. Khan, MD FAAAAI*
**11:30 Writing Immunotherapy Prescriptions: A Case-Based Workshop**
*Gerald W. Volcheck, MD FAAAAI*
**12:00 Lunch and Networking Organizations' Announcements**
**12:30 ABCs of Coding and Documentation**
*Gary N. Gross, MD FAAAAI*
**1:15 Post-Fellowship Realities**
*Eric C. Chenworth, DO**Bridgette L. Jones, MD**Susan Lee Limb, MD FAAAAI**Whitney Elizabeth Molis, MD FAAAAI**Tushar Shah, MD*

Upon completion of this session, participants should be able to: Review the underlying mechanisms driving allergic and non-allergic upper airway disease processes; Recognize the clinical indications and administration techniques for immunotherapy; Explore novel approaches to immunotherapy.

**Allied Health Course**   
**1101 Advanced Practice Course**

8:00 am to 4:00 pm

**Peabody, Windermere Ballroom X, Convention Level**

Pre-registration and ticket required. No fee. Lunch included.

*Programmed by the AAAAI. Supported by an in-kind contribution from Aerocrine.*

Credit: 5.50 CME / 6.60 CE

*Morning Moderator: Gabriel Ortiz, MPAS PA-C DFAAPA**Afternoon Moderator: Nina A. Zimmermann, MSN RN ANP-BC AE-C*
**8:15 Masqueraders of Asthma: Chronic Cough in Adults**
*Nina A. Zimmermann, MSN RN ANP-BC AE-C*
**9:00 Masqueraders of Asthma: Pediatric Case Studies with PFT Examples**
*Edward O. Corazalla, MS RPFT*
**9:45 Break**
**10:00 Management Issues in the Obese Asthmatic**
*Christine W. Wagner, CPNP CFNP AE-C*
**10:45 Alpha-1 Antitrypsin Deficiency**
*Jeanette L. Arnold, MSN RN C-FNP*
**11:30 Lunch Break**
**12:00 Hereditary Angioedema (HAE)**
*Gabriel Ortiz, MPAS PA-C DFAAPA*
**12:45 IVIG: Difficult Cases and Clinical Pearls**
*Debra A. Sedlak, MSN CPNP*
**1:30 The Allergic Gut**
*Sally A. Noone, RN MSN CCRC*
**2:15 Break**
**2:30 Workshops (Attendees will choose one of the following sessions.)**

Pre-registration and ticket required. Fee: \$20.

Credit: 1.50 CME / 1.80 CE

**1101A: Punch Biopsy**
**Peabody, Bayhill 19, Lobby Level***Jeanette L. Arnold, MSN RN C-FNP**Don J. Cui, PA-C AE-C*
**1101B: eNO**
**Peabody, Bayhill 20, Lobby Level***Edward O. Corazalla, MS RPFT*
**1101C: Atopic Dermatitis Patch Testing**
**Peabody, Bayhill 21, Lobby Level***Karol G. Timmons, RN MS CPNP*
**1101D: Food Allergy Lab**
**Peabody, Bayhill 23 & 24, Lobby Level***Sally A. Noone, RN MSN CCRC*

Upon completion of this session, participants should be able to: Differentiate between the patient assessment and differential diagnosis of chronic cough of the pediatric vs. adult patient populations; Identify various treatments of the diagnosis of chronic cough in pediatric and adult populations; Define obesity in adults and children and identify education strategies to assist patients in understanding the relationship between obesity and asthma; Recognize characteristics of pulmonary manifestations of Alpha-1 antitrypsin deficiency and recall the most common extrapulmonary manifestations of AAT deficiency; Recognize the signs and symptoms of HAE; Describe current practice in the diagnosis and treatment of EoE.



**Clinical Research Workshop** 

**1102 Health Literacy: What It Is and How You Measure It**

8:00 to 9:15 am  
**Peabody, Bayhill 21, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Carol A. Jones, RNAE-C*  
*Christine W. Wagner, CPNP CFNP AE-C*

Upon completion of this session, participants should be able to: Define health literacy and its importance in a research setting; Describe ways to easily assess health literacy in a research setting; Identify techniques to provide patient education by incorporating health literacy techniques.

**Chrysalis Program** 

**1111 2012 Chrysalis Program**

8:00 am to 12:00 pm  
**Peabody, Bayhill 17 & 18, Lobby Level**  
 Pre-registration and ticket required. No fee.  
 Credit: No CME / No CE

- 8:00 Welcome and Introduction to A/I Training**  
*Kimberly A. Risma, MD PhD FAAAAI*
- 8:15 Food Allergy**  
*A. Wesley Burks, MD FAAAAI*
- 8:45 Immunodeficiency**  
*Thomas A. Fleisher, MD FAAAAI*
- 9:15 Eosinophilic Disorders**  
*Amy D. Klion, MD*
- 9:45 Asthma**  
*Gurjit K. Khurana Hershey, MD PhD FAAAAI*
- 10:15 Break**
- 10:30 Welcome from AAAAI President**  
*Dennis K. Ledford, MD FAAAAI*
- 10:45 Atopic Dermatitis**  
*Donald Y.M. Leung, MD PhD FAAAAI*
- 11:15 Academic Career Paths**  
*Kimberly A. Risma, MD PhD FAAAAI*
- 11:30 Industry Career Paths**  
*Thao T. Doan, MD*
- 11:45 Private Practice Career Paths**  
*Adina Kay Knight, MD*

**Course**  

**1201 Basic Aeroallergen Course**

9:00 am to 5:00 pm  
**Convention Center, S330GH, Level III**  
 Pre-registration and ticket required. Fee: \$250. Box lunch included.  
 Credit: 7.00 CME / 8.40 CE  
*Moderator: Estelle Levetin, PhD FAAAAI*

**9:10 Introduction to Fungal Aerobiology**  
*W. Elliott Horner, PhD LEED AP FAAAAI*

**9:50 Fungal Spore Morphology**  
*Estelle Levetin, PhD FAAAAI*

**10:40 Hands-On Instruction; Question & Answer**

**12:00 Lunch Break**

**1:00 Setting Up a Sampling Station**  
*Estelle Levetin, PhD FAAAAI*

**1:30 Introduction to Pollen Aerobiology**  
*Peter Van de Water, PhD*

**2:10 Pollen Morphology**  
*Richard W. Weber, MD FAAAAI*

**3:00 Hands-On Instruction; Question & Answer**

Upon completion of this session, participants should be able to: Discuss the fundamentals of fungal and plant reproductive biology, aerobiology and air sampling; Describe the basic features of spore and pollen morphology; Identify the major airborne pollen types and fungal spores.

**Course** 

**1202 Difficult Cases (Part 1)**

9:00 am to 12:00 pm  
**Convention Center, S310ABFE, Level III**  
 Credit: 2.75 CME / 3.20 CE  
*Moderators: Dorothy S. Cheung, MD FAAAAI*  
*Pramod S. Kelkar, MD FAAAAI*

**9:00 Eosinophilic Esophagitis / EGID**  
*Seema Sharma Aceves, MD PhD FAAAAI*  
*Princess U. Ogbogu, MD*

**9:35 Innate Immunity**  
*Jordan Orange, MD PhD FAAAAI*  
*Sakina S. Bajowala, MD*

**10:10 Break**

**10:30 PFT Interpretation**  
*Joseph D. Spahn, MD*  
*Todd L. Hostetler, MD*

**11:05 Atopy in Older Adults**  
*Paula J. Busse, MD FAAAAI*  
*Vinay Mehta, MD*

**11:40 Question & Answer**

Upon completion of this session, participants should be able to: Identify difficulties in the clinical management of eosinophilic gastrointestinal disease; Describe difficulties in the clinical management of innate immune defects; Explain difficulties in the interpretation of pulmonary function studies; Discuss difficulties in the clinical management of atopy in older adults.

New!

PUBLIC  
EDUCATION MATERIALS

PREVIEW

In the Member Resource Center  
and receive special Annual Meeting discounts

**Course****1203 Deeper Insights into the Mechanisms of Asthma and Allergic Inflammation**

9:00 am to 12:00 pm

**Convention Center, S330AB, Level III**

Credit: 2.75 CME / 3.20 CE

*Moderators: Svetlana P. Chapoval, MD PhD**Achsah Keegan, PhD***9:00 STAT6 Regulation of Th2/T reg Balance***Achsah Keegan, PhD***9:20 Lung DC Subsets and Differential Role in T Helper vs. T reg Responses***Anuradha Ray, PhD***9:40 Novel Endogenous Regulator of Th2 Inflammation: Epithelial Reticulon Nogo-B***Paulette Wright Andreotta, PhD***10:00 Novel Endogenous Regulators of Th2 Inflammation: Semaphorins***Hitoshi Kikutani, PhD***10:20 Break****10:40 Chitinase-Like Proteins in the Regulation of Th2 Inflammation***Jack A. Elias, MD***11:00 Regulation of Allergic Airway Disease by IFN-Gamma***Lauren Cohn, MD***11:20 Novel Therapy for Asthma***Stephen B. Liggett, MD***11:40 Question & Answer**

Upon completion of this session, participants should be able to: Discuss recent developments regarding cell subpopulations and immune factors in allergic asthma complexity; Identify novel endogenous regulators of Th2 inflammation and their potential as novel therapeutic agents; Identify how increased knowledge of novel cellular and molecular regulators of allergic disease enables new therapeutic applications; Define novel mechanistic concepts in specific function of dendritic cells and regulatory T Cells in allergic disease.

**Course****1204 NIAID Morning Course: Allergen Immunotherapy: Innovative Approaches**

9:00 am to 12:00 pm

**Convention Center, S310CDGH, Level III**

Credit: 2.75 CME / 3.30 CE

*Moderator: Marshall Plaut, MD FAAAAI***9:00 Subcutaneous vs. Sublingual Immunotherapy for Aeroallergens***Stephen R. Durham, MA MD***9:25 Oral Immunotherapy for Food Allergens***A. Wesley Burks, MD FAAAAI***9:50 Intralymphatic and Epicutaneous Immunotherapy***Thomas M. Kuendig, MD***10:15 Break****10:30 Peptide Immunotherapy***Mark Larche, PhD***10:55 New Insights into the Mechanisms of Immunotherapy***Kari C. Nadeau, MD PhD FAAAAI***11:20 Effects of Immunotherapy on Antigen-Specific T Cells***William W. Kwok, PhD***11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss current knowledge on the comparative efficacy of SCIT vs. SLIT and ongoing head-to-head comparison trials; Discuss recent data on food allergy immunotherapy comparing sublingual and oral approaches; Identify new forms of immunotherapy under development and discuss their potential usefulness and limitations; Discuss new insights in the mechanisms of immunotherapy.

**Course****1205 Allergy Diagnostics and Immunotherapy: The Nuts, the Bolts, the Science and the Art (Part 1)**

9:00 am to 12:00 pm

**Convention Center, S320AB, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderators: Désirée E.S. Larenas Linnemann, MD FAAAAI**Michael S. Tankersley, MD FAAAAI***9:00 All You Need to Know About Rush and Cluster Schedules***Thomas Chacko, MD***9:30 Special Situations that Need Dose-Adjustment During AIT***Christopher W. Calabria, MD***10:00 Hands-on Workshops (Attendees will rotate between two workshops.)**


Pre-registration and ticket required to attend the hands-on workshops.

Fee: \$25.

Credit: 2.00 CME / 2.40 CE

**1205A: Allergen Extract Preparation and Take the Media Fill Test****Convention Center, S320EF, Level III***Michael S. Blaiss, MD FAAAAI**Susan E. Kosisky, MA**Bryan L. Martin, DO FAAAAI**Cecilia Mikita, MD MPH FAAAAI**Michael R. Nelson, MD PhD FAAAAI***1205B: Preparing Your Office for Anaphylaxis and Other Emergencies****Convention Center, S320GH, Level III****Preparing Office Equipment and Staff***Dana V. Wallace, MD FAAAAI***Going Through a Code***Nabil El Sanadi, MD*

Upon completion of this session, participants should be able to: Discuss rush and cluster immunotherapy schedules, premedication and patient selection; Propose immunotherapy schedule adjustments after a gap in administration, adverse reactions and switching from one manufacturer to another; Discuss what equipment is needed in the office for treatment of an anaphylactic reaction; Demonstrate the ability to make a sterile immunotherapy vial.



**Course**

**1206 Allergens and “Dirt”: Molecular Pathways and Consequences for the Allergic Epidemic (Part 1)**

9:00 am to 12:00 pm  
**Convention Center, S230GH, Level II**  
 Credit: 2.75 CME / 3.30 CE  
*Moderator: Ulus Atasoy, MD FAAAAI*

**9:00 The Molecular Biology of Allergens**  
*Anna Pomés, PhD FAAAAI*

**9:25 Allergens as Triggers of Pattern Recognition Receptor Pathways**  
*Marsha A. Wills-Karp, PhD*

**9:50 Particulate Allergens: New Insights into Allergic Mechanisms**  
*Soman N. Abraham, PhD*

**10:15 Break**

**10:30 Targeting Allergens to FC Receptors: Evaluating the Impact on Allergic Responses**  
*Judith A. Woodfolk, MBChB PhD FAAAAI*

**10:55 DAMPS, PAMPs and More: Integrating the Allergic Response**  
*Bart N. Lambrecht, MD PhD*

**11:20 NOD-Like Receptors: Overview and Relevance to Allergic Disease**  
*Stephanie C. Eisenbarth, MD PhD*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain the diverse structural and functional properties of allergens and how this relates to allergenicity; Discuss how allergens trigger pattern recognition receptor pathways and how this impacts allergic inflammation; Identify the molecular basis for how particulate matter from air pollutants prolongs IgE receptor-initiated signaling and potentiates asthma; Describe how pollen-associated lipid mediators activate innate immune cells and modulate dendritic cell function; Identify how signals from allergen contaminants and damage-associated molecular patterns collaborate to initiate the allergic response; Explain how NOD-like receptors may shape the allergic response.

**Course**

**1207 Objective Measure of Lung Function in the Pediatric Population**

9:00 am to 12:00 pm  
**Convention Center, S330CD, Level III**  
 Credit: 3.00 CME / 3.60 CE  
*Moderator: Howard Eigen, MD*

**9:00 Impulse Oscillometry Techniques for PFTs in Very Young Children**  
*Stanley P. Galant, MD FAAAAI*

**9:55 Techniques for Optimizing Spirometry in Preschool Aged Children**  
*Howard Eigen, MD*

**10:50 Standards and Validation Criteria (ATS/ERS) for Spirometry in Young Children**  
*Wayne Joseph Morgan, MD*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain impulse oscillometry technique for pulmonary function testing in young children; Describe techniques for optimizing spirometry in preschool-aged children; Identify valid criteria for successful spirometry in preschool aged children.

**Medical Administrator Workshop**

**1211 Patient Safety: Adverse Events as Guides to Care**

9:00 to 10:15 am  
**Peabody, Bayhill 25 & 26, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Jeanette Booker*  
*Donald W. Aaronson, MD FAAAAI*

Upon completion of this session, participants should be able to: Identify the basic tenets and common causes of medical errors in the allergist's office; Anticipate and prevent medical errors before reaching the patient; Disclose errors when they do occur.

**Clinical Research Workshop**

**1212 The Anatomy of the Clinical Trial Agreement (Contract) and Successful Budget Negotiation**

9:30 to 10:45 am  
**Peabody, Bayhill 22, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Cheryl Koff Bernstein, RN BSN CCRC*  
*Kay Weiler, BSN JD MA*

Upon completion of this session, participants should be able to: Identify the components of the Clinical Trial Agreement; Describe the importance of identifying the indemnification language in the Clinical Trial Agreement; Discuss principles of budget preparation and negotiation.

**Medical Administrator Workshop**

**1301 CPT Coding for the Allergist in 2012**

10:30 to 11:45 am  
**Peabody, Bayhill 20, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: John D. Milewski, Med. Admin.*  
*Teresa Thompson, CPC CMSCS CCC*

Upon completion of this session, participants should be able to: Use the current guidelines for CPT and diagnosis coding; Comply with Medicare guidelines.

**Clinical Research Workshop**

**1302 Data Management: Your Research Data from Collection to Paper**

11:00 am to 12:15 pm  
**Peabody, Bayhill 23 & 24, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Jean Curtin-Brosnan, MA*  
*Patrick J. Lenehan*  
*Carrie L. Vibbert, RN BSN*

Upon completion of this session, participants should be able to: Setup, maintain and modify case report forms to collect study data to be integrated into a data set; Design a basic database to include various types of research data including case reports and lab results; Interpret basic biostatistical results used in presenting research data.

**Clinical Research Workshop**

**1303 The IRB and Research Ethics**

11:00 am to 12:15 pm  
**Peabody, Bayhill 31, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*David Belde, PhD*  
*Tracy S. Estes, PhD RN FNP*

Upon completion of this session, participants should be able to: Describe the historical development of, and need for, formal human subject protections; Identify common ethical issues associated with human subject research; Describe the role and function of the Institutional Review Board.

**Medical Administrator Workshop**   **1501 Roundtable Luncheon: Nuts and Bolts of Practice Management**

12:00 to 1:15 pm

**Peabody, Bayhill 32, Lobby Level**

Pre-registration and ticket required. Fee: \$40. Box lunch included.

Credit: 1.25 CME / 1.50 CE

*Moderator: John D. Milewski, Med. Admin.**Dennis W. Boo, CPA**Jeanette Booker**Lena G. Combs, CPA**Thomas V. Durkee, CPA**Teresa Thompson, CPC CMSCS CCC*

Upon completion of this session, participants should be able to: Recognize and discuss the operational challenges that exist within a clinic arena; Demonstrate enhanced knowledge in operations through peer to peer interaction with experts in marketing, human resources, social media, EHR and legal matters; Recognize operational best practices that are demonstrated in other clinics.

**ARTrust™ Financial Planning**  **1551 Simple Wealth Planning: You Work Hard for Your Money, Does Your Money Work Hard for You?**

12:30 to 2:00 pm

**Convention Center, S322, Level III**

Pre-registration and ticket required. Fee: \$30. Box lunch included.

Credit: No CME / No CE

*Peter M. Wilmot, CFP**MetLife***Program Directors' Business Meeting**

2:00 to 4:00pm

All Program Directors and Co-Directors are invited to attend this business meeting.

**Course** **1601 Technology in the Clinical Practice Made Ridiculously Simple**

2:00 to 5:00 pm

**Convention Center, S230EF, Level II**

Credit: 3.00 CME / 3.60 CE

*Moderators: Dan Dalan, MD FAAAAI**Tao Le, MD MHS FAAAAI***2:00 What Can Technology Do for Your Practice?***Tao Le, MD MHS FAAAAI***2:20 EHRs and the Meaningful Use of Life***Russell B. Leftwich, MD FAAAAI***3:00 Practice Management Systems and Other Office Automation Tools***Linda D. Green, MD FAAAAI***3:30 Mobile Devices: iPhones, iPads and Androids, Oh My!***Melinda M. Rathkopf, MD FAAAAI***4:10 Tools for Marketing and Communications***Vesselin Dimov, MD***4:40 Making the Technology Work and Pay Off***David J. Shulan, MD FAAAAI*

Upon completion of this session, participants should be able to: Identify the implications of EHR meaningful use for the clinical practice; Describe practice management systems and office automation technologies appropriate for the clinical practice; Explain the role of mobile technologies in the practice; List web and social media tools for practice marketing and communications; Discuss strategies for successful technology implementation.

**Course** **1602 Difficult Cases (Part 2)**

2:00 to 5:00 pm

**Convention Center, S310ABFE, Level III**

Credit: 2.75 CME / 3.20 CE

*Moderators: David W. Hauswirth, MD FAAAAI**Pramod S. Kelkar, MD FAAAAI***2:00 Atopy in Pregnancy***Michael Schatz, MD MS FAAAAI**Eugene M. Choo, MD***2:35 Sleep Disorders***Eli O. Meltzer, MD FAAAAI**Christina E. Ciaccio, MD***3:10 Break****3:30 Mystery Difficult Cases***Phillip L. Lieberman, MD FAAAAI**Michael H. Land, MD***4:05 Reactions to Aspirin and NSAIDs***Donald D. Stevenson, MD FAAAAI**Tolly Epstein, MD***4:40 Question & Answer**

Upon completion of this session, participants should be able to: Identify and address difficulties in the clinical management of atopy during pregnancy; Identify and address difficulties in the clinical management of sleep disorders; Identify and address difficulties in the clinical management of reactions to NSAIDs; Identify and address diagnostic difficulties unique to difficult mystery cases.

**Course**   **1603 Endoscopic Evaluation and Management of Chronic Rhinosinusitis (Pre and Post-Surgery) Including Cultures**

2:00 to 5:00 pm


**Convention Center, S230CD, Level II**

Pre-registration and ticket required. Fee: \$25.

Credit: 3.00 CME / 3.60 CE

*Moderator: Wellington S. Tichenor, MD FAAAAI***2:00 Anatomy, Endoscopic Videos and Case Management***Wellington S. Tichenor, MD FAAAAI***3:00 Radiology***S. James Zinreich, MD***4:00 Anatomy and Surgery***Robert C. Kern, MD*

Upon completion of this session, participants should be able to: Describe the anatomy of the sinuses and related structures; Identify pathology on CT scan; Recall indications for surgery and complications of surgery; Perform endoscopy in pre- and post-surgical patients; Perform cultures of middle meatus and/or sinuses.



**Course**

**1604 NIAID Afternoon Course: Links Between Innate and Adaptive Immunity**

2:00 to 5:00 pm  
**Convention Center, S320CD, Level III**  
 Credit: 2.75 CME / 3.30 CE  
 Moderator: *Gang Dong, MD PhD*

- 2:00 The Role of Microbial Flora in Immune Responses**  
*Ronald Collman, MD*
- 2:25 TSLP and Regulation of Allergic Inflammation**  
*Steve Ziegler, PhD*
- 2:50 Linking Innate and Adaptive Responses to Vaccines**  
*Bali Pulendran, PhD*
- 3:15 Break**
- 3:30 Innate and Adaptive Immune Responses in Chronic Upper Airway Inflammation**  
*Robert P. Schleimer, PhD FAAAAI*
- 3:55 Innate and Adaptive Immunity in Allergic Respiratory Inflammation**  
*Bart N. Lambrecht, MD PhD*
- 4:20 Innate and Adaptive Immunity in the Gastrointestinal Tract**  
*Gary B. Huffnagle, PhD*
- 4:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss current knowledge of the innate and adaptive immune responses; Describe the role of the microbiome on the innate and adaptive immune responses; Discuss new insights for the role of the innate immune response on the development of allergic disorders.

**Course**    

**1605 Allergy Diagnostics and Immunotherapy: The Nuts, the Bolts, the Science and the Art (Part 2)**

2:00 to 5:00 pm  
**Convention Center, S320AB, Level III**  
 Credit: 1.00 CME / 1.20 CE  
 Moderators: *Linda Cox, MD FAAAAI*  
*Ira Finegold, MD FAAAAI*

- 2:00 Future of Inhalant Allergen Immunotherapy**  
*Thomas B. Casale, MD FAAAAI*
- 2:30 Use of Immunotherapy in the Treatment of Food Allergy**  
*Hugh A. Sampson, MD FAAAAI*
- 3:00 Hands-On Workshops (Attendees will rotate between two workshops.)**

Pre-registration and ticket required. Fee: \$25.  
 Credit: 2.00 CME/ 2.40 CE

**1605A: Coding, Documentation and ABCs of Regulatory Guidelines**

**Convention Center, S320EF, Level III**  
*Donald W. Aaronson, MD FAAAAI*  
*David A. Brown, MD*  
*Gary N. Gross, MD FAAAAI*

**1605B: Allergy Skin Testing: Basics and Beyond**

**Convention Center, S320GH, Level III**

**Skin Testing in Clinical Practice**

*John Oppenheimer, MD FAAAAI*

**Skin Testing for Clinical Trials**

*Peter S. Creticos, MD FAAAAI*

**Art and Science of Percutaneous Skin Testing**

*Sten K.G. Dreborg, MD PhD FAAAAI*

Upon completion of this session, participants should be able to: Discuss novel variants of immunotherapy, some of them already on the market and others still under investigation; Discuss the usefulness of immunotherapy in food allergy and the current status of these investigations; Apply adequately the coding, documentation and regulatory guidelines for immunotherapy.

**Course**

**1606 Allergens and “Dirt”: Molecular Pathways and Consequences for the Allergic Epidemic (Part 2)**

2:00 to 5:00 pm  
**Convention Center, S230GH, Level II**  
 Credit: 2.75 CME / 3.30 CE  
 Moderator: *Matthew S. Perzanowski, PhD*

- 2:00 Studying the Epidemiology of Asthma: Multiple Factors and Confounders**  
*Gurjit K. Khurana Hershey, MD PhD FAAAAI*
- 2:25 Geographic Determinants of the Asthma Epidemic**  
*Thomas A.E. Platts-Mills, MD PhD FAAAAI*
- 2:50 Gene-Environment Interactions and Asthma: Update**  
*Fernando D. Martinez, MD*
- 3:15 Break**
- 3:30 The Risk of Atopy and Microbial Exposure: Where Do We Stand?**  
*Erika Von Mutius, MD MSc*
- 3:55 Asthma and the Urban Environment: Lessons from the Inner City Asthma Consortium**  
*Rebecca S. Gruchalla, MD PhD FAAAAI*
- 4:20 Lessons from the URECA Birth Cohort Study: Allergens, Microbes and More**  
*James E. Gern, MD FAAAAI*
- 4:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain how to perform well designed studies on the epidemiology of asthma; Describe current knowledge of gene-environment interactions that contribute to asthma; Apply current knowledge of microbial exposure as a determinant of atopy; Discuss how the urban environment impacts asthma; Explain how a birth cohort study aims to examine the multi-factorial origins of asthma; Identify the geographic determinants of asthma.

**Course****1607 NIEHS Course: Epidemiologic Methods in Asthma and Allergy Research**

2:00 to 5:00 pm

**Convention Center, S331AB, Level III**

Credit: 2.75 CME / 3.30 CE

*Moderator: Darryl C. Zeldin, MD***2:00 Overview of Epidemiological Methods in Asthma and Allergy Research***Christine Cole Johnson, PhD MPH FAAAAI***2:20 Introduction to Genetic Epidemiology***Kathleen C. Barnes, PhD FAAAAI***2:40 Respiratory Disease Questionnaires***George T. O' Connor, MD***3:00 Outdoor Exposure Assessment***Jaime Hart, ScD***3:20 Break****3:35 Indoor Exposure Assessment***Darryl C. Zeldin, MD***3:55 Defining Allergy and Asthma Outcomes in Epidemiologic Studies***Dennis R. Ownby, MD FAAAAI***4:15 Publicly Available Databases of Asthma and Allergy Research***David M. Mannino, MD***4:35 Panel Discussion**

Upon completion of this session, participants should be able to: Apply epidemiologic methods to asthma and allergy research; Identify exposure and outcome measures.

**Course**    **1608 Interpretation of Pulmonary Function Tests**

2:00 to 5:00 pm

**Convention Center, S331CD, Level III**

Pre-registration and ticket required. Fee: \$25.

Credit: 3.00 CME / 3.60 CE

*Moderator: Mark F. Sands, MD FAAAAI***2:00 Lung Pathophysiology and the PFT***Mark F. Sands, MD FAAAAI***2:30 Putting it All Together: From Physiology to Interpretation***Donald P. Tashkin, MD***3:05 Question & Answer****3:15 Hands-On Session***Donald W. Cockcroft, MD FAAAAI**Meredith C. McCormack, MD**Riccardo Polosa, MD PhD FAAAAI**Mark F. Sands, MD FAAAAI**Donald P. Tashkin, MD**John M. Weiler, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss basic lung physiology and pathophysiology and mechanics relating to restrictive and obstructive disease; Discuss ATS/ERS criteria for diagnosis of simple and complex restrictive and obstructive defects; Discuss criteria for technically acceptable PFTs and corrective measures for technical problems; Define lung volumes, capacities and the effect of restrictive and obstructive diseases thereupon; Identify flow volume loop patterns in restrictive/obstructive/mixed and variable obstructive conditions; Independently interpret spirometry and complete PFTs, demonstrating skill in flow-volume loop pattern recognition.

**Course****1609 Finding a Job and Getting Started in Practice**

2:00 to 5:00 pm

**Convention Center, S230AB, Level II**

Credit: 3.00 CME / 3.60 CE

*Moderator: Brian A. Smart, MD FAAAAI***2:00 Overview & Introductions****2:10 Finding a Job and Negotiating the Agreement***Weily Soong, MD***2:45 Getting Licensed and Transitioning into Practice***Brian A. Smart, MD FAAAAI***3:00 Basic Operations of a Practice***David L. Patterson, MD FAAAAI***3:45 Practice Finances 101***Marshall P. Grodofsky, MD FAAAAI***4:20 Marketing Your Practice***Stanley M. Fineman, MD MBA FAAAAI*

Upon completion of this session, participants should be able to: Explain how to identify and join the right practice opportunity; Discuss the fundamentals of office management; Identify strategies for marketing a practice and building a patient base.

**Course** **1610 Upper Airway Disease and Comorbidities**

2:00 to 5:00 pm

**Convention Center, S330CD, Level III**

Credit: 2.75 CME / 3.30 CE

*Moderators: Motohiro Ebisawa, MD PhD FAAAAI**Anne-Marie A. Irani, MD FAAAAI**Ruby U. Pawankar, MD PhD FAAAAI**Allan S. Puterman, MD FAAAAI***2:00 Comorbidities of Allergic Rhinitis: Asthma, Rhinosinusitis and Otitis***Ruby U. Pawankar, MD PhD FAAAAI***2:25 Chronic Cough in Upper Airway Disease***Nelson A. Rosario, MD PhD FAAAAI***2:50 Viral Infections in Pediatric Upper Airway Disease***Omer Kalayci, MD***3:15 Break****3:30 Upper Airway Disease and Sleep Disorders***Richard J. Schwab, MD***3:55 Eosinophilic Esophagitis and Pollinosis***Carla Irani, MD FAAAAI***4:20 Upper Airway Disease and Oral Allergy Syndrome***Montserrat Fernández-Rivas, MD PhD***4:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the latest evidence on co-morbidities of allergic rhinitis, impact on quality of life and work productivity; Identify the cough symptomatology, mechanisms and impact of chronic cough in upper airway disease; Describe the role of viral infections in exacerbation of upper airway disease as they pertain to both the pathogenesis and treatment; Explain the comorbidity of sleep disorders with upper airway disease incidence, consequences and morbidity; Describe the inter-relation between pollinosis and eosinophilic esophagitis and underlying mechanisms; Discuss the symptom profile, mechanisms and specifics of treatment of oral allergy syndrome.





**Course** ▼

- 1611 Refresher in Basic Immunology to Support a Cutting-Edge Allergy/Immunology Practice**  
2:00 to 5:00 pm  
**Convention Center, S310CDGH, Level III**  
Credit: 2.75 CME / 3.30 CE  
*Moderator: David D. Chaplin, MD PhD FAAAAI*
- 2:00 Mechanisms of Adaptive Immunity**  
*E. Richard Stiehm, MD FAAAAI*
- 2:50 Subsets, Subsets, Subsets: Important Immune Cell Populations in the News and Our Literature**  
*Kathleen E. Sullivan, MD PhD FAAAAI*
- 3:15 Break**
- 3:30 When Immunity Becomes Confused: Immunological Understanding from Autoimmunity and Inflammatory Disease**  
*John S. Sundry, MD PhD FAAAAI*
- 3:55 When Immunity Breaks: Immunological Understanding from Primary Immunodeficiency**  
*Francisco A. Bonilla, MD PhD FAAAAI*
- 4:20 Recent Basic Immunological Discoveries that are Likely to Impact the Practice of Allergy and Immunology**  
*Troy R. Torgerson, MD PhD*
- 4:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain how the different components of the immune system are coordinated within the body to generate an immune response; Discuss recent developments regarding cell subpopulations and immune factors required for physiologic and aberrant (allergic or anti-self) immune responses; Identify how increased knowledge of signaling pathways enables new therapeutic applications in allergy/immunology.

**Course**

- 1612 Clinical Management of Allergic Skin Diseases**  
2:00 to 5:00 pm  
**Convention Center, S330AB, Level III**  
Credit: 2.75 CME / 3.30 CE  
*Moderators: Luz S. Fonacier, MD FAAAAI  
Sarbjit Singh Saini, MD FAAAAI*
- 2:00 Diagnostic Testing in Atopic Dermatitis**  
*Andreas Wollenberg, MD FAAAAI*
- 2:30 Therapy of Atopic Dermatitis**  
*Lynda C. Schneider, MD FAAAAI*
- 3:00 Break**
- 3:15 Management of Urticaria/Angioedema**  
*Jonathan A. Bernstein, MD FAAAAI*
- 3:45 Diagnostic Testing in Cutaneous Drug Reactions**  
*David A. Khan, MD FAAAAI*
- 4:15 Management of Cutaneous Drug Reactions**  
*Neil Shear, MD*
- 4:45 Question & Answer**

Upon completion of this session, participants should be able to: Select appropriate diagnostic procedures in atopic dermatitis patients and develop a management strategy; Perform state-of-the-art diagnostics and treatment of urticaria and angioedema according to the new practice parameters; Select appropriate diagnostic procedures in diagnosis and management of drug allergies.

**Course**

- 1613 Biomarkers in Airway Diseases**  
2:00 to 5:00 pm  
**Convention Center, S330EF, Level III**  
Credit: 2.75 CME / 3.20 CE  
*Moderator: William W. Busse, MD FAAAAI*
- 2:00 The “Dream” Biomarker**  
*Andrew H. Liu, MD FAAAAI*
- 2:20 Sputum Cell Counts in Clinical Practice**  
*Parameswaran K. Nair, MD*
- 2:40 Exhaled NO: Easy, but How Useful?**  
*Stanley J. Szefler, MD FAAAAI*
- 3:00 Break**
- 3:20 Measurements in Exhaled Breath Condensate**  
*John Hunt, MD FAAAAI*
- 3:40 Proteomics in Sputum**  
*Ratko Djukanovic, MD*
- 4:00 Urine Metabolomics**  
*Darryl J. Adamko, MD*
- 4:20 Gene Expression Profiling**  
*Prescott Woodruff, MD MPH*
- 4:40 Question & Answer**

Upon completion of this session, participants should be able to: Explain what biomarkers can be measured in sputum, blood, and exhaled breath; Describe what is required for the reliable measurement of these biomarkers; Discuss the practicality of these measurement tools; Identify when measurements are required and how are they interpreted; Discuss current research related to biomarkers.

**Medical Administrator Symposium** ▲ ▼

- 1614 Financial 102 for Medical Office Administrators**  
1:30 to 2:45 pm  
**Peabody, Bayhill 17 & 18, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: John D. Milewski, Med. Admin.  
Dennis W. Boo, CPA  
Lena G. Combs, CPA  
Thomas V. Durkee, CPA*

Upon completion of this session, participants should be able to: Identify the financial issues facing physician groups; Improve presentation of financial information to physician groups; Discuss financial reporting issues and basic recent tax changes.

**Clinical Research Symposium** ▲ ▼

- 1615 An FDA Audit: Real Life Experiences**  
2:00 to 3:15 pm  
**Peabody, Bayhill 25 & 26, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Kathy L. Pinzone, RN AE-C CCRC*
- 2:00 Perspective of a Coordinator**  
*Sarah K. Knorr, RN MPH CCRP*
- 2:25 A Perspective from the FDA**  
*Speaker to be announced.*
- 2:50 Perspectives of a PI**  
*Corinne Keet, MD*

Upon completion of this session, participants should be able to: Describe what is involved in the preparation and completion of an FDA audit of a research study.

**Medical Administrator Workshop** **1711 Meaningful Use of EHR and Capturing Stimulus Dollars**

3:00 to 4:15 pm

**Peabody, Bayhill 31, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Moderator: Jeanette Booker**Russell B. Leftwich, MD FAAAAI*

Upon completion of this session, participants should be able to: Recognize the benefits of an EHR, including those gained through the American Recovery and Reinvestment Act of 2009 (HITECH Act); Identify the meaningful use criteria and those software vendors that are currently certified to capture and report against those criteria; Utilize proven methods to overcome resistance to change, remembering that "change is hard."

**Clinical Research Workshop** **1712 Ethics and Research**

3:30 to 4:45 pm

**Peabody, Bayhill 32, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Kim E. Mudd, RN MSN CCRP**Elizabeth D. Strong, RN CRC*

Upon completion of this session, participants should be able to: Discuss the regulations that impact recruitment and remuneration; Discuss the process of developing a plan that addresses minority and/or vulnerable populations; Discuss the ethics of research in vulnerable and/or minority populations.

**AAAAI Federation of RSLAAS Assembly Forum**

5:00 to 6:30 pm

Credit: No CME / No CE

**5:00 Wine and Cheese Reception****5:10 Business Meeting****5:20 Promoting the Value of our Specialty***Sharon B. Markovics, MD FAAAAI***5:30 Does Allergen-Specific Immunotherapy Provide Cost/Benefits for Children with Allergic Rhinitis?***Cheryl S. Hankin, PhD***5:50 Advocating for our Specialty: How Outcomes can Impact Your Practice***Linda Cox, MD FAAAAI***6:10 Question & Answer; Panel Discussion****6:20 Current Directions of the RSLAAS****Seminars**  

5:15 to 6:15 pm

Pre-registration and ticket required. Fee: \$40. Refreshments included. Sessions and refreshments limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**1811 Immunodeficiencies Discovered in the Last Five Years***Thomas A. Fleisher, MD FAAAAI**Gulbu Uzel, MD***Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Discuss the new Primary Immunodeficiency Diseases, with a focus on those described during the past five years; Identify the newer technologies used for discovery of these and future disorders; Explain the expanding overlap between immunodeficiency and inflammatory disorders.

**1812 Challenges of Managing Multiple Food Allergies***Julie Wang, MD FAAAAI**Michael C. Young, MD FAAAAI***Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Identify the diagnostic and management challenges of multiple food allergies; Recognize the nutritional, feeding and social risk factors; Develop and implement a feeding plan for adequate nutrition, feeding skill and social development of children with multiple food allergies.

**1813 Approach to Patients Presenting with Reactions to NSAIDs***Ronald A. Simon, MD FAAAAI**Katharine M. Woessner, MD FAAAAI***Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Describe the different types of pseudoallergic and allergic reactions to ASA/NSAIDs and underlying diseases; Discuss the approach to the evaluation of patients who give a history of reactions to ASA and other NSAIDs; Discuss the approach to identifying and describing skin lesions.

**1814 SLIT vs. SCIT in Children***Giovanni Passalacqua, MD**David P. Skoner, MD***Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Summarize experience with SLIT and compare and contrast its safety/efficacy vs. SCIT; Appreciate recent data describing SLIT; Appreciate methodologic variation in SLIT.

**1815 Non-Allergic Rhinitis: Insights into the Pathophysiology, Classification and Clinical Management***Michael A. Kaliner, MD FAAAAI**Eli O. Meltzer, MD FAAAAI***Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Explore evidence for immunologic and neurogenic mechanisms in non-allergic rhinitis; Discuss new approaches to phenotyping chronic nonallergic rhinitis subtypes using validated instruments; Review current treatment options for non-allergic rhinitis and discuss new study designs for future non-allergic rhinitis clinical trials.

**Allied Health Wine and Cheese Reception**  

5:00 to 6:00 pm

**Peabody, Orchid Room, Recreation Level**

All allied health members and guests are invited to attend this reception for an evening of networking with other allied health professionals.

**International Assembly Business Meeting and Reception**

5:15 to 7:15 pm

**Convention Center, S330CD, Level III**

All international members and delegates are invited to attend this business meeting and reception.



**Seminars** 

7:00 to 8:00 am

Pre-registration and ticket required. Fee: \$40. Continental breakfast included. Sessions and meals limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**2001 The Evolution of Childhood Wheezing to Asthma**

*Leonard B. Bacharier, MD FAAAAI*

*Bradley E. Chipps, MD FAAAAI*

**Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Determine the diagnostic criteria for varied phenotypic expression of childhood asthma; Examine the progression of immunopathologic events in the development of childhood asthma; Explore the implication for treatment given the varied immunopathologic and phenotypic expressions.

**2002 Clinical Management of Asthma in the Older Adult**

*Alan P. Baptist, MD MPH*

*Carol A. Saltoun, MD FAAAAI*

**Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Explain how asthma symptoms and spirometry may differ in older adults compared to younger populations; Identify unique factors associated with poor asthma control and quality of life in older adults; Discuss the optimal pharmacologic and non-pharmacologic management strategies for older adults with asthma.

**2003 Patients with Antibody Deficiency: Non-Infectious Complications**

*Charlotte Cunningham-Rundles, MD PhD FAAAAI*

*Francisco J. Espinosa-Rosales, MD*

**Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Identify the complications which occur in patients with primary antibody disorders; Describe clinical elements and laboratory tests for surveillance of these non-infectious complications; Appreciate therapeutic approaches to non-infectious complications in primary immunodeficiency.

**2004 An Update on Regulatory T Cells**

*Christine M. Seroogy, MD FAAAAI*

*Dat Q. Tran, MD*

**Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Describe regulatory T Cell subsets, including markers/cytokines distinguishing types of regulatory T Cells; Describe the current evidence of regulatory T Cells in allergic diseases and treatments, such as asthma and eczema; Appreciate the functional capacity and limitations of regulatory T Cells.

**2005 The Role of the Allergist /Immunologist at the Policy Table**

*Steven L. Kagen, MD FAAAAI*

*Daniel G. Steinberg, MD FAAAAI*

**Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Recognize current state and national trends in health care reform; Appreciate the importance of representing our patients as well as our specialty in this changing healthcare climate; Describe the current literature detailing the value added by allergy/immunology in the overall health management of our patients; Develop strategies for effective representation and delivery of supporting data for the importance of our continued role in the changing healthcare model.

**2006 Environmental Biodiversity and the Impact on Environmental Allergens**

*Estelle Levetin, PhD FAAAAI*

*Richard W. Weber, MD FAAAAI*

**Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Discuss biodiversity as it pertains to changes in aerobiology and environmental patterns, with a focus on shifting of global pollen patterns; Discuss awareness of clinical trends associated with increased duration, intensity and allergenicity of environmental allergens; Develop strategies for adaptation of these patterns, including becoming a resource for the development of public policy, a resource for the media and an advocate for our patients.

**2007 Problem-Based Learning: The Practical Aspects of Beta Lactam Allergies**

*Ray S. Davis, MD FAAAAI*

*Eric M. Macy, MD FAAAAI*

**Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Discuss the different components of the penicillin skin test and how they affect the predictive value of the skin test; Discuss the evaluation and management of patients with other beta lactam allergies; Describe the risks for allergies against multiple and related antibiotics.

**2008 Exercise-Induced Anaphylaxis and Food-Dependent Exercise-Induced Anaphylaxis**

*Anna M. Feldweg, MD*

*Kirsi M. Jarvinen-Seppo, MD PhD*

**Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Review the most common clinical presentations of EIAN and typical foods that can trigger FD-EIAN; Learn about recent publications relevant to EIAN and FD-EIAN; Increase understanding of treatment options for EIAN and FD-EIAN.

**2009 Marketing Your Practice on the Web**

*Vesselin Dimov, MD*

*David J. Shulan, MD FAAAAI*

**Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Identify appropriate tools for developing and maintaining a practice website; Implement social media and search engine optimization to market a practice; Discuss strategies for optimizing listings on healthcare rating websites; Discuss use of practice website to enhance/improve patient care.

**2010 How to Successfully Submit an IRB Proposal**

*Mary M. Klote, MD*

*Christopher Martin, MD*

**Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: Identify research that involves human subjects and identify the regulatory requirements for different levels of review; Describe unique requirements when partnering with DOD to conduct research; Explain how the HIPAA rules apply to research and preparatory to research.

**2011 Immunotherapy: Transitioning from Fellowship to Practice**

*Michael B. Wein, MD FAAAAI*

*Hugh H. Windom, MD FAAAAI*

**Peabody, Celebration 11, Convention Level**

Upon completion of this session, participants should be able to: Identify EMRs available to assist with immunotherapy; Develop office staff skills in immunotherapy; Describe the regulatory issues in starting an immunotherapy program.

### 2012 New Insect Allergens: Fire Ant, Mosquito, Deerfly and Asian Lady Beetle

Christopher W. Calabria, MD  
Richard F. Lockey, MD FAAAAI

Peabody, Celebration 12, Convention Level

Upon completion of this session, participants should be able to: Describe the epidemiology and diagnosis of mosquito and deerfly allergy; Discuss eventual indications for immunotherapy in these cases; Describe the pros and cons of the available whole body extracts.

### 2013 Inflammasome and Allergic Diseases

Suzanne L. Cassel, MD  
Shyam S. Mohapatra, PhD FAAAAI

Peabody, Celebration 13, Convention Level

Upon completion of this session, participants should be able to: Define inflammasome; Discuss the role of inflammasome in allergic inflammation; Describe the link between allergic and infection-induced inflammation.

### 2014 Personalized Medicine: The Importance of Biomarkers

Claus Bachert, MD PhD  
Hans-Uwe Simon, MD PhD FAAAAI

Peabody, Celebration 14, Convention Level

Upon completion of this session, participants should be able to: Review novel biomarkers in chronic rhinosinusitis; Discuss biomarkers of bronchial asthma; Identify biomarkers of hypereosinophilic syndromes.

### 2015 The Enigmatic Role of Basophils in Allergic Inflammation

David E. Sloane, MD  
Caroline L. Sokol, MD PhD

Peabody, Celebration 15, Convention Level

Upon completion of this session, participants should be able to: Discuss murine models of basophil function and their relevance to humans; Describe the importance of basophil - dendritic cell crosstalk in Th2 inflammation; Review the role of basophils in the initiation of Th2 inflammation.

### Allied Health Advanced Workshop

#### 2021 Immunotherapy Guidelines: Third Edition and USP 797 Compliance

6:45 to 8:00 am

Peabody, Bayhill 19, Lobby Level

Credit: 1.25 CME / 1.50 CE

Cheryl Koff Bernstein, RN BSN CCRP  
Linda Cox, MD FAAAAI

Upon completion of this session, participants should be able to: Describe the compliance requirements for allergen extract preparation according to the USP chapter 797 and Immunotherapy Practice Parameter Guidelines third edition update; Discuss the practical applications of the guidelines in the private practice and identify practical approaches for implementation of the guidelines.

### Allied Health Workshop

#### 2022 Educating Teens: Sneezes, Wheezes and Triggers, Too

6:45 to 8:00 am

Peabody, Bayhill 17 & 18, Lobby Level

Credit: 1.25 CME / 1.50 CE

Moderator: Dee Mallam, RN AE-C  
Giselle Mosnaim, MD MS FAAAAI  
Kathleen Kelly Shanovich, BSN MS CPNP

Upon completion of this session, participants should be able to: Identify the unique learning modalities of the adolescent patient; Engage in mechanisms to create change and positive outcomes in the adolescent population; Identify the allied health professional's role with this population in the clinical setting.

### Allied Health Workshop

#### 2023 Common Dilemmas in Caring for Children with Food Allergies

6:45 to 8:00 am

Peabody, Bayhill 20, Lobby Level

Credit: 1.25 CME / 1.50 CE

Teri Holbrook, CRNP  
Kim E. Mudd, RN MSN CCRP

Upon completion of this session, participants should be able to: Identify common clinical dilemmas in caring for children with food allergies; Discuss ideas and experiences of participants to develop treatment plans for the cases presented; Provide a forum for pediatric nurse practitioners and nurses to meet each other and establish future contacts.

### Presidential Plenary

#### 2101 Next Generation Science

8:15 to 9:45 am

Convention Center, South Hall A1, Level I

Credit: 1.50 CME / 1.80 CE

Moderators: Charlotte Cunningham-Rundles, MD PhD FAAAAI  
Dennis K. Ledford, MD FAAAAI



#### 8:25 A Mutation in the Human Uncoordinated 119 Gene Impairs TCR Signaling and is Associated with CD4 Lymphopenia

Magdalena M. Gorska, MD PhD

#### 8:45 Delayed Food Challenge Reactions Correspond Temporally to the Appearance of CD63+ Basophils in Subjects with IgE to alpha-Gal

Scott P. Commins, MD PhD

#### 9:05 Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer

Paul J. Bryce, PhD

#### 9:25 Increased FcεRI Expression on Basophils at Birth Predicts Subsequent Allergic Sensitization

Daniel J. Jackson, MD

Upon completion of this session, participants should be able to: Discuss high-quality scientific research undertaken by junior faculty in the field of allergy/immunology.

### Medical Administrator Workshop

#### 2111 Practice Management: What Do I Need to Know?

9:00 to 10:15 am

Peabody, Bayhill 23 & 24, Lobby Level

Credit: 1.25 CME / 1.50 CE

Moderator: John D. Milewski, Med. Admin.  
Jeanette Booker

Upon completion of this session, participants should be able to: State what responsibilities fall to the office manager/administrator; Recognize the positives and negatives of good practice management; Identify resources available to achieve the goals of more efficient practice management and more effective total patient care.



**Posters**

9:45 to 10:45 am  
**Convention Center, South Hall A2, Level I**  
 Posters on display from 7:00 am to 6:00 pm. Authors present from 9:45 to 10:45 am.  
 Credit: No CME / No CE  
 Refer to pages 75-128 for abstracts and authors.

- 2201** **Diagnosis and Monitoring in Asthma Management**
- 2202** **Immune Cells**
- 2203** **Biologic Therapy, Immunoglobulin Replacement**
- 2204** **Bioaerosols**
- 2205** **Urban Allergen and Pollutant Exposures**
- 2206** **Food Allergy I—Diagnosis and Treatment**
- 2207** **Food Allergy Related Issues/Immune Skin Disease**
- 2208** **A Focus on Asthma**
- 2209** **Rhinosinusitis: Mechanisms and Therapy**
- 2210** **Immunotherapy**
- 2211** **Allergic Inflammation**
- 2212** **Innate Immunity**
- 2213** **Allied Health Poster Session**

**Hands-On Workshop**

- 2251** **Anaphylaxis Simulation**  
 10:00 am to 3:00 pm  
**Convention Center, Exhibit and Resource Hall, Level I**  
 Sessions limited to 3 small groups of 4 learners per hour.  
 Credit: 0.25 CME/ 0.30 CE  
 Participate in a live simulation of treating a patient experiencing Anaphylaxis, working with faculty and standardized patients from Florida International University. Space in these workshops is available on a first-come, first-served basis; participants must sign up onsite to complete this activity. This session is located in the training station within the Exhibit and Resource Hall..

Upon completion of this session, participants should be able to demonstrate appropriate clinical skills to be used when treating a patient at risk of, or experiencing, anaphylaxis.

**Symposium**

- 2301** **Cleaning Agents, Asthma and Other Respiratory Maladies**  
 10:45 am to 12:00 pm  
**Convention Center, S330EF, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Santiago Quirce, MD PhD*
- 10:45** **Asthma in Cleaning Personnel: Epidemiologic Evidence**  
*Santiago Quirce, MD PhD*
- 11:05** **Cleaning Agents in Office Settings And Homes: Are They Safe?**  
*Susan M. Tarlo, MBBS FAAAAI*
- 11:25** **Quaternaryonium: Sensitizers or Irritants**  
*Frederic de Blay, MD*
- 11:45** **Question & Answer**

Upon completion of this session, participants should be able to: Discuss the prevalence of asthma and respiratory disease in cleaning personnel; Identify the variety of cleaning agents used in both professional settings and domiciles; Discuss the mechanisms of injury from quaternaryonium compounds.

**Symposium**

- 2303** **Patients with Unusual Infections: When to Think Toll-Like Receptor Pathway Defects**  
 10:45 am to 12:00 pm  
**Convention Center, S330AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator to be announced.*
- 10:45** **Extended Phenotype of CARD9 Deficiency**  
*Bodo Grimbacher, MD*
- 11:05** **TLR-Containing Adaptors and Susceptibility to Disease**  
*Ashley Mansell, PhD*
- 11:25** **Inborn Error of TLR Immunity**  
*Kathleen E. Sullivan, MD PhD FAAAAI*
- 11:45** **Question & Answer**

Upon completion of this session, participants should be able to: Recognize TLR signaling pathway defects that present as severe or unusual viral infections; Describe the role of TLR-containing adaptors in TLR pathway signaling; Discuss TLR polymorphisms that are associated with susceptibility to fungal infections.

**Symposium**

- 2304** **Drug Allergy in the 21<sup>st</sup> Century**  
 10:45 am to 12:00 pm  
**Convention Center, S310ABFE, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Mariana C. Castells, MD PhD FAAAAI*
- 10:45** **Genetics of Drug Allergy**  
*Munir Pirmohamed, MD PhD*
- 11:05** **Patterns of Cutaneous Eruptions in Drug Allergy**  
*Neil Shear, MD*
- 11:25** **Role of Viral Infections in Drug Allergy**  
*Tetsuo Shiohara, MD*
- 11:45** **Question & Answer**

Upon completion of this session, participants should be able to: Discuss the role of genetics in drug allergy; Describe the role of viral infections in drug allergy; Explain different patterns of cutaneous drug eruptions.

**Symposium**

- 2305** **Health Information Technology (HIT): Implications for Research and Clinical Care**  
 10:45 am to 12:00 pm  
**Convention Center, S330GH, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Dan Dalan, MD FAAAAI*
- 10:45** **Health Information Technology (HIT): What Has It Done for You Lately?**  
*Charles Jaffe, MD PhD*  
*Robert J. Becker, MD, Memorial Lectureship Recipient*
- 11:05** **The Impact of HIT on the Allergy/Immunology Practice**  
*Russell B. Leftwich, MD FAAAAI*
- 11:25** **EHRs in Comparative Effectiveness Research**  
*Speaker to be announced.*
- 11:45** **Question & Answer**

Upon completion of this session, participants should be able to: Explain recent trends and advances in health information technology (HIT) and medical informatics for research and patient care; Discuss the ramifications and challenges of EHRs, clinical decision support software, ASTHMA IQ and other clinical HIT for care of the allergy/immunology patient; Explain how comparative effectiveness research can leverage EHR and patient registry data in major chronic disease states such as asthma.

**Symposium** ▼**2306 Dissecting Mechanisms of Oral Tolerance in Food Allergy**

10:45 am to 12:00 pm

Convention Center, S320AB, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Wayne G. Shreffler, MD PhD FAAAAI

**10:45 Epithelial Cell and Dendritic Cell Handling of Food Antigens at the Mucosa**

M. Cecilia Berin, PhD

**11:05 Induction of Tolerance with Baked Milk: Potential Mechanisms**

Jennifer S. Kim, MD FAAAAI

**11:25 T Cell Heterogeneity: The Role of Th2 Subsets and T regs**

Paul J. Bryce, PhD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain the role of gastrointestinal dendritic cell subsets and T Cells in tolerance and allergic sensitization; Recognize novel approaches to the study of food allergen-specific T Cells and their relationship to clinical disease; Describe how immunotherapy alters the food allergen-specific T Cell response to promote clinical tolerance.

**Symposium****2307 Factors Influencing Asthma Exacerbations in Children: Findings from the Childhood Asthma Research and Education Network**

10:45 am to 12:00 pm

Convention Center, S310CDGH, Level III

Credit: 1.25 CME / 1.50 CE

Moderators: James P. Kiley, MD

Lynn M. Taussig, MD

**10:45 Measuring Asthma Outcomes: Lessons Learned from CARE**

Stanley J. Szefler, MD FAAAAI

**11:05 The Effect of Oral Corticosteroids During Acute Lower Respiratory Tract Illnesses in Preschool Children**

Avraham Beigelman, MD

**11:25 Exacerbations and Loss of Lung Function**

Ronina A. Covar, MD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Identify factors which influence the expression of asthma exacerbations in children; Discuss the effect of oral corticosteroids treatment for acute lower respiratory tract illness in preschool children; Characterize the strengths and weaknesses of different measures of asthma outcomes in childhood asthma.

**Symposium** ▼**2308 EAACI Symposium: Immunotherapy from Noon 'til Dawn, from Bench to Bedside**

10:45 am to 12:00 pm

Convention Center, S330CD, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Cezmi A. Akdis, MD FAAAAI

**10:45 Mechanisms of Allergen-Specific Immunotherapy and Immune Tolerance to Allergens**

Cezmi A. Akdis, MD FAAAAI

**11:00 Results from Recent Large Scale Clinical Trials**

Victoria Cardona, MD PhD

**11:15 Novel Approaches to Allergen Immunotherapy**

Marek Jutel, MD PhD

**11:30 Recent Developments of Allergen Immunotherapy for Food Allergy**

Maria Antonella Muraro, MD PhD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain molecular mechanisms of immune tolerance to allergens and how they are regulated by allergen immunotherapy; Recall recent additions to the evidence base for immunotherapy based on large scale clinical trials; List novel developments in the area of oral immunotherapy for food allergy.

**Medical Administrator Workshop** **2311 Social Media for the Practicing Allergist: A No-Nonsense Guide**

10:30 to 11:45 am

Peabody, Bayhill 17 &amp; 18, Lobby Level

Credit: 1.25 CME / 1.50 CE

Moderator: Jeanette Booker

Sakina S. Bajowala, MD

Upon completion of this session, participants should be able to: Explain how the utilization of social media in allergy and immunology practices can lead to improved patient education and satisfaction; Create a step-wise plan for the implementation and maintenance of a social media strategy; Identify and implement processes designed to protect PHI and prevent HIPAA violations when using healthcare social media.

**Clinical Research Workshop** **2312 Research Subject Recruitment, Remuneration and Retention**

10:45 am to 12:00 pm

Peabody, Bayhill 21, Lobby Level

Credit: 1.25 CME / 1.50 CE

Kim E. Mudd, RN MSN CCRP

Kathy L. Pinzone, RN AE-C CCRC

Upon completion of this session, participants should be able to: Discuss the process of developing a research project recruitment, remuneration and retention plan; Identify the regulatory issues involved with vulnerable populations; Explain the ethics and issues of research in minority populations.

**Allied Health Symposium** **2313 Primer on IgE: Applications for Clinical Practice with a Focus on Immunotherapy and Omalizumab**

10:45 am to 12:00 pm

Peabody, Bayhill 23 &amp; 24, Lobby Level

Credit: 1.25 CME / 1.50 CE

Moderator: Jeanette L. Arnold, MSN RN C-FNP

**11:10 What is IgE?**

Thomas B. Casale, MD FAAAAI

**11:35 IgE in Asthma and Allergy**

Jeanette L. Arnold, MSN RN C-FNP

**10:45 The Future of IgE**

Debra A. Sedlak, MSN CPNP

Upon completion of this session, participants should be able to: Discuss the discovery of immunoglobulins and their role in asthma and allergy; Identify standard anti-IgE therapies; Describe other potential therapies.



**Allied Health Advanced Workshop** 

**2314 Difficult Cases in Education and Adherence**

10:45 am to 12:00 pm

**Peabody, Bayhill 22, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Moderator: Maureen George, PhD RN AE-C*

*Marcia Rose Winston, MSN CPNP AE-C*

*Nina A. Zimmermann, MSN RN ANP-BC AE-C*

Upon completion of this session, participants should be able to: Elicit and respond to unconventional patient beliefs; Demonstrate increasing competence in the delivery of low literacy education; Implement partnership-enhancing strategies.

**Allied Health Advanced Workshop**  

**2315 Bronchial Provocation: Mannitol vs. Methacholine**

10:45 am to 12:00 pm

**Peabody, Bayhill 19, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Moderator: Karen L. Gregory, DNP APRN-BC CNS RRT AE-C*

*Edward O. Corazalla, MS RPFT*

Upon completion of this session, participants should be able to: Demonstrate proper procedures for methacholine challenge testing and mannitol challenge testing; Explain the mechanisms of action of both agents; List pros and cons of each type of test.

**Allied Health Advanced Workshop**  

**2316 Don't Cross Me! Guiding Patients with Food Allergy Regarding Cross Contact, Ingredient Allergenicity and Precautionary Labeling**

10:45 am to 12:00 pm

**Peabody, Bayhill 20, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Moderator: Stephen L. Taylor, PhD*

*G. Lynn Christie, MS RD*

Upon completion of this session, participants should be able to: Identify risk factors associated with manufactured foods; Explain food science principles and how they apply to the allergen content of various foods; Apply knowledge of food science and cross-contact risk in assessing ingredients and products for families on allergen avoidance diets.

**Allied Health Professionals Assembly Forum**

12:30 to 1:30 pm

All allied health professionals are invited to attend this forum. Box lunch included.

**Seminars**  

12:30 to 1:30 pm

Pre-registration and ticket required. Fee: \$40. Box lunch included.

Sessions and meals limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**2501 Methacholine Bronchoprovocation**

*Louis-Philippe Boulet, MD*

*Donald W. Cockcroft, MD FAAAAI*

**Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Discuss the caveats for interpretation of methacholine tests; Describe the differences between direct (methacholine) and indirect (AMO, EVH, mannitol) challenges; Describe the different protocols available to perform BHR studies.

**2502 An Update in Asthma Therapeutics Since the Last NHLBI Executive Summary**

*Timothy J. Craig, DO FAAAAI*

*Michael B. Foggs, MD FAAAAI*

**Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Explore new paradigms to treat asthma; Discuss stepping up and stepping down therapies; Explore alternatives to LABAS.

**2503 Problem-Based Learning: Immunodeficiency Evaluation**

*Meredith Lee Heltzer, MD*

*E. Richard Stiehm, MD FAAAAI*

**Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Make an alternative diagnosis of a patient with recurrent infections; Order lab tests to evaluate a patient for immune deficiency; Interpret lab tests for suspected immune deficiency; Develop a treatment plan for an immune deficient patient.

**2504 Advances in the Diagnosis and Management of Chronic Granulomatous Disease**

*I. Celine Hanson, MD FAAAAI*

*Elena E. Perez, MD PhD*

**Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Describe current diagnostic tests, including genetic, for CGD; Identify current antifungals and outcomes of bone marrow transplantation; Explain the predictive value of certain objective laboratory and clinical values in CGD.

**2505 An Iota About Our Microbiota**

*Jayant M. Pinto, MD*

*Erika Von Mutius, MD MSc*

**Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Describe recent advances in characterizing the microbiome of the airway and gastrointestinal mucosa; Discuss the evidence for microbial influences on asthma and allergy; Discuss the therapeutic implications of manipulating the microbiome for the prevention and/or treatment of asthma and allergic diseases.

**2506 Role of IgE in Virus-Induced Asthma**

*William W. Busse, MD FAAAAI*

*Michelle A. Gill, MD PhD*

**Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Discuss the interactions of allergic sensitization and viral respiratory infections in asthma; Discuss the evidence for a role for IgE and its receptors in modulating host responses to respiratory virus infections; Examine whether targeting IgE might be a useful strategy in the management of virus-induced asthma exacerbations.

**2507 Experimental Approaches to the Study of Food Allergy**

*M. Cecilia Berin, PhD*

*Madhan Masilamani, PhD*

**Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Explain the utility and limitations of current animal models of IgE-mediated food allergy; Describe how the human gastrointestinal mucosa can be modeled using a variety of in vitro approaches; Appreciate how newer technologies such as iPSC cells may apply to these questions in the future.

**2508 Diagnosis and Management of Mastocytosis**

*Cem Akin, MD PhD FAAAAI*

*Benjamin P. Soule, MD*

**Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Recognize a patient with a potential clonal mast cell disorder; Apply the diagnostic criteria for mastocytosis; Determine when to refer the patient to a hematologist for a marrow examination.

**2509 There's an App for That: iPhone/iPad, Android and Web Tools for Clinical Practice**

Linda D. Green, MD FAAAAI  
Melinda M. Rathkopf, MD FAAAAI

**Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Discuss novel applications of the iPhone/iPad, Android and other smart devices in daily practice; Present use case scenarios of web tools for improving patient care, education and outreach; Navigate and find features of the new AAAAAI website.

**2510 Addressing Complementary and Alternative Medicine (CAM) Within a Traditional Allergy Practice**

Gailen D. Marshall Jr., MD PhD FAAAAI  
Julie Wang, MD FAAAAI

**Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: Identify some of the more common CAM practices that may be considered by allergy patients; Describe the proposed mechanisms through which common CAM therapies may produce effects; Identify possible risks, benefits and interactions associated with CAM therapies; Describe paradigms of shared medical decision making and apply them appropriately.

**2511 Eustachian Tube Obstruction in Allergy**

Sigrid Payne DaVeiga, MD  
David P. Skoner, MD

**Peabody, Celebration 11, Convention Level**

Upon completion of this session, participants should be able to: Describe the presentation, pathophysiology and complications of Eustachian tube dysfunction; Explain how to manage Eustachian tube dysfunction; Discuss the role of allergy/allergic rhinitis in this condition.

**2512 Problem-Based Learning: Immunotherapy Dose Adjustment Issues That the Practice Parameters Did Not Solve**

David W. Hauswirth, MD FAAAAI  
Désirée E.S. Larenas Linnemann, MD FAAAAI

**Peabody, Celebration 12, Convention Level**

Upon completion of this session, participants should be able to: Discuss how to dose in special cases (e.g. after missed doses, local or systemic reactions, in pregnancy, AIDS and cancer); Learn dosing of AIT during build-up and maintenance; Discuss issues concerning dosing of AIT with non-standardized extracts.

**2513 Airway Epithelium as the Interplay Between Innate and Th2 Immunity**

Zoulfia Allakhverdi, PhD FAAAAI  
Angela Haczku, MD PhD FAAAAI

**Peabody, Celebration 13, Convention Level**

Upon completion of this session, participants should be able to: Discuss the role of epithelial cell-derived cytokines/immune modulators in chronic airway inflammation; Discuss the role of epithelial cell-derived cytokines/immune modulators in the innate immune and Th2 responses; Explain the direct role of epithelial cells to both initiating and resolving the inflammatory response.

**2514 Inflammaging and Late Onset Asthma**

Paula J. Busse, MD FAAAAI  
Sameer K. Mathur, MD PhD

**Peabody, Celebration 14, Convention Level**

Upon completion of this session, participants should be able to: Explain the mechanisms of inflammaging; Discuss cellular and molecular mechanisms of inflammaging; Describe how inflammaging contributes to asthma in elderly patients.

**2515 How Certain Medications Might Affect the Efficacy and Safety of Immunotherapy**

Robert E. Coifman, MD FAAAAI  
Aidan A. Long, MD FAAAAI

**Peabody, Celebration 15, Convention Level**

Upon completion of this session, participants should be able to: Discuss controlled trials showing the effect of corticosteroids, antileukotrienes and vitamin D on the clinical and immunological benefits of SCIT; Update the discussion on the actual data on beta-blockers affecting SCIT safety; Update the discussion on the actual data on ACE inhibitors affecting SCIT safety.

**State-of-the-Art****2521 Safety of LABA/ICS Dynamic Dosing**

12:30 to 1:30 pm  
**Convention Center, S310ABFE, Level III**  
Credit: 1.00 CME / 1.20 CE  
Moderator: John Oppenheimer, MD FAAAAI  
Badrul A. Chowdhury, MD PhD FAAAAI  
Paul M. O'Byrne, MD FAAAAI

Upon completion of this session, participants should be able to: List reasons for concern regarding dynamic dosing of combination therapy; Discuss the pros and cons of this form of dosing; Highlight unmet needs in our present asthma armamentarium.

**State-of-the-Art****2522 Reducing the Genome to Explain Congenital Susceptibility to Infection: Unusual Phenotypes and Primary Immunodeficiency**

12:30 to 1:30 pm  
**Convention Center, S320AB, Level III**  
Credit: 1.00 CME / 1.20 CE  
Moderator: Jordan Orange, MD PhD FAAAAI  
**A Molecular and Clinical Perspective in the Evolving Understanding of Primary Immunodeficiency**  
Jennifer M. Puck, MD

Upon completion of this session, participants should be able to: Identify how genomic advances are being successfully applied in complicated primary immunodeficiency phenotypes where there have not previously been clear leads; Describe new genetic immune deficient infectious susceptibility phenotypes that have been discovered as a result of advanced technologies; Review what unexpected immunology has been provided by taking these intellectual quantum leaps.

**State-of-the-Art****2523 Fungal Diseases of the Lower Airways: A Fresh Look at an Old Problem**

12:30 to 1:30 pm  
**Convention Center, S330CD, Level III**  
Credit: 1.00 CME / 1.20 CE  
Moderator: Richard W. Weber, MD FAAAAI

**12:30 Epidemiology of Fungal Sensitivity and Asthma**

Robert K. Bush, MD FAAAAI

**12:50 Redefining Allergic Bronchopulmonary Aspergillosis**

Leslie C. Grammer, MD FAAAAI

**1:10 Mold in the Workplace: Unrecognized Causes of Occupational Respiratory Disease**

Karin A. Pacheco, MD MSPH FAAAAI

Upon completion of this session, participants should be able to: Identify the epidemiology of fungal sensitivity and its role in pulmonary disease; Explain a new approach to a better understanding of ABPA, including controversies in diagnosis; Recognize the role mold exposure plays in occupational lung disease.





**State-of-the-Art** ▼

**2524 Hypersensitivity to Drugs and Rapid Desensitization in the 21<sup>st</sup> Century: A True Niche for the Allergy Specialist**

12:30 to 1:30 pm  
**Convention Center, S330AB, Level III**  
 Credit: 1.00 CME / 1.20 CE  
*Moderator: David A. Khan, MD FAAAAI*  
*Mariana C. Castells, MD PhD FAAAAI*

Upon completion of this session, participants should be able to: Identify the new presentation of ADR for monoclonals, chemotherapeutics and antibiotics amenable to rapid desensitization in the 21<sup>st</sup> century; Recognize the populations at risk and review the most useful protocols; Evaluate the safety and efficacy of rapid desensitizations in the context of quality of life parameters.

**State-of-the-Art** ▼

**2525 So You Suspect Your Patient is Non-Adherent: Now What?**

12:30 to 1:30 pm  
**Convention Center, S330EF, Level III**  
 Credit: 1.00 CME / 1.20 CE  
*Moderator: Giselle Mosnaim, MD MS FAAAAI*

**12:30 Determining if Your Patient is Adherent or Non-Adherent**  
*Andrew G. Weinstein, MD FAAAAI*

**1:00 Brief In-Office Strategies to Improve Adherence**  
*Bruce G. Bender, PhD FAAAAI*

Upon completion of this session, participants should be able to: Discuss the causes of poor adherence; Identify tools to diagnose adherence status; Review strategies to promote adherence.

**State-of-the-Art** ▼

**2526 State of Sublingual Immunotherapy (SLIT) in the United States**

12:30 to 1:30 pm  
**Convention Center, S310CDGH, Level III**  
 Credit: 1.00 CME / 1.20 CE  
*Moderator: Fuad M. Baroody, MD FAAAAI*

**12:30 Immunologic Mechanisms of SLIT**  
*Kari C. Nadeau, MD PhD FAAAAI*

**1:00 Update on SLIT Clinical Trials in the U.S.**  
*Michael S. Blaiss, MD FAAAAI*

Upon completion of this session, participants should be able to: Identify the immunological changes after sublingual immunotherapy; Describe the status of clinical trials in the U.S. using SLIT.

**State-of-the-Art** ▼

**2527 Th2 Immunity and Potential Therapies**

12:30 to 1:30 pm  
**Convention Center, S320CD, Level III**  
 Credit: 1.00 CME / 1.20 CE  
*Moderator: Susan M. MacDonald, MD FAAAAI*

**12:30 New Insights into the Generation of Th2 Immunity and Potential Therapeutic Targets for the Treatment of Asthma**  
*Paul S. Foster, PhD*

Upon completion of this session, participants should be able to: Learn the role that the innate immune system plays in Th2 responses; Discuss the potential mechanisms of the pathogenesis of allergic asthma.

**Oral Abstract**

**2601 Asthma Highlights**

2:00 to 3:15 pm  
**Convention Center, S320EF, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Faoud Terrence Ishmael, MD PhD*  
*Mark Sands, MD FAAAAI*

**2:00 Elevated Cord Blood Soluble CD14 Levels Predict Wheezing in the First Year of Life**  
*Yu-Lin Huang, MD*

**2:15 Improvements In Quality Of Life Measures In A Structured Exercise Program For Persistent Asthma**  
*Susan M. Pollart, MD MS*

**2:30 Real-world Effectiveness Of Asthma Step-up Options: Matched Comparison Of Extrafine Hydrofluoroalkane-beclometasone AND Inhaled Corticosteroid / Long-Acting Beta-Agonist**  
*David B. Price, MA*

**2:45 Alternaria Sensitization is Associated with Increased Airway Hyperresponsiveness and Sinusitis in Children with Severe Asthma**  
*Jennifer Shih, MD*

**3:00 Disconnect Between Sputum Neutrophilia and Indices of Mucosal Inflammation in Severe Asthma**  
*Joseph R. Arron, MD PhD*

**Oral Abstract**

**2602 Immunogenetics**

2:00 to 3:15 pm  
**Convention Center, S230AB, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Kathleen C. Barnes, PhD FAAAAI*  
*Michael O'Daines, MD*

**2:00 Co-associations Between IL10 Genetic Variants, IL 10 Production And Helminth Infection In A Tropical Population Of Brazil With High Prevalence Of Asthma**  
*Camila A. Figueiredo, PhD*

**2:15 Glucocorticoid Receptor Translational Isoforms Contribute to Distinct Glucocorticoid Responses of Neutrophils and Eosinophils**  
*Joy Hsu, MD*

**2:30 Epigenetic Biomarkers of Established Allergic Disease in Peripheral Blood Mononuclear Cells**  
*Michelle L. North, PhD*

**2:45 Genetic Polymorphisms of Transforming Growth Factor- $\beta$  Signaling Pathway and Kawasaki Disease in the Taiwanese population**  
*Ho-Chang C. Kuo, MD*

**3:00 The German Mouse Clinic (gmc): A Systemic Phenotyping Platform To Uncover New Models For Allergic Diseases**  
*Juan A. Aguilar-Pimentel*

**Oral Abstract**

- 2603 Healthy Homes: Do They Make a Difference in Disease?**  
2:00 to 3:15 pm  
Convention Center, S330GH, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Peter Heymann, MD  
Wanda Phipatanakul, MD MS FAAAAI
- 2:00 Exposure to Indoor Allergens in Urban Elementary Schools and Homes of Children with Asthma**  
Perdita Permaul, MD
- 2:15 Reduction in Dust Allergen Exposure through Healthy Homes Education**  
Freddy Pacheco, MS
- 2:30 Neither Dust Mite nor Cat Allergen Exposure Is Associated with Lung Function or Asthma Morbidity in Sensitized Baltimore City Children**  
Sharon K. Ahluwalia, MD
- 2:45 Among Middle-income Children In NYC, Neighborhood Reports Of Mouse Sightings Were Associated With Sensitization To Mouse**  
Medina S. Jackson-Browne, MS
- 3:00 Indoor Airborne Spore Levels Before and After Healthy Homes Education and Remediation**  
Minati G. Dhar, PhD

**Oral Abstract**

- 2604 Food Allergy**  
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Antonella M. Muraro, PhD
- 2:00 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance**  
Stacie M. Jones, MD
- 2:15 Peanut Challenge Outcomes Following Sublingual Immunotherapy (SLIT) Correlate With Increased Peanut-Specific Salivary IgA**  
Michael D. Kulis, PhD
- 2:30 Plasma from Subjects on Peanut Oral Immunotherapy (OIT) Suppresses ex vivo Basophil Activation in Peanut-Allergic Subjects**  
Caitlin Burk
- 2:45 Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial (CoFAR)**  
David Mark Fleisher, MD FAAAAI
- 3:00 Development of Clinical Tolerance after Peanut OIT**  
A. Wesley Burks, MD FAAAAI

**Oral Abstract**

- 2605 Determinants of Asthma Treatment Choices**  
2:00 to 3:15 pm  
Convention Center, S331CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Giselle Mosnaim, MD MS FAAAAI
- 2:00 Differences in Asthma Controller Medication Adherence by Age and Gender**  
Leslie J. Hinyard, PhD MSW
- 2:15 Survey of Asthma Management and Referral Preferences by Primary Care Pediatricians at a Pediatric Training Hospital.**  
Nabeel Farooqui, MD
- 2:30 The Comparison of Asthma Control Judgment Based on Japanese Guidelines for Asthma, GINA, EPR3, and ACT**  
Hiroyuki Nagase, MD PhD
- 2:45 Combined Corticosteroid Use in Patients with Asthma, Allergic Rhinitis, and Atopic Dermatitis**  
Min Jung Lee, MD
- 3:00 Depressive Symptoms in African American and Caucasian Women Participating in Telephone-Based Asthma Management Programs**  
Georgiana Sanders, MD

**Oral Abstract**

- 2606 Rhinosinusitis Mechanisms and Management**  
2:00 to 3:15 pm  
Convention Center, S320GH, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Seong H. Cho, MD  
Martin Wagenmann, MD FAAAAI
- 2:00 Differential Regional Expression Of Innate Immune Antimicrobial Proteins In Sinonasal Mucosa.**  
Sudarshan Seshadri, PhD
- 2:15 STAT3 and NF- $\kappa$ B Regulate S100A7 Expression in Human Bronchial Epithelial Cells**  
Kathryn E. Hulse, PhD
- 2:30 Clinical Characteristics of Patients with Chronic Rhinosinusitis and Specific Antibody Deficiency**  
Sara Kashani
- 2:45 Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And Asthma.**  
Philippe Gevaert, MD PhD
- 3:00 IL-21 is Increased in Nasal Polyposis and after Stimulation with Staphylococcus Aureus Enterotoxins**  
Lien Calus, MD



**Oral Abstract**

- 2607 Cytokines Initiating Allergic Responses**  
2:00 to 3:15 pm  
**Convention Center, S230EF, Level II**  
Credit: 1.25 CME / 1.50 CE  
*Moderators: Yui-Hsi Wang, PhD  
Judith A. Woodfolk, MBChB PhD FAAAAI*
- 2:00 The Interaction Between Ara h 1 and TSLP Selectively Expands Skin-Homing Th2 Cells in Peanut-Sensitized Children**  
*Julia A. Wisniewski, MD*
- 2:15 Allergen Induces Dual Upregulation of TSLP Receptor on Circulating Basophils and Dendritic Cells in Atopic Dermatitis**  
*Rachana Agrawal, PhD*
- 2:30 IL-33 Mediates Both Innate and Adaptive Th2-type Responses Induced by Proteases in the Airway**  
*Kenichiro Hara, MD*
- 2:45 Roles for IL-33 and TSLP in Chronic Eosinophilic Airway Inflammation Induced by Airborne Allergen Exposure**  
*Koji Iijima, PhD*
- 3:00 Role of Thymic Stromal Lymphopoietin (TSLP) in Chronic Rhinosinusitis**  
*Atsushi Kato, PhD*

**Oral Abstract**

- 2608 Drug Allergy**  
2:00 to 3:15 pm  
**Convention Center, S319, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderators: Aleena Banerji, MD  
Roland Solensky, MD FAAAAI*
- 2:00 Influenza Vaccine Administration in Egg Allergic Children**  
*Fatima S. Khan, MD*
- 2:15 Experience With Carboplatin Desensitization: A Case Series**  
*Adam Updegraff, DO*
- 2:30 Nasal Inflammatory Mediators In Non-steroidal Anti-inflammatory Drugs (nsaids) Cross-intolerant Subjects After Lysine Nasal Challenge**  
*Inmaculada Dona, MD PhD*
- 2:45 Anaphylaxis as a Potential Cause of Death in Heroin Users**  
*Ziaoying Zhou, PhD*
- 3:00 Beta Blocker Pretreatment before Coronary CT Angiography does not Increase the Rate of Contrast Reactions**  
*Carl B. Lauter, MD*

**Clinical Research Symposium**

- 2621 Food Allergy Research Update**  
2:00 to 3:15 pm  
**Peabody, Bayhill 17 & 18, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Kim E. Mudd, RN MSN CCRP*
- 2:00 Food Allergy Treatment: Research Update**  
*Satya Narisety, MD*
- 2:20 Safety and Protocol Implementation**  
*Pamela H. Steele, MSN CPNP AE-C*
- 2:40 Research Participant Recruitment and Retention**  
*Sally A. Noone, RN MSN CCRP*
- 3:00 Question & Answer**  
Upon completion of this session, participants should be able to: Describe current research approaches to food immunotherapy; Discuss implications of current research on the future of food allergy treatment; Discuss safety, regulatory issues and research protocol implementation.

**Allied Health Workshop**

- 2622 Problem-Based Learning: Improving Asthma Self-Management in Diverse Populations**  
2:00 to 3:15 pm  
**Peabody, Bayhill 20, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Antonina G. Evans, BSPHarm AE-C  
Marciarose Winston, MSN CPNP AE-C*
- Upon completion of this session, participants should be able to: Discuss the importance of asking probing questions when evaluating a patient's adherence to an asthma management plan; Identify the barriers to adherence and proper asthma self-management in a diverse patient population; Develop solutions to improve adherence and asthma self-management skills.

**Allied Health Workshop**

- 2623 Eosinophilic Esophagitis: Care and Controversies**  
2:00 to 3:15 pm  
**Peabody, Bayhill 19, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Carrie L. Vibbert, RN BSN  
Mary E. Bollinger, DO FAAAAI  
Marion E. Groetch, MS RD*
- Upon completion of this session, participants should be able to: Describe the pathophysiology and the diagnostic process of eosinophilic esophagitis; Discuss the utility and limitations of food allergy and testing to determine implicated food in EoE; Participate in the interdisciplinary management of EoE.

**Allied Health Workshop**

- 2624 Primary Immune Deficiency: Laboratory Evaluation and Management Strategies**  
2:00 to 3:15 pm  
**Peabody, Bayhill 21, Lobby Level**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Donna W. Mitchell, RN MSN NP  
Magee L. DeFelice, MD  
Thomas A. Fleisher, MD FAAAAI  
M. Elizabeth M. Younger, CRNP PhD*
- Upon completion of this session, participants should be able to: Identify indications for flow cytometry, functional antibody testing and cellular function tests; Develop appropriate management plans for subtypes of primary immune deficiency.

**Allied Health Workshop**   **2625 Spirometry: Hands-On Training**

2:00 to 3:15 pm

**Peabody, Bayhill 22, Lobby Level**

Pre-registration and ticket required. Fee: \$20.

Credit: 1.25 CME / 1.50 CE

*MaryKay Bossard, BS RRT AE-C**Maureen George, PhD RN AE-C**Concettina Tolomeo, DNP APRN FNP-BC AE-C*

Upon completion of this session, participants should be able to: Demonstrate appropriate spirometry techniques.

**Keynote** **2701 Hard Knocks: Communicating Science to the Public**

3:30 to 4:30 pm

**Convention Center, South Hall A1, Level I**

Credit: 1.00 CME / 1.20 CE

*Moderator: Jonathan M. Spergel, MD PhD FAAAAI**Paul A. Offit, MD**Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children's Hospital of Philadelphia; Maurie R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at the University of Pennsylvania School of Medicine.*

Upon completion of this session, participants should be able to: Discuss the optimal approaches for communicating medical information to patients and the public; Discuss various approaches to deal with medical misinformation; List examples of medical misinformation and potential harm from misinformation.

**Hands-On Workshop**  **2801 Achieving Part IV MOC Credit Using the ASTHMA IQ Module**

4:45 to 6:00 pm

**Convention Center, S331AB, Level III**

Pre-registration and ticket required. Fee: \$50.

Credit: 1.25 CME / 1.50 CE

*Moderator: Stuart L. Abramson, MD PhD FAAAAI***4:45 Overview of the ASTHMA IQ Program***Thomas B. Casale, MD FAAAAI***5:00 Utilization and Navigation of the ASTHMA IQ Program in Busy Practice Settings***Mary Beth Fasano, MD FAAAAI***5:15 Tips and Experience in Successful Completion of Part IV MOC***Stuart L. Abramson, MD PhD FAAAAI***5:30 Hands-On Instruction**

Upon completion of this session, participants should be able to: Assess baseline practice gaps in asthma management in one's individual practice; Prepare a plan to address practice gaps using ASTHMA IQ; Demonstrate use of the ASTHMA IQ module to complete Part IV MOC credit.

**Panel Discussion Workshop****2802 Methacholine vs. Mannitol Challenge in Evaluation of Asthma**

4:45 to 6:00 pm

**Convention Center, S331CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Donald W. Cockcroft, MD FAAAAI**Sandra D. Anderson, PhD DSc**Timothy J. Craig, DO FAAAAI**Catherine Lemiere, MD*

Upon completion of this session, participants should be able to: Describe how and when to apply these tests to diagnose asthma; Discuss appropriate treatment and a strategy to withdraw treatment in those who are well controlled; Review how the tests can be used to assess new treatments for asthma.

**Q & A Workshop** **2803 New Insights into Diagnosis and Treatment of Angioedema**

4:45 to 6:00 pm

**Convention Center, S330EF, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Allen P. Kaplan, MD FAAAAI***4:45 Novel Treatments for HAE and Bradykinin Related Angioedema: Which One Works Better for Acute Attacks and for Preventive Therapy?***Konrad Bork, MD***5:00 Laboratory Diagnosis of HAE: Is There a Role for Molecular Analysis in Routine Clinical Practice?***Marco Cicardi, MD***5:15 Non-Hereditary Angioedema: Treatment Update and Challenges***Michael M. Frank, MD FAAAAI***5:30 Question & Answer**

Upon completion of this session, participants should be able to: Evaluate in detail the indications and efficacy of the new generation HAE treatments for acute attacks and preventive therapy; Discuss the use of molecular diagnosis of angioedema in routine clinical practice; Describe knowledge of clinical presentation and therapy of patients with non-hereditary angioedema.

**Q & A Workshop****2804 New Immunological Insights from the Study of Primary Immunodeficiency Disease**

4:45 to 6:00 pm

**Convention Center, S320GH, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Jordan Orange, MD PhD FAAAAI***4:45 Mendelian Susceptibility to Mycobacterial Diseases***Capucine Picard, PhD***5:00 Insights into B Cell Function from New Discoveries in Hyper IgM Syndromes***Ashish Jain, MD***5:15 Insights from Newborn Screenings for SCID and Potential Application to Agammaglobulinemia***Vincent R. Bonagura, MD***5:30 Question & Answer**

Upon completion of this session, participants should be able to: Appreciate new immunologic understanding from recent discoveries in primary immunodeficiency; Describe knowledge of how immune pathways newly elucidated through the study of primary immunodeficiencies is reshaping paradigms in host defense.



**Q & A Workshop** ▼

**2805 Hot Topics in Pediatric Allergy and Immunology**

4:45 to 6:00 pm

Convention Center, S310ABFE, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Elizabeth Matsui, MD

**4:45 Allergic Respiratory Disease**

Bradley E. Chippis, MD FAAAAI

**5:00 Food and Drug Allergies**

Jennifer S. Kim, MD FAAAAI

**5:15 Immunologic Disorders**

Vivian P. Hernandez-Trujillo, MD FAAAAI

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe the latest developments in pediatric allergy and immunology; Discuss how these might impact the care of pediatric patients with respiratory allergic disease, food and drug allergy and immunologic disorders.

**Q & A Workshop**

**2806 Home Inspections for Indoor Molds**

4:45 to 6:00 pm

Convention Center, S330AB, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Rosa M. Codina-Overcash, PhD FAAAAI

**4:45 Air Sampling Techniques**

Charles S. Barnes, PhD

**5:00 Interpretation**

Karin A. Pacheco, MD MSPH FAAAAI

**5:15 Indications and Overview**

Robert L. Jacobs, MD

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Review the components of a proper home inspection; Describe the air sampling methods and laboratory analysis; Interpret the mold report.

**Year-in-Review Workshop** ▼

**2807 Occupational Disease: What the Allergist Should Know**

4:45 to 6:00 pm

Convention Center, S320AB, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Jill A. Poole, MD FAAAAI

**4:45 Occupational: Asthma, Rhinitis and Hypersensitivity Pneumonitis**

Mark S. Dykewicz, MD FAAAAI

**5:00 Work-Exacerbated Asthma**

Susan M. Tarlo, MBBS FAAAAI

**5:15 Occupational Dermatologic Disease: Differential Diagnosis and Patch Testing**

D. Linn Holness, MD

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Identify recently described key occupational exposures; Explain the respiratory and cutaneous diseases caused by occupational exposures; Describe how to better assess and treat patients.

**Q & A Workshop**

**2808 Eosinophilic Esophagitis: the Allergist, the Gastroenterologist and the Pathologist: How to Build a Winning Team in Your Community**

4:45 to 6:00 pm

Convention Center, S230CD, Level II

Credit: 1.25 CME / 1.50 CE

Moderator: Fred (Dan) McDaniel Atkins, MD FAAAAI

**4:45 The Allergist**

Mark Holbreich, MD FAAAAI

**5:00 The Gastroenterologist**

Amir F. Kagalwalla, MD

**5:15 The Pathologist**

Nina Tatevian, MD

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Demonstrate the knowledge to begin or improve cooperative communication and interaction with gastroenterologists and pathologists in the community; Demonstrate the ability to establish more consistent and reliable referrals from pediatric and adult gastroenterology; Demonstrate the ability to discuss with the pathologist specific histological findings characteristic of eosinophilic esophagitis.

**Q & A Workshop**

**2809 Oral Food Challenges in the Office vs. Research Setting**

4:45 to 6:00 pm

Convention Center, S320EF, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Stacie M. Jones, MD

**4:45 Choosing the Right Challenge for the Right Patient**

Anna H. Nowak-Wegrzyn, MD FAAAAI

**5:00 Selecting and Preparing the Challenge Food**

Carina Venter, PhD RD

**5:15 Conducting and Interpreting Blinded vs. Open Food Challenges**

David Mark Fleischer, MD FAAAAI

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Identify which patients should be referred for which type of oral food challenge (open vs. single-blind vs. double-blind placebo-controlled); Review the differences between each protocol; Interpret observed results in aiding diagnosis of food allergy.

**BYOP Workshop**  **2810 Insect Allergy: Difficult Cases and New Hymenoptera Guidelines**

4:45 to 6:00 pm

**Convention Center, S330CD, Level III**

Pre-registration and ticket required. No fee.

Credit: 1.25 CME / 1.50 CE

Moderator: Theodore M. Freeman, MD FAAAAI

**4:45 Cross-Reactivity in Venom Allergy: *In Vivo* and *In Vitro* Tests**

James M. Tracy, DO FAAAAI

**5:00 When to Stop Immunotherapy**

David B.K. Golden, MD FAAAAI

**5:15 Imported Fire Ant Stings: A Rising Problem?**

Michael S. Tankersley, MD FAAAAI

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Explain cross-reactivity among various species and new tools to address this issue in the clinic; Discuss the rising prevalence of fire ant stings and how this phenomenon might impact practice; Review the unique aspects of various hymenoptera.

**Hands-On Workshop**  **2811 EMR Roundtable: What Are Other Allergists Using?**

4:45 to 6:00 pm

**Convention Center, S230GH, Level II**

Pre-registration and ticket required. Fee: \$50.

Credit: 1.25 CME / 1.50 CE

Moderators: Vesselin Dimov, MD

Melinda M. Rathkopf, MD FAAAAI

**GE Centricity**

A. Sean McKnight, MD FAAAAI

**Allscripts**

Melinda M. Rathkopf, MD FAAAAI

**Epic**

Vesselin Dimov, MD

**Meditab-IMS**

Dan Dalan, MD FAAAAI

**NextGen**

Robert Anolik, MD FAAAAI

**ModuleMD**

Ira Finegold, MD FAAAAI

**eClinical Works**

Hugh H. Windom, MD FAAAAI

**Rosch**

Nathaniel D. Hare, MD

**AmericanEHR Partners**

Russell B. Leftwich, MD FAAAAI

**Open Discussion Table**

Tao Le, MD MHS FAAAAI

**5:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the challenges allergists face in EMR selection; Discuss tips on EMR implementation specific for the allergist; Review specific EMRs with allergists currently using them in practice.

**Q & A Workshop****2812 Update from the U.S. Food and Drug Administration (FDA)**

4:45 to 6:00 pm

**Convention Center, S310CDGH, Level III**

Credit: 1.25 CME / 1.50 CE

Moderator: F. Estelle R. Simons, MD FAAAAI

**4:45 Year-in-Review at the FDA**

Badrul A. Chowdhury, MD PhD FAAAAI

**5:00 Food Allergen Labeling**

Stefano Lucciolli, MD FAAAAI

**5:15 Epinephrine and the Treatment of Anaphylaxis**

Susan Lee Limb, MD FAAAAI

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Recognize recent issues of scientific importance at FDA and their regulatory implications; Identify aspects of allergen labeling in food product labels; Explore the regulatory history of epinephrine for the treatment of anaphylaxis and identify approved epinephrine products.

**Q & A Workshop****2813 JCAAI: The Allergist and Healthcare in 2012: What Can YOU Do About It?**

4:45 to 6:00 pm

**Convention Center, S230AB, Level II**

Credit: 1.25 CME / 1.50 CE

Programmed by the AAAAI and JCAAI. Funded through an educational grant from Robert J. Becker, MD, Joint Council of Allergy, Asthma & Immunology Memorial Lectureship Fund.

Moderator: Richard W. Honsinger, MD MACP FAAAAI

**4:45 Health Care Reform and Your Practice**

Donald W. Aaronson, MD FAAAAI

**5:00 News You Can Use: Legal/ Coding Updates**

Gary N. Gross, MD FAAAAI

**5:15 Health Care is Local: Affecting Allergy Care in Your Neighborhood**

James L. Sublett, MD FAAAAI

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Adjust their practice formats to new practice forms suggested in the Affordable Care Act passed in 2010; Participate in activities which are required in order to receive federal incentive payments; Describe how to affect local healthcare delivery issues.

**Q & A Workshop**  **2814 Introductory Rhinologyngoscopy**

4:45 to 6:00 pm

**Convention Center, S319, Level III**

Pre-registration and ticket required. Fee: \$50.

Credit: 1.25 CME / 1.50 CE

Moderator: Jerald W. Koepke, MD FAAAAI

Upon completion of this session, participants should be able to: Describe the advantages of being skilled in rhinologyngoscopy; Perform rhinologyngoscopy; Identify normal and abnormal variations in the upper airway anatomy, as well as upper airway pathology only visible with a rhinoscope.



**Q & A Workshop** ▼

**2815 Chronic Rhinosinusitis in Children**

4:45 to 6:00 pm  
**Convention Center, S320CD, Level III**

Credit: 1.25 CME / 1.50 CE  
*Moderator: Martin Wagenmann, MD FAAAAI*

**4:45 Pathophysiology of Pediatric Rhinosinusitis**

*Daniel L. Hamilos, MD FAAAAI*

**5:00 Medical Workup and Management of Pediatric Rhinosinusitis**

*Melanie M. Makhija, MD*

**5:15 Surgical Management Options in Pediatric Rhinosinusitis**

*Fuad M. Baroody, MD FAAAAI*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the pathophysiology of chronic rhinosinusitis in pediatric patients; Describe medical treatment options; Review available surgical treatment modalities.

**Q & A Workshop**

**2816 Tolerance Beyond Regulatory T Cells**

4:45 to 6:00 pm  
**Convention Center, S230EF, Level II**

Credit: 1.25 CME / 1.50 CE  
*Moderator: Anne Marie Singh, MD*

**4:45 B Cells That Control T Cells**

*Thomas Tedder, MD*

**5:00 Natural Killer Cells That Don't Kill**

*Mübeccel Akdis, MD PhD*

**5:15 Myeloid-Derived Suppressor Cells**

*Dmitry I. Gabrilovich, MD PhD*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe how B cells can provide regulatory control; Discuss how NK cells are capable of performing regulatory functions; Demonstrate understanding of how myeloid derived suppressor cells function.

**Q & A Workshop**

**2817 The Greatness of Granulocytes**

4:45 to 6:00 pm  
**Convention Center, S330GH, Level III**

Credit: 1.25 CME / 1.50 CE  
*Moderator: Monica Vasudev, MD*

**4:45 Neutrophils in the Modulation of the Immune Response**

*Mitchell H. Grayson, MD FAAAAI*

**5:00 Basophils as Antigen Presenting Cells**

*John T. Schroeder, PhD*

**5:15 Eosinophils Driving the Immune Response**

*Peter F. Weller, MD FAAAAI*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe how neutrophils can drive a pro-atopic immune response; Describe how basophils can function as antigen presenting cells; Discuss how eosinophils are able to initiate and modulate an immune response.

**Clinical Research Workshop** ▲

**2821 Research Project Monitoring: Do You Have an Internal Monitoring Plan?**

4:45 to 6:00 pm  
**Peabody, Bayhill 22, Lobby Level**

Credit: 1.25 CME / 1.50 CE  
*Sarah K. Knorr, RN MPH CCRP*  
*Pamela H. Steele, MSN CPNP AE-C*

Upon completion of this session, participants should be able to: Discuss the regulatory issues concerning research project monitoring; Discuss the process of developing an internal monitoring plan; Demonstrate existing monitoring plans.

**Allied Health Workshop** ▲ ▼

**2822 Nursing Pro/Con: Clinical Considerations of Immune Replacement: IVIG vs. SCIG: Does One Therapy Fit All?**

4:45 to 6:00 pm  
**Peabody, Bayhill 19, Lobby Level**

Credit: 1.25 CME / 1.50 CE  
*Moderator: Sheelagh M. Stewart, MPH RN*  
*William R. Blouin, ARNP*  
*Carla M. Duff, CPNP MSN CCRP*

Upon completion of this session, participants should be able to: Describe the process to make appropriate selection of delivery method of immune replacement (risks, advantages, patient management).

**Allied Health Workshop** ▲

**2823 The Asthma Journey: Mapping Successful Travels**

4:45 to 6:00 pm  
**Peabody, Bayhill 17 & 18, Lobby Level**

Credit: 1.25 CME / 1.50 CE  
*Moderator: Jennifer Darr, MSW LCSW*  
*Melissa T. Korenblat-Hanin, ACSW LCSW*

Upon completion of this session, participants should be able to: Demonstrate the importance of utilizing a biopsychosocial methodology in the assessment and treatment of asthma; Discuss and explore strategies and techniques in successful asthma management; Identify patient centered approaches that maximize adherence and asthma control.

**Allied Health Workshop** ▲

**2824 Problem-Based Learning: Shifting Control: The Food Allergic Child Starts School**

4:45 to 6:00 pm  
**Peabody, Bayhill 20, Lobby Level**

Credit: 1.25 CME / 1.50 CE  
*Karen L. Gregory, DNP APRN-BC CNS RRT AE-C*  
*Dee Mallam, RN AE-C*

Upon completion of this session, participants should be able to: Recognize issues and concerns of a parent/guardian of a food-allergic child; Review evidence-based information regarding exposure of offending food allergens; Discuss school management of food allergies, including current state and federal laws.

**Allied Health Workshop** 

**2825 Using Desktop Publishing to Create Patient Education Material for Children and Adults**

4:45 to 6:00 pm

**Peabody, Bayhill 21, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Moderator: Maureen George, PhD RN AE-C*

*Concettina Tolomeo, DNP APRN FNP-BC AE-C*

Upon completion of this session, participants should be able to: Describe Microsoft Publisher; Implement suitable formatting of patient education materials; Use adult learning principles in the implementation of key components of patient education materials; Identify AAAAI resources for patient education.

**New Allergist/Immunologist Assembly Business Meeting**

4:45 to 6:15 pm

**Peabody, Peabody Grand Ballroom Q, Convention Level**

All new allergy/immunology specialists are invited to attend this business meeting and reception.

**Chrysalis Reception**

6:00 to 7:00 pm

**Peabody, Bayhill 25 & 26, Lobby Level**

Chrysalis participants are encouraged to attend this closing reception along with their FIT mentors.

**Allergy, Asthma & Immunology Education and Research Trust Event "The Big Splash"**  

7:00 to 10:00 pm

**Peabody, Terrace Pool, Recreation Level**

All AAAAI members, delegates and guests are invited to attend this Saturday evening event. The Big Splash for ARTrust™ will take place at the Peabody Terrace Poolside. Admission by ticket only. See page 12 for more details.

**New!** **THE EDITOR OF THE AAAAI'S NEW JOURNAL**

**MEET**

**Dr. Michael Schatz in the Member Resource Center**  
*Saturday & Monday from 10:30 to 11:30 am*





**ANNUAL MEETING**



**AAAAAI**

**2013**

**SAN ANTONIO FEBRUARY 22-26**

**American Academy of Allergy, Asthma & Immunology**

## Seminars



7:00 to 8:00 am

Pre-registration and ticket required. Fee: \$40. Continental breakfast included. Sessions and meals limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**3001 Induced Sputum Cell Counts in Practice and Research***Stephen C. Lazarus, MD**Parameswaran K. Nair, MD***Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Discuss how to establish a reliable clinical or research service; Describe when measurements are needed; Explain how cell counts help in practice and research.

**3002 Chest Pain and Death in Sports***Jack M. Becker, MD**William Silvers, MD FAAAAI***Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Identify the worrisome signs and symptoms indicating cardiac disease; Review what is known about asthma death and the athlete and what if anything can be done to effect a change; Describe what is benign chest pain and how to make the diagnosis.

**3003 Recurrent Infections in Pediatrics: Allergies or Immunodeficiency?***Jason W. Caldwell, DO**Laurence E. Cheng, MD PhD***Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Describe the factors that increase the risk of recurrent infections; Describe the workup of patients to determine if a clinically significant immune defect is present; Explain the "red flags" for rare vs. common presentations of routine infectious presentations to the allergy office.

**3004 Understanding Autoimmunity in Immunodeficiencies***Troy R. Torgerson, MD PhD**Jolan E. Walter, MD PhD***Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Review immunodeficiencies with high incidence of autoimmunity and presence of autoantibodies; Describe the clinical implications of autoantibodies in primary immunodeficiencies; Identify the mechanistic underpinnings of autoantibody generation in primary immunodeficiency.

**3005 Fungal Diseases of the Lower Airway: Report from the Task Force***Paul A. Greenberger, MD FAAAAI**Alan P. Knutsen, MD FAAAAI***Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Identify the characteristics and distinctions between different fungal pulmonary diseases; Describe and implement appropriate diagnostic approaches to fungal lung disease; Discuss environmental and pharmacologic therapeutic approaches.

**3006 The Impact of Environmental Factors on the Progression of Atopic Diseases***David Elkayam, MD**Wanda Phipatanakul, MD MS FAAAAI***Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Describe evidence of the benefit of implementing prevention strategies that are effective in reducing atopy; Identify environmental allergens/host factors/endotoxin that may increase risk for the development of atopy; Develop strategies for implementation of prevention strategies with at-risk populations.

**3007 Food Challenges in the Office Setting***S. Allan Bock, MD FAAAAI**Justin M. Skripak, MD***Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Determine which subjects are suitable for office food challenges; List which foods are most likely to be safely challenged in an office and how to choose them; Describe which challenge procedures are most useful including, baked egg and milk challenges.

**3008 Physical Urticaria and Idiopathic Urticaria: Clinical Perspectives***Laura Gober, MD**David Weldon, MD FAAAAI***Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Discuss the differential diagnosis for physical urticaria and idiopathic urticaria; Explain the diagnostic approaches; Review the treatment options.

**3009 Anaphylaxis to Ingested Environmental Allergens***Morna J. Dorsey, MD MMSc FAAAAI**Mario Sanchez-Borges, MD FAAAAI***Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Explain the role of oral consumption of environmental allergens in select presentations of anaphylaxis; Appreciate which allergens are most likely to be causative in proven cases; Discuss which approaches are appropriate for diagnosis and management.

**3010 Electronic Medical Records: What an Allergist Needs***David L. Patterson, MD FAAAAI**David J. Shulan, MD FAAAAI***Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: Discuss what an allergist/immunologist should look for in an EMR; Discuss development of an RFP for the allergist/immunologist; Demonstrate use of A/I templates.

**3011 Improved Patient Care Through Lawsuit Protection and Prevention***James L. Sublett, MD FAAAAI**James M. Tracy, DO FAAAAI***Peabody, Celebration 11, Convention Level**

Upon completion of this session, participants should be able to: Describe how to maintain focus on improved patient care rather than lawsuit defense; Discuss structuring practice for lawsuit protection and prevention; Examine how to reduce liability insurance costs.

**3012 New Insights on Local and Systemic Mechanisms of Allergen and Peptide Immunotherapy***Mark Larche, PhD**Mohamed Shamji, BSc MSc PhD***Peabody, Celebration 12, Convention Level**

Upon completion of this session, participants should be able to: Review local mechanisms of allergen and peptide immunotherapy based on the current literature; Discuss why peptide immunotherapy might have different mechanisms; Describe new techniques to measure these mechanisms.

**3013 Topical Therapy for Chronic Rhinosinusitis***Daniel L. Hamilos, MD FAAAAI**Anju Peters, MD FAAAAI***Peabody, Celebration 13, Convention Level**

Upon completion of this session, participants should be able to: Describe the use of nasal saline rinses and alternative sinus delivery devices; Explain the role of topical antibiotics, antifungals and steroids in treatment of rhinosinusitis using an evidence-based approach; Appreciate the variables of volume and frequency as they relate to outcome.



**3014 Use of Cultured Mast Cells and Mast Cell Lines in the Study of Allergic Inflammation**

Larry Borish, MD FAAAAI  
David F. LaRosa, MD

**Peabody, Celebration 14, Convention Level**

Upon completion of this session, participants should be able to: Identify current, optimal culture methods for human CD34+ - derived mast cells; Describe LAD2, LUVA and related functional human mast cell lines and the MTA or licensing processes for obtaining cells; Describe how mast cell lines and cultured mast cells can aid the study of allergic disease.

**3015 Vitamin D in Allergic and Immune Disorders**

Audreesh Banerjee, MD  
Marianne Frieri, MD PhD FAAAAI

**Peabody, Celebration 15, Convention Level**

Upon completion of this session, participants should be able to: Discuss the results of the NHANES survey related to Vitamin D; Explain the role of Vitamin D on various allergic and immune conditions, the science of the immune response, findings in asthmatic children and steroid resistance; Discuss the importance of both the clinical and basic science of Vitamin D.

**Allied Health Workshop**

**3021 Up in the Air: What You and Your Patients Need to Know about Outdoor Air Quality**

6:45 to 8:00 am

**Peabody, Bayhill 17 & 18, Lobby Level**

Credit: 1.25 CME / 1.50 CE

Moderator: Maureen George, PhD RN AE-C

Wade G. Hill, PhD APRN

Kim Knowlton, PhD

Upon completion of this session, participants should be able to: Contrast differences between ozone and particle pollution; Teach patients how to interpret air quality alerts in urban and rural areas; Identify critical components of asthma self management in response to the air quality index.

**Allied Health Advanced Workshop**

**3022 What You Need to Know about Adverse Drug Reactions**

6:45 to 8:00 am

**Peabody, Bayhill 19, Lobby Level**

Credit: 1.25 CME / 1.50 CE

Moderator: Kristin E. Kloos Olson, RN

Antonina G. Evans, BSPHarm AE-C

Miguel A. Park, MD

Upon completion of this session, participants should be able to: Discuss the key components of the drug allergy history; Identify the diagnostic tests and work-up for drug allergies; Discuss the treatment options for drug allergies.

**Allied Health Seminars**

7:00 to 8:00 am

Pre-registration and ticket required. Fee: \$10.

Credit: 1.00 CME / 1.20 CE

**3041 Practical Nutrition Advice for Patients and Families with Multiple Food Allergies**

G. Lynn Christie, MS RD  
Wendy Elverson, RD LDN

**Peabody, Bayhill 20, Lobby Level**

Upon completion of this session, participants should be able to: Discuss common nutrition issues in patients with food allergies; Discuss common substitutions for food allergens; Discuss practical tips for patients with food allergies.

**3042 The Components of Control: Environment, Medication and Immunotherapy: Pros and Cons**

Karen S. Rance, DNP RN CPNP AE-C  
Deidra Henley Sanders, NP

**Peabody, Bayhill 21, Lobby Level**

Upon completion of this session, participants should be able to: Examine the relationship of controlling environmental triggers, medication use and immunotherapy to modify or improve allergy and asthma symptoms; Describe both generic and specific measures to control allergic triggers in the home or work environment to reduce allergenic exposure; Discuss types of environmental assessments to include those done by the patient and/or a professional service.

**3043 Where Food Allergy Stops and Eosinophilic Esophagitis Begins**

Patricia J. Markus, BSN RN AE-C  
Catherine R. Weiler, MD PhD FAAAAI

**Peabody, Bayhill 22, Lobby Level**

Upon completion of this session, participants should be able to: Diagnose eosinophilic esophagitis; Discuss foods commonly associated with EoE; List common treatments.

**3044 Case Studies in Recurrent Infections**

Marcia Rose Winston, MSN CPNP AE-C  
M. Elizabeth M. Younger, CRNP PhD

**Peabody, Bayhill 23 & 24, Lobby Level**

Upon completion of this session, participants should be able to: Recognize the varied presentations of recurrent infections that indicate when patients should be evaluated for Primary Immune Deficiency (PID).

**Plenary**

**3101 Environmental Impacts on Asthma**

8:15 to 9:45 am

**Convention Center, South Hall A1, Level I**

Credit: 1.50 CME / 1.80 CE

Moderator: Jonathan A. Bernstein, MD FAAAAI

**8:15 Sensitizations of Chemical Allergens: From the Skin to the Airway**

Rebecca J. Dearman, PhD

**8:15 Occupational Asthma: Lessons Learned from Seafood Workers**

Andre Cartier, MD FAAAAI

**8:15 How Pollutants Affect Wheezing and Childhood Asthma**

David I. Bernstein, MD FAAAAI

Upon completion of this session, participants should be able to: Discuss how mechanisms that promote skin sensitization could apply to airway responses to chemical allergens; List steps in the clinical evaluation of occupational asthma, using the seafood industry experience as a model; Describe how airborne pollutants affect lung development and asthma disease activity in children.

## Posters

7:00 am to 5:30 pm

**Convention Center, South Hall A2, Level I**

Posters on display from 7:00 am to 5:30 pm. Authors present from 9:45 to 10:45 am.

Credit: No CME / No CE

Refer to pages 75-128 for abstracts and authors.

- 3201 Asthma Therapeutics and Management**
- 3202 Immunogenetics and Immunophenotyping**
- 3203 Immune Deficiency**
- 3204 Novel Allergens and Extracts: New Ways to Measure Sensitization**
- 3205 Measuring Allergen Exposures**
- 3206 EGID/Immunologic GI Disorders**
- 3207 Drug Allergy**
- 3208 Atopic Disease**
- 3209 Mechanisms of Allergic Rhinitis**
- 3210 Mechanisms of Immunotherapy**
- 3211 Eosinophils**
- 3212 Mast Cells, Basophils and IgE**

## Symposium ▼

### 3301 New Approaches to Asthma Diagnosis and Treatment

10:45 am to 12:00 pm

**Convention Center, S310CDGH, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Monica Kraft, MD*

#### 10:45 Update on Asthma Phenotypes

*Sally E. Wenzel, MD FAAAAI*

#### 11:05 What is an Asthma Endotype?

*Paul A. Greenberger, MD FAAAAI*

#### 11:25 Personalized Asthma Treatment

*Parameswaran K. Nair, MD*

#### 11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the difference between severe refractory asthma and difficult asthma; Explain why personalized treatment is important and how it is optimized; Evaluate which biologics show promise for improvement in treatment.

## Symposium ▼

### 3302 Demystifying Aspirin-Exacerbated Respiratory Disease

10:45 am to 12:00 pm

**Convention Center, S320CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Mariana C. Castells, MD PhD FAAAAI*

#### 10:45 Understanding Mediators in Aspirin Reactions: The Role of COX1-COX2

*Joshua A. Boyce, MD FAAAAI*

#### 11:05 Evidence for Platelets as Effectors in Human Asthma

*Tanya M. Laidlaw, MD*

#### 11:25 Aspirin Reactions and Desensitizations: Safety and Outcomes

*Katherine M. Woessner, MD FAAAAI*

#### 11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe the role of mediators in aspirin reactions; Explain the role of platelets as effector cells in asthma; Discuss the role of aspirin desensitization in patients with AERD.

## Symposium ▼

### 3303 Innate Effectors of Allergic Responses

10:45 am to 12:00 pm

**Convention Center, S330EF, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Larry Borish, MD FAAAAI*

#### 10:45 Epithelial Cell-Dendritic Cell Interactions in the Airway Mucosa

*Hirohito Kita, MD*

#### 11:05 Innate Effector Mechanisms in Food Allergy

*Paul J. Bryce, PhD*

#### 11:25 Nuocytes and the Expanding World of Innate Lymphoid Cells

*Andrew McKenzie, PhD*

#### 11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe the role of the epithelium in conditioning adaptive immune responses and its potential as a target for therapeutics in asthma; Explain the role of epithelial cell-derived cytokines; Define the newly described family of innate lymphoid cells and their relevance to allergic pulmonary inflammation.

## Symposium ▼

### 3304 Bacteria and Viruses: Fighting Dirty

10:45 am to 12:00 pm

**Convention Center, S330AB, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Nikolaos G. Papadopoulos, MD FAAAAI*

#### 10:45 Bacteria and Microbiome in Early Life and Asthma

*Hans Bisgaard, MD*

#### 11:05 Clinical Evidence for Defective Responses to Infection among Asthmatic Individuals

*Tina V. Hartert, MD MPH*

#### 11:25 Viral Suppression of Antibacterial Immune Response

*Jay K. Kolls, MD*

#### 11:45 Question & Answer

Upon completion of this session, participants should be able to: Discuss the evidence for deficient innate and acquired immunity which may account for impaired responses to respiratory pathogens; Describe the clinical evidence for susceptibility to the pathogenic effects of respiratory tract infections among asthmatic individuals; Describe mechanisms for viral modulation of IL-17 responses.

## Symposium ▼

### 3305 Epithelial Breakdown and Susceptibility to Disease: Immunological Insights

10:45 am to 12:00 pm

**Convention Center, S320AB, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: John W. Steinke, PhD FAAAAI*

#### 10:45 Breakdown of Skin Epithelium and Development of Atopic Dermatitis

*Michael D. Howell, PhD*

#### 11:05 Apoptosis of Lung Epithelium and Induction of Inflammation

*Kodi S. Ravichandran, MD*

#### 11:25 Airway Epithelium and Induction of the Innate and Adaptive Immune Response

*Atsushi Kato, PhD*

#### 11:45 Question & Answer

Upon completion of this session, participants should be able to: Describe how breakdowns in the epithelial layer can lead to disease and inflammation; Explain how apoptosis can fuel inflammatory responses; Identify specific features of the sinus epithelium relevant to inducing innate immunity.



**Symposium** ▼

**3306 Molecular Diagnosis: Potential Tools for the Practicing Allergist**

10:45 am to 12:00 pm  
**Convention Center, S330CD, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Jörg Kleine-Tebbe, MD FAAAAI*

**10:45 Multiplex and Singleplex Systems: Improving Diagnosis of Cross-Reactivity for Inhalant Allergens**

*Ronald Van Ree, PhD FAAAAI*

**11:05 Food Allergy Protein Families: Skin Testing and IgE Molecular Diagnosis to Predict Risk**

*Montserrat Fernández-Rivas, MD PhD*

**11:25 Allergenic Molecules in Hymenoptera Venom Hypersensitivity: Improved Differentiation and Higher Analytical Sensitivity**

*Markus W. Ollert, MD*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Recognize new findings regarding allergenic molecules and how they will affect our interpretation of diagnostic workup, cross-reactivity and multisensitizations to inhalants; Describe which protein families harbor the most important allergens, the diagnostic value of food components and how they will lead to improved diagnostic answers and advice to the patient; Identify how components from bee and wasp venom will facilitate definitive answers in case of presumed double sensitizations and enhance analytical sensitivity.

**Symposium** ▼

**3307 World Allergy Forum: Food Allergy: Pathogenesis and Prevention**



10:45 am to 12:00 pm  
*Programmed by the AAAAI and WAO. Funded through an educational grant from Novartis.*

**Convention Center, S310ABFE, Level III**

Credit: 1.25 CME / 1.50 CE  
*Moderators: Dennis K. Ledford, MD FAAAAI  
 Ruby U. Pawankar, MD PhD FAAAAI*

**10:45 Prenatal Events and Development of Food Allergies**

*Susan L. Prescott, MD PhD*

**11:05 Early Dietary Exposures and Feeding Practices**

*Scott H. Sicherer, MD FAAAAI*

**11:25 Food Allergy and Atopic Eczema**

*Gideon Lack, MD*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe the genetic and environmental events which predispose individuals to food allergy; Identify the possible dietary and environmental interventions to prevent food sensitization; Recognize when food allergy is implicated in a patient with atopic eczema.

**Allied Health Symposium** ▲

**3311 Asthma and Obesity: Should We Do More?**

10:45 am to 12:00 pm  
**Peabody, Bayhill 17 & 18, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Maureen George, PhD RN AE-C*

**10:45 Is There a Link Between Asthma and Obesity?**

*Peyton A. Eggleston, MD FAAAAI*

**11:15 Manage Across the Ages: Is the Focus That Different?**

*Christine W. Wagner, CPNP CFNP AE-C*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe the impact of obesity on asthma management; Identify effects of obesity on commonly prescribed asthma medications; Develop an educational intervention for the obese asthma patient.

**Allied Health Symposium** ▲

**3312 IVIG and Other Options**

10:45 am to 12:00 pm  
**Peabody, Bayhill 21, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: M. Elizabeth M. Younger, CRNP PhD*

**10:45 When to Use IVIG**

*Mark Ballou, MD FAAAAI*

**11:05 Practical Aspects of SubQ vs. IVIG**

*M. Elizabeth M. Younger, CRNP PhD*

**11:25 Non-Standard Uses of IVIG**

*Stephen J. McGeady, MD FAAAAI*

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss when to use IVIG; Explain the practical differences between SubQ and IVIG; Identify the non-standard uses of IVIG.

**Allied Health Workshop** ▲ ▼

**3313 Practical Behavioral and Management Tips for Atopic Dermatitis: Case Studies from the Trenches**

10:45 am to 12:00 pm  
**Peabody, Bayhill 19, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Lynda C. Schneider, MD FAAAAI  
 Jennifer S. LeBovidge, PhD  
 Karol G. Timmons, RN MS CPNP*

Upon completion of this session, participants should be able to: Describe management and treatment of recalcitrant atopic dermatitis; Describe tips for patient education for atopic dermatitis; Discuss behavioral management for atopic dermatitis.

**Allied Health Workshop** ▲ ▼

**3314 The ABCs of Vitamin D and Asthma**

10:45 am to 12:00 pm  
**Peabody, Bayhill 20, Lobby Level**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Karen S. Rance, DNP RN CPNP AE-C  
 Nicolette De Jong, PhD  
 Karen L. Gregory, DNP APRN-BC CNS RRT AE-C  
 Karen S. Rance, DNP RN CPNP AE-C*

Upon completion of this session, participants should be able to: Describe the link between Vitamin D deficiency and asthma; Describe when and how to screen patients for Vitamin D deficiency; Educate Vitamin D deficient patients to best improve their asthma outcomes.

**Allied Health Advanced Workshop** **3315 Smoking Cessation Pearls for the Clinician**

10:45 am to 12:00 pm

**Peabody, Bayhill 22, Lobby Level**

Credit: 1.25 CME / 1.50 CE

*Beth A. Allison, NP**Michael S. Tankersley, MD FAAAAI*

Upon completion of this session, participants should be able to: Describe how to educate patients about the process of quitting smoking, including patients who are resistant to quit; Discuss evidence based use of smoking cessation medications; Describe nicotine dependence and nicotine withdrawal.

**Seminars**  

12:30 to 1:30 pm

Pre-registration and ticket required. Fee: \$40. Box lunch included.

Sessions and meals limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**3501 Mechanisms of Corticosteroid Insensitivity in Asthma***Elena Goleva, PhD**Pia J. Hauk, MD***Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Explain glucocorticoid receptor function on the cellular level; Describe basic mechanisms that result in corticosteroid insensitivity in asthma; Explore alternative therapies in steroid insensitive patients.

**3502 Pulmonary Function Testing in Infants***Howard Eigen, MD**Robert S. Tepper, MD***Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Identify different pulmonary function techniques for use with infants; Discuss the reliability and predictive value of infant pulmonary function testing; Review which infants need pulmonary function testing.

**3503 Elevated IgE and Infections: Is it a Primary Immunodeficiency?***Alexandro Freeman, MD**Bodo Grimbacher, MD***Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Identify diagnostic elements of primary immunodeficiencies with elevated IgE; Review the Hyper IgE syndromes; Appreciate the “red-flags” that suggest IgE is resulting from an inherent immunological defect and not atopy.

**3504 What's New in Testing for Primary Immunodeficiency Disorders?***Roshini S. Abraham, PhD FAAAAI**Harry R. Hill, MD***Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Review the laboratory tests used to work up patients with recurrent infection, including a description of the assays; Describe the clinical value of these tests and interpretation of the results; Appreciate how newer technologies are being applied to diagnostic laboratories for primary immunodeficiency.

**3505 Universal Newborn Screening for T Cell Deficiencies: Achievements and Surprising Findings***Lisa J. Kobrynski, MD MPH FAAAAI**Jennifer M. Puck, MD***Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Outline the rationale for universal newborn screening for SCID; Review contrasting findings in different states; Appreciate the technology used to screen for SCID.

**3506 Problem-Based Learning: How to Inform Your Patients about Home Indoor Air Quality (Healthy Homes)***Kevin Kennedy, MD CEIS**Jay M. Portnoy, MD FAAAAI***Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Discuss the house as a system; Describe air quality and house systems; Outline methods to keep a home dry and properly ventilated.

**3507 Let's Take the Myth-stery Out of Mold***James J. Anderson, MLT**Peter J. Pityn, PhD***Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Provide evidence that the risk of mold is often overstated; Learn the proven risk presented by mold; Explore challenges of workplace mold investigations.

**3508 Hereditary Angioedema: Home Therapy***Marc A. Riedl, MD**Lanny J. Rosenwasser, MD FAAAAI***Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Explain the need for starting treatment early in treating HAE attacks; Discuss the practical concerns and hurdles for in-home therapy; Review the clinical experience and guidelines.

**3509 Difficult Cases in Anaphylaxis: Biphasic and Protracted Anaphylaxis***Terri F. Brown-Whitehorn, MD**Frank J. Twarog, MD PhD FAAAAI***Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Describe cases of multiphasic and protracted anaphylaxis; Review risk factors related to protracted reactions; Discuss proper treatment and current recommendations for patients with biphasic anaphylaxis.

**3510 The Adolescent Patient and Asthma***Andrea J. Apter, MD MA MSc FAAAAI**David R. Naimi, DO***Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: Identify the barriers to self-management in adolescents with asthma; Describe adolescent development and how beliefs and attitudes may impact asthma self-management; Describe ways to effectively communicate to the adolescent patient with asthma, including technology.

**3511 Electronic Health Records: Selection and Implementation***Dan Dalan, MD FAAAAI**David L. Patterson, MD FAAAAI***Peabody, Celebration 11, Convention Level**

Upon completion of this session, participants should be able to: Discuss how to select an EHR; Discuss implementation of an EHR; List the key variables in an EHR that need to be matched to a practice.

**3512 Immunotherapy Niche Uses***Jonathan A. Bernstein, MD FAAAAI**Brian P. Vickery, MD***Peabody, Celebration 12, Convention Level**

Upon completion of this session, participants should be able to: Discuss niche uses for IT including atopic dermatitis and food sublingual immunotherapy; Discuss the reimbursement environment as it applies to alternative uses of IT; Appreciate variables in IT preparation as they apply to alternative uses.



**3513 The Child with Chronic Cough**

*Alan B. Goldsobel, MD FAAAAI*  
*Jason E. Knuffman, MD*

**Peabody, Celebration 13, Convention Level**

Upon completion of this session, participants should be able to: Review the diagnosis and treatment of chronic cough in children; Identify the differential diagnosis of chronic cough; Discuss treatment strategies in patients with chronic cough.

**3514 Office-Based Assessment of Patients with Suspected Monoclonal Mast Cell Disorders**

*Melody C. Carter, MD*  
*Arnold Kirshenbaum, MD FAAAAI*

**Peabody, Celebration 14, Convention Level**

Upon completion of this session, participants should be able to: Discuss clonal and non-clonal mast cell activation disorders; Describe recommendations for conducting office based evaluation and when to refer for bone marrow biopsy; Examine the impact of these disorders and associated symptoms with the upcoming new ICD-10-CM system.

**3515 Management of Children and Adult Patients with Atopic Dermatitis**

*Mark Boguniewicz, MD FAAAAI*  
*Dagmar Simon, MD*

**Peabody, Celebration 15, Convention Level**

Upon completion of this session, participants should be able to: Describe the presentation, pathophysiology and complications of atopic dermatitis; Discuss the management of these patients, including their education; Discuss possible therapeutic consequences due to new insights into the pathogenesis of atopic dermatitis.

**Allied Health Oral Abstract Session**



**3520 Oral Abstract Luncheon**

12:15 to 1:30 pm

**Peabody, Bayhill 25 & 26, Lobby Level**

Pre-registration and ticket required. Fee: \$40. Box lunch included.

Registration open to allied health professionals only.

Credit: 1.25 CME / 1.50 CE

Upon completion of this session, participants should be able to: Discuss the diversity in care provided to the allergy and immunology patient population.

**Pro/Con Debate**

**3521 Peanut Oral Immunotherapy is Ready for Use in Clinical Practice**

12:30 to 1:30 pm

**Convention Center, S310ABFE, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: S. Allan Bock, MD FAAAAI*

**Pro**

*Richard L. Wasserman, MD FAAAAI*

**Con**

*Hugh A. Sampson, MD FAAAAI*

Upon completion of this session, participants should be able to: Outline the evidence base for oral immunotherapy with peanut; Describe the risks and benefits of OIT; Describe the current recommendations for and against clinical use of peanut OIT.

**Pro/Con Debate**

**3522 Rhinovirus is More Important than RSV in Asthma Inception**

12:30 to 1:30 pm

**Convention Center, S320AB, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Giovanni Piedimonte, MD*

**Pro**

*Robert F. Lemanske Jr., MD FAAAAI*

**Con**

*Tina V. Hartert, MD MPH*

Upon completion of this session, participants should be able to: Discuss the role of early life viral wheezing illnesses in the development of asthma; Evaluate the evidence for a causative role for RSV wheezing illnesses in the development of asthma; Evaluate the evidence for a causative role for rhinovirus wheezing illnesses in the development of asthma.

**Pro/Con Debate**

**3523 The Atopy Patch Test is a Clinically Useful Tool for Diagnostic Workup of Atopic Dermatitis**

12:30 to 1:30 pm

**Convention Center, S320CD, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Lisa A. Beck, MD FAAAAI*

**Pro**

*Andreas Wollenberg, MD FAAAAI*

**Con**

*Luz S. Fonacier, MD FAAAAI*

Upon completion of this session, participants should be able to: Describe the immunobiology of the Atopy Patch Test; Discuss the advantages and limitations of the Atopy Patch Test; Explain the key requirements for performing an Atopy Patch Test in a clinical setting.

**Pro/Con Debate**

**3524 Functional Endoscopic Sinus Surgery Offers Advantage Over Medical Management of Chronic Rhinosinusitis**

12:30 to 1:30 pm

**Convention Center, S330AB, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Daniel L. Hamilos, MD FAAAAI*

**Pro**

*Robert C. Kern, MD*

**Con**

*Raymond G. Slavin, MD MS FAAAAI*

Upon completion of this session, participants should be able to: Identify clinical scenarios in which medical treatment of CRS is preferred; Define clinical scenarios in which surgical treatment of CRS is preferred.

**Symposium** ▼**3525 Future Funding of Graduate Medical Education in Allergy/Immunology**

12:30 to 1:30 pm

**Convention Center, S330CD, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Lawrence B. Schwartz, MD PhD FAAAAI**Atul Grover, MD PhD*

Upon completion of this session, participants should be able to: Discuss how AAAAI can influence support for graduate medical education; Discuss how federal funding for graduate medical education occurs; Identify the advocates in Washington, DC for GME.

**Symposium** ▼**3526 FDA's Review of the Efficacy and Safety of Non-Standardized Allergen Extracts**

12:30 to 1:30 pm

**Convention Center, S310CDGH, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Jay E. Slater, MD***12:30 FDA's Efficacy Review of Non-Standardized Allergen Extracts***Ronald L. Rabin, MD FAAAAI***12:55 Efficacy and Safety of Non-Standardized Allergen Extracts Used in the U.S.***Jay E. Slater, MD***1:15 Question & Answer**

Upon completion of this session, participants should be able to: Explain the evidence for the safety and efficacy of U.S. licensed nonstandardized allergen extracts; Discuss the process by which FDA has been evaluating these products; Identify the implications of the FDA assessments for the use of nonstandardized extracts in allergy practice.

**Symposium** ▼**3527 The Regional Advocacy Discussion and Response Initiative (RADAR): Training the Practicing Allergist**

12:30 to 1:30 pm

**Convention Center, S330EF, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Sharon B. Markovics, MD FAAAAI***12:30 RADAR Initiative: Description and Goals***James M. Tracy, DO FAAAAI***12:50 RADAR Mechanics Overview***J. Allen Meadows, MD***1:10 JCAAI Integration***James L. Sublett, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss and apply advocacy techniques; Identify resources available for plan implementation; Develop a repository of information that would be nationally available; Establish bi-directional communication skills with both professional and advocacy organizations.

**Symposium****3528 Developmental Origins of Asthma in the First 1,000 Days of Life: How and When Should Primary Prevention of Asthma Begin?**

12:30 to 1:30 pm

**Convention Center, S330GH, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderators: David P. Huston, MD FAAAAI**William J. Martin II, MD***12:30 Allergen Sensitization: A Target for Asthma Intervention in the First 1,000 Days***James E. Gern, MD FAAAAI***1:00 Microbiome and Microbial Products: A Target for Asthma Intervention in the First 1,000 Days***Fernando D. Martinez, MD*

Upon completion of this session, participants should be able to: Examine the evidence for the role of allergens during the first 1,000 days of life on the development of asthma and the feasibility of designing an effective intervention; Examine the evidence for the role of microbiome during the first 1,000 days of life on the development of asthma and the feasibility of designing an effective intervention.

**Oral Abstract****3601 Asthma Therapeutics: What's Below the Surface?**

2:00 to 3:15 pm

**Convention Center, S330EF, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: David Broide***2:00 Body Mass and Corticosteroid Response in Childhood Asthma***Rolando A. Nunez, MD***2:15 Steroid Requirements and Immune Associations With Vitamin D Are Stronger In Children Than Adults With Asthma***Donald Y. M. Leung, MD PhD***2:30 Ganoderic Acid C Isolated From Ganoderma Lucidum Suppress Lps-induced Macrophage Tnf- $\alpha$  Production By Down-regulating Mapk, Nf-kappab And Ap-1 Signaling Pathways***Changda Liu, PhD***2:45 Methoxyphenols Exhibit Anti-inflammatory Effects on Airway Epithelial Cells by Acting Post-transcriptionally***Fouad Terrence Ishmael, MD PhD***3:00 Asthma Control And Disordered Microbial Communities In The Lower Airways Of Patients With Poorly Controlled Asthma***Elena Goleva, PhD*





**Oral Abstract**

- 3602 Immunophenotyping**  
2:00 to 3:15 pm  
**Convention Center, S230AB, Level II**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Francico J. Espinosa-Rosales, MD*
- 2:00 TH IL-17 Immunophenotyping Reference for Children**  
*Katherine A. Gonzaga, MD*
- 2:15 Ex Vivo Identification and Phenotyping of Allergen-Specific T Helper Cells In Human Peripheral Blood based on CD154 Expression**  
*Karen A. Smith, MSc*
- 2:30 Calculated Globulin (CG): A Viable Tool for the Identification of Patients with Potential Antibody Deficiency**  
*Stephen Jolles, MB ChB MRCP FRCPath*
- 2:45 TH2A Cells As a Unique TH2 Cell Subset in Allergic Individuals: Steps Toward a T Cell Biomarker For Allergy**  
*Erik R.G. Wambre, PhD*
- 3:00 A Central B Cell Tolerance Defect In Group Ia CVID Patients**  
*Neil Romberg, MD*

**Oral Abstract**

- 3603 Biological Dust Exposures and Atopic & Allergic Diseases**  
2:00 to 3:15 pm  
**Convention Center, S330GH, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderators: Neil Alexis, PhD  
Martin D. Chapman, PhD FAAAAI*
- 2:00 Enhanced Organic Dust Induced Airway Inflammation in Protein Kinase C Epsilon Deficient Mice is Associated with Dysregulation of Nitric Oxide**  
*Jill A. Poole, MD FAAAAI*
- 2:15 Cigarette Smoke Exposure and its Effect on Bronchial Responsiveness and Response to Fluticasone Propionate, Salmeterol and their Combination**  
*Kiran Sapkota, MS Pharm.*
- 2:30 The Prevalence of Asthma, Hay Fever and Allergic Sensitization in Amish Children**  
*Mark Holbreich, MD FAAAAI*
- 2:45 Influence of Rural and Urban Dietary and Lifestyle Patterns in Atopic Diseases in a Colombian African-descent Population**  
*Javier A. Marrugo, MD*
- 3:00 Vitamin E Reduces Airway Granulocyte Recruitment after Inhaled Endotoxin Challenge in Normal Volunteers**  
*Michelle L. Hernandez, MD*

**Oral Abstract**

- 3604 Anaphylaxis**  
2:00 to 3:15 pm  
**Convention Center, S230GH, Level II**  
Credit: 1.25 CME / 1.50 CE  
*Moderators: Paul J. Bryce, PhD  
Scott P. Commins, MD PhD*
- 2:00 Maternal Low Dose Peanut and Cholera Toxin Subunit B Induces Oral Tolerance Associated with An Increased Number of T Regulatory Cells**  
*Ying Song, MD*
- 2:15 SHIP-1 Is Critical in Regulation of Severe Anaphylaxis**  
*Sun Young Oh, PhD*
- 2:30 Development of a Dendrimeric Structure containing ole e 1 and CpG to Modulate an Allergic Response in an Experimental Model**  
*Ana B. Blazquez, PhD*
- 2:45 Isolation and Identification of Compounds in Rubia cordifolia L. (Qian Cao) that Inhibit Human B cell IgE production**  
*Vincent Chan*
- 3:00 Anaphylaxis in America - Results from a National Telephone Survey**  
*John Boyle, PhD*

**Oral Abstract**

- 3605 Management of Food Allergies**  
2:00 to 3:15 pm  
**Convention Center, S331AB, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Andrew G. Weinstein, MD FAAAAI*
- 2:00 Food Allergy and Increased Asthma Morbidity in a School Inner-city Asthma Study**  
*James Friedlander, MD*
- 2:15 Outcome Rather Than the Type of Diagnostic Intervention Predicts Improvement in Health-Related Quality of Life Score Among Children With Food Allergy Between 0-12 Years**  
*Linda Kirste, BSc RD*
- 2:30 Bullying and Teasing In Children With Food Allergy: A Survey of Pediatric Patients In Urban Jackson, Mississippi Outpatient Allergy and Immunology Clinics**  
*Annette E. Morris, MD*
- 2:45 Novel Use of a Social Network for Families with Food Allergic Children**  
*Tao Le, MD MHS FAAAAI*
- 3:00 Food Allergy Attitudes and Beliefs among School Nurses in an Urban Public School District**  
*Hermant P. Sharma, MD*

**Oral Abstract**

- 3606 Treatment of Allergic Rhinitis**  
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Sam Friedlander, MD
- 2:00 Comparing the Effect of Intranasal Fluticasone Furoate (FF) to Intracocular Olopatadine (OLO) on the Ocular Response to Nasal Allergen Challenge (NAC).**  
Marcy DeTineo, BSN
- 2:15 Long-term Safety Study of MP29-02 (Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in Subjects with Chronic Allergic or Non-allergic Rhinitis**  
William E. Berger
- 2:30 MP29-02 (Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in the Treatment of Ocular Symptoms of Seasonal Allergic Rhinitis (SAR)**  
Paul Ratner, MD
- 2:45 The Addition of Vitamin D (VitD) to an Intranasal Steroid (INS) Improves Control of Symptoms in Seasonal Allergic Rhinitis (SAR).**  
Fuad M. Baroody, MD FAAAAI
- 3:00 Ocular Safety of Fluticasone furoate Nasal Spray in Subjects with Perennial Allergic Rhinitis**  
S. D. Miller, MD

**Oral Abstract**

- 3607 Regulation of Allergic Inflammation**  
2:00 to 3:15 pm  
Convention Center, S230EF, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Joshua A. Boyce, MD FAAAAI
- 2:00 Allergen Specific IL-10 Producing T regulatory Cells Are Upregulated in Children Who Have Acquired Tolerance to Egg**  
Anna B. Fishbein, MD
- 2:15 IL-4, But Not IL-2, Induces Th2 Cells To Resist The IL-27 Counterregulation By Downregulating Stat1 Phosphorylation**  
Zhihong Chen, MD PhD
- 2:30 Increased Number of Regulatory T Cells in Skin Draining Lymph Nodes Suppress Priming Towards New Antigens**  
Subhashree Mahapatra, MSc
- 2:45 IgE Cross-Linking Downregulates Expression of Glycolytic Genes in Human Plasmacytoid Dendritic Cells**  
Gagan Bajwa, MSc
- 3:00 Increased Platelet Adherence to Leukocytes Results in Cysteinyl Leukotriene (cysLT) Overproduction in Aspirin Exacerbated Respiratory Disease (AERD)**  
Tanya M. Laidlaw, MD

**Interest Section Forum**

- 3701 ADT Interest Section Forum**  
3:30 to 5:30 pm  
Convention Center, S320CD, Level III  
Credit: 1.50 CME / 1.80 CE  
Moderator: John Oppenheimer, MD FAAAAI
- 3:30 Business Meeting**
- 3:45 Adherence**  
Cynthia S. Rand, PhD
- 4:10 Maintenance and Reliever**  
Paul M. O'Byrne, MD FAAAAI
- 4:35 Break**
- 4:50 Once Daily or As Needed Therapy**  
Stephen P. Peters, MD PhD FAAAAI
- 5:15 Question & Answer**  
Upon completion of this session, participants should be able to: Describe the impact of poor adherence on asthma care; Describe options for dynamic dosing (stepping up and down) in the care of asthmatic patients.

**Interest Section Forum ▼**

- 3702 BCI Interest Section Forum**  
3:30 to 5:30 pm  
Convention Center, S320AB, Level III  
Credit: 1.50 CME / 1.80 CE  
Moderator: Jordan Orange, MD PhD FAAAAI
- 3:30 Announcements and Recognitions**
- 3:40 Controlling Immune Responses from Within: Human Defects Identified Through a Passion for Lymphocyte Biology**  
Steven M. Holland, MD
- 4:25 Committee Acknowledgements and Committee Reports**
- 4:35 Genetics of the Most Common Antibody Deficiencies**  
Bodo Grimbacher, MD
- 5:20 AMPC Future Planning and Venues for New Business**  
Upon completion of this session, participants should be able to: Identify new human defects that were discovered due to a comprehensive knowledge of basic T Cell biology; Identify newer human immune defects that interfere with anti-viral defense; Compare the interplay between genetic influence and microbiome as reflected in immune deviation and host defense; Appreciate insights into microbiome interaction and immune output as derived from immune genetic disease.



**Interest Section Forum** ▼

**3703 EORD Interest Section Forum**

3:30 to 5:30 pm  
**Convention Center, S330CD, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Karin A. Pacheco, MD MSPH FAAAAI*

**3:30 Climate Change and Our Environment: The Impact on Allergic Diseases**

*Estelle Levetin, PhD FAAAAI*

**4:00 How Our Changing Ecosystem Affects Respiratory Disease and the Allergist**

*Gennaro D'Amato, MD FAAAAI*

**4:30 Question & Answer**

**4:45 Business Meeting**

Upon completion of this session, participants should be able to: Identify the influence of climate change on pollen and mold spore levels, distribution and allergenicity; Develop insights into the effects of changing aerobiology on upper and lower respiratory disease prevalence and severity; Address the global nature of our changing environment and how it affects our patients and our practice of medicine.

**Interest Section Forum** ▼

**3704 FADDA Interest Section Forum**

3:30 to 5:30 pm  
**Convention Center, S310ABFE, Level III**  
 Credit: 1.50 CME / 1.80 CE  
*Moderator: Mariana C. Castells, MD PhD FAAAAI*

**3:30 Angioedema**

*Bruce L. Zuraw, MD*

**4:00 FADDA Committee Reports**

**4:15 Stinging Insect Hypersensitivity**

*David B.K. Golden, MD FAAAAI*

**4:45 FADDA Awards and Updates**

*Mariana C. Castells, MD PhD FAAAAI*

**5:00 Food Allergy Guidelines**

*A. Wesley Burks, MD FAAAAI*

Upon completion of this session, participants should be able to: Describe the new 2011 practice parameters on angioedema and stinging insect hypersensitivity, as well as the new food allergy guidelines; Evaluate the indications and outcomes of the new drugs for HAE including kallikrein and bradykinin inhibitors and recognize the new presentations of HAE and their treatment; Evaluate the safety and outcomes for insect IT and potential new treatments, including anti-IgE as well as the new treatments for food allergy including anti-IgE and tolerization; Recognize the new criteria and indications for food immunotherapy and desensitizations, as well as the indications for insect immunotherapy.

**Interest Section Forum** ▼

**3705 HEDQ Interest Section Forum**

3:30 to 5:30 pm  
**Convention Center, S330EF, Level III**  
 Credit: 1.75 CME / 2.00 CE  
*Moderator: Andrew G. Weinstein, MD FAAAAI*

**3:30 Accountable Care Organizations: The Vision, Evolving Trends and Future Realities**

*Jonathan Niloff, MD*

**4:30 Business Meeting**

**4:50 Accountable Care and Chronic Disease Management: Allergy Case Study**

*Daniel G. Steinberg, MD FAAAAI*

**5:15 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the national trends driving ACO development; Describe the mechanics of how ACOs are being developed; Identify potential areas where ACO development impacts chronic disease management, allergy/asthma patients and the physicians who care for them.

**Interest Section Forum** ▼

**3706 IRSOC Interest Section Forum**

3:30 to 5:30 pm  
**Convention Center, S310CDGH, Level III**  
 Credit: 1.00 CME / 1.20 CE  
*Moderator: Fuad M. Baroody, MD FAAAAI*

**3:30 Rhinosinusitis and Ocular Allergy Committee Report**

*Sergio Bonini, MD*

**3:50 Phenotyping Chronic Rhinosinusitis**

*Claus Bachert, MD PhD*

**4:10 Genotyping Chronic Rhinosinusitis**

*Martin Desrosiers, MD*

**4:30 Tying it all Together and a Path for Future Discovery**

*Larry Borish, MD FAAAAI*

**4:50 Immunotherapy, Allergen Standardization and Allergy Diagnostics Committee Report**

*Désirée E.S. Larenas Linnemann, MD FAAAAI*

**5:10 Cough Committee Report**

*Arvind Madaan, MD FAAAAI*

Upon completion of this session, participants should be able to: Identify different inflammatory phenotypes of chronic rhinosinusitis; Describe the different approaches to genotyping chronic rhinosinusitis; Explain how these two approaches might influence potential therapy of the disease.

**Interest Section Forum** ▼**3707 MAAI Interest Section Forum**

3:30 to 5:30 pm

Convention Center, S330AB, Level III

Credit: 1.50 CME / 1.80 CE

Moderator: Susan M. MacDonald, MD FAAAAI

**3:30 Business Meeting****4:00 Role of Macrophages in the Regulation of Th2 Responses**

Thomas A. Wynn, PhD

**4:30 Dendritic Cell-Basophil Cooperation in the Th2 Response to Cysteine Proteases**

Bali Pulendran, PhD

**5:00 Effect of Anti-IgE Treatment on Dendritic Cell Response**

John T. Schroeder, PhD

Upon completion of this session, participants should be able to: Discuss the state-of-the-art as to whether basophils can act as antigen presenting cells and are more potent than dendritic cells; Describe the cooperation between dendritic cells and basophils; Discuss the contribution of IgE levels to antigen presentation by dendritic cells.

**Featured Poster Session and Reception**

5:30 to 7:30 pm

Convention Center, S210, Level II

All Annual Meeting delegates and their guests are invited to attend this event. No fee and no pre-registration required.

Credit: No CME / No CE

Featured Posters are the highest quality abstracts submitted for presentation at the Annual Meeting. These posters will be displayed throughout the meeting in the second floor lobby of the Convention Center. During the Featured Poster Session and Reception on Sunday evening, authors will be present with their posters to discuss their research. Take this opportunity to talk with these authors and network with other meeting delegates.

**3801 ADT Featured Poster Session****3802 BCI Featured Poster Session****3803 EORD Featured Poster Session****3804 FADDA Featured Poster Session****3805 HEDQ Featured Poster Session****3806 IRSOC Featured Poster Session****3807 MAAI Featured Poster Session****3811 Allied Health Featured Poster Session****Dinner Symposia****3901 Office Anaphylaxis: Risk Factors, Treatment and Guidelines**

7:30 to 9:30 pm

Peabody, Peabody Grand Ballroom PQ, Convention Level

Credit: 1.50 CME / 1.80 CE

Programmed by the AAAAI. Funded through an educational grant from Dey Pharma L.P.

Moderator: Vivian P. Hernandez-Trujillo, MD FAAAAI

**7:30 Dinner Served****8:00 Anaphylaxis After Immunotherapy**

David I. Bernstein, MD FAAAAI

**8:30 Anaphylaxis Treatment: Is Your Office Prepared?**

Richard A. Nicklas, MD FAAAAI

**9:00 Highlights of the Anaphylaxis Practice Parameter 2010 Update**

Phillip L. Lieberman, MD FAAAAI

Upon completion of this session, participants should be able to: Describe which patients are at risk of anaphylaxis within the office setting and recognize that a variety of presentations exist; List supplies that are needed to manage anaphylaxis in an office setting; Describe current evidence-based guidelines for the treatment of anaphylaxis (WAO guidelines/Practice Parameters)

**3902 New Insights into Asthma Therapy**

7:30 to 9:30 pm

Peabody, Peabody Grand Ballroom R, Convention Level

Credit: 1.50 CME / 1.80 CE

Programmed by the AAAAI. Funded through an educational grant from Teva Respiratory.

Moderator: Leslie Hendeles, PharmD

**7:30 Dinner Served****8:00 New and Current LABAs in the Management of Asthma**

Speaker to be announced


**8:30 Is it Really Important to Target the Small Airways in Asthma?**

Richard J. Martin, MD

**9:00 When Should Anticholinergics Be Prescribed for Asthma?**

William J. Calhoun, MD FAAAAI

Upon completion of this session, participants should be able to: Describe indications and potential risks for use of LABA in asthma; Discuss the evidence base for treatment of small airway inflammation in asthma; Describe indications for anticholinergics in treating acute and chronic symptoms of asthma.



**Seminars**



7:00 to 8:00 am  
Pre-registration and ticket required. Fee: \$40. Continental breakfast included. Sessions and meals limited to 30 people.  
Credit: 1.00 CME / 1.20 CE

**4001 Asthma and Smoking: From Physiology to Diagnosis and Therapy**

*James F. Donohue, MD*  
*Mark F. Sands, MD FAAAAI*

**Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Identify barriers and strategies in the diagnosis of asthma in smokers; Describe and compare anti-inflammatory and bronchodilator and cessation treatment for smokers; Describe additive, synergistic and deleterious effects of first- and second-hand smoke on lung function over time in asthmatics.

**4002 Biomarkers for Evaluating and Treating Asthma**

*Ian D. Pavord, MD*  
*Sally E. Wenzel, MD FAAAAI*

**Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Discuss the pros and cons of each measurement; Explain when biomarkers are useful; Describe how to interpret biomarkers.

**4003 What is New in Exercise-Induced Bronchial Constriction**

*Teal Hallstrand, MD MPH*  
*Christopher C. Randolph, MD FAAAAI*

**Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Explain the differences between EIB alone and chronic asthma with EIB; Discuss different techniques in evaluating the patient with symptoms with exercise; Discuss different external triggers (i.e. allergic rhinitis, GERD, stress) that may be contributing to the symptoms of EIB.

**4004 Approach to the Evaluation of Immunodeficiency in Adults**

*Zuhair K. Ballas, MD FAAAAI*  
*Joyce E. Yu, MD*

**Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Discuss the workup and management of adults with suspected immunodeficiency; Compare and contrast the differential diagnosis for hypogammaglobulinemia in adult patients; List key differences between the immunodeficiency diagnostic spectrum in adults vs. adolescents and children.

**4005 Update on the Immunology and Management of HIV Infections**

*Elizabeth A. Secord, MD FAAAAI*  
*William T. Shearer, MD PhD FAAAAI*

**Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Review the latest concepts on immunoreconstitution and anti-HIV immunity; Describe changes in the recommendation for the management of HIV therapy; Identify the changing epidemiology of HIV in 2012.

**4006 Pesticides, Herbicides and Other VOCs in Indoor Environments as Causes of Allergies and Asthma: What is Real?**

*John R. Cohn, MD FAAAAI*  
*Ronald A. Simon, MD FAAAAI*

**Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Develop improved understanding of the characteristics of unrelated chemicals that may be involved in inducing development of allergic disease and which may become increasingly important if predicted scenarios of climate change come to pass; Explain the role and mechanism of volatile organic compounds in causing allergic disease; Explain the epidemiologic evidence linking pesticides and herbicides with allergic disease, including asthma and their underlying mechanisms.

**4007 Evaluation of an Index Case of Work-Related Asthma**

*Leslie C. Grammer, MD FAAAAI*  
*Hae-Sim Park, MD FAAAAI*

**Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Identify the key steps in the investigation of work-related asthma to ensure better diagnosis and management of their patients; Discuss how to work with public authorities in evaluation; Appreciate how to protect the patient medically and legally during an evaluation.

**4008 Problem-Based Learning: A Child with Recurrent Anaphylaxis**

*Amal H. Assa'ad, MD FAAAAI*  
*Michelle B. Lierl, MD FAAAAI*

**Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Explain the causes of anaphylaxis in pediatric patients; Describe the diagnostic evaluation for this condition; Design a treatment plan for a child with anaphylactic food allergy.

**4009 Allergic Reactions to Vaccines**

*Amanda Cox, MD*  
*John M. Kelso, MD FAAAAI*

**Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Review allergies which present a risk of reaction to certain vaccines; Describe the current data on the safety of the influenza vaccination for egg-allergic individuals; Discuss approaches to testing or appropriate administration of vaccines where there is a concern about vaccine allergy.

**4010 Adherence Management for Adults with Asthma**

*Cynthia S. Rand, PhD*  
*Daniel A. Searing, MD*

**Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: Determine the many reasons why adult asthma patients do not follow asthma management recommendations; Discuss proven patient-centered communication strategies to promote patient adherence; Determine how to use technology to accurately diagnose and maintain patient adherence.

**4011 Getting Ready for ICD-10: Cracking the Code**

*Marshall P. Grodofsky, MD FAAAAI*  
*Stephen A. Imbeau, MD FAAAAI*

**Peabody, Celebration 11, Convention Level**

Upon completion of this session, participants should be able to: Discuss basics in coding, contrasting ICD-10 with ICD-9-CM; Describe the impact of ICD-10 on billing and coding; Identify strategies for implementing ICD-10 in clinical practice.

**4012 Are We Ready to Use Parasites to Treat Allergic Diseases?**

Luisa Karla P. Arruda, MD FAAAAI  
Philip J. Cooper, PhD

**Peabody, Celebration 12, Convention Level**

Upon completion of this session, participants should be able to: Evaluate critically the data available on treatment of allergic diseases with parasites; Describe the mechanisms by which parasites may down regulate allergic responses; Discuss parasite molecules with potential immunomodulatory effects.

**4013 Problem-Based Learning: Rhinitis and Aging**

Jayant M. Pinto, MD  
Raymond G. Slavin, MD MS FAAAAI

**Peabody, Celebration 13, Convention Level**

Upon completion of this session, participants should be able to: Review pathophysiology of the nose during the aging process; Identify treatment of rhinitis in the elderly; Distinguish the difference in rhinitis between adults and the elderly.

**4014 Surrogate Markers of Mast Cell Activation**

Joshua A. Boyce, MD FAAAAI  
Melody C. Carter, MD

**Peabody, Celebration 14, Convention Level**

Upon completion of this session, participants should be able to: Identify mast cell mediators and associated functions; Discuss utilization of mast cell markers as a diagnostic tool; Examine use of serum tryptase in clinical evaluation and as a management tool in children.

**4015 Pediatric Asthma: Mechanisms, Management by the New Guidelines and Early Intervention**

Ronina A. Covar, MD  
Lynn M. Taussig, MD

**Peabody, Celebration 15, Convention Level**

Upon completion of this session, participants should be able to: Discuss the latest information about predisposing risk factors including new genetic and epigenetic studies; Discuss the latest guidelines on diagnostic criteria (NAEPP); Relate the pros and cons for aggressive and early pharmacotherapeutic intervention in newly diagnosed asthmatics.

**Allied Health Course**

**4030 Practical Applications of Immune Replacement Therapy**

8:00 am to 3:00 pm

**Peabody, Bayhill 21 & 22, Lobby Level**

Pre-registration and ticket required. Fee: \$85. Box lunch included.

Credit: 6.75 CME / 8.10 CE

Moderator: Debra A. Sedlak, MSN CPNP

**8:15 Therapeutic Immunoglobulin: What It Is and How It Works**

Mark Ballow, MD FAAAAI

**9:00 The Good, the Bad and the Challenges of Immune Therapy**

Carla M. Duff, CPNP MSN CCRP

**9:45 Break**

**10:00 PIDD Indications of Immune Therapy**

Jordan Orange, MD PhD FAAAAI

**10:45 Non-PIDD Uses of Immune Therapy**

Stephen J. McGeedy, MD FAAAAI

**11:30 Quality of Life: Patient Care, Support and Education**

Margaret R. Dodds, RN MS CPNP

**12:15 Luncheon Discussion of Difficult Cases**

Margaret R. Dodds, RN MS CPNP  
Carla M. Duff, CPNP MSN CCRP  
Debbie Manning, RN  
Stephen J. McGeedy, MD FAAAAI  
Jordan Orange, MD PhD FAAAAI

**1:30 Infusion Pumps for Therapy**

William R. Blouin, ARNP  
Carla M. Duff, RN BSN CCRP

**2:15 Administration Devices for SCIG**

Margaret R. Dodds, RN MS CPNP  
Debra A. Sedlak, MSN CPNP

Upon completion of this session, participants should be able to: Describe the process of immune globulin production and differences in the types of available products; Apply methods for dosing and administration including potential adverse events and the management of these events; Discuss the sub-types of Primary Immune Deficiency for which immune replacement therapy is appropriate; Identify diseases and indications other than primary immune deficiency in which immune replacement therapy is utilized; Explain the role nursing has in promoting quality of life in families of and patients with Primary Immune Deficiency; Describe the process and devices required to administer SCIG therapy.

**Plenary**

**4101 Anaphylaxis in the New Millennium**

8:15 to 9:45 am

**Convention Center, South Hall A1, Level I**

Credit: 1.50 CME / 1.80 CE

Moderator: Vivian P. Hernandez-Trujillo, MD FAAAAI

**8:15 Pathophysiology of Anaphylaxis: New Concepts**

Stephen J. Galli, MD

**8:45 Clinical Aspects of Mast Cell Dysfunction**

Dean D. Metcalfe, MD FAAAAI

**9:15 Risk Factors for Severe and Fatal Anaphylaxis**

F. Estelle R. Simons, MD FAAAAI

Upon completion of this session, participants should be able to: Describe immunologic mechanisms in anaphylaxis, including non-IgE-mediated; Explain why the heart is an important target; State the unique principles of anaphylaxis assessment and management promulgated in the World Allergy Organization Anaphylaxis Guidelines.

**Posters**

7:00 am to 6:00 pm

**Convention Center, South Hall A2, Level I**

Posters on display from 7:00 am to 6:00 pm. Authors present from 9:45 to 10:45 am.

Credit: No CME / No CE

Refer to pages 75-128 for abstracts and authors.

**4201 Asthma Epidemiology and Environmental Influences**

**4202 Immune Deficiency**

**4203 Dendritic Cells, Pattern Recognition Receptors and Signaling**

**4204 Infections and Allergic Disease**

**4205 Epidemiology of Sensitization, Asthma and Occupational Asthma**

**4206 Food Allergy II**

**4207 Anaphylaxis**

**4208 Provider Knowledge and Training**

**4209 Treatment of Allergic Rhinitis/Conjunctivitis**

**4210 Immunotherapy Outcomes**

**4211 T Cells**

**4212 Cytokines and Chemokines**



**Symposium ▼**

- 4301 Macrophages: More than an Alternative in Airway Diseases**  
10:45 am to 12:00 pm  
**Convention Center, S230GH, Level II**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Joshua A. Boyce, MD FAAAAI*
- 10:45 Regulatory Myeloid Cells Influence DCs to Temper Allergic Airway Inflammation**  
*Anuradha Ray, PhD*
- 11:05 Macrophages: The Neglected Effector Cell of Allergic Inflammation**  
*Barbara Balestrieri, MD*
- 11:25 Macrophages and Chronic Inflammation**  
*Thomas A. Wynn, PhD*
- 11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain the contribution of macrophages to the development and progression of pulmonary inflammation; Recognize the critical role of macrophages in allergic pulmonary inflammation; Describe the interplay of macrophages, dendritic cells and T Cells in airway diseases.

**Symposium ▼**

- 4302 What's New in Indoor Mold: An Update on Health Effects and Exposure Assessment**  
10:45 am to 12:00 pm  
**Convention Center, S330AB, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: W. Elliott Horner, PhD LEED AP FAAAAI*
- 10:45 World Health Organization Guidelines for Indoor Air Quality**  
*Jay M. Portnoy, MD FAAAAI*
- 11:05 What is New in Exposure Assessment for Indoor Mold and Remediation**  
*Brett J. Green, PhD*
- 11:25 Indoor Mold and Asthma Onset**  
*Tina Reponen, PhD*
- 11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe recent research on the health effects of indoor mold exposure; Assess the status and value of new exposure assessment tools under development; Translate practical preventive steps for avoidance into patient management; Identify the role of mold in asthma onset or morbidity.

**Symposium ▼**

- 4303 Mast Cell Activation Syndromes**  
10:45 am to 12:00 pm  
**Convention Center, S330CD, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Cem Akin, MD PhD FAAAAI*
  - 10:45 Mast Cell Activation Syndrome: Symptoms and Presentation**  
*Mariana C. Castells, MD PhD FAAAAI*
  - 11:05 Differentiating Idiopathic Anaphylaxis from Mast Cell Clonal Disorder**  
*Phillip L. Lieberman, MD FAAAAI*
  - 11:25 Mast Cell Surface Markers for Activation and Clonality**  
*Dean D. Metcalfe, MD FAAAAI*
  - 11:45 Question & Answer**
- Upon completion of this session, participants should be able to: Describe the symptoms of mast cell activation; Review the differential diagnosis of mast cell activation disorders; Recognize the different management issues in mast cell activation syndromes.

**Symposium ▼**

- 4304 Epigenetics and Immunologic Disease**  
10:45 am to 12:00 pm  
**Convention Center, S330EF, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Malcolm N. Blumenthal, MD FAAAAI*
  - 10:45 How Epigenetics Contributes to Asthma and Allergy**  
*Shuk-Mei Ho, PhD*
  - 11:05 The Role of Epigenetics in Host Defense**  
*Hao Shen, MD*
  - 11:25 Epigenetics, Autoimmunity and Auto Inflammation**  
*Wesley Brooks, PhD MBA*
  - 11:45 Question & Answer**
- Upon completion of this session, participants should be able to: Discuss the triggers and modulators of allergy; Describe epigenetics and what role it has in the phenotypes of allergy; Explain the role of targeted epigenetic therapy in the treatment of allergy.

**Symposium ▼**

- 4305 Novel Treatment of Food Allergy**  
10:45 am to 12:00 pm  
**Convention Center, S310ABFE, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: J. Andrew Bird, MD*
  - 10:45 Oral Desensitization in Patients with Peanut Allergy**  
*A. Wesley Burks, MD FAAAAI*
  - 11:05 Oral Desensitization Enabled with Omalizumab for Food Allergy**  
*Kari C. Nadeau, MD PhD FAAAAI*
  - 11:25 Traditional Chinese Medicine as Therapy for Food Allergy**  
*Julie Wang, MD FAAAAI*
  - 11:45 Question & Answer**
- Upon completion of this session, participants should be able to: Discuss the recent clinical and immunological outcomes in oral food immunotherapy; Discuss the role of anti-IgE therapy in concert with oral food immunotherapy; Describe recent clinical and immunological outcomes with traditional Chinese medicine in food allergy.

**Symposium** ▼**4306 Sneezey or Wheezy: Effect of Viral Diversity on Illness Severity**

10:45 am to 12:00 pm

**Convention Center, S320AB, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Robert F. Lemanske Jr., MD FAAAAI***10:45 Etiology of Viral Wheeze Determines Risk for Childhood Asthma***Tuomas Jartti, MD***11:05 HRV-C: Bad Actor or Just Another Rhinovirus?***E. Kathryn Miller, MD***11:25 RSV: A Role for Viral Genetic Diversity in Illness Severity?***Martin L. Moore, PhD***11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe the evidence indicating that the identity of viruses causing early life wheezing episodes is a predictor of risk for developing childhood asthma; Discuss whether the recently discovered rhinovirus species, HRV-C, is more likely than other rhinoviruses to induce lower airway symptoms, leading to wheeze and exacerbations of asthma; Discuss the role that sequence diversity in viral virulence genes might play in determining the severity and clinical outcomes of RSV illnesses.

**Symposium** ▼**4307 Making Sense of Lymphocyte Development**

10:45 am to 12:00 pm

**Convention Center, S230EF, Level II**

Credit: 1.25 CME / 1.50 CE

*Moderator: Christine M. Seroogy, MD FAAAAI***10:45 Sorting out T Cell Development***M. Louise Markert, MD PhD FAAAAI***11:05 B Cell Differentiation and Control***Hans D. Ochs, MD***11:25 Birth of a Killer: NK Cell Development***Jeffrey Miller, MD***11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe the factors driving T, B and NK cell lymphocyte development; Describe the transcription factors regulating progression along the phylogeny of developing lymphocytes; Explain the anatomic compartmentalization of lymphocytic development through stages of terminal maturation.

**Symposium** ▼**4308 New Trends in Immunotherapy**

10:45 am to 12:00 pm

**Convention Center, S320CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Désirée E.S. Larenas Linnemann, MD FAAAAI***10:45 Intralymphatic and Epicutaneous Immunotherapy***Thomas M. Kuendig, MD***11:05 The Dust Mite Story: How Do SCIT and SLIT Differ? Which is Better?***Stephen R. Durham, MA MD***11:25 New Molecules for Immunotherapy: Peptides and Modified Molecules Under Investigation***Mark Larche, PhD***11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss mechanisms and clinical aspects of intralymphatic and transcutaneous immunotherapy; Describe the current knowledge of immunologic changes associated with house dust mite specific immunotherapy, including the efficacy and safety of SCIT and SLIT with house dust mites; Comment on the safety and efficacy of peptide immunotherapy and other forms of immunotherapy that are under investigation.

**AAAAI Business Meeting**

12:30 to 1:30 pm

**Convention Center, S310CDGH, Level III**

All AAAAI Fellows and members are invited to attend this annual business meeting. Box lunches included. No Fee. No pre-registration required.

**Oral Abstract****4601 Update in Asthma Therapeutics and Monitoring**

2:00 to 3:15 pm

**Convention Center, S330EF, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Riccardo Polosa, MD PhD FAAAAI***2:00 Early Non-Respiratory Symptom Patterns Precede Loss of Asthma Control in Children***Lisanne Newton, MD***2:15 Adverse Reaction Preparedness for Allergen Immunotherapy in the Primary Care Setting***Vinitha Reddy, MD***2:30 Clinical Efficacy and Safety of Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)***Edward Kerwin, MD***2:45 ASHMI (Antiasthma Simplified Herbal Medicine Intervention) is a Potent Inhibitor of Interferon- $\alpha$  Production from Human Dendritic Cells by Increasing Pro-inflammatory Cytokines***Jody R. Tversky, MD***3:00 Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study***William W. Busse, MD FAAAAI*





**Oral Abstract**

- 4602 Immunoglobulin and Biological Therapy**  
 2:00 to 3:15 pm  
**Convention Center, S230EF, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Vincent R. Bonagura, MD*
- 2:00 The Sialylated Fraction Of IVIg Suppresses Th2-driven Airway Inflammation Via The Induction Of Tolerogenic Dendritic Cells**  
*Amir Hossein Massoud, MD*
- 2:15 The Effect of Anti-IL-5 Therapy on Esophageal Mastocytosis in Pediatric Eosinophilic Esophagitis**  
*Iris M. Otani, MD*
- 2:30 Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PID)**  
*Isaac Melamed*
- 2:45 A Scoring System to Guide Decisions on Immunoglobulin Replacement Treatment in Hypogammaglobulinemia**  
*Shradha Agarwal, MD*
- 3:00 Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome**  
*Amy D. Klion, MD*

**Oral Abstract**

- 4603 The Effect of Pollution on Allergic Disease**  
 2:00 to 3:15 pm  
**Convention Center, S230GH, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Christopher Chang, MD PhD FAAAAI  
 Rachel Miller, MD FAAAAI*
- 2:00 Postnatal Ozone Exposure Enhances House Dust Mite Induced Airway Hyperresponsiveness Without Increasing Inflammation**  
*Kelsa Gabehart, PhD*
- 2:15 Frequent Allergy Symptoms Among Children Living Near The World Trade Center Associated With Elevated Peripheral Airways Resistance**  
*Yi Feng Chen*
- 2:30 Annual New York City Trends Of Ambient Fine Particulate Matter, Black Carbon And Ambient Metals Implicated In Airway Disease**  
*Fei Li Kuang, MD PhD*
- 2:45 Relationship Between Environmental Phenols And Aeroallergen And Food Allergies In The US: Results From The National Health And Nutrition Examination Survey 2005-2006**  
*Natalia Vernon, MD*
- 3:00 Distance From A Heavily Trafficked Highway Is Implicated In The Presence Of Allergic Rhinoconjunctivitis And Asthma In Adults**  
*Maria-Anna Vastardi, MD*

**Oral Abstract**

- 4604 Genetic and Other Mechanisms of Atopic and Skin Diseases**  
 2:00 to 3:15 pm  
**Convention Center, S330AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Luz S. Fonacier, MD FAAAAI  
 Pia J. Hauk, MD*
- 2:00 Effect of Th2 and Th17 Cytokines on Human Epidermal Tight Junctions**  
*Anna De Benedetto, MD*
- 2:15 The Association Between HLA B7 Alleles and Human Atopic Dermatitis Complicated by Eczema Herpeticum**  
*Rasika A. Mathias, PhD*
- 2:30 C3a Receptor (C3aR) is Important for Viral Containment in Mice Inoculated with Vaccinia Virus (VV) at Sites of Allergic Skin Inflammation**  
*Lalit Kumar, PhD*
- 2:45 Staphylococcus Aureus Alpha-Toxin Augments Viral Load In Keratinocytes**  
*Lianghua Bin, PhD*
- 3:00 Genetic Variants Associated With Asthma and Related Phenotypes are Also Risk Factors for Food Allergy**  
*Candelaria Vergara, MD PhD*

**Oral Abstract**

- 4605 New Insights into Allergy and Asthma Assessment**  
 2:00 to 3:15 pm  
**Convention Center, S331AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Peter J. Crietupa, MD  
 Harvey L. Leo, MD*
- 2:00 Reliability, Validity, and Responsiveness of the Asthma Control Questionnaire among Pediatric Patients.**  
*Jessica M. Nguyen, MD*
- 2:15 A Retrospective Analysis of Anti-Allergy Drug Efficacy tested in an Environmental Exposure Chamber (EEC) Model compared to that observed in the Traditional Allergy Field Trials demonstrates the clinical relevance of allergen exposure models.**  
*Anne Marie Salapatek, MD*
- 2:30 Online Allergy Surveys - is There an App For That? A Quantitative and Qualitative Study of Allergic Rhinitis Patients During a Pollen Season**  
*Dan Dalan, MD FAAAAI*
- 2:45 A Personalized Care Platform: Incorporating Structured Data In Allergy Clinical Care**  
*Jianfeng Meng, MD MPH MS*
- 3:00 The First Phase of Instrument Development: The Conventional and Alternative Management (CAM) for Asthma Questionnaire**  
*Maureen George, PhD RN AE-C*

**Oral Abstract**

- 4606 Mechanisms of Rhinitis**  
2:00 to 3:15 pm  
Convention Center, S330CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators: Mark C. Glaum, MD PhD FAAAAI  
Brian A. Smart, MD FAAAAI
- 2:00 Local Allergic Rhinitis is Highly Prevalent in a Population Attended for the Evaluation of Rhinitis**  
Carmen Rodon Segovia, MD PhD
- 2:15 Interleukin-35 Suppresses Allergen-specific Th2 Response in Patients with Grass pollen induced Seasonal Allergic Rhinitis**  
Daniela Achkova, MSc
- 2:30 Effects of Repetitive Allergen Challenge on Expression of TGF- $\beta$ , Activin -A and Its Receptor ALK4 in Nasal Mucosa of Allergic Rhinitis**  
Huifen Wu, MD
- 2:45 Basophils In Peripheral Blood can be Sensitized in Local Allergic Rhinitis**  
Enrique Gomez
- 3:00 Evaluation of Thymic Stromal Lymphopoietin (TSLP) and its Receptor in Adults with Allergic Rhinitis Following Controlled Allergen Challenge in the Environmental Exposure Unit (EEU).**  
Tahira Batool, MD

**Oral Abstract**

- 4607 Myeloid Cells in Allergic Inflammation**  
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Francesca Levi-Schaffer, PhD FAAAAI
- 2:00 Group V sPLA2 is Required in Alternative Activated Macrophages for the Development of Allergic Pulmonary Inflammation**  
Shin Ohta, MD PhD
- 2:15 Thioredoxin is Positively Associated with Eosinophils in Induced Sputum from Patients with Asthma**  
Joel M. Hartman, MD
- 2:30 Histamine is Necessary for IL-4-driven Eosinophilic Allergic Responses**  
Julie A. Swartzendruber, BA
- 2:45 Hypoxia Regulates Activation/Inhibitory Receptors on Eosinophils.**  
Alon H. Nissim Ben Efraim, MSc
- 3:00 Mechanisms Involved In IL-5 Enhancement Of Siglec-8-induced Eosinophil Apoptosis: Role For Reactive Oxygen Species (ROS)-enhanced MEK/ERK Activation**  
Gen Kano, MD PhD

**Late Breaking Oral Abstract Session**

- 4611 Basic/Translational Sciences**  
2:00 to 3:15 pm  
Convention Center, S329, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators to be announced.
- 2:00 IFN- $\alpha$  Destabilizes Human CD4+ T Helper Type 2 (Th2) Cells By Disrupting the Th2-Specific Transcription Program**  
Jonathan Huber
- 2:15 Association of Gene Variant in IL12B Gene with Atopic Dermatitis Complicated by Eczema Herpeticum (ADEH)**  
P.S. Gao, MD PhD
- 2:30 IL-25 Down-regulates Epidermal Barrier Proteins and Enhances Viral Replication**  
Byung Eui Kim, MD
- 2:45 Paired Immunoglobulin-like Receptor B Is Required For Allergic Eosinophilic Airway Inflammation**  
Ariel Munitz, PhD
- 3:00 Ragweed Pollen Lipid is an Immunoadjuvant of the Humoral and Cellular Immune Response in BALB/c Mice**  
Mohamed Elfatih Bashir, PhD

**Cutting-Edge Research Keynote****4701 Understanding Disease Mechanisms: Past, Present and Future**

3:30 to 4:30 pm  
Convention Center, South Hall A1, Level I  
Credit: 1.00 CME / 1.20 CE  
Moderator: Ray Stokes Peebles, Jr., MD FAAAAI

**3:30 Two Hundred Years of Reporting Medical News**  
Jeffrey M. Drazen, MD FAAAAI**4:00 The Antibody Paradox**  
Jeffrey V. Ravetch, MD PhD

Upon completion of this session, participants should be able to: Discuss the evolution of understanding the mechanisms and treatment of asthma; Describe mechanisms for antibodies to provoke disease, and induce tolerance.

**Q & A Workshop**

- 4801 Asthma in the Elderly**  
4:45 to 6:00 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Monroe J. King, DO FAAAAI
- 4:45 Asthma in the Elderly**  
Paula J. Busse, MD FAAAAI
- 5:00 Non-Allergic Rhinitis and Asthma**  
Sharmilee M. Nyenhuis, MD
- 5:15 Allergic Rhinitis and Asthma**  
Joram S. Seggev, MD FAAAAI
- 5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe the aging of the U.S. population and problems associated with it; Evaluate elderly patients for co-morbidities that may complicate the management of asthma or mimic the disease; Formulate a comprehensive management plan.



**Q & A Workshop**

**4802 Tools and Resources for Scientists in Allergy Research**

4:45 to 6:00 pm  
**Convention Center, S330AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Judith A. Woodfolk, MBChB PhD FAAAAI*

**4:45 Approaches to Molecular Modeling of Allergens**

*Anna Pomés, PhD FAAAAI*

**5:00 The Immune Epitope Database: Navigation and Applications**

*Alessandro Sette, PhD*

**5:15 Class II MHC/Peptide Tetramers: Insights into Allergen-Specific T Cells**

*William W. Kwok, PhD*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe how molecular modeling of allergens is performed and how it can be used to advance our knowledge of allergen structure and function; Review how the Immune Epitope Database can be used for allergen epitope discovery; Describe how Class II MHC/peptide tetramers can be used to identify allergen-specific T Cells and to identify relevant applications.

**Q & A Workshop**

**4803 Shaping Immunologic Responses with Environmental Exposures**

4:45 to 6:00 pm  
**Convention Center, S320CD, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: R. Stokes Peebles Jr., MD FAAAAI*

**4:45 Interactions Between the Innate and Adaptive Immune Systems that Impact the Development of Allergen Sensitization**

*Harald E. Renz, MD*

**5:00 The Impact of the Farming Environment on Neonatal Immune Responses**

*Erika Von Mutius, MD MSc*

**5:15 The Impact of Environmental Exposures on Pulmonary Dendritic Cell Function**

*Mitchell H. Grayson, MD FAAAAI*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Describe the interplay between the innate and adaptive immune system; Explain how in utero maternal exposures can modulate neonatal immune responses and how this relates to the development of allergic disease; Discuss how mucosal dendritic cells are impacted by environmental exposures and the effect on immune responses.

**Panel Discussion Workshop**

**4804 Opportunities for Improving Immunoglobulin Therapy**

4:45 to 6:00 pm  
**Convention Center, S310CDGH, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Marc A. Riedl, MD*  
*W.A. Carrock Sewell, MD PhD FAAAAI*  
*Erwin W. Gelfand, MD FAAAAI*  
*Mark R. Stein, MD FAAAAI*

Upon completion of this session, participants should be able to: Review the variables underlying effective and optimal IVIG therapy and if there are strategies that can allow improved outcomes; Discuss the innovations being applied to the method for administering SCIG and whether or not they present any value in improving care; Discuss how interpretation of patient-specific data can or cannot be used to guide optimization of therapy.

**Panel Discussion Workshop**

**4805 Writing and Publishing a Manuscript: A Roadmap for the Allergist/Immunologist**

4:45 to 6:00 pm  
**Convention Center, S230EF, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Michael H. Clayton, MD FAAAAI*  
*Richard W. Honsinger, MD FAAAAI*  
*James T. Li, MD PhD FAAAAI*  
*Richard F. Lockey, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss writing an article: formulating a concept, reviewing the literature and telling the story; Identify nuances in publishing a case report: determining the uniqueness, single case vs. case series and constructing the message; Discuss getting it published: the manuscript, authorship and choosing the right journal.

**Problem-Based Learning Workshop**

**4806 Optimal Treatment of Heredity Angioedema**

4:45 to 6:00 pm  
**Convention Center, S320EF, Level III**  
 Pre-registration and ticket required. Fee: \$50.  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Timothy J. Craig, DO FAAAAI*  
*Bruce L. Zuraw, MD*

Upon completion of this session, participants should be able to: Describe risks and benefits of treatment options for exacerbations of HAE; Describe treatment options for HAE prophylaxis.

**Problem-Based Learning Workshop**

**4807 Atopic Dermatitis**

4:45 to 6:00 pm  
**Convention Center, S320GH, Level III**  
 Pre-registration and ticket required. Fee: \$50.  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Lynda C. Schneider, MD FAAAAI*  
*Vivian P. Hernandez-Trujillo, MD FAAAAI*

Upon completion of this session, participants should be able to: Identify triggers of atopic dermatitis; Develop a treatment plan for atopic dermatitis; Design an action plan to treat worsening of atopic dermatitis.

**Problem-Based Learning Workshop**

**4808 The Intricacy of Penicillin Allergy Testing and Cross-Reactivity with Cephalosporin Allergy**

4:45 to 6:00 pm  
**Convention Center, S230AB, Level II**  
 Pre-registration and ticket required. Fee: \$50.  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Eric M. Macy, MD FAAAAI*  
*Miguel A. Park, MD*

Upon completion of this session, participants should be able to: Discuss the different components of the penicillin skin test; Discuss how the different components of the penicillin skin test affect the negative predictive value; Discuss the role of oral challenges to penicillin and/or amoxicillin in the evaluation of penicillin allergy.

**Q & A Workshop** ▼**4809 Prevention of Food Allergy in Children**

4:45 to 6:00 pm

**Convention Center, S310ABFE, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Sami L. Bahna, MD DrPH FAAAAI***4:45 Maternal Dietary Interventions***Gideon Lack, MD***5:00 Breastfeeding, Formula Feeding and Formula Options***Marion E. Groetch, MS RD***5:15 Timing and Selection of Solid Food Introduction***J. Andrew Bird, MD***5:30 Question & Answer**

Upon completion of this session, participants should be able to: Review available data for maternal dietary interventions during pregnancy/lactation; Discuss available dietary interventions for infants/young children with food allergies or at risk of developing food allergies; Discuss ideal timing of introduction of solids and allergenic foods into the infant/child diet.

**Panel Discussion Workshop** ▼**4810 ABAI Maintenance of Certification (MOC) and Beyond**

4:45 to 6:00 pm

**Convention Center, S330CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Mary Beth Fasano, MD FAAAAI**John M. James, MD FAAAAI**Sarah Johnson**Stephen I. Wasserman, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss how to successfully report their MOC activities to the ABAI; Discuss the mechanics of the four major components of the ABAI MOC program (i.e. Parts I – IV), with an emphasis on Part IV modules; Identify current issues of MOC that are pertinent to all ABAI diplomates including future initiatives and programs.

**Q & A Workshop** ▼**4811 Using Information Technology to Maximize Outcomes and Reimbursement**

4:45 to 6:00 pm

**Convention Center, S330EF, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: David J. Shulan, MD FAAAAI***4:45 Proving I Should be Paid for My Performance***Todd A. Mahr, MD FAAAAI***5:00 Using Online Resources to Evaluate Asthma Control and Patient Adherence***Andrew G. Weinstein, MD FAAAAI***5:15 Questions to Consider When Determining the Optimal Software to Evaluate Patient Outcomes***Richard L. Wasserman, MD PhD FAAAAI***5:30 Question & Answer**

Upon completion of this session, participants should be able to: Employ EMR to track outcomes and provide proof of performance; Identify websites and clinical tools to evaluate asthma control and technology to monitor adherence; Review software that facilitates tracking patient outcomes.

**Problem-Based Learning Workshop**  **4812 The Child with Chronic Vomiting and Diarrhea**

4:45 to 6:00 pm

**Convention Center, S331AB, Level III**

Pre-registration and ticket required. Fee: \$50.

Credit: 1.25 CME / 1.50 CE

*Moderator: Scott H. Sicherer, MD FAAAAI**Stanley M. Fineman, MD MBA FAAAAI*

Upon completion of this session, participants should be able to: Discuss the differential diagnosis of the child who presents with chronic vomiting and diarrhea; Discuss the diagnosis of EGID, FPIES, Celiac Disease and other non-IgE mediated food allergies; Discuss treatment of these disorders.

**Q & A Workshop****4813 Teaching Residents and Students in the Clinical Practice**

4:45 to 6:00 pm

**Convention Center, S329, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Mark H. Moss, MD***4:45 The Six Core Competencies***Asriani M. Chiu, MD FAAAAI***5:00 Designing a Clinical Rotation***Lily Pien, MD FAAAAI***5:15 Evaluating Residents and Medical Students***Jeffrey R. Stokes, MD FAAAAI***5:30 Question & Answer**

Upon completion of this session, participants should be able to: Identify the six core competencies of postgraduate medical training; Describe resources to enhance teaching of trainees in the office setting; Discuss qualities of a clinical rotation that lend value to a medical training program.

**Hands-On Workshop** **4814 Hands-On Rhinologyngoscopy**

4:45 to 6:00 pm

**Convention Center, S331CD, Level III**

Pre-registration and ticket required. No fee. Ticket included with registration for Workshop 2814: Introductory Rhinologyngoscopy.

Credit: 1.25 CME / 1.50 CE

*Allen D. Adinoff, MD FAAAAI**Jerald W. Koepke, MD FAAAAI**Kevin R. Murphy, MD**Grant C. Olson, MD**Nathan Segall, MD**C. Ross Westley, MD FAAAAI*

Upon completion of this session, participants should be able to: Demonstrate the initial skills needed to perform a comprehensive upper airway examination with a fiber optic endoscope; Discuss information regarding the upper airway anatomy learned in the didactic session.



**Q & A Workshop**

**4815 CNS Consequences of Allergic Rhinitis in Children and Adults: Sleep Disturbance, Behavioral Problems and Migraine Headache**

4:45 to 6:00 pm  
**Convention Center, S230GH, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Lyndon E. Mansfield, MD FAAAAI  
 Eli O. Meltzer, MD FAAAAI*

**4:45 Allergic Rhinitis and Migraine Headache: Effect of Allergy Treatment**

*Jonathan A. Bernstein, MD FAAAAI*

**5:00 Overview of the CNS Consequences of Allergic Rhinitis**

*Mark S. Dykewicz, MD FAAAAI*

**5:15 ADHD, Sleep Apnea and Allergic Rhinitis in Children**

*Bernard Silverman, MD FAAAAI*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Identify the associations and theories of causality among allergic rhinitis, adenotonsillar hypertrophy and sleep obstruction; Explore the association and theories of causality between allergic rhinitis and migraine headache; Identify the demonstrated effects and possible benefits of intranasal corticosteroids and other allergic rhinitis treatment.

**Hands-On Workshop**

**4816 Skin Testing: How to Get the Right Swing**

4:45 to 6:00 pm  
**Convention Center, S330GH, Level III**  
 Pre-registration and ticket required. Fee: \$50.  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Kaiser G. Lim, MD FAAAAI*

**Minor Details That Can Improve Your Skin Prick Testing Accuracy**

*John Oppenheimer, MD FAAAAI*

**Extracts and Devices**

*Désirée E.S. Larenas Linnemann, MD FAAAAI*

**Documentation of Skin Test Results**

*Warner W. Carr, MD FAAAAI*

**Hands-On Instruction**

Upon completion of this session, participants should be able to: Demonstrate proper technique for skin testing; Review for and take a proficiency test; Experiment with different SPT devices (mono and multitest).

**Q & A Workshop**

**4817 Beyond Th2 Cells and Mediators of Allergic Inflammation**

4:45 to 6:00 pm  
**Convention Center, S320AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Larry Borish, MD FAAAAI*

**4:45 Allergic Inflammation Regulating Th17 Immunity**

*Dawn C. Newcomb, PhD*

**5:00 IL9, Th9 Cells and Allergic Inflammation**

*Clare M. Lloyd, PhD*

**5:15 Complement in Allergic Inflammation**

*Marsha A. Wills-Karp, PhD*

**5:30 Question & Answer**

Upon completion of this session, participants should be able to: Define how Th17 cells modulate allergic inflammatory disorders such as asthma; Describe the role of IL9 and Th9 cells in allergic inflammation; Discuss how complement plays a critical role in allergic inflammatory response.

**Seminars**

4:45 to 5:45 pm  
 Pre-registration and ticket required. Fee: \$40. Refreshments included.  
 Sessions and refreshments limited to 30 people.  
 Credit: 1.00 CME / 1.20 CE

**4821 How to Advise Patients on Home Pest Control, Indoor Contaminants and Clean and Safe Indoor Environments**

*Kevin Kennedy  
 Elizabeth Matsui, MD*  
**Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Describe pest management practices consistent with a healthy home; Explain integrated pest management; Discuss chemical contamination in the home environment.

**4822 Oral Immunotherapy for Food Allergy: Contrasting Practices in the U.S. and in Europe**

*Giovanni Battista Pajno, MD FAAAAI  
 Rushani W. Saltzman, MD*  
**Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Discuss the right patients for the right OIT; Describe food allergens which are worth OIT; Review food allergies which are worth active treatment.

**4823 Using Technology in Teaching and Medical Education**

*Adrian Casillas, MD FAAAAI  
 Tao Le, MD MHS FAAAAI*  
**Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Describe low cost learning technologies such as webinars, online video and social media; Discuss best use case scenarios for low cost learning technologies; Explain advanced PowerPoint techniques and presentation alternatives to PowerPoint.

**4824 Use of Pneumococcal Vaccination in Immunodeficiency Diagnosis and Management**

*Francisco A. Bonilla, MD PhD FAAAAI  
 Kenneth Paris, MD MPH*  
**Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Use and interpret pneumococcal immunization in evaluation of patients with possible primary immunodeficiency disorders.

**4825 Advanced Therapeutics: Managing the Severe and Refractory Eczema Patient**

*Jennifer S. Kim, MD FAAAAI  
 Peter Lio, MD*  
**Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Identify common pitfalls in the treatment of eczema, with special emphasis on compliance; Describe the rationale for an extended therapeutic ladder for patients refractory to standard treatments; Evaluate treatments and interventions that have been shown to be of no benefit in the disease.

**Seminars**

7:00 to 8:00 am

Pre-registration and ticket required. Fee: \$40. Continental breakfast included. Sessions and meals limited to 30 people.

Credit: 1.00 CME / 1.20 CE

**5001 Eosinophilic Esophagitis: Practical Aspects of Assessing Immediate and Delayed Food Hypersensitivity***Mark Holbreich, MD FAAAAI**Amir F. Kagalwalla, MD***Peabody, Celebration 1, Convention Level**

Upon completion of this session, participants should be able to: Complete a comprehensive food allergy evaluation in children and adults with eosinophilic esophagitis; Explain the practical aspects of the preparation of food allergens for prick and patch testing; Describe the role of immunoassays for foods in eosinophilic esophagitis.

**5002 Outpatient Evaluation of Patients with Multiple Drug Allergy Syndrome***David A. Khan, MD FAAAAI**Roland Solensky, MD FAAAAI***Peabody, Celebration 2, Convention Level**

Upon completion of this session, participants should be able to: Discuss multiple antibiotic allergy syndrome; Evaluate and manage patients with multiple drug allergies; Appreciate the pitfalls in introducing new drugs to the patient with multiple allergies.

**5003 How to Safely Do Drug Challenges in the Office: A Practical Approach***Eric M. Macy, MD FAAAAI**Stephen A. Tilles, MD FAAAAI***Peabody, Celebration 3, Convention Level**

Upon completion of this session, participants should be able to: Identify drug allergic patients well suited for a graded challenge; Design a drug challenge protocol; Discuss different methods for administration of placebos during drug challenges.

**5004 Dermatology for the Allergist***Vincent S. Beltrani, MD FAAAAI**Peter Lio, MD***Peabody, Celebration 4, Convention Level**

Upon completion of this session, participants should be able to: Describe the basic clinical features of atopic dermatitis, other eczemas, allergic contact dermatitis and drug eruptions; Discuss the approach to identifying and describing skin lesions; Discuss the role of biopsy in diagnosis and management.

**5005 Food Protein-Induced Enterocolitis Syndrome (FPIES): Diagnosis and Management***Jonathan M. Spergel, MD PhD FAAAAI**Robert A. Wood, MD FAAAAI***Peabody, Celebration 5, Convention Level**

Upon completion of this session, participants should be able to: Describe pathophysiology and symptoms of FPIES; Discuss current diagnostic tests; Explain the oral food challenge procedure for FPIES to a colleague.

**5006 Rush/Cluster Immunotherapy: Pearls and Protocols***Linda Cox, MD FAAAAI**Joseph T. Ingelfield III, MD***Peabody, Celebration 6, Convention Level**

Upon completion of this session, participants should be able to: Define schemes used for accelerated IT and identify practical pearls and patient selection criteria; Formulate the best premedication strategies; Employ rush immunotherapy in a safe and cost-effective way.

**5007 Laryngoscopy for VCD and GERD***Allen D. Adinoff, MD FAAAAI**Corinna S. Bowser, MD FAAAAI***Peabody, Celebration 7, Convention Level**

Upon completion of this session, participants should be able to: Describe the findings obtainable with office laryngoscopy; State the equipment needed for direct flexible laryngoscopy; Employ methods to trigger VCD exacerbations in order to directly visualize the laryngeal dysfunction; Identify setup costs, coding and reimbursement considerations for these procedures.

**5008 Hypereosinophilic Disorders: Diagnosis and Treatment of Difficult Cases***Carla M. Davis, MD**Amy D. Klion, MD***Peabody, Celebration 8, Convention Level**

Upon completion of this session, participants should be able to: Identify how to diagnose and evaluate difficult patients presenting with hypereosinophilia; Describe the evaluation and workup of hypereosinophilic syndrome, eosinophilic vasculitides and organ specific eosinophilic disorders such as eosinophilic esophagitis; Discuss the management of the hypereosinophilic patient including novel therapies currently under investigation such as anti-IL-5.

**5009 Advanced Coding for Allergists***Noga Askenazi, MD FAAAAI**Stephen A. Imbeau, MD FAAAAI***Peabody, Celebration 9, Convention Level**

Upon completion of this session, participants should be able to: Discuss the use of codes pertinent to A/I practice; Describe details of coding for patients' allergy testing and immunotherapy; Identify changes in coding for allergists on the horizon.

**5010 Perioperative Anaphylaxis: Anesthetics, Antibiotics, Latex and Others***Gordon L. Sussman, MD FAAAAI**Kristen K. Volkman, MD***Peabody, Celebration 10, Convention Level**

Upon completion of this session, participants should be able to: List the most common medications causing perioperative anaphylaxis; Discuss the utility of the different skin tests to medications that commonly cause perioperative anaphylaxis; Describe an effective method of evaluating and managing patients with perioperative anaphylaxis.

**EDUCATIONAL GAMES  
FOR KIDS**

DISCOVER

*Innovative website tools  
in the Member Resource Center*



**Plenary** ▾

- 5101 Immunology at the Epithelial Frontier**  
8:15 to 9:45 am  
**Convention Center, South Hall A1, Level I**  
Credit: 1.50 CME / 1.80 CE  
*Moderator: Steve Ziegler, PhD*
- 8:15 Allergen Interactions with Epithelial Surfaces**  
*Marsha A. Wills-Karp, PhD*
- 8:15 Epithelial Cells Determine Balance Between Tolerance and Immunity**  
*David Artis, PhD*
- 8:15 Epithelial Barrier Recovery: A New Frontier in the Management of Allergic Diseases**  
*Lisa A. Beck, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss how the expression of pattern recognition receptors (Toll-like receptors, NOD1) expressed on the epithelium distinguishes between commensal and pathogenic microbes to maintain tolerance vs. induction of a protective immune response to pathogens; Explain how the release of Th2-promoting cytokines such as TSLP, IL-25 and IL-33 from bronchial epithelial cells contributes to the pathogenesis of asthma and atopic dermatitis; Describe evidence for epithelial cells acting as antigen presenting cells; Describe how epithelial cells play an active role in the initiation, regulation and resolution of immune responses; Discuss the evidence for epithelial barrier disruption in allergic diseases, biological consequences of this disruption and potential repair mechanisms.

**Posters**

- 7:00 am to 5:00 pm  
**Convention Center, South Hall A2, Level I**  
Posters on display from 7:00 am to 5:00 pm. Authors present from 9:45 to 10:45 am.  
Credit: No CME / No CE  
*Refer to pages 75-128 for abstracts and authors.*
- 5201 Critical Asthma Issues**
- 5202 Autoimmunity and Other Topics**
- 5203 Mechanisms of Allergy, HIV**
- 5204 Urticaria and Angioedema**
- 5205 Insect Hypersensitivity, Food Epidemiology, Food Allergens**
- 5206 Epidemiology of Rhinitis**
- 5207 Allergenic Products: Diagnostics and Standardization**

**Symposium** ▾

- 5301 Updated Look at Asthma in Older Adults: From Basic Immunology to the Clinic**  
10:45 am to 12:00 pm  
**Convention Center, S330EF, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Mark F. Sands, MD FAAAAI*
- 10:45 Immunology, Aging and Asthma**  
*Sameer K. Mathur, MD PhD*
- 11:05 Asthma Severity in Older Adults: Impact of Genetic and Environmental Factors**  
*Tolly Epstein, MD*
- 11:25 Outcomes and Treatment of Asthma in Older Adults**  
*Carol A. Saltoun, MD FAAAAI*
- 11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe current findings from experimental models of asthma pertinent to the effects of aging on the immune system; Define the impact of genetic susceptibilities and environmental exposures on asthma severity in older adults; Describe the significant interaction of asthma and aging on quality of life; Identify therapeutic and preventive measures to achieve best outcomes in this vulnerable population.

**Symposium** ▾

- 5302 Lessons from the Inner City Environment on the Immunologic Basis and Treatment of Allergy and Asthma**  
10:45 am to 12:00 pm  
**Convention Center, S320AB, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: William W. Busse, MD FAAAAI*
- 10:45 Immunologic Effects of Cockroach Sublingual Immunotherapy**  
*Robert A. Wood, MD FAAAAI*
- 11:05 Insights into the Management of Asthma in Urban Children**  
*Stephen Teach, MD*
- 11:25 Risk Factors for Early Wheezing**  
*James E. Gern, MD FAAAAI*
- 11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe which urban environmental exposures affect the development of recurrent wheeze in early life; Compare immunologic effects of cockroach sublingual immunotherapy to those reported for other antigens; Discuss the evidence base for the treatment of asthma in children from poor urban environments.

**Symposium** ▾

- 5303 Silencing is Golden: microRNA Regulation of Immunity**  
10:45 am to 12:00 pm  
**Convention Center, S320CD, Level III**  
Credit: 1.25 CME / 1.50 CE  
*Moderator: Ivan K. Chinn, MD*
- 10:45 Physiologic and Pathologic Roles for microRNA in Immune Development and Function**  
*Carl Novina, MD PhD*
- 11:05 The Biology of microRNA Accessory Proteins**  
*Rachel Jane Senturia, PhD*
- 11:25 Diagnostic and Therapeutic Potential of microRNA in Allergic Disease**  
*Paul S. Foster, PhD*
- 11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the role of microRNAs in the development and function of immune cells; Recognize the role of accessory proteins in processing microRNAs; Discuss potential therapeutic uses of microRNA technology.

**Symposium** ▼**5304 Biomarkers for Monitoring Allergen Immunotherapy Induced Tolerance**

10:45 am to 12:00 pm

Convention Center, S310CDGH, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Mohamed Shamji, BSc MSc PhD

**10:45 Serum and Local Biomarkers for Monitoring Allergen Immunotherapy**

Stephen R. Durham, MA MD

**11:05 Use of IgG4 Arrays in Monitoring Allergen Immunotherapy: Are They Any Good?**

Robert G. Hamilton, PhD D.ABMLI FAAAAI

**11:25 Cellular Assays for Monitoring Allergen Immunotherapy**

Wayne G. Shreffler, MD PhD FAAAAI

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss which serum biomarkers can be used for monitoring allergen immunotherapy and their clinical uses; Describe the use of IgG4 arrays in monitoring allergen immunotherapy; Evaluate which cellular assays are being studied to monitor AIT.

**Symposium** ▼**5305 Genetics of Food Allergy: Into the Future**

10:45 am to 12:00 pm

Convention Center, S310ABFE, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: A. Wesley Burks, MD FAAAAI

**10:45 Peanut Allergy and Loss-of-Function Variants in the Filaggrin Gene**

Sara Brown, MBChB

**11:05 Eosinophilic Esophagitis and Variants of TSLP/TSLP Receptor**

Antonella Cianferoni, MD PhD

**11:25 Mechanistic and Clinical Insights from a Novel Food Allergy Related Syndrome**

Pamela A. Guerrerio, MD PhD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Describe the link between peanut allergy and loss-of-function variants in the Filaggrin gene; Explain the relationship between variants of TSLP/TSLP receptor and eosinophilic esophagitis; Discuss how identification of a new link between a rare syndrome and food allergy could provide new insight into the genetics of food allergy.

**Symposium** ▼**5306 Beyond Necrosis and Apoptosis: Spectrum of Cell Death**

10:45 am to 12:00 pm

Convention Center, S330CD, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Nives Zimmermann, MD FAAAAI

**10:45 Interplay of Autophagy with Apoptosis and Necrosis in T Cell Homeostasis**

Craig Walsh, MD

**11:05 Role and Mechanism of Necroptosis in Homeostasis**

John W. Elrod, PhD

**11:25 Mechanism of NETosis: Neutrophil Cell Death Following Extrusion of DNA Traps**

Arturo Zychlinsky, PhD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Explain the role and mechanism of necroptosis in cell death and how it relates to immune cell homeostasis; Describe the role and mechanism of autophagy in cell death and how it relates to immune cell homeostasis; Discuss the role and mechanism of NETosis in cell death and how it relates to immune cell homeostasis.

**Symposium** ▼**5307 What You Need to Know About STATs**

10:45 am to 12:00 pm

Convention Center, S330AB, Level III

Credit: 1.25 CME / 1.50 CE

Moderator: Gurjit K. Khurana Hershey, MD PhD FAAAAI

**10:45 Mechanisms of STAT-induced CD4+ T Cell Differentiation**

John J. O'Shea Jr., MD

**11:05 STAT Defects in the Pathogenesis of Primary Immunodeficiency Diseases**

Joshua D. Milner, MD

**11:25 STAT Genetic Susceptibility Loci for Autoimmunity**

John B. Harley, MD PhD

**11:45 Question & Answer**

Upon completion of this session, participants should be able to: Discuss how STAT molecules impact the differentiation of CD4+ T cells; Identify STAT defects that result in specific primary immunodeficiency diseases; Discuss polymorphisms in STAT genes that are associated with susceptibility to autoimmune diseases.

**Pro/Con Debate** ▼**5501 Skin Testing is Required in Choosing an Elimination Diet in Eosinophilic Esophagitis**

12:30 to 1:30 pm

Convention Center, S330AB, Level III

Credit: 1.00 CME / 1.20 CE

Moderator: Wayne G. Shreffler, MD PhD FAAAAI

**Pro**

Katrina J. Allen, MD PhD

**Con**

Mirna Chehade, MD

Upon completion of this session, participants should be able to: Describe the difference in approach to EoE between allergist/immunologists and gastroenterologists; Explain evidence of the effectiveness of various protocols for dietary elimination; Review prognostic implications for sub-phenotypes of EoE for both children and adults dependent on response to dietary elimination.





**Pro/Con Debate** ▼

**5502 Immunotherapy Works via Regulatory T Cells**

12:30 to 1:30 pm

**Convention Center, S310CDGH, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Dorothy S. Cheung, MD FAAAAI*

**Pro**

*Carsten B. Schmidt-Weber, PhD*

**Con**

*Thomas A.E. Platts-Mills, MD PhD FAAAAI*

Upon completion of this session, participants should be able to: Describe the data supporting a primary role for regulatory T Cells in driving the efficacy of immunotherapy; Define the various alternative explanations for how immunotherapy is an effective therapy in allergic disease; Discuss how the various potential mechanisms operative in immunotherapy interact to provide effective treatment.

**Pro/Con Debate** ▼

**5503 Subcutaneous Immunoglobulin is the Preferred Mode of Therapy for Primary Immunodeficiency**

12:30 to 1:30 pm

**Convention Center, S320AB, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Christine M. Seroogy, MD FAAAAI*

**Pro**

*Ralph Shapiro, MD*

**Con**

*Erwin W. Gelfand, MD FAAAAI*

Upon completion of this session, participants should be able to: Describe an overview of both routes of administration of gammaglobulin; Discuss clinical considerations when choosing which route of administration of IgG replacement will benefit the patient; Describe the options for IgG replacement.

**Pro/Con Debate**

**5504 Use of Probiotics Can Prevent and Treat Allergic Diseases**

12:30 to 1:30 pm

**Convention Center, S330CD, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Anna H. Nowak-Wegrzyn, MD FAAAAI*

**Pro**

*Liam O'Mahony, MD*

**Con**

*Susan L. Prescott, MD PhD*

Upon completion of this session, participants should be able to: Explain the importance of bacterial flora for normal development of the immune system; Describe the evidence for the use of probiotics in prevention of allergic diseases; Review the evidence for the use of probiotics in treatment of allergic diseases.

**Symposium** ▼

**5505 Evidence-Based Approach to Asthma Step Down: ICS or LABA**

12:45 to 1:45 pm

**Convention Center, S310ABFE, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Christine A. Sorkness, PharmD*

**12:45 LABAs: The Good, Bad and Ugly**

*Thomas B. Casale, MD FAAAAI*

**1:05 Drop the LABA or Decrease the ICS? Evidence Based Approach to Step-Down Care**

*Jan Brozek, MD*

**1:25 Balancing the FDA and EPR3 Recommendations on LABA Use**

*Monica Kraft, MD*

Upon completion of this session, participants should be able to: Review the data and controversy surrounding LABA safety; Discuss the evidence for the most appropriate approach to step down care in a well controlled asthma patient on ICS/LABA combination; Explore how best to use LABAs in clinical asthma care.

**Pro/Con Debate**

**5506 Acetaminophen (Paracetamol) Causes Wheezing and Asthma in Children**

12:45 to 1:45 pm

**Convention Center, S330EF, Level III**

Credit: 1.00 CME / 1.20 CE

*Moderator: Ronald A. Simon, MD FAAAAI*

**Pro**

*Dennis R. Ownby, MD FAAAAI*

**Con**

*Christine Cole Johnson, PhD MPH FAAAAI*

Upon completion of this session, participants should be able to: Describe experimental evidence linking acetaminophen use to childhood wheezing illnesses and asthma; Discuss potential confounding effects of concurrent illnesses.

**Oral Abstract**

**5601 Novel Mechanisms in Asthma Therapeutics**

2:00 to 3:15 pm

**Convention Center, S230AB, Level II**

Credit: 1.25 CME / 1.50 CE

*Moderators: Timothy Craig, DO FAAAAI*

*Heather K. Lenman, MD*

**2:00 Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy**

*Daniel M. Moldaver, BSc*

**2:15 A Comparison of the Local and Systemic Effects of AZD3199, an Inhaled Ultra-long-acting  $\beta$ 2-adrenoceptor Agonist (uLABA), With Formoterol in Patients With Asthma**

*Leif Bjermer, MD*

**2:30 Selective Blockade of Pulmonary Epithelial Stat3 for the Treatment of Asthma**

*Serge De Golovine, MD*

**2:45 Maternal Ashmi Therapy Reduces Offspring Susceptibility To Developing Airway Inflammation In A Murine Model**

*Kamal D. Srivastava, PhD*

**3:00 Myeloid Derived Suppressor Cells Attenuate Murine Allergic Airway Inflammation**

*Qingdong Guan, MSc*

**Oral Abstract****5602 Cellular Mechanisms of Allergy**

2:00 to 3:15 pm

Convention Center, S230GH, Level II

Credit: 1.25 CME / 1.50 CE

Moderator: Lisa R. Forbes, MD

**2:00 Expression of the Regulatory Protein Caveolin-1 is reduced in Asthma**

Sonia N. Bains, MD

**2:15 Mechanical Skin Injury Induces TLR4/MyD88 Dependent IL-23 Expression In Epidermal Keratinocytes**

Juhan Yoon, PhD

**2:30 Human Dendritic Cells Stimulated with a Novel Peanut Protein Express High Levels of RALDH2 and Induce RA-Sensitive Genes in Naïve T Cells**

Bert Ruiter, PhD

**2:45 Interaction With Myd88-dependent CD8-CD11c+ Cells Mediates Rapid Induction Of Antigen-specific IgE-suppressive Gamma Delta T Cells**

Yafei Huang, PhD

**3:00 Combined Blockade Of The Histamine H1 and H4 Receptor Suppresses Peanut-Induced Diarrhea And Intestinal Inflammation By Regulating Dendritic Cell Function**

Meiqin Wang, MD PhD

**Oral Abstract****5603 Viral Bronchiolitis and Asthma in Children**

2:00 to 3:15 pm

Convention Center, S330EF, Level III

Credit: 1.25 CME / 1.50 CE

Moderators: Pedro Avila, MD FAAAAI

Jeffrey G. Demain, MD FAAAAI

**2:00 Upregulation Of Glucocorticoids Beta Receptors In Severe Rsv Bronchiolitis In Infants.**

Patricia V. Diaz, MD PhD

**2:15 Sequence Analysis of a Cloned Human Rhinovirus Designed For Use in Human Inoculation Studies**

Kazuyuki Nakagome, MD PhD

**2:30 Risk of Childhood Asthma Following Infant Bronchiolitis During RSV Season**

Kristina M. James, MD

**2:45 Clinical Factors and Response to Albuterol in Wheezing Infants with Bronchiolitis & Respiratory Failure**

Christopher L. Carroll, MD

**3:00 Bacterial Detection In The Fall Is Associated With Increased Viral Respiratory Infections**

Kristen M. Kloefer, MD

**Oral Abstract****5604 Mechanisms of EGID**

2:00 to 3:15 pm

Convention Center, S330CD, Level III

Credit: 1.25 CME / 1.50 CE

Moderators: Juan Pablo Abonia, MD

Antonella Ciaferoni, MD PhD

**2:00 Proton-sensing Receptor GPR65 Regulates Allergic Gastrointestinal Eosinophilia**

Xiang Zhu, PhD

**2:15 Twin Shared Environment Increases Risk of Eosinophilic Esophagitis in Families.**

Eileen S. Alexander, MD

**2:30 Interleukin (il)-15 Overexpression In The Esophagus Promotes IgE Associated Experimental EoE**

Priya Rajavelu, PhD

**2:45 Increased CD3+CD69+ T-Cells and CD40+ Eosinophils in the Esophageal Tissue of Eosinophilic Esophagitis**

Minou Le-Carlson, MD

**3:00 Dietary Therapy and Topical Corticosteroids Can Reverse Esophageal Fibrosis in Patients with Eosinophilic Esophagitis**

Jay Lieberman, MD

**Oral Abstract****5605 Treatment of Immunodeficiency and Angioedema**

2:00 to 3:15 pm

Convention Center, S330GH, Level III

Credit: 1.25 CME / 1.50 CE

Moderators: Marcus S. Shaker, MD MS FAAAAI FAAP

John M. Weiler, MD FAAAAI

**2:00 Preferences for Immunoglobulin Treatment Administration Attributes by Patients and Parents**

Ateesha Mohamed, MA

**2:15 Financial Impact of Late Diagnosis of Severe Combined Immunodeficiency: Why It is Fiscally Sound for States to Invest in the Implementation of Newborn Screening**

Catherine Kubiak, MD

**2:30 Tolerability of Subcutaneous Immunoglobulin (SCIG) in Patients Receiving Antiplatelet (AP) and Anticoagulant (AC) Therapy**

John Kurryan, MD

**2:45 Discrepancies Between Guidelines and International Practice in the Treatment of Hereditary Angioedema: Results from a World Allergy Organization Survey of Physicians**

Melanie C. Dispenza, PhD

**3:00 Cost of Treating Hereditary Angioedema with Newly Available Medications in Five Different Settings**

Ajay Bhasin



**Oral Abstract**

- 5606 Immunotherapy**  
2:00 to 3:15 pm  
Convention Center, S230CD, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: David Hauswirth, MD FAAAAI
- 2:00 How Molecular Diagnosis Can Change Allergen-specific Immunotherapy Prescription In A Complex Area Of Pollen Sensitization (madrid, Spain).**  
Maria Eulalia Landivar Encalada, MD
- 2:15 Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer**  
Chia-Lin Hsu, MS
- 2:30 Bispecific Antibody-induced Allergen-specific Regulatory T cells (Tregs) Suppress Der-P-1-induced Airway Inflammation**  
Bellur S. Prabhakar, PhD
- 2:45 Long-term Safety Of A 300IR Sublingual Tablet Of 5-grass-pollen Allergen Extract In Adults With Grass-pollen-induced Allergic Rhinoconjunctivitis**  
Alain Didier, MD
- 3:00 Ragweed Allergy Immunotherapy Tablet Reduces Nasal and Ocular Symptoms of Allergic Rhinoconjunctivitis Over the Peak Ragweed Pollen Season in North America**  
Gary Berman, MD

**Oral Abstract**

- 5607 Mechanism of Allergic Sensitization**  
2:00 to 3:15 pm  
Convention Center, S230EF, Level II  
Credit: 1.25 CME / 1.50 CE  
Moderator: Nives Zimmerman, MD FAAAAI
- 2:00 Age-related Differences in Antigen Sensitization and the Allergic Airway Responses in Acute and Resolved Viral Respiratory Infection**  
Janette Birmingham, MS
- 2:15 Diesel Exhaust Particles Induce Cysteine Oxidation and S-Glutathionylation in House Dust Mite Induced Murine Asthma**  
Gerald B. Lee, MD
- 2:30 The Gut Mucosa Microenvironment Affects Allergic Sensitization vs tolerance to Food proteins**  
Karine Adel-Patient, PhD
- 2:45 Rhinovirus Matures Dendritic Cells (DCs) and Primes Them for Antigen Presentation**  
John W. Steinke, PhD FAAAAI
- 3:00 Leukocyte Ig-like Receptor LILRB4 (LILRB4) Downregulates Key Events in the Migration of Antigen (Ag)-bearing Lung Dendritic Cells in Th2 Inflammation**  
Laura B. Fanning, MD

**Late Breaking Oral Abstract**

- 5611 Clinical Sciences**  
2:00 to 3:15 pm  
Convention Center, S331CD, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderators to be announced.
- 2:00 Findings From Year 3 Of The National AAAAI/ACAAI Surveillance Study: Clinical Practices Related To Subcutaneous Immunotherapy (SCIT) Administration And The Risk Of Systemic Reactions (SRS)**  
Molly E.G. Epstein, MD MS
- 2:15 Prevalence of Eczema and Food Allergy is Associated with Latitude in Australia**  
Nicholas J. Osborne, PhD
- 2:30 Bacterial Lipopolysaccharide Triggers Dose-Dependent, Distinct Airway Inflammation in Childhood Asthma**  
Pia J. Hauk, MD
- 2:45 Novel Rituximab Desensitization Protocol Increases Safety of Drug Desensitization**  
Caroline L. Sokol, MD PhD
- 3:00 Can Novel Histologic Biomarkers Predict Correct Diagnosis And Treatment Response In Patients With Matched Esophageal Eosinophilia?**  
Srividya Sridhara, MD

**Problem-Based Learning Workshop**



- 5701 The Child with Chronic Cough**  
3:30 to 4:45 pm  
Convention Center, S331AB, Level III  
Pre-registration and ticket required. Fee: \$50.  
Credit: 1.25 CME / 1.50 CE  
Mary Beth Fasano, MD FAAAAI  
Alan B. Goldsobel, MD FAAAAI  
Upon completion of this session, participants should be able to: Determine the etiology of chronic cough at various ages; Define appropriate diagnostic tests; Evaluate appropriate therapeutic interventions for each diagnosis.

**Panel Discussion Workshop**

- 5702 Asthma and COPD: Similarities and Differences**  
3:30 to 4:45 pm  
Convention Center, S330AB, Level III  
Credit: 1.25 CME / 1.50 CE  
Moderator: Sally E. Wenzel, MD FAAAAI  
Eugene R. Bleecker, MD  
Monica Kraft, MD  
Ian D. Pavord, MD  
Upon completion of this session, participants should be able to: Compare and contrast asthma and COPD; Define how asthma and COPD are assessed.

**Q & A Workshop** ▼**5703 Diesel Exhaust Exposure and Children's Health**

3:30 to 4:45 pm

**Convention Center, S330CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Andrew M. Smith, MD***3:30 New Insights from the Cincinnati Birth Cohort***David I. Bernstein, MD FAAAAI***3:45 Immunologic Mechanisms***Gurjit K. Khurana Hershey, MD PhD FAAAAI***4:00 Diesel Exhaust and Allergen Interactions***David Diaz Sanchez, PhD***4:15 Question & Answer**

Upon completion of this session, participants should be able to: Discuss the most recent findings regarding the association between diesel exposure and wheezing in young children; Describe the interaction with DEP and allergens; Review the immunologic mechanisms by which diesel exposure promotes wheezing in young children.

**Q & A Workshop****5704 Innate Immunity and Allergic Disease: Evidence and Controversies**

3:30 to 4:45 pm

**Convention Center, S230CD, Level II**

Credit: 1.25 CME / 1.50 CE

*Moderator: Dale T. Umetsu, MD PhD FAAAAI***3:30 NK in Atopic Diseases: What is the Evidence?***Gunnur Deniz, MD***3:45 iNKT and Lipid Allergens: Their Role in Environmental and Food Allergies***Antonella Cianferoni, MD PhD***4:00 Macrophages: Which Role Do They Play in Asthma?***Mitchell H. Grayson, MD FAAAAI***4:15 Question & Answer**

Upon completion of this session, participants should be able to: Describe the biology of NK, iNKT and macrophages; Describe the role of NK, iNKT and macrophages in allergic inflammation; Discuss the role macrophages play in asthma.

**Panel Discussion Workshop****5705 Mechanisms of Virus/Allergen Interactions**

3:30 to 4:45 pm

**Convention Center, S230GH, Level II**

Credit: 1.25 CME / 1.50 CE

*Moderator: Peter W. Heymann, MD**Pedro Avila, MD FAAAAI**Michael Edwards, PhD**Daniel J. Jackson, MD**Nikolaos G. Papadopoulos, MD FAAAAI*

Upon completion of this session, participants should be able to: Describe three potential mechanisms for virus/allergen interactions; Discuss the role of reducing IgE-mediated inflammation on viral outcomes in patients with asthma; Explain the three risk factors for virus-induced exacerbations of asthma.

**Q & A Workshop****5706 Eosinophilic Esophagitis: Treatment Options**

3:30 to 4:45 pm

**Convention Center, S230AB, Level II**

Credit: 1.25 CME / 1.50 CE

*Moderator: Neal Jain, MD FAAAAI***3:30 Dietary Elimination in EE Patients***Mirna Chehade, MD***3:45 Food Reintroduction***Katrina J. Allen, MD PhD***4:00 When Dietary Elimination is Not Enough: Prognosis***Jonathan M. Spergel, MD PhD FAAAAI***4:15 Question & Answer**

Upon completion of this session, participants should be able to: Appreciate the complexity of food avoidance as a part of long-term therapy and highlight the evidence of the effectiveness of various protocols of dietary elimination; Gain insight into the methods used to reintroduce foods into the diet in EoE patients; Demonstrate what to do when dietary elimination is not enough.

**Q & A Workshop** ▼**5707 Alternate Models of Anaphylaxis**

3:30 to 4:45 pm

**Convention Center, S320CD, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Phillip L. Lieberman, MD FAAAAI***3:30 IgE and Non-IgE Mediated Models of Anaphylaxis***Fred D. Finkelman, MD***3:45 Anaphylaxis to Parasites***Thomas Nutman, MD***4:00 Anaphylaxis to Mammalian Meat After Tick Bites***Thomas A.E. Platts-Mills, MD PhD FAAAAI***4:15 Question & Answer**

Upon completion of this session, participants should be able to: Explain the paradigm of IgE and non-IgE mediated anaphylaxis; Describe the relevance of invasive and ectoparasites in anaphylaxis.

**Q & A Workshop** ▼**5708 Asthma Therapies and the FDA: Black Box Warning**

3:30 to 4:45 pm

**Convention Center, S310ABFE, Level III**

Credit: 1.25 CME / 1.50 CE

*Moderator: Stephen A. Tilles, MD FAAAAI***3:30 The LABAs***Malcolm R. Sears, MD FAAAAI***3:45 Leukotriene Modifiers***Jay M. Portnoy, MD FAAAAI***4:00 Omalizumab and the FDA***William W. Busse, MD FAAAAI***4:15 Question & Answer**

Upon completion of this session, participants should be able to: Discuss FDA labeling requirements for omalizumab; Discuss FDA warnings for montelukast; Discuss FDA warnings for LABAs.



**Q & A Workshop**

**5709 Fundamentals of Clinical Research Studies: Principles and Processes**

3:30 to 4:45 pm  
**Convention Center, S331CD, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Mary M. Klote, MD*

**3:30 Principles of Good Clinical Practice in Conducting Clinical Research Studies**

*Mary M. Klote, MD*

**3:45 Understanding the Basics in Managing Clinical Research Studies**

*Mark H. Moss, MD*

**4:00 Investigator and Study Site Responsibilities and Liability in Clinical Trials**

*Christine A. Sorkness, PharmD*

**4:15 Question & Answer**

Upon completion of this session, participants should be able to: Describe the activities associated with conducting responsible clinical research studies and reporting the results; Describe the responsibilities of various members of the clinical research team and understand the concepts of institutional review, informed consent and financial disclosure; Develop knowledge about concepts and functions associated with insuring overall quality and ethics of clinical research studies.

**Panel Discussion Workshop**

**5710 Is your Office Providing Optimal Allergen Immunotherapy?**

3:30 to 4:45 pm  
**Convention Center, S310CDGH, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderators: Richard F. Lockey, MD FAAAAI*  
*Mark S. La Shell, MD*  
*Bryan L. Martin, DO FAAAAI*  
*Michael S. Tankersley, MD FAAAAI*

Upon completion of this session, participants should be able to: Discuss the selection criteria one uses to select which patients might be the best candidates for immunotherapy, taking into account probability of success vs. risk of adverse events; Describe methods to improve clinic logistics, such as electronic records, tracking of stock vials and clinic supplies; Compare techniques for vial preparation used in one's office/ clinic with the new guidelines on vials.

**Q & A Workshop**

**5711 Experimental Models of Allergic Rhinitis: What is Their Clinical Relevance?**

3:30 to 4:45 pm  
**Convention Center, S330EF, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Fuad M. Barood, MD FAAAAI*

**3:30 Experimental Allergen Challenge Techniques in Allergic Rhinitis**

*Martin Wagenmann, MD FAAAAI*

**3:45 Utility of Environmental Exposure Units in Allergic Rhinitis**

*Anne K. Ellis, MD*

**4:00 Clinical Relevance of Allergen Challenges in the Therapy of Allergic Rhinitis**

*Alkis Togias, MD FAAAAI*

**4:15 Question & Answer**

Upon completion of this session, participants should be able to: Describe the most commonly used methods of experimental nasal allergen challenge for the investigation of allergic rhinitis; Describe the methodology utilized in Environmental Exposure Unit type studies of allergic rhinitis; Identify the clinical relevance of both models with respect to the natural history/treatment of allergic rhinitis.

**Q & A Workshop**

**5712 Anaphylaxis and Mastocytosis: The Spectrum of Clonal and Non-Clonal Systemic Mast Cell Activation**

3:30 to 4:45 pm  
**Convention Center, S320AB, Level III**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Luis Escribano, MD PhD FAAAAI*

**3:30 Mast Cell Activation and Signaling Pathways**

*Dean D. Metcalfe, MD FAAAAI*

**3:45 Immune Deficiency in Urticaria: New Molecular Understanding**

*Joshua D. Milner, MD*

**4:00 Mast Cell Mediators: Release and Systemic Consequences in Anaphylaxis and Mastocytosis**

*Melody C. Carter, MD*

**4:15 Question & Answer**

Upon completion of this session, participants should be able to: Recognize the mechanisms and pathways through which mast cells get activated; Describe the genetic basis of mast cell disorders; Describe the clinical features and treatment of mast cell disorders.

**Q & A Workshop**

**5713 Th2 Heterogeneity: Does Function Follow Form?**

3:30 to 4:45 pm  
**Convention Center, S230EF, Level II**  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Mark Larche, PhD*

**3:30 CCR8+, IL-5+ Th2 Cells in Mouse Models of Atopic Dermatitis**

*Sabina Islam, MD*

**3:45 Regulatory & Th2 Cell Contribution to Atopic Dermatitis**

*Judith A. Woodfolk, MChB PhD FAAAAI*

**4:00 Th2+17 Cells in Asthma**

*Yui-Hsi Wang, PhD*

**4:15 Question & Answer**

Upon completion of this session, participants should be able to: Identify recently described subpopulations of Th2 cells and how they are generated; Describe the different functional properties of various Th2 subpopulations that allow them to make different contributions to allergic disease pathogenesis; Explain different therapeutic strategies that may be used to target these Th2 subpopulations.

**BYOP Workshop**

**5714 Difficult Situations in Practice Management**

3:30 to 4:45 pm  
**Convention Center, S330GH, Level III**  
 Pre-registration and ticket required. No fee.  
 Credit: 1.25 CME / 1.50 CE  
*Moderator: Weily Soong, MD*

**Contracts**

*David A. Brown, MD*  
*Adhuna C. Mathuria, MD*

**Hiring and Firing**

*Marshall P. Grodofsky, MD FAAAAI*  
*Vinay Mehta, MD*

**Marketing**

*Paul M. Carter, MD, MHCM FAAAAI*  
*Stanley M. Fineman, MD MBA FAAAAI*

Upon completion of this session, participants should be able to: Identify and address difficult situations regarding employment and partnership contracts; Evaluate difficult situations in hiring and firing; Investigate difficult situations in marketing.



# Scientific Abstract Sessions

## Presidential Plenary

## Next Generation Science

2101

Session Time: Saturday, March 3, 2012,  
8:15 AM - 9:45 AM

- 1 **A Mutation in the Human Uncoordinated 119 Gene Impairs TCR Signaling and is Associated with CD4 Lymphopenia**  
M. M. Gorska<sup>1,2</sup>, R. Alam<sup>1,2</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Colorado Denver, Aurora, CO.
- 2 **Delayed Food Challenge Reactions Correspond Temporally to the Appearance of CD63+ Basophils in Subjects with IgE to alpha-Gal**  
S. Mozzicato<sup>1</sup>, H. R. James<sup>1</sup>, M. H. Land<sup>2</sup>, S. L. Pochan<sup>1</sup>, L. J. Workman<sup>1</sup>, T. A. E. Platts-Mills<sup>1</sup>, S. P. Commins<sup>1</sup>;  
<sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Duke University, Durham, NC.
- 3 **Rapid Induction Of Tolerance To Peanut By Antigen-coupled Cell Transfer**  
C. Hsu, C. B. Smarr, A. J. Byrne, S. D. Miller, P. J. Bryce;  
Northwestern University, Chicago, IL.
- 4 **Increased FcεRI Expression on Basophils at Birth Predicts Subsequent Allergic Sensitization**  
D. J. Jackson, M. D. Evans, S. Sahu, R. E. Gangnon, J. E. Gern, R. F. Lemanske, Jr.;  
University of Wisconsin School of Medicine and Public Health, Madison, WI.

## Poster Session

### Diagnostic and Monitoring in Asthma Management

2201

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 5 **Bronchial Hyperresponsiveness in sportschildren; Different methods to reach a diagnosis**  
L. Arochena, M. Fernandez-Nieto, V. Andregnette, M. Garcia del Potro, E. Aguado, J. Sastre;  
Fundacion Jimenez Diaz, Madrid, SPAIN.
- 6 **Probable Asthma Is Associated With Reduced Lung Function Among Recurrent Wheezing Infants**  
G. F. Wandalsen, F. C. Lanza, A. Dela Bianca, C. L. Cruz, D. Sole;  
Federal University of São Paulo, Sao Paulo - SP, BRAZIL.
- 7 **Mannitol Bronchoprovocation in the Evaluation of Airway Reactivity in a High-Risk Pediatric Cohort**  
A. Y. Okupa, D. J. Jackson, C. A. Sorkness, V. P. Rajamanickam, T. J. Kang, I. A. Awoyinka, E. L. Anderson, R. F. Lemanske, Jr;  
University of Wisconsin, Madison, WI.
- 8 **Comparison Between Methacholine And Mannitol Tests For The Study Of Bronchial Hyperresponsiveness In Asthma Induced By Exercise In Pediatric Athletes**

- M. Andregnette, M. Fernandez Nieto, L. Arochena, M. Garcia Del Potro, E. Aguado, J. Sastre;  
Fundacion Jimenez Diaz, Madrid, Spain.
- 9 **Association between Atopy and Bronchial Hyperresponsiveness in Preschool children with Recurrent Wheezing**  
J. Lee, D. Suh, Y. Koh;  
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.
  - 10 **Is Methacholine Challenge Sufficient To Rule Out Bronchial Hyperresponsiveness In Patients With Suspected Asthma?**  
I. D. Bobolea, P. Barranco, V. Lopez-Carrasco, O. Calderon, D. Guillen, S. Quirce;  
La Paz Hospital, Madrid, SPAIN.
  - 11 **Mannitol Challenge for Diagnosis of Exercise -Induced Bronchoconstriction :Experience in Practice**  
C. C. Randolph<sup>1,2</sup>, C. Kaplan<sup>1</sup>, M. Randolph<sup>1</sup>, S. Asevica<sup>1</sup>;  
<sup>1</sup>Center for Allergy, Asthma & Immunology, Waterbury, CT, <sup>2</sup>Yale Univ Medical Center, New Haven, CT.
  - 12 **Exercise-Induced Bronchoconstriction in Thai Pediatric Asthma: Prevalence and Risk Factors**  
U. Yimsuwan;  
Queen Sirikit National Institute of Child Health, Bangkok, THAILAND.
  - 13 **Usefulness Of Impulse Oscillometry In Children With Eosinophilic Bronchitis**  
Y. Kim<sup>1</sup>, K. Kim<sup>1</sup>, J. Baek<sup>1</sup>, H. Park<sup>1</sup>, H. Lee<sup>2</sup>, M. Sohn<sup>1</sup>, K. Kim<sup>1</sup>;  
<sup>1</sup>Department of Pediatrics and Institute of Allergy, Severance Biomedical Science Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Kwandong University College of Medicine, Goyang, KOREA, REPUBLIC OF.
  - 14 **Eucapnic Voluntary Hyperventilation Screen for Bronchospasm Risk During a SCUBA Dive**  
R. R. Rosenthal;  
Johns Hopkins School of Medicine, Baltimore, MD.
  - 15 **BMI Does Not Correlate with PFTs in Asthma Screening**  
L. A. Wiens;  
BreatheAmerica, Tulsa, OK.
  - 16 **Patterns of Aeroallergen Sensitization and Development of Sputum Eosinophilia and Airway Hyperresponsiveness**  
S. Kim<sup>1,2</sup>, W. Song<sup>1,2</sup>, T. Kim<sup>2</sup>, S. Lee<sup>2</sup>, H. Kang<sup>2</sup>, H. Park<sup>2</sup>, S. Kim<sup>2</sup>, Y. Chang<sup>1,2</sup>, S. Cho<sup>2</sup>, K. Min<sup>2</sup>;  
<sup>1</sup>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>2</sup>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.
  - 17 **Pitfalls In The Diagnosis Of Allergic Bronchopulmonary Aspergillosis In Patients With Asthma In Real Clinical Practice**  
S. Lee, M. Park, K. Kim, Y. Nam, H. Lee, I. Jeong, S. Park, S. Um, C. Son;  
Dong-A University, Busan, KOREA, REPUBLIC OF.
  - 18 **A rare case of Allergic Bronchopulmonary Mycosis secondary to Penicillium**  
K. Zakarian, S. Min, P. Huynh, L. Scott;  
LAC-USC, Los Angeles, CA.
  - 19 **Genetics of Asthma Exacerbations: A Candidate Gene and Genome-Wide Association Study**  
H. G. Ortega, L. Huang, B. Koshy, S. Sinnett, M. Mosteller, W. Anderson;  
GlaxoSmithKline, Research Triangle Park, NC.

- 20 **Changes in Prevalence with Different Definitions of a "Positive" Skin Test**  
J. Wildfire<sup>1</sup>, S. Arbes<sup>1</sup>, P. Gerger<sup>2</sup>;  
<sup>1</sup>Rho, Inc, Chapel Hill, NC, <sup>2</sup>National Institute of Allergy and Infectious Diseases, Bethesda, MD.
- 21 **Cord Blood Cellular Proliferative Response As A Predictive Factor For Atopic Dermatitis At 6 Months of Age**  
H. Kim<sup>1</sup>, J. Seo<sup>2</sup>, H. Kim<sup>2</sup>, J. Kwon<sup>3</sup>, B. Kim<sup>4</sup>, J. Shim<sup>5</sup>, W. Kim<sup>6</sup>, D. Song<sup>7</sup>, S. Lee<sup>8</sup>, S. Lee<sup>9</sup>, G. Jang<sup>10</sup>, K. Kim<sup>11</sup>, K. Ahn<sup>5</sup>, Y. Shin<sup>12</sup>, J. Yu<sup>2</sup>, M. Kang<sup>2</sup>, K. Lee<sup>2</sup>, S. Hong<sup>2</sup>;  
<sup>1</sup>Inje University Sanggye Paik Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>4</sup>Inje University Haeundae Paik Hospital, Pusan, KOREA, REPUBLIC OF, <sup>5</sup>Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>6</sup>Inje University Seoul Paik Hospital, Seoul, KOREA, REPUBLIC OF, <sup>7</sup>College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>8</sup>Hallym University College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>9</sup>Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, <sup>10</sup>National Health Insurance Corporation Ilsan Hospital, Ilsan, KOREA, REPUBLIC OF, <sup>11</sup>Yonsei University, Seoul, KOREA, REPUBLIC OF, <sup>12</sup>CHA University School of Medicine, Seoul, KOREA, REPUBLIC OF.
- 22 **Allergic Airways Responses Are Associated With A Late-phase Systemic Inflammatory Response In An Environmental Allergen Challenge Model**  
E. N. Torjusen, S. Biswal, M. Ong, B. Thomas, S. Noel, G. Diette, P. Breysse, E. Matsui;  
Johns Hopkins, Baltimore, MD.
- 23 **Real Time Pcr Detection Of Aspergillus Fumigatus, Aspergillus Flavus And Aspergillus Niger Based On Polyketide Synthase Gene P. J. Bhetariya<sup>1</sup>, Y. Singh<sup>1</sup>, T. Madan<sup>1</sup>, S. Basir<sup>2</sup>, P. Sarma<sup>3</sup>;**  
<sup>1</sup>Institute of Genomics and Integrative Biology, Delhi, INDIA, <sup>2</sup>Jamia Milia Islamia, New Delhi, INDIA, <sup>3</sup>Indian Agricultural Research Institute, New Delhi, INDIA.
- 24 **Sex-related Differences in Atopic Phenotype Expression and Immune Responses in Childhood**  
A. Thomas, D. J. Jackson, C. J. Tisler, V. Rajamanickam, R. E. Gangnon, R. F. Lemanske, Jr;  
University of Wisconsin, Madison, WI.
- 25 **Asthma Phenotypes in School-aged Children from the Population Study: Cluster Analysis**  
J. Kwon<sup>1</sup>, J. Seo<sup>2</sup>, H. Kim<sup>2</sup>, B. Kim<sup>3</sup>, H. Kim<sup>4</sup>, S. Lee<sup>5</sup>, K. Park<sup>6</sup>, S. Hong<sup>2</sup>;  
<sup>1</sup>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>2</sup>Department of Pediatrics, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, Haeundae Paik Hospital, Inje University College of Medicine, Busan, KOREA, REPUBLIC OF, <sup>4</sup>Department of Pediatrics, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>5</sup>Department of Pediatrics, Hallym University Sacred Heart Hospital, Suwon, KOREA, REPUBLIC OF, <sup>6</sup>Department of Pediatrics, Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF.
- 26 **Ectoparasite Induced Elevations of alpha-gal Specific IgE are Associated with Increased Total Serum IgE and Cat Sensitization but not with Asthma**  
L. A. Kelly, S. L. Pochan, H. R. James, L. J. Workman, P. W. Heymann, S. P. Commins, T. A. E. Platts-Mills;  
University of Virginia, Charlottesville, VA.
- 27 **Helicobacter Pylori, A Protective Agent For Asthma Or Not?**  
C. Camacho, J. Santiago, V. VELAZQUEZ, M. Gonzalez, A. Sepulveda, J. Ramos;  
Hospital Episcopal San Lucas, Ponce, PR.
- 28 **The Role of Atopy as a Predictor of Childhood Atopic Asthma**  
S. Abbott, R. Green, C. Els;  
University of Pretoria, Pretoria, SOUTH AFRICA.
- 29 **Assessment of Repeated Measures of Fractional Exhaled Nitric Oxide in Clinically Stable Persistent Asthma**  
A. Elizalde, R. J. Khan, S. Chinratanapisit, M. J. Dorsey;  
University of South Florida, Saint Petersburg, FL.
- 30 **Identification of Vocal Cord Dysfunction by Methacholine Laryngoscopy Reduces Inhaled Corticosteroid and Rescue Inhaler Use in Children and Adults**  
J. S. Tam<sup>1</sup>, N. L. Hartog<sup>2</sup>, K. Divine<sup>1</sup>, M. Dasgupta<sup>1</sup>, R. K. Hoffman<sup>1</sup>, M. Vasudev<sup>1</sup>;  
<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>University of Iowa, Iowa City, IA.
- 31 **Asthma In The Elderly: The Role Of Exhaled Nitric Oxide Measurements**  
M. Columbo<sup>1</sup>, B. Wong<sup>2</sup>, R. A. Panettieri, Jr.<sup>3</sup>, A. S. Rohr<sup>1</sup>;  
<sup>1</sup>Asthma, Allergy and Immunology Specialists, Bryn Mawr, PA, <sup>2</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
- 32 **Ipratropium Normalizes FEV1 Following Methacholine Challenge in Patients Diagnosed with Vocal Cord Dysfunction**  
B. A. Locke, J. Tam, N. L. Hartog, K. Divine, M. Dasgupta, R. Hoffmann, M. Vasudev;  
Medical College of Wisconsin, Milwaukee, WI.
- 33 **Gastroesophageal Reflux in Patients with Chronic Cough**  
R. Agondi, J. Kalil, P. Giavina-Bianchi;  
University of Sao Paulo, Sao Paulo, BRAZIL.
- 34 **Development and Preliminary Validation of the Asthma Intensity Manifestations Score (AIMS) Derived from Asthma Control Test, FEV<sub>1</sub>, Exhaled Nitric Oxide, and Step Therapy Assessments**  
M. Schatz, R. Zeiger, F. Zhang, W. Chen;  
Kaiser Permanente, San Diego, CA.
- 35 **The Role Of Induced Sputum Cytology In Clinical Monitoring Of Childhood Asthma**  
Z. Tamay<sup>1</sup>, B. Kucukemre Aydin<sup>2</sup>, G. Kılıc<sup>3</sup>, A. Suleyman<sup>4</sup>, F. Aydin<sup>2</sup>, D. Yilmazbayhan<sup>5</sup>, N. Guler<sup>1</sup>;  
<sup>1</sup>Istanbul University, Istanbul Medical Faculty, Department of Pediatric Allergy, İstanbul, TURKEY, <sup>2</sup>Istanbul University, Istanbul Medical Faculty, Department of Pediatrics, İstanbul, TURKEY, <sup>3</sup>Bursa Dörtcelik Çocuk Hastanesi, Bursa, TURKEY, <sup>4</sup>Istanbul University, Istanbul Medical Faculty; Department of Pediatrics, İstanbul, TURKEY, <sup>5</sup>Istanbul University, Istanbul Medical Faculty Department of Pathology, İstanbul, TURKEY.
- 36 **A Retrospective Analysis of Distinguishing Features Between Asthma and Vocal Cord Dysfunction**  
R. S. Traister, E. Whitman, W. C. Anderson, D. P. Landsittel, M. Fajt, A. A. Petrov;  
University of Pittsburgh Medical Center, Pittsburgh, PA.
- 37 **Phenotypes of Rhinitis and Difficult Asthma**  
I. Agache<sup>1</sup>, C. Ciobanu<sup>2</sup>, V. Barbieru<sup>1</sup>;  
<sup>1</sup>Transylvania University Brasov, Faculty of Medicine, Brasov, ROMANIA, <sup>2</sup>SC Theramed SRL, Brasov, ROMANIA.

## Poster Session

## Immune Cells

2202

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 38 **Sprouty2 is a Novel Regulator of T cell Activation and Differentiation**  
L. Guo<sup>1</sup>, C. Chen<sup>1</sup>, M. Gorska<sup>1,2</sup>, R. Alam<sup>1,2</sup>;



- <sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Colorado at Denver and Health Sciences Center, Denver, CO.
- 39 **Stat5b (Signal Transducer and Activator of Transcription 5b), Not Stat5a, Is a Critical Modulator of Human Treg Development and Function**  
J. Jenks, S. Seki, J. Huang, R. Nath, M. Madmedov, V. Hwa, R. Rosenfeld, K. C. Nadeau;  
Stanford University School of Medicine, Stanford, CA.
- 40 **Hyperthermia enhances Th1 differentiation and downregulates FOX3 expression in Tregs**  
D. Q. Tran, J. M. Bull;  
University of Texas Medical School at Houston, Houston, TX.
- 41 **Critical Role Of T Follicular-helper Cells In B Cell Autoimmunity During Lymphopenia**  
M. Imamura<sup>1</sup>, T. Kanzaki<sup>1</sup>, K. Kawahata<sup>1</sup>, L. Akahira<sup>1</sup>, K. Michishita<sup>1</sup>, T. Eri<sup>1</sup>, M. Dohi<sup>1</sup>, T. Tokuhisa<sup>2</sup>, K. Yamamoto<sup>1</sup>;  
<sup>1</sup>the University of Tokyo, Tokyo, JAPAN, <sup>2</sup>Chiba University, Chiba, JAPAN.
- 42 **Per a 10 Protease Activity Induces Th2 Polarization That Is Amplified By Allergic Status**  
N. Arora<sup>1</sup>, C. Goel<sup>1</sup>, N. Kalra<sup>2</sup>, B. S. Dwarakanath<sup>2</sup>, S. N. Gaur<sup>3</sup>;  
<sup>1</sup>Institute of Genomics and Integrative Biology, Delhi, INDIA, <sup>2</sup>Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA, <sup>3</sup>Vallabhbhai Patel chest Institute, Delhi, INDIA.
- 43 **IgE and Atopy Are Associated With Phosphorylated P38 MAPK Expression By CD4 and CD8 T Lymphocytes**  
J. I. Silverberg<sup>1,2</sup>, H. G. Durkin<sup>2</sup>, R. Joks<sup>2</sup>;  
<sup>1</sup>St Lukes-Roosevelt Hospital Center, New York, NY, <sup>2</sup>State University of New York Downstate Medical Center, Brooklyn, NY.
- 44 **Regulatory T cell regulation by STAT5B**  
T. Kanai, S. Seki, J. Jenks, K. Nadeau;  
Stanford University, stanford, CA.
- 45 **The Effect Of Phototherapy On Lymphocyte Subsets In New-born Infants**  
R. A. A. ELFeky<sup>1</sup>, M. A. Abdel Fattah<sup>1</sup>, D. M. Gaafar<sup>1</sup>, H. M. Afifi<sup>2</sup>;  
<sup>1</sup>Pediatric Department Ain Shams University, Cairo, EGYPT, <sup>2</sup>Clinical Pathology Department, Ain Shams University, Cairo, EGYPT.
- 46 **CD27<sup>+</sup> Developing B Cells are Common in Human Fetal Liver**  
L. M. McWilliams, K. Y. Su, X. Liang, S. Floyd, J. Amos, M. Moody, G. Kelseo, M. Kuraoka;  
Duke University Medical Center, Durham, NC.
- 47 **Intravenous Immunoglobulins Suppress Antibody-Dependent Effector Functions of Human Peripheral Blood Cells**  
S. Bunk, A. Trbic, A. M. Winkler, A. Weber, H. P. Schwarz, B. M. Reipert, C. Hermann;  
Baxter BioScience, Vienna, AUSTRIA.
- 48 **Physiologic DNA Breaks Activate Non-canonical NFkB Signaling in Developing B Cells**  
A. A. Trott, J. J. Bednarski, B. P. Sleckman;  
Washington University School of Medicine, St. Louis, MO.
- 49 **Phenotypic Characterization Of Immune Cells Isolated From Adenoids And Tonsils Of Children With Adenoid And Tonsil Hypertrophy**  
L. P. Titov<sup>1</sup>, A. M. Dashkevich<sup>1</sup>, V. L. Chekan<sup>2</sup>, L. M. DuBuske<sup>3</sup>;  
<sup>1</sup>Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, <sup>2</sup>Republica Scientific-and-Practical Center for Epidemiology and Microbiology, Minsk, BELARUS, <sup>3</sup>Immunology Research Institute of New England, Gardner, MA.
- 50 **B Cell Phenotype in Patients with Common Variable Immunodeficiency (CVID) and its Relation to their Clinical Characteristics**  
A. M. Kahn<sup>1</sup>, G. Luque<sup>1</sup>, G. Gatti<sup>2</sup>, M. Maccioni<sup>2</sup>, J. J. Garcia<sup>1</sup>, E. Cuestas<sup>1</sup>, A. Basquiera<sup>1</sup>, B. Ricchi<sup>1</sup>, V. E. Rivero<sup>2</sup>;  
<sup>1</sup>Hospital Privado, Cordoba, ARGENTINA, <sup>2</sup>Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET),

Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, ARGENTINA.

- 51 **Altered Frequency And Composition Of Cultured Natural Killer Cells From Food Allergic Subjects**  
A. Bhatt, L. Ford, M. Masilamani, H. Sampson;  
Mount Sinai Medical Center, New York, NY.

## Poster Session

### Biologic Therapy, Immunoglobulin Replacement

2203

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 52 **Glycine vs. L-Proline Stabilization of IGIV Solution: 18-Month Follow-up Data to Support Equally Effective Stabilization**  
A. K. Sun<sup>1</sup>, Y. Wu<sup>2</sup>, G. Pot<sup>3</sup>, E. Vandamme<sup>3</sup>, W. Teschner<sup>4</sup>, H. P. Schwarz<sup>4</sup>;  
<sup>1</sup>Baxter Healthcare Corporation, Los Angeles, CA, <sup>2</sup>Baxter Healthcare Corporation, Westlake Village, CA, <sup>3</sup>Baxter Healthcare Corporation, Lessines, BELGIUM, <sup>4</sup>Baxter Healthcare Corporation, Vienna, AUSTRIA.
- 53 **Home Care Use of Intravenous and Subcutaneous Immunoglobulin for Primary Immunodeficiency in the United States**  
F. Huang, C. Cunningham-Rundles;  
Mount Sinai School of Medicine, New York, NY.
- 54 **Factors Affecting Infusion of High (20%) vs Lower Concentration (16%) SCIG in Primary Immunodeficiency Disorders**  
Z. Panahloo<sup>1</sup>, S. Jolles<sup>2</sup>;  
<sup>1</sup>CSL Behring Ltd, Haywards Heath, UNITED KINGDOM, <sup>2</sup>University Hospital of Wales, Cardiff, UNITED KINGDOM.
- 55 **Pharmacokinetics (PK) of Human Immunoglobulin 10% (IGG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PID)**  
M. Stein<sup>1</sup>, R. L. Wasserman<sup>2</sup>, I. Melamed<sup>3</sup>, J. Puck<sup>4</sup>, S. Gupta<sup>5</sup>, W. Engl<sup>6</sup>, H. Leibl<sup>6</sup>, D. Gelmont<sup>7</sup>, R. I. Schiff, on behalf of IGSC, 10% rHuPH20 Study Group<sup>7</sup>;  
<sup>1</sup>IMMUNOe, Centennial, CO, <sup>2</sup>Dallas Allergy Immunology, Dallas, TX, <sup>3</sup>Allergy Associates of the Palm Beaches, North Palm Beach, FL, <sup>4</sup>University of California, San Francisco, CA, <sup>5</sup>University of California, Irvine, CA, <sup>6</sup>Baxter BioScience, Vienna, AUSTRIA, <sup>7</sup>Baxter BioScience, Westlake Village, CA.
- 56 **Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PID)**  
R. L. Wasserman<sup>1</sup>, I. Melamed<sup>2</sup>, M. Stein<sup>3</sup>, J. Puck<sup>4</sup>, S. Gupta<sup>5</sup>, W. Engl<sup>6</sup>, H. Leibl<sup>6</sup>, D. Gelmont<sup>7</sup>, R. I. Schiff on behalf of IGSC 10% rHuPH20 Study Group<sup>7</sup>;  
<sup>1</sup>Dallas Allergy Immunology, Dallas, TX, <sup>2</sup>Allergy Associates of the Palm beaches, North Palm Beach, FL, <sup>3</sup>IMMUNOe, Centennial, CO, <sup>4</sup>University of California, San Francisco, CA, <sup>5</sup>University of California, Irvine, CA, <sup>6</sup>Baxter BioScience, Vienna, AUSTRIA, <sup>7</sup>Baxter BioScience, Westlake Village, CA.
- 57 **Subcutaneous Hizentra® (20%) Is Better Tolerated And Shares Similar Efficacy Compared To Subcutaneous Vivaglobin® (16%)**  
D. Nguyen, M. Dorsey, T. Alberdi, C. Duff, J. Sleasman;  
University of South Florida/All Children's Hospital, St. Petersburg, FL.

- 58 **Targeting IL-18 by Employing a Recombinant IL-18 Peptide-based Vaccine Ameliorates TNBS-induced Murine Acute and Chronic Colitis**  
S. Moreno, Q. Guan, C. Weiss, Q. Gefei, C. Bernstein, Z. Peng; University of Manitoba, Winnipeg, MB, CANADA.
- 59 **In Patients With Hereditary Angioedema, Self-administration Of Intravenous C1 Esterase Inhibitor Decreases The Number Of Days Spent In An Emergency Room**  
C. Rizk<sup>1</sup>, S. Santucci<sup>2</sup>, S. McDiarmid<sup>1</sup>, J. Karsh<sup>1</sup>, W. H. Yang<sup>1</sup>; <sup>1</sup>University of Ottawa, Ottawa, ON, CANADA, <sup>2</sup>Yang Medicine, Ottawa, ON, CANADA.
- 60 **IgG Trough Levels are Poor Predictors of Infectious Outcomes in Pediatric Patients on Immunoglobulin Replacement**  
M. Mahendra<sup>1</sup>, S. McGhee<sup>1,2</sup>; <sup>1</sup>UCLA, Westwood, CA, <sup>2</sup>Stanford University, Palo Alto, CA.
- 61 **Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Two Infants with Immunodeficiency**  
J. L. Gallagher, N. C. Patel; Carolinas Medical Center, Charlotte, NC.
- 62 **Desensitization Approach Using High-Concentration Subcutaneous Immunoglobulin in a Bruton's-Like Patient With a Previous Anaphylactic Reaction to Intravenous Immunoglobulin**  
T. Prince, M. Gettys; The Allergy Asthma and Sinus Center, Maryville, TN.
- 63 **Immunoglobulin Replacement Therapy: A 20 Year Review and Current Update**  
M. Saeedian<sup>1</sup>, I. Randhawa<sup>2</sup>; <sup>1</sup>UCLA, Los Angeles, CA, <sup>2</sup>UC Irvine, Miller Children's Hospital, Irvine, CA.

## Poster Session

## Bioaerosols

2204

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 64 **Exposure to Smaller-Sized Fungal Fragments in Homes with a Childhood Asthmatic**  
S. Seo<sup>1</sup>, Y. Cho<sup>1</sup>, J. Choi<sup>1</sup>, Y. Yoo<sup>2</sup>, D. Kim<sup>3</sup>, J. Choung<sup>2</sup>; <sup>1</sup>Korea University, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Korea University Medical Center, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Public Administration, North Carolina Central University, Durham, NC.
- 65 **Effect of meteorological parameters on airborne fungal spore counts: Sixteen Year Study (1995-2010) in Sarasota, FL**  
N. Talreja, M. Jelks, M. Haq, G. Helleman, D. K. Ledford, R. F. Lockey; University Of South Florida, Tampa, FL.
- 66 **Profiling of Endotoxin Induced Immune Regulatory Network in Ovalbumin Sensitized Mice**  
S. Kumar, E. Kettleman, M. T. Borchers, J. Chakrabarti, T. Reponen, S. A. Grinshpun, A. Adhikari; University of Cincinnati, Cincinnati, OH.
- 67 **Airborne Fungus Diversity and Concentrations in Inner City Elementary Schools**  
S. N. Baxi<sup>1</sup>, W. J. Sheehan<sup>1</sup>, P. Permaul<sup>2</sup>, J. M. Gaffin<sup>1</sup>, D. Rao<sup>1</sup>, C. Fu<sup>3</sup>, C. Rogers<sup>4</sup>, M. Muilenberg<sup>4</sup>, E. B. Hoffman<sup>5</sup>, D. R. Gold<sup>6</sup>, W. Phipatanakul<sup>1</sup>; <sup>1</sup>Children's Hospital Boston, Boston, MA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>Channing Laboratory, Boston, MA,
- 68 **Evaluation Of The Proinflammatory Activity Of Basidiospores And Spore-bearing Tissues From The Mushroom *Chlorophyllum Molybdites* Using Human Whole Blood**  
F. E. Rivera-Mariani, T. Hartung, P. N. Breyse; Johns Hopkins University, School of Public Health, Baltimore, MD.
- 69 **Inactivation of Stachybotrys Antigen by Mold Remediation Chemicals**  
A. Dixit, B. R. Tumala; Saint Louis University School of Medicine, St. Louis, MO.
- 70 **Differences of Indoor Endotoxin Levels from South Florida versus Latin American Bedrooms of Hispanic/Latino Children**  
M. J. Lanz<sup>1</sup>, B. Efav<sup>2</sup>, R. Harbeck<sup>2</sup>, A. H. Liu<sup>2</sup>; <sup>1</sup>AAADRS, Coral Gables, FL, <sup>2</sup>National Jewish Health, Denver, CO.
- 71 **Metagenomic Analysis Of Bacteria And Bacteria-derived Nanovesicles Collected From Indoor Dust**  
Y. Kim<sup>1</sup>, Y. Jee<sup>2</sup>, Y. Gho<sup>1</sup>, Y. Kim<sup>1</sup>; <sup>1</sup>POSTECH, Pohang/Gyungbuk, KOREA, REPUBLIC OF, <sup>2</sup>Dankook University College of Medicine, Cheonan, KOREA, REPUBLIC OF.

## Poster Session

## Urban Allergen and Pollutant Exposures

2205

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 72 **Ambient Air Pollution and Allergic Sensitization: Results from the National Health and Examination Survey (NHANES) 2005-2006**  
C. Weir<sup>1</sup>, K. Yeatts<sup>1</sup>, W. Vizuete<sup>1</sup>, S. London<sup>2</sup>, P. M. Salo<sup>2</sup>, R. Jaramillo<sup>3</sup>, D. Zeldin<sup>4</sup>; <sup>1</sup>Univ of North Carolina Chapel Hill, Chapel Hill, NC, <sup>2</sup>National Institute of Environmental Health Sciences, Research Triangle Park, NC, <sup>3</sup>SRA International Inc., Durham, NC, <sup>4</sup>National Institute of Environmental Health Sciences, Durham, NC.
- 73 **Time Trends In Residential Indoor Polycyclic Aromatic Hydrocarbon Exposures Among Inner City Children**  
S. Hasan<sup>1</sup>, K. H. Jung<sup>2</sup>, S. Hsu<sup>2</sup>, K. Moors<sup>2</sup>, B. Yan<sup>3</sup>, P. L. Kinney<sup>4</sup>, S. Chillrud<sup>3</sup>, R. Whyatt<sup>4</sup>, D. Camann<sup>5</sup>, F. P. Perera<sup>4</sup>, R. L. Miller<sup>2</sup>; <sup>1</sup>Department of Medicine, Columbia Presbyterian Medical Center, New York, NY, <sup>2</sup>Division of Pulmonary, Allergy and Critical Care of Medicine, Department of Medicine, College of Physicians and Surgeons, New York, NY, <sup>3</sup>Lamont-Doherty Earth Observatory, Columbia University, New York, NY, <sup>4</sup>Columbia Center for Childrens Environmental Health, Mailman School of Public Health, Columbia University, New York, NY, <sup>5</sup>Chemistry and Chemical Engineering Division, Southwest Research Institute, San Antonio, TX.
- 74 **Urban Heat And Humidity Islands And The Preferential Deposition Of Airborne Pollen**  
P. K. Van de Water<sup>1</sup>, L. Bunderson<sup>2</sup>, J. Luval<sup>3</sup>, E. Levetin<sup>2</sup>; <sup>1</sup>California State University Fresno, Fresno, CA, <sup>2</sup>University of Tulsa, Tulsa, OK, <sup>3</sup>Marshall Space Flight Center, Huntsville, AL.
- 75 **Risks Factors for Exercise-Induced Wheeze Among Asthmatics in NYC Include Neighborhood Asthma Prevalence and Differ by Seroatopy**  
T. Mainardi<sup>1</sup>, A. Cornelli<sup>2</sup>, L. Acosta<sup>3</sup>, I. Goldstein<sup>4</sup>, A. Rundle<sup>4</sup>, R. Mellins<sup>5</sup>, L. Hoepner<sup>3,6</sup>, F. Perera<sup>3</sup>, J. Jacobson<sup>4</sup>, R. Miller<sup>1,3</sup>, M. Perzanowski<sup>3</sup>;

<sup>1</sup>Division of Pulmonary, Allergy, Critical Care Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, NY, <sup>2</sup>Division of Pediatric Pulmonology, Dartmouth-Hitchcock Medical Center, Hanover, NH, <sup>3</sup>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York City, NY, <sup>4</sup>Department of Epidemiology, Mailman School of Public Health, Columbia University, New York City, NY, <sup>5</sup>Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York City, NY, <sup>6</sup>Data Coordinating Center, Mailman School of Public Health, New York City, NY.

- 76 **Seasonal Variation of Pollen and Spore Counts Does Not Influence Severity of Sleep Apnea**  
S. Cajjgal, V. Krishnan;  
MetroHealth Medical Center, Cleveland, OH.

## Poster Session

### Food Allergy I-Diagnosis and Treatment

2206

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 77 **The Role Of Skin Prick Testing And Specific IgE To Boiled Versus Unheated Cow Milk In Cow Milk Allergic Children**  
J. C. Hong, A. P. Knutsen;  
Saint Louis University, Saint Louis, MO.
- 78 **Characterization Of Immunologic Parameters In Children With Variable Milk Protein Tolerance**  
A. H. Nowak-Węgrzyn, E. Strong, M. Groetch, H. A. Sampson;  
Mt. Sinai School of Medicine, New York, NY.
- 79 **Casein-specific Regulatory T Cells and Effector T Cells in Patients with Variable Milk Protein Tolerance**  
J. D. Kattan, A. Nowak-Węgrzyn, M. Masilamani, A. O. Bhatt, H. A. Sampson;  
Mount Sinai School of Medicine, New York, NY.
- 80 **Predicting Food Challenge Outcomes for Baked Milk: Role of Specific IgE and Skin Prick Testing**  
L. M. Bartnikas, W. J. Sheehan, L. C. Schneider, W. Phipatanakul;  
Children's Hospital Boston, Boston, MA.
- 81 **Reaction in the First Month of Life and a Lower Eliciting Dose are Risk Factors for Persistence of IgE-Mediated Cow's Milk Allergy**  
A. Elizur<sup>1,2</sup>, N. Rajuan<sup>1</sup>, M. R. Goldberg<sup>1</sup>, M. Leshno<sup>3</sup>, A. Cohen<sup>1</sup>, Y. Katz<sup>1,2</sup>;  
<sup>1</sup>Allergy and Immunology Institute, Asaf Harofeh Medical Center, Sackler School of Medicine, Tel Aviv University, Zerifin, ISRAEL, <sup>2</sup>Department of Pediatrics, Asaf harofeh Medical Center, Zerifin, ISRAEL, <sup>3</sup>Faculty of Management, Tel Aviv University, Tel Aviv, ISRAEL.
- 82 **Role Of Egg-white-specific Iga And Iga2 Levels In Egg Allergy: A Longitudinal Cohort Study**  
G. N. Konstantinou, A. Nowak-Węgrzyn, L. Bardina, S. H. Sicherer, H. Sampson;  
Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY.
- 83 **Ovalbumin and Ovomuroid IgE/IgG4 Epitopes in Patients Ingesting Baked Egg Products by Peptide Microarray Immunoassay**  
G. Gimenez, J. C. Caubet, S. Leonard, J. Lin, Z. Fu, L. Bardina, H. A. Sampson, A. Nowak-Węgrzyn;  
Mount Sinai School of Medicine, New York, NY.
- 84 **Identifying Characteristics in Egg-Allergic Subjects to Predict Heated Egg Tolerance: A Retrospective Review**  
N. U. Swamy<sup>1</sup>, M. Crain<sup>2</sup>, J. A. Bird<sup>2</sup>;  
<sup>1</sup>UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Childrens Medical Center, Dallas, TX.
- 85 **Association To Other Food Allergies And Persistence Of IgE-mediated Hen's Egg Allergy**  
F. J. Ruano, N. Blanca-Lopez, M. Garcimartin, M. Vazquez De La Torre, E. Seoane, G. Canto;  
Hospital Infanta Leonor, Madrid, Spain.
- 86 **Baked Egg Food Challenges - Clinical Outcomes And Determination Of Negative And Positive Predictive Values For Skin Test To Baked Egg And Ovomuroid**  
J. W. TAN, D. Campbell, P. Turner, A. Kakakios, M. Wong, S. Mehr, P. Joshi;  
Children's Hospital at Westmead, Westmead, Sydney, AUSTRALIA.
- 87 **Development of a National Guideline for the Diagnosis of Cow's Milk Allergy (CMA) in The Netherlands**  
B. J. Vlieg-Boerstra<sup>1</sup>, C. Wensing<sup>2</sup>, Y. Meijer<sup>3</sup>, T. Kuijpers<sup>4</sup>, H. Silvius<sup>5</sup>, M. Luning<sup>6</sup>, E. de Vries<sup>7</sup>, T. Hendriks<sup>8</sup>, C. M. F. Kneepkens<sup>9</sup>, A. B. Sprickelman<sup>1</sup>;  
<sup>1</sup>Emma Children's Hospital, Academic Medical Center, Amsterdam, NETHERLANDS, <sup>2</sup>Baby Health Clinic, Lisse, NETHERLANDS, <sup>3</sup>Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, NETHERLANDS, <sup>4</sup>Dutch Institute for Healthcare Improvement CBO, Utrecht, NETHERLANDS, <sup>5</sup>General Practice Boshuizen, Leiden, NETHERLANDS, <sup>6</sup>Dutch College of General Practitioners, Utrecht, NETHERLANDS, <sup>7</sup>Jeroen Bosch Hospital, 's-Hertogenbosch, NETHERLANDS, <sup>8</sup>Catharina Hospital, Eindhoven, NETHERLANDS, <sup>9</sup>VU Medical Center, Amsterdam, NETHERLANDS.
- 88 **Predicting Positive Food Challenges at the Introduction of Nuts in Sensitised Children**  
S. W. Ludman<sup>1</sup>, P. Ballabeni<sup>2</sup>, M. Hofer<sup>1</sup>, P. A. Eigenmann<sup>3</sup>, J. Wassenberg<sup>1</sup>;  
<sup>1</sup>Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University Hospital, Lausanne, SWITZERLAND, <sup>2</sup>Institute of Social and Preventative Medicine, University Hospital, Lausanne, SWITZERLAND, <sup>3</sup>Paediatric Allergy, University Hospitals, Geneva, SWITZERLAND.
- 89 **The Prevalence of Clinical Cross-reactivity of Non-peanut Legumes to Peanut in Patients with Persistent Peanut Allergy**  
D. L. Neuman-Sunshine<sup>1</sup>, J. A. Eckman<sup>2</sup>, C. A. Keet<sup>3</sup>, E. C. Matsui<sup>3</sup>, R. D. Peng<sup>4</sup>, P. J. Lenehan<sup>3</sup>, R. A. Wood<sup>3</sup>;  
<sup>1</sup>The Johns Hopkins University School of Medicine, Department of Medicine, Division of Allergy and Immunology, Baltimore, MD, <sup>2</sup>University of Cincinnati, Department of Internal Medicine, Division of Immunology, Cincinnati, OH, <sup>3</sup>The Johns Hopkins University School of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Baltimore, MD, <sup>4</sup>The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 90 **Evaluation of Oral Food Challenges With Hazelnut And Actual Reintroduction Of Hazelnut In The Diet After Negative OFC**  
N. W. De Jong<sup>1</sup>, N. Tirzikhani<sup>1</sup>, H. F. J. Savelkoul<sup>2</sup>, R. Gerth van Wijk<sup>1</sup>;  
<sup>1</sup>ErasmusMC, Rotterdam, NETHERLANDS, <sup>2</sup>Wageningen University, Wageningen, NETHERLANDS.
- 91 **Milk And Egg Allergy In Adulthood**  
G. Marco, E. Rodriguez, T. Nunez, P. Martinez, C. Pinto, R. Pineda, D. Perez, J. Zubeldia, M. L. Baeza;  
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.
- 92 **Cellular and Serologic Profiling of Adults with Peanut Allergen Sensitization**  
E. C. McGowan, J. H. Savage, J. P. Courneya, P. M. Sterba, A. S. Parihar, R. A. Wood, R. G. Hamilton, S. S. Saini;  
Johns Hopkins Hospital, Baltimore, MD.

- 93 The Effects of CCR9+ and CD103+ Dendritic Cells on Regulatory T-cells in Food Allergy**  
M. A. Garcia, K. Nadeau;  
Stanford University, Stanford, CA.
- 94 Relationship of Cytokine and Regulatory Gene Expression to the Outcomes of Milk and Egg Allergy in an Atopic Cohort (COFAR2)**  
S. H. Sicherer<sup>1</sup>, D. Stablein<sup>2</sup>, R. A. Wood<sup>3</sup>, A. W. Burks<sup>4</sup>, A. H. Liu<sup>5</sup>, S. M. Jones<sup>6</sup>, D. M. Fleischer<sup>5</sup>, L. Mayer<sup>1</sup>, R. Lindblad<sup>2</sup>, A. Grishin<sup>1</sup>, H. A. Sampson<sup>1</sup>, .. for the Consortium of Food Allergy Research<sup>1</sup>;  
<sup>1</sup>Mt. Sinai School of Medicine, New York, NY, <sup>2</sup>EMMES Corp., Rockville, MD, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4</sup>Duke, Durham, NC, <sup>5</sup>National Jewish Health, Denver, CO, <sup>6</sup>University of Arkansas for Medical Sciences, Little Rock, AR.
- 95 Oral Immunotherapy for Egg Allergy Clinical and Immunologic Results**  
G. B. Pajno, L. Caminiti, D. Vita, G. Crisafulli;  
University of Messina, Messina, ITALY.
- 96 Milk Oral Immunotherapy: A Single-Center Pilot Study of Safety and Efficacy**  
R. W. Saltzman<sup>1</sup>, M. Kelleher<sup>1</sup>, T. Brown-Whitehorn<sup>1</sup>, J. Fiedler<sup>1</sup>, J. Corry<sup>1</sup>, L. Gober<sup>1</sup>, E. Dudek<sup>2</sup>, A. Cianferoni<sup>1,2</sup>, J. Spergel<sup>1,2</sup>;  
<sup>1</sup>The Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>The Children's Hospital of Philadelphia Research Institute, Philadelphia, PA.
- 97 Milk Oral Desensitization: Role of Invariant Natural Killer T Cells (iNKTs)**  
F. Saretta<sup>1</sup>, R. W. Saltzman<sup>2</sup>, V. Abraham<sup>2</sup>, E. Dudek<sup>2</sup>, J. Spergel<sup>2</sup>, A. Cianferoni<sup>2</sup>;  
<sup>1</sup>University of Udine, Pediatric Department, Udine, ITALY, <sup>2</sup>The Children's Hospital of Philadelphia, Division of Allergy and Immunology, Philadelphia, PA.
- 98 Clinical Follow-Up After An Oral Induction Tolerance Protocol with Cow Milk: 4 Years Later**  
M. Reche Frutos, T. Valbuena, A. Padiá, C. Pascual;  
Hospital Infanta Sofía, San Sebastian de los Reyes, SPAIN.
- 99 Rush Oral Immunotherapy For Wheat-induced Anaphylaxis In Japan**  
T. Utsunomiya, T. Imai, K. Ogura, M. Goto, K. Iikura, Y. Koike, K. Otani, S. Sato, A. Shukuya, M. Ebisawa;  
Sagamihara National Hospital, Sagamihara, JAPAN.
- 100 Baked Proteins In The Management Of Cow'S Milk And Egg Allergic Children, Less Than 2 Years Of Age: Are Infants At Increased Risk Of Breakthrough Reactions?**  
M. I. Kidon<sup>1,2</sup>, M. Deutch<sup>1</sup>, M. Yaron<sup>2</sup>, A. Goren<sup>1</sup>, A. Siedletzki<sup>1</sup>, S. Steinberg<sup>2</sup>, A. Reshef<sup>1</sup>;  
<sup>1</sup>Sheba Medical Center, Tel Hashomer, ISRAEL, <sup>2</sup>Children's Health Center, "Clalit" Health Services, Rishon LeZion, ISRAEL.
- 101 Induction of Regulatory T Cells After Peanut Sublingual Immunotherapy**  
E. Kim<sup>1</sup>, M. Kulis<sup>2</sup>, B. Vickery<sup>2</sup>, A. Burks<sup>2</sup>;  
<sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>2</sup>Duke University Medical Center, Durham, NC.
- 102 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual versus Oral Immunotherapy for the Treatment of Peanut Allergy**  
S. D. Narisety<sup>1</sup>, C. Keet<sup>1</sup>, P. Guerrero<sup>1</sup>, J. Schroeder<sup>2</sup>, R. Hamilton<sup>2</sup>, R. A. Wood<sup>1</sup>;  
<sup>1</sup>Department of Pediatrics, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Department of Medicine, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MD.
- 103 Early Intervention with Oral Immunotherapy is a Promising Strategy for the Treatment of Peanut Allergy**  
B. P. Vickery, P. Steele, J. Kamilaris, A. Edie, M. Kulis, A. Burks;  
Duke University, Durham, NC.
- 104 A Phase 1 Study of Heat/Phenol Killed, E. coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the Treatment of Peanut Allergy**  
R. Wood<sup>1</sup>, D. Stablein<sup>2</sup>, A. Henning<sup>2</sup>, R. Lindblad<sup>2</sup>, S. Sicherer<sup>3</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Emmes Corporation, Rockville, MD, <sup>3</sup>Mount Sinai School of Medicine, New York, NY.
- 105 Peanut Oral Immunotherapy and Omalizumab Treatment for Peanut Allergy**  
M. Henson, A. Edie, P. Steele, J. Kamilaris, M. Kulis, A. Thyagarajan, B. P. Vickery, A. W. Burks;  
Duke University School of Medicine, Durham, NC.
- 106 Measurement of the Eliciting Dose Threshold at Baseline is Useful for Establishing the Starting Dose in Peanut Oral Immunotherapy (OIT)**  
J. A. Bird<sup>1</sup>, A. Clark<sup>2</sup>, M. G. Crain<sup>2</sup>, A. Arneson<sup>2</sup>;  
<sup>1</sup>UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Children's Medical Center, Dallas, TX.
- 107 A Prospective, Randomized, Case Controlled Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated with Peanut Desensitization in Children with Peanut Allergies**  
N. Berlin<sup>1</sup>, S. Maclachlan<sup>1</sup>, N. Leader<sup>1</sup>, D. Penn<sup>2</sup>, G. Sussman<sup>1,3</sup>;  
<sup>1</sup>Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA, <sup>2</sup>Mast Cell Pharmaceuticals Inc., Raleigh, NC, <sup>3</sup>University of Toronto, Toronto, ON, CANADA.
- 108 Oral Food Immunotherapy: Protective Doses Reached Within Two Months**  
M. B. Levy, M. R. Goldberg, M. L. Stein, A. Elizur, L. Nachshon, Y. Katz;  
Assaf Harofe Medical Center, Tzrifin, ISRAEL.
- 109 Classification, Prevalence and Outcomes of Non-IgE Mediated Reactions to Oral Food Immunotherapy**  
M. L. Stein<sup>1</sup>, M. B. Levy<sup>1</sup>, M. R. Goldberg<sup>1</sup>, G. Hermann<sup>2</sup>, E. Broide<sup>3</sup>, A. Elizur<sup>1</sup>, L. Nachshon<sup>1</sup>, Y. Katz<sup>1</sup>;  
<sup>1</sup>Allergy and Clinical Immunology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL, <sup>2</sup>Pathology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL, <sup>3</sup>Gastroenterology Institute, Assaf-Harofeh Medical Center, Zrifin, ISRAEL.
- 110 Participation in Peanut Oral Immunotherapy Improves Quality of Life**  
J. S. Kamilaris, P. H. Steele, M. D. Kulis, A. H. Edie, B. P. Vickery, A. W. Burks;  
Duke University Medical Center, Durham, NC.
- 111 Food Allergy Quality of Life (FAQOL) Is Improved For Food Oral Immunotherapy (OIT) Treated Patients and Their Families**  
A. R. Hague, R. L. Wasserman, R. W. Sugerman;  
DallasAllergyImmunology, Dallas, TX.
- 112 The Effects of Peanut Oral Immunotherapy on Food Allergy Related Quality of Life**  
J. M. Factor, M. R. Lester, L. M. Mendelson, J. O. Lee, J. Sproviero, G. Nouman;  
New England Food Allergy Treatment Center, West Hartford, CT.
- 113 Patient and Parent Perspectives on Quality of Life during Participation in a Study of Rapid Oral Desensitization with Omalizumab Therapy in Patients with Milk Allergy**  
J. S. LeBovidge<sup>1</sup>, S. Haskell<sup>1</sup>, I. Borrás<sup>1</sup>, E. Hoyte<sup>2</sup>, D. T. Umetsu<sup>1</sup>, K. C. Nadeau<sup>2</sup>, L. C. Schneider<sup>1</sup>;  
<sup>1</sup>Children's Hospital Boston, Boston, MA, <sup>2</sup>Stanford Medical School, Stanford, CA.
- 114 Effect of A Reaction During Oral Food Challenges (OFC) on Food-specific IgE levels (sIgE)**  
Y. Hui, J. A. Lieberman, S. H. Sicherer;  
Mt. Sinai School of Medicine, New York, NY.

**115 Biphasic Reactions in Children Undergoing Oral Food Challenges**

J. Lee, J. P. Garrett, T. F. Brown-Whitehorn, J. M. Spergel;  
Children's Hospital of Philadelphia, Philadelphia, PA.

**116 Clinical Protocols For Allergen Threshold Studies: Does One Stand Above The Rest?**

B. Remington, J. L. Baumert, S. L. Taylor;  
University of Nebraska, Lincoln, NE.

Poster Session

Food Allergy Related Issues/Immune Skin Disease

2207

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

**117 Hen's Egg White Hypersensitivity among a group of Egyptian Allergic Children**

D. H. El-Ghoneimy<sup>1</sup>, S. M. Reda<sup>1</sup>, E. A. Mohammed<sup>1</sup>, A. E. Shehab<sup>2</sup>;

<sup>1</sup>Department of Pediatric Allergy and Immunology, Ain Shams University, Cairo, EGYPT, <sup>2</sup>Department of Clinical Pathology, Ain Shams University, Cairo, EGYPT.

**118 Outcomes Of Pediatric Oral Food Challenges In A Singapore Hospital**

M. M. Tan;

National University Hospital, Singapore, SINGAPORE.

**119 Oral Food Challenge Outcomes in a Tertiary Care Allergy Center**

E. M. Abrams, N. Cisneros, A. B. Becker;

University of Manitoba, Winnipeg, MB, CANADA.

**120 Bullying of Food-Allergic Youth: Results from a Parent and Child Survey**

M. Ambrose<sup>1</sup>, R. Annunziato<sup>2</sup>, N. Ravid<sup>1</sup>, K. Chuang<sup>1</sup>, C. Mullarkey<sup>1</sup>, E. Shemesh<sup>1</sup>, S. H. Sicherer<sup>1</sup>;

<sup>1</sup>Mt. Sinai School of Medicine, New York, NY, <sup>2</sup>Fordham University, New York, NY.

**121 Administration Of Influenza Vaccine To Pediatric Patients With Egg Anaphylaxis**

I. Fung, J. M. Spergel;

Children's Hospital of Philadelphia, Philadelphia, PA.

**122 Parental Perceptions of Anaphylaxis in Children with Egg Allergy**

L. E. Howe, M. J. Greenhawt, G. Sanders;

University of Michigan, ANN ARBOR, MI.

**123 Dietary Advice and Accidental Exposures to Egg in Allergic Children**

C. A. Fillion, L. Paradis, A. Des Roches;

University of Montreal, Montreal, QC, CANADA.

**124 Geographical Variability In The Ltp Recognition In A Large Sample Of Rosaceae Fruit Allergic Patients**

A. Diaz-Perales<sup>1</sup>, A. Palacin<sup>1</sup>, C. Gmez-Casado<sup>1</sup>, L. A. Rivas<sup>2</sup>, L. Tordesillas<sup>1</sup>, J. Bartra<sup>3</sup>, C. Blanco<sup>4</sup>, T. Carrillo<sup>5</sup>, J. Cuesta-Herranz<sup>6</sup>, J. Fernandez<sup>7</sup>, S. Varela<sup>8</sup>, G. Garca Alvarez-Eire<sup>8</sup>, P. Gamboa<sup>9</sup>, V. Parro<sup>2</sup>, M. A. Villalba<sup>10</sup>, M. Blanca<sup>11</sup>;

<sup>1</sup>Plant Biotechnology and Genomics Institute, UPM-INIA, Pozuelo de Alarcon (Madrid), SPAIN, <sup>2</sup>Departamento de Evolucion Molecular, Centro de Astrobiologia (INTA-CSIC), Torrejn de Ardoz, Madrid, SPAIN, <sup>3</sup>Unitat d'Alrgia. Servei Pneumologia i Alrgia Respiratria. Hospital Clinic, Unitat d'Alrgia. Servei de

Pneumologia. Hospital Clinic. Universitat de Barcelona, Institut d'Investigacions Biomdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN, <sup>4</sup>Servicio de Alergia, Hospital Universitario de la Princesa, Instituto de Investigacin Sanitaria Princesa (IP), Madrid, SPAIN, <sup>5</sup>Hospital Universitario de Gran Canaria Dr. Negrn, Las Palmas de Gran Canaria, SPAIN, <sup>6</sup>Unidad Servicio de Alergia, Fundacin Jimnez Daz, Madrid, SPAIN, <sup>7</sup>Allergy Section, General University Hospital, Miguel Hernndez University, Elche, SPAIN, <sup>8</sup>Unidad de Alergologa, Complejo Hospitalario, Ourense, SPAIN, <sup>9</sup>Servicio de Alergia, Hospital de Basurto, Bilbao, SPAIN, <sup>10</sup>Departamento de Bioqumica y Biologa Molecular I, Facultad de Qumicas, Universidad Complutense, Madrid, SPAIN, <sup>11</sup>Research Laboratory, Fundacin IMABIS-Carlos Haya Hospital; Hospital Civil, Malaga, SPAIN.

**125 In Vivo And In Vitro Studies On The Sensitisation To A Panel Of Allergens In A Large Rosacea Allergic Group Of Patients**

I. Garcia-Nunez<sup>1</sup>, A. Aranda<sup>1</sup>, A. Blazquez<sup>1</sup>, M. Torres<sup>1</sup>, M. Galindo<sup>1</sup>, M. Sanz<sup>2</sup>, M. Blanca<sup>1</sup>;

<sup>1</sup>Hospital Universitario Carlos Haya, Malaga, SPAIN, <sup>2</sup>Clnica Universitaria de Navarra, Pamplona, SPAIN.

**126 Co-sensitization Between Specific IgE to nAct d 2 and rAlt a 1 O. M. Calderon;**

La Paz University Hospital, Madrid, SPAIN.

**127 Assessing Specialists' Opinion Related to Prescribing Auto-injectable Epinephrine In An Unusual Case of Peanut Sensitivity with Oral Allergy**

J. R. Parkerson, D. K. Ledford;

University of South Florida, Tampa, FL.

**128 Reaction To Soymilk But Not Other Soy Products In Gly m 4 Sensitized Birch Pollen-Allergic Patients**

R. Q. Chaudhry<sup>1</sup>, R. Bigelsen<sup>2</sup>, A. Wolff<sup>1</sup>;

<sup>1</sup>University of Medicine and Dentistry of New Jersey, Newark, NJ,

<sup>2</sup>Tulane University, New Orleans, LA.

**129 Gastrointestinal food allergies in children with Ehlers Danlos type 3 syndrome**

R. M. Cutts, R. Meyer, N. Thapar, K. Rigby, C. Schwarz, S. Mailliard, N. Shah;

Great Ormond Street Hospital for Children, London, UNITED KINGDOM.

**130 Food Protein-induced Enterocolitis Syndrome (FPIES): Our Experience**

M. Ruiz Garcia;

Fundacion Jimenez Diaz, Madrid, SPAIN.

**131 The Acquisition of Food Allergy in Children after Liver Transplantation**

T. Shoda, I. Nomura, M. Futamura, K. Horimukai, M. Narita, Y. Ohya, S. Sakamoto, M. Kasahara;

National Center for Child Health and Development, Tokyo, JAPAN.

**132 Atopic Dermatitis And Assessment Of Food Tolerance By Oral Food Challenges**

L. A. Crandall, J. E. Connor, S. A. Lowe, M. B. Ho, C. M. Lee, M. B. Feuling, C. L. Sova, M. Vasudev;

Medical College of Wisconsin, Milwaukee, WI.

**133 Frequency of Sensitization to Egg and Cow's Milk in Children with Atopic Dermatitis and Associated Factors**

N. P. M. Rubini, F. L. B. Limongi, B. O. Figueiredo, N. A. Costa, N. S. Santos, N. M. Almeida, F. S. Sion, C. Morais-de-Sa;

Federal University of Rio de Janeiro State, Rio de Janeiro, BRAZIL.

**134 What Allergens Would You Miss? Utilization of T.R.U.E.® Test Versus Expanded Patch Test Panels for Allergic Contact Dermatitis. A 5-year, Multi-Center Review from Allergy Practices**

T. Mucci<sup>1</sup>, S. Axelrod<sup>1</sup>, M. Michelis<sup>2</sup>, S. Lighvani<sup>3</sup>, M. Aquino<sup>1</sup>, M. Davis-Lorton<sup>1</sup>, L. Fonacier<sup>1</sup>;

- <sup>1</sup>Winthrop University Hospital, Mineola, NY, <sup>2</sup>Hackensack University Medical Center, Hackensack, NJ, <sup>3</sup>Weill Cornell Medical Center, New York, NY.
- 135 Skin Immunity Is Regulated By Histamine Receptors Through Dendritic Cell Number And Function**  
T. A. Kamdar, A. Byrne, P. Bryce;  
Northwestern University Feinberg School of Medicine, Chicago, IL.
- 136 Role of Mast Cells in the Development of Atopic Dermatitis Induced by IL-13**  
M. OH<sup>1</sup>, Z. Zhu<sup>1</sup>, J. Yu<sup>2</sup>, T. Zheng<sup>1</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Asan Medical Center, Ulsan University, College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 137 Involvement of Human Histamine N-methyltransferase Gene Polymorphisms in Susceptibility to Atopic Dermatitis in Korean Children**  
H. S. Lee<sup>1</sup>, S. H. Kim<sup>2</sup>, K. W. Kim<sup>1</sup>, H. B. Park<sup>1</sup>, Y. H. Kim<sup>1</sup>, H. M. Jee<sup>3</sup>, H. S. Park<sup>2</sup>, M. H. Sohn<sup>1</sup>, K. E. Kim<sup>1</sup>;  
<sup>1</sup>Department of Pediatrics and Institute of Allergy, Severance Biomedical Science Institute, BK21 Project for Medical Science, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Department of Allergy and Rheumatology, Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, CHA University School of Medicine, Seongnam, KOREA, REPUBLIC OF.
- 138 The Association of Polymorphisms in the Interleukin 33 (IL33) and Interleukin 1 Receptor-like 1 (IL1RL1) Genes with Risk of Atopic Dermatitis**  
L. Gao<sup>1</sup>, D. Taylor<sup>1</sup>, N. M. Rafaels<sup>1</sup>, M. Campbell<sup>1</sup>, R. Lewis<sup>1</sup>, C. V. Ribera<sup>1</sup>, L. A. Beck<sup>2</sup>, R. A. Mathias<sup>1</sup>, D. Y. Leung<sup>3</sup>, K. C. Barnes<sup>1</sup>;  
<sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>University of Rochester Medical Center, Rochester, NY, <sup>3</sup>National Jewish Health, Denver, CO.
- 139 TLR4 Deficiency Exacerbates Allergen-Induced Atopic Dermatitis**  
E. B. BRANDT, A. M. Gibson, S. Bass, M. Lindsey, G. K. Khurana Hershey;  
Cincinnati Children's Hospital Medical center, Cincinnati, OH.
- 140 In Silico Analyses Reveal Putative Regulatory Elements Upstream of the Thymic Stromal Lymphopoietin Receptor Gene**  
M. J. Romeo, J. A. Woodfolk;  
University of Virginia, Charlottesville, VA.
- 141 Filaggrin Deficiency Impairs Viral Containment in Mice Cutaneously Inoculated with Vaccinia Virus (VV)**  
R. S. Geha, M. K. Oyoshi;  
Children's Hospital Boston, Boston, MA.
- 142 Sequencing Of The Flg2 Gene In Patients With Atopic Dermatitis And Eczema Herpeticum In A Population Of European Descent**  
N. M. Rafaels<sup>1</sup>, D. Y. Leung<sup>2</sup>, L. Beck<sup>3</sup>, R. Lewis<sup>1</sup>, L. Huang<sup>1</sup>, P. Gao<sup>1</sup>, M. Boguniewicz<sup>2</sup>, T. Hata<sup>4</sup>, L. Schneider<sup>5</sup>, J. Hanifin<sup>6</sup>, R. Gallo<sup>4</sup>, L. Gao<sup>1</sup>, R. A. Mathias<sup>1</sup>, K. C. Barnes<sup>1</sup>;  
<sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Department of Pediatrics, National Jewish Health, Denver, CO, <sup>3</sup>Department of Dermatology, University of Rochester Medical Center, Rochester, NY, <sup>4</sup>Division of Dermatology, University of California, San Diego, CA, <sup>5</sup>Division of Immunology, Children's Hospital Boston, Boston, MA, <sup>6</sup>Department of Dermatology, Oregon Health & Science University, Portland, OR.
- 143 Relevance of Patch Test Results to the Clinical Diagnosis of Allergic Contact Dermatitis - Need for Standardization**  
H. Morissette, B. McGoey, M. Michelis;  
Hackensack University Medical Center, Hackensack, NJ.
- 144 Systemic Tolerability of Intermittent Topical Corticosteroid Therapy Using Salivary Cortisol Measurements in Infants with Atopic Dermatitis**  
T. Fukuie<sup>1</sup>, S. Sano<sup>1</sup>, I. Nomura<sup>2</sup>, M. Narita<sup>2</sup>, T. Taguchi<sup>1</sup>, T. Ogata<sup>1</sup>, K. Matsumoto<sup>3</sup>, Y. Ohya<sup>2</sup>;  
<sup>1</sup>Hamamatsu University School of Medicine, Shizuoka, JAPAN, <sup>2</sup>National Center for Child Health and Development, Tokyo, JAPAN, <sup>3</sup>National Research Institute for Child Health and Development, Tokyo, JAPAN.
- 145 Factors Determining The Effectiveness Of Oral Cyclosporine In Children With Severe Atopic Dermatitis (AD)**  
P. D. Arkwright, D. R. Beaumont;  
University of Manchester, Manchester, UNITED KINGDOM.
- 146 Omalizumab - One Year Experience In The Treatment Of Severe Atopic Dermatitis**  
A. M. Mendes, A. C. C. Costa, S. Luz, E. Pedro, M. Pereira-Barbosa;  
Santa Maria Hospital, Lisbon, PORTUGAL.
- 147 A Case Series Of Severe Atopic Dermatitis Treated By Anti-ige Therapy: A Paediatric Perspective**  
J. Lacombe Barrios<sup>1,2</sup>, L. Paradis<sup>2</sup>, A. Hatami<sup>1</sup>, J. Paradis<sup>2</sup>, A. Des Roches<sup>1</sup>;  
<sup>1</sup>Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, CANADA, <sup>2</sup>Centre Hospitalier de l'Universite de Montreal, Montreal, QC, CANADA.
- 148 MRSA Skin Colonization Is Associated With Higher Total IgE in Young Children With Atopic Dermatitis**  
J. Abbott, D. C. Everett, D. Y. Leung;  
National Jewish Health, Denver, CO.
- 149 Bifidobacterium in Gut Microbiota for Infants with and without Eczema**  
G. Yap<sup>1</sup>, K. Chee<sup>1</sup>, P. Hong<sup>2</sup>, M. Aw<sup>1</sup>, L. Shek<sup>1</sup>, K. Chua<sup>1</sup>, X. Zhang<sup>3</sup>, D. Leow<sup>3</sup>, B. Lee<sup>1</sup>;  
<sup>1</sup>National University of Singapore, Singapore, SINGAPORE, <sup>2</sup>University of Illinois, Urbana-Champaign, IL, <sup>3</sup>Singapore Clinical Research Institute, Singapore, SINGAPORE.
- 150 Relationship of Serum 25-hydroxyvitamin D Levels with the Severity of Atopic Dermatitis in Children**  
J. Shim, M. Kim, Y. Kim, J. Shim, D. Kim, H. Jung, M. Park;  
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF.
- 151 Nutritional Status and Bone Metabolism in Children With Atopic Dermatitis**  
V. R. A. Penterich, A. C. Yang, R. M. R. Pereira, J. Kalil, F. F. M. Castro;  
School of Medicine - University of Sao Paulo, Sao Paulo, BRAZIL.
- 152 Dietary Intervention With Specific Non-digestible Oligosaccharide Mixtures Is Effective During Induction Of Murine Cow'S Milk Allergy But Not Suitable As Treatment In The Same Allergic Disease Model**  
P. V. Jeurink<sup>1,2</sup>, J. Kerperien<sup>2</sup>, T. M. D. Wehkamp<sup>1,2</sup>, E. C. A. M. van Esch<sup>1,2</sup>, A. Rijnierse<sup>1,2</sup>, G. A. Hofman<sup>2</sup>, L. E. M. Willemsen<sup>2</sup>, J. Garssen<sup>1,2</sup>, L. M. J. Knippels<sup>1,2</sup>;  
<sup>1</sup>Danone Research - Centre of Specialised Nutrition, Wageningen, NETHERLANDS, <sup>2</sup>Utrecht Institute of Pharmaceutical Sciences, Utrecht, NETHERLANDS.
- 153 Different Timings of Prenatal or Postnatal Tobacco Smoke Exposure have Different Effects on The Development of Atopic Eczema/Dermatitis Syndrome (AEDS) during Infancy**  
M. Shinohara<sup>1,2</sup>, H. Saito<sup>3</sup>, K. Matsumoto<sup>4</sup>;  
<sup>1</sup>National Shimosizu Hospital, Department of Pediatric Allergy and Clinical Research, 934-5 Shikawatashi, Yotsukaido-City, Chiba, JAPAN, <sup>2</sup>Kochi University, Department of Pediatrics, Kochi, JAPAN, <sup>3</sup>National Research Institute for Child Health and Development, Department of Allergy & Immunology, 2-10-1 Okura Setagaya-ku Tokyo, 157-8535 Japan, JAPAN, <sup>4</sup>National Research Institute for Child Health and Development, Department of Allergy & Immunology, -10-1 Okura Setagaya-ku Tokyo, 157-8535 Japan, JAPAN.

Poster Session

A Focus on Asthma

2208

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 154 Asthma and Physical Activity in Adolescents: A Cross Sectional Analysis**  
A. L. Leyton, A. P. Baptist;  
University of Michigan, Ann Arbor, MI.
- 155 Correlates of Asthma Deaths at a Children's hospital with a Multidisciplinary Team (MDT) Asthma Program for High Risk Asthmatics.**  
S. Z. Faghhi<sup>1,2</sup>, P. Abghari<sup>1,2</sup>, K. Dhekney<sup>1,2</sup>, S. Marzec<sup>2</sup>, E. Secord<sup>1,2</sup>;  
<sup>1</sup>Children's Hospital Of Michigan, Detroit, MI, <sup>2</sup>Wayne State University, Detroit, MI.
- 156 Reducing Health Disparities For Asthma With a School Based Asthma Education Program**  
S. E. Monforte, M. Gleason, R. Covar, L. Cicutto, S. J. Szelfer;  
National Jewish Health, Denver, CO.
- 157 Relationship Of Canister Weight To The Amount Of Medication Actuated From Metered-dose Inhalers**  
t. saharupat, P. Sangsupawanich;  
Allergy & Immunology Division, Hadyai, THAILAND.
- 158 Asthma and Risk of the Novel 2009 H1N1 Influenza Infection in Children: A Population-Based Case-Control Study**  
C. F. Santillan Salas<sup>1</sup>, S. Mehra<sup>1</sup>, E. J. Park<sup>1</sup>, B. D. Lahr<sup>1</sup>, B. P. Yawn<sup>2</sup>, Y. J. Juhn<sup>1</sup>;  
<sup>1</sup>Mayo Clinic Rochester, Rochester, MN, <sup>2</sup>Olmsted Medical Center, Rochester, MN.
- 159 Prevalence Of The Correct Technique Of Using An Inhaler Among Asthmatic Patients Reporting In Tertiary Care Hospitals Of Rawalpindi, Pakistan**  
M. Bilal, A. Ahmed, A. R. Shah, H. A. Mirza, A. K. Anwar, S. B. H. Zaidi;  
Army Medical College, National University of Science & Technology, Rawalpindi, PAKISTAN.
- 160 Risk of Hospitalization in Thai Children with Acute Asthma**  
P. Kulalert, P. Sangsupawanich;  
Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hatyai, THAILAND.
- 161 Metered-Dose Inhaler Spacers: A Double Edged Sword?**  
J. L. Mutnick;  
Stevens Community Medical Center, Morris, MN.
- 162 Fluticasone- propionate/Salmeterol is Associated with a Higher Likelihood of Achieving an Optimal Controller-to-Total Asthma Medication Ratio Compared to Inhaled Corticosteroid Alone**  
R. H. Stanford<sup>1</sup>, A. DSouza<sup>2</sup>, A. Dhama<sup>2</sup>, M. Shah<sup>2</sup>;  
<sup>1</sup>GlaxoSmithKline, Research Triangle Park, NC, <sup>2</sup>Xcenda, Palm Harbor, FL.

Poster Session

Rhinosinusitis: Mechanisms and Therapy

2209

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 163 Mast Cells with a Unique Phenotype Are Highly Elevated in Chronic Rhinosinusitis with Nasal Polyps**

**T. Takabayashi<sup>1,2</sup>, A. Kato<sup>1</sup>, A. T. Peter<sup>1</sup>, L. A. Suh<sup>1</sup>, R. Carter<sup>1</sup>, J. Norton<sup>1</sup>, L. C. Grammer<sup>1</sup>, B. K. Tan<sup>3</sup>, R. K. Chandra<sup>3</sup>, D. B. Conley<sup>3</sup>, R. C. Kern<sup>3</sup>, S. Fujieda<sup>2</sup>, R. P. Schleimer<sup>1</sup>;**

<sup>1</sup>The Division of Allergy and Immunology Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>The Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, University of Fukui, Fukui, JAPAN, <sup>3</sup>Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.

- 164 Age-related Reduction Of S100A8/A9 In Chronic Rhinosinusitis Is Associated With Increased Production Of Soluble gp130**

S. H. Lee<sup>1</sup>, K. Hulse<sup>1</sup>, J. Siebert<sup>1</sup>, J. Norton<sup>1</sup>, D. B. Conley<sup>2</sup>, R. Chandra<sup>2</sup>, R. C. Kern<sup>1,2</sup>, S. Hong<sup>1,3</sup>, R. P. Schleimer<sup>1</sup>, S. H. Cho<sup>1</sup>;

<sup>1</sup>Division of Allergy-Immunology, Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Department of Otolaryngology, Feinberg School of Medicine Northwestern University, Chicago, IL, <sup>3</sup>Division of Rheumatology, Department of Medicine, College of Medicine, Kyunghee University, Seoul, KOREA, REPUBLIC OF.

- 165 Elevated Expression of mRNA for CCL2, CCL19, CCR7 and CXCR3 in Chronic Rhinosinusitis with Nasal Polyposis**

C. J. Ocampo, A. Kato, J. Norton, R. C. Kern, D. B. Conley, R. Chandra, B. Tan, A. T. Peters, L. C. Grammer, R. P. Schleimer;  
Northwestern University Feinberg School of Medicine, Chicago, IL.

- 166 Vitamin D Modulates Immune Defense Molecules in Patients with Chronic Rhinosinusitis**

S. Watanabe<sup>1</sup>, X. Jiang<sup>2</sup>, S. Sharma<sup>3</sup>, J. Lane<sup>2</sup>, M. DeTineo<sup>2</sup>, T. Muninopasa<sup>2</sup>, M. Bashir<sup>2</sup>, N. Joyner<sup>2</sup>, F. M. Baroody<sup>2</sup>, R. M. Nacclerio<sup>2</sup>, J. M. Pinto<sup>2</sup>;

<sup>1</sup>Showa University School of Medicine, Tokyo, JAPAN, <sup>2</sup>University of Chicago, Chicago, IL, <sup>3</sup>University of Michigan, Ann Arbor, MI.

- 167 Efficacy of Mometasone Furoate Nasal Spray in Relieving Congestion in Patients With Nasal Polyps With or Without Eosinophilia**

C. B. Small<sup>1</sup>, P. Stryczak<sup>2</sup>, A. Teper<sup>2</sup>;  
<sup>1</sup>New York Medical College, Valhalla, NY, <sup>2</sup>Merck Research Laboratories, Kenilworth, NJ.

- 168 Efficacy Of Gentamicin Nasal Irrigation In Chronic Rhinosinusitis In Children**

S. Kurasirikul, P. Vichyanond, O. Piboonpocanun, J. Praikanahok, N. Visitsunthorn;  
siriraj, bangkok, THAILAND.

- 169 Impacts of Sinus Surgery on Lower Airway Disease**

R. Kagoya<sup>1</sup>, M. Shinogami<sup>1</sup>, H. Mouri<sup>1</sup>, S. Suzuki<sup>1</sup>, W. Nakanishi<sup>2</sup>, H. Yoshinami<sup>3</sup>;

<sup>1</sup>Tokyo Metropolitan Police Hospital, Tokyo, JAPAN, <sup>2</sup>University of Tokyo, Tokyo, JAPAN, <sup>3</sup>Saitama Medical University Hospital, Saitama, JAPAN.

- 170 Eleven Year Follow Up of an African-American Adolescent with Destructive Sinus Disease and Intermittent Asthma Diagnosed with Allergic Fungal Sinusitis (AFS) and Incidentally Found to have Allergic Bronchopulmonary Mycosis (ABPM)**

A. G. Hall, A. E. Morris, G. D. Marshall, Jr.;  
University of Mississippi Medical Center, Jackson, MS.

- 171 The Adenoid Inflammation of Children with Rhinosinusitis and Alternaria Hypersensitivity**

S. Shin<sup>1</sup>, K. Lee<sup>1</sup>, S. Kim<sup>1</sup>, J. Cho<sup>1</sup>, H. Park<sup>2</sup>;  
<sup>1</sup>Kyung Hee University, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Ajou University, Suwon, KOREA, REPUBLIC OF.

- 172 The Examination of the Association Between the Chronic Rhinosinusitis and the Inflammation of the Lower Respiratory Airway by Using the Exhaled Nitric Oxide(NO) and the Respiratory Function Test**

H. Yoshinami;  
Saitama Medical University, Saitama, JAPAN.

## Poster Session

## Immunotherapy

2210

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 173 Absence Of IgE Neosensitization In House Dust Mite Allergic Patients Following Sublingual Immunotherapy**  
**P. Moingeon;**  
Stallergenes SA, Antony, FRANCE.
- 174 Improvement In Quality Of Life With Administration Of A 300 IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis**  
**F. Horak<sup>1</sup>, A. Didier<sup>2</sup>, M. Worm<sup>3</sup>, H. Malling<sup>4</sup>, K. Abiteboul<sup>5</sup>, A. Montagut<sup>5</sup>, R. K. Zeldin<sup>5</sup>;**  
<sup>1</sup>Allergy Centre Vienna, Vienna, AUSTRIA, <sup>2</sup>Rangueil-Larrey Hospital, Toulouse, FRANCE, <sup>3</sup>Allergie-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, <sup>4</sup>National University Hospital, Copenhagen, DENMARK, <sup>5</sup>Stallergenes, Antony, FRANCE.
- 175 Characteristics of Systemic Reactions to Inhalant Allergen Immunotherapy (SRIT) in the University of Michigan Health System (UMHS)**  
**J. L. Baldwin,** K. Samuels, C. L. Holland, J. Postma;  
University of Michigan Allergy Immunology Specialty Clinic, Ann Arbor, MI.
- 176 A Us Study Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis - Results Of Secondary Efficacy Assessments**  
**L. Cox<sup>1</sup>, T. B. Casale<sup>2</sup>, A. Nayak<sup>3</sup>, P. Creticos<sup>4</sup>, A. Montagut<sup>5</sup>, R. K. Zeldin<sup>5</sup>;**  
<sup>1</sup>Nova Southeastern University School of Osteopathic Medicine, Davie, FL, <sup>2</sup>Division of Allergy and Immunology, Department of Medicine, Creighton University - Allergy & Asthma, Omaha, NE, <sup>3</sup>Sneeze, Wheeze and Itch Associates, Normal, IL, <sup>4</sup>Johns Hopkins University, Baltimore, MD, <sup>5</sup>Stallergenes, Antony, FRANCE.
- 177 Post-treatment, Long-term Efficacy Of A 300IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis: The Relationship With Disease Severity**  
**M. Worm<sup>1</sup>, A. Didier<sup>2</sup>, F. Horak<sup>3</sup>, H. Malling<sup>4</sup>, S. Soulie<sup>5</sup>, R. K. Zeldin<sup>5</sup>;**  
<sup>1</sup>Allergie-Centrum-Charit, Klinik fr Dermatologie, Berlin, GERMANY, <sup>2</sup>Rangueil-Larrey Hospital, Toulouse, FRANCE, <sup>3</sup>Allergy Centre Vienna, Vienna, AUSTRIA, <sup>4</sup>National University Hospital, Copenhagen, DENMARK, <sup>5</sup>Stallergenes, Antony, FRANCE.
- 178 Comparative Efficacy and Tolerability of Subcutaneous and Sublingual Allergen Specific Immunotherapy**  
**A. Blaziene<sup>1</sup>, A. Chomiciene<sup>1</sup>, L. M. DuBuske<sup>2</sup>;**  
<sup>1</sup>Vilnius University, Center of Pulmonology and Allergology, Vilnius, LITHUANIA, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.
- 179 Grass Pollen Immunotherapy In Children: Safety Aspects**  
**M. I. Garcimartin,** M. Vazquez De La Torre Gaspar, F. Ruano Perez, N. Blanca Lopez, E. Seoane Reula, M. De Diego, M. Canto Diez;  
Hospital Infanta Leonor, Madrid, Madrid, Spain.
- 180 Dose-related Effects of Ragweed Allergy Immunotherapy Tablet on Nasal and Ocular Symptoms of Allergic Rhinoconjunctivitis During the Peak Ragweed Pollen Seasons in Europe and North America**  
**J. Maloney<sup>1</sup>, H. Nolte<sup>1</sup>, K. Nekam<sup>2</sup>, P. Creticos<sup>3</sup>, G. Berman<sup>4</sup>, A. Kaur<sup>1</sup>, J. Hebert<sup>5</sup>;**

<sup>1</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>2</sup>Hospital of the Hospitaller Brothers of St John of God, Budapest, HUNGARY, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4</sup>Allergy & Asthma Specialists, Minneapolis, MN, <sup>5</sup>Centre de Recherche Appliquee en Allergie de Quebec, Quebec, QC, CANADA.

## Poster Session

## Allergic Inflammation

2211

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 181 Controlled Allergen Exposure in the Environmental Exposure Chamber (EEC) Results in a Late Phase Inflammatory Response Evidenced by Increased Eosinophils in the Upper Airway of Allergic Patients**  
**N. Camuso,** S. Zafar, N. Najera, A. Liac, G. Aguirre, A. Salapatek;  
Cetero Research, Mississauga, ON, CANADA.
- 182 Mold and House Dust Mite Allergens Activate and Sensitize Sensory Neurons Innervating Airways**  
**M. J. Patil<sup>1</sup>, M. A. Henry<sup>2</sup>, A. N. Akopian<sup>2</sup>;**  
<sup>1</sup>Pharmacology Dept, Graduate School, UTHSCSA, San Antonio, TX, <sup>2</sup>Dental School, UTHSCSA, San Antonio, TX.
- 183 Peripheral Blood Mononuclear cells from Patients with Bronchial Asthma show impaired regulatory responses to Rhinovirus in vitro**  
**K. Iikura;**  
Sagamihara National Hospital, Kanagawa, JAPAN.
- 184 Pharmacological Characterization of TASP0412098, A Selective CRTH2 (Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells) Antagonist**  
**M. Kawanishi<sup>1</sup>, K. Watanabe<sup>1</sup>, Y. Asakura<sup>1</sup>, A. Oka<sup>1</sup>, T. Naruse<sup>1</sup>, R. Nishikawa<sup>2</sup>, T. Takayama<sup>2</sup>, T. Koami<sup>2</sup>, D. Wakasugi<sup>2</sup>, M. Kawamura<sup>2</sup>, A. Takaoka<sup>1</sup>, S. Tokita<sup>1</sup>;**  
<sup>1</sup>Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Saitama, JAPAN, <sup>2</sup>Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., Saitama-shi, Saitama, JAPAN.
- 185 Pro-fibrotic Effect Of Dexamethasone In Human Airway Fibroblasts**  
**W. Manuyakorn<sup>1,2</sup>, D. Davies<sup>1</sup>, P. Howarth<sup>1</sup>;**  
<sup>1</sup>Faculty of Medicine, University of Southampton, Southampton, UNITED KINGDOM, <sup>2</sup>Faculty of Medicine, Ramathobodi Hospital, Mahidol University, Bangkok, THAILAND.
- 186 Characterization of a Novel, Potent and Selective Small Molecule Spleen Tyrosine Kinase (SYK) Inhibitor in In Vitro and In Vivo Models of Asthma**  
**M. A. Crackower<sup>1</sup>, L. Y. Moy<sup>1</sup>, Y. Jia<sup>2</sup>, H. Yu<sup>1</sup>, S. Vincent<sup>1</sup>, J. R. Miller<sup>1</sup>, G. Lieber<sup>2</sup>, X. Fernandez<sup>2</sup>, M. Caniga<sup>1</sup>, M. Gil<sup>1</sup>, A. Wilhelm<sup>1</sup>, H. Houshyar<sup>1</sup>, A. Northrup<sup>1</sup>, R. Chapman<sup>1</sup>, W. M. Abraham<sup>3</sup>, N. Kelly<sup>1</sup>, E. Hickey<sup>2</sup>, T. Miller<sup>1</sup>;**  
<sup>1</sup>Merck Research Labs, Boston, MA, <sup>2</sup>Merck Research Labs, Kenilworth, NJ, <sup>3</sup>Mount Sinai Medical Center, Miami Beach, FL.
- 187 Increased Expression of Importin  $\alpha$ 3 (KPNA4) and Decreased VDR in the Lung of OVA-Sensitized and Challenged Mice**  
**T. Agrawal,** G. K. Gupta, M. Kim, D. K. Agrawal;  
Creighton University, Omaha, NE.
- 188 Similarities And Differences Between Lung Ligands For Mouse Siglec-f And Human Siglec-8**  
**T. Kiwamoto<sup>1</sup>, H. J. Na<sup>1</sup>, M. E. Brummet<sup>1</sup>, D. F. Smith<sup>2</sup>, B. S. Bochner<sup>1</sup>;**



- <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Emory University School of Medicine, Atlanta, GA.
- 189 Relationship Between Leptin/Bronchial Hyperresponsiveness To Mannitol And Urinary Leukotriene E<sub>4</sub>/exhaled Nitric Oxide Ratio In Asthmatic Children**  
H. Baek<sup>1</sup>, J. Oh<sup>2</sup>, H. Lee<sup>2</sup>;  
<sup>1</sup>Hallym University Gangdong Sacred Heart Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Hanyang University College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 190 Silymarin Reduces OVA-induced Allergic Airway Inflammation**  
D. C. Newcomb<sup>1</sup>, M. G. Boswell<sup>1</sup>, M. M. Huckabee<sup>1</sup>, J. S. Markowitz<sup>2</sup>, T. V. Hartert<sup>1</sup>, R. S. Peebles, Jr<sup>1</sup>;  
<sup>1</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>University of Florida, Gainesville, FL.
- 191 ¿Does the Immunological Status Influence in Behavior of Albino Mice with Experimental Asthma Model?**  
J. C. Muino<sup>1</sup>, J. C. Cosiansi Bai<sup>2</sup>, M. Glocker<sup>2</sup>, S. Cossy Isasi<sup>2</sup>;  
<sup>1</sup>Universidad Nacional de Córdoba, Córdoba, ARGENTINA, <sup>2</sup>Universidad Nacional de Córdoba, Córdoba, ARGENTINA.
- 192 The Effects of Omalizumab on the Late-Phase Response to Nasal and Skin Allergen Challenge**  
M. O. Paterniti, L. M. Breslin, J. Courneya, P. M. Sterba, M. E. Brummet, Y. Park, D. W. MacGlashan, Jr., B. S. Bochner, S. S. Saini;  
Johns Hopkins University School of Medicine, Baltimore, MD.
- 193 Preventive Effects of *Lactobacillus rhamnosus* (Lcr35) through the suppression of inflammatory cytokines in Mouse Model with Atopic Dermatitis**  
H. Kim<sup>1</sup>, Y. Kim<sup>1</sup>, M. Kang<sup>1</sup>, J. Seo<sup>2</sup>, H. Kim<sup>2</sup>, J. Yu<sup>3</sup>, S. Hong<sup>2</sup>;  
<sup>1</sup>Asan Institute for Life Sciences, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Research Center for Standardization of Allergic Diseases, Childhood Asthma, Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Childhood Asthma, Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 194 Vitamin D As An Immunomodulator In Ova Induced Allergic Mice**  
S. Park<sup>1,2</sup>, B. Kang<sup>1</sup>, S. Ahn<sup>2</sup>, J. Kim<sup>1,2</sup>, B. Son<sup>1,2</sup>, D. Lim<sup>1,2</sup>;  
<sup>1</sup>Department of Pediatrics, Inha University Hospital, Incheon, KOREA, REPUBLIC OF, <sup>2</sup>Environmental Health Center for Allergic Rhinitis, Inha University Hospital, Ministry of Environment, Seoul, KOREA, REPUBLIC OF.
- 195 Expression of Vitamin D Receptor and CYP24A1 Enzyme in Airway Epithelium in Allergic Asthma**  
T. O. Makinde, R. Gaurav, R. Steininger, D. K. Agrawal;  
Center for Clinical and Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE.
- 196 Challenge With Ragweed Pollen Extract (RWPE) In Allergic Rhinitis Induces Rapid Increase In 8-hydroxydeoxyguanosine (8-OHdG), IL-10 and G-CSF**  
H. Qi, D. Redding, A. Kurosky, B. Singh, J. Lane, M. Bain, I. Boldog, T. Hazra, S. Sur;  
University of Texas Medical Branch, Galveston, TX.
- 197 Phosphorylation of N-Terminal Serine Residues of Glucocorticoid Receptor (GR) and Anti-inflammatory Response by Resolvin E1 (RvE1)**  
L. Kaphalia, M. Jamaluddin, B. T. Ameredes, W. J. Calhoun;  
The University of Texas Medical Branch, Galveston, TX.
- 198 IL-8 And Neutrophils In Bronchoalveolar Lavage Fluids Distinguish Mild Asthma From Moderate To Severe Asthma**  
S. Sur<sup>1</sup>, S. Ying<sup>2</sup>, C. Corrigan<sup>2</sup>, A. Kurosky<sup>1</sup>, I. Boldog<sup>1</sup>, H. Qi<sup>1</sup>;  
<sup>1</sup>University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Kings College, London, UNITED KINGDOM.
- 199 Histamine And Endogenously Produced Spasmogenic Prostaglandins Increase The Strength Of Airway Smooth Muscle**  
Y. Bosse, P. D. Pare;  
University of British Columbia, Vancouver, BC, CANADA.
- 200 A Model for the Investigation of Allergic Sinus Congestion and Treatment**  
B. T. Ameredes, J. L. Parks, IV, W. C. Spear;  
University of Texas Medical Branch, Galveston, TX.
- 201 Influence of Maternal Allergen Exposure in the Development of Allergic Airway Disease in the Offspring: Effects of Antigen and Timing of Exposure**  
J. Yang, K. Gabehart, K. A. Correll, A. George, M. L. Collins, E. W. Gelfand, A. Dakhama;  
National Jewish Health, Denver, CO.
- 202 Effect of Prenatal Cigarette Smoke Exposure on the Development of Allergic Airway Disease in Mice**  
K. A. Correll, K. Gabehart, J. Yang, A. George, M. L. Collins, A. Dakhama;  
National Jewish Health, Denver, CO.
- 203 The Single Nucleotide Polymorphism, *CRTh2*-6373G>A, is Associated with Allergic Asthma and Increased Expression of *CRTh2***  
L. Cameron<sup>1</sup>, E. Campos Alberto<sup>1</sup>, E. MacLean<sup>1</sup>, C. Davidson<sup>1</sup>, D. Brenner<sup>2</sup>, A. El-Soheily<sup>2</sup>, H. Vliagoftis<sup>1</sup>;  
<sup>1</sup>University of Alberta, Edmonton, AB, CANADA, <sup>2</sup>University of Toronto, Toronto, ON, CANADA.
- 204 Transglutaminase 2 Knock-out Protects Against Airway Inflammation And Tissue Remodeling In Ova-specific Allergic Asthma In Mice**  
G. Hong<sup>1</sup>, B. Park<sup>1</sup>, J. Park<sup>2</sup>, S. Kim<sup>3</sup>, J. Ro<sup>1</sup>;  
<sup>1</sup>sungkyunkwan university of medicine, suwon, KOREA, REPUBLIC OF, <sup>2</sup>Department of Internal Medicine, Yonsei University College of Medicine, Division of Allergy and Immunology, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Cancer Cell and Molecular Biology Branch, Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, KOREA, REPUBLIC OF.

## Poster Session

### Innate Immunity

2212

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 205 Diesel Exhaust Alters Nasal Innate Immune Mechanisms in Allergic Rhinitis**  
C. V. E. Chehrazi, B. J. Horton, H. Zhou, T. Noah, D. Diaz-Sanchez, I. Jaspers;  
University of North Carolina, Chapel Hill, NC.
- 206 Silica Crystals Cause Cellular Injury in TLR3-Activated Human Bronchial Epithelial Cells**  
H. Unno, K. Futamura, R. Kojima, H. Morita, H. Saito, K. Matsumoto, A. Matsuda;  
National Research Institute for Child Health & Development, Tokyo, JAPAN.
- 207 Alternaria Induces Stat-6 Dependent Acute Airway Eosinophilia And Epithelial Fizz1 Expression That Promotes Airway Fibrosis And Epithelial Thickness**  
N. Khorram<sup>1</sup>, K. Sugimoto<sup>2</sup>, D. Sheppard<sup>2</sup>, P. Rosenthal<sup>1</sup>, J. Cho<sup>1</sup>, A. Pham<sup>1</sup>, M. Miller<sup>1</sup>, B. Zuraw<sup>1</sup>, M. Croft<sup>3</sup>, D. H. Broide<sup>1</sup>, T. A. Doherty<sup>1</sup>;  
<sup>1</sup>University of California, San Diego, La Jolla, CA, <sup>2</sup>University of

- California, San Francisco, San Francisco, CA, <sup>3</sup>La Jolla Institute for Allergy and Immunology, La Jolla, CA.
- 208 Chemokines, Soluble Receptors and Mediators of Cord Blood Mononuclear Cells and Atopic Sensitization at 2 Years of Age in At Risk Infants Participating in a Probiotic Supplementation Clinical Trial**  
P. Quah, C. Huang, P. Shek, M. Aw, K. Chua, B. Lee, I. Kuo; National University of Singapore, Singapore, SINGAPORE.
- 209 Gene-Environment Interaction Between Early Life Exposure and CD14, TLR4, IL13 in Development of Allergic Diseases or Atopy**  
J. Seo<sup>1</sup>, H. Kim<sup>1</sup>, M. Kang<sup>2</sup>, Y. Kim<sup>2</sup>, J. Kwon<sup>3</sup>, B. Kim<sup>4</sup>, K. Park<sup>5</sup>, S. Lee<sup>6</sup>, S. Hong<sup>1</sup>;  
<sup>1</sup>Department of Pediatrics, Childhood Asthma Atopy Center, Research Center for Standardization of Allergic Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Asan Institute for Life Sciences, University of Ulsan, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>4</sup>Department of Pediatrics, Inje University Haeundae Paik Hospital, Pusan, KOREA, REPUBLIC OF, <sup>5</sup>Department of Pediatrics, Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF, <sup>6</sup>Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF.
- 210 Exogenous Interferons Reduce Rhinovirus Replication in Human Bronchial Epithelial Cells**  
T. M. Becker, S. R. Durrani, V. Rajamanickam, Y. A. Bochkov, D. J. Jackson;  
University of Wisconsin School of Medicine and Public Health, Madison, WI.
- 211 Transforming Growth Factor- $\beta$  Regulates the Expression of Toll-Like Receptors in Human Bronchial Epithelial Cells**  
K. Fischer<sup>1</sup>, R. Gaurav<sup>2</sup>, D. K. Agrawal<sup>2</sup>;  
<sup>1</sup>Center for Clinical & Translational Science, and Department of Microbiology & Immunology, Creighton University School of Medicine, Omaha, NE, <sup>2</sup>Center for Clinical & Translational Science, and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE.
- 212 Enhancer of Zeste Homolog 2 induces Pulmonary Artery Smooth Muscle Cell Proliferation and Migration**  
S. A. Aljbran, R. Cox, P. Tamarapu Parthasarathy, G. KR, S. M. Mohapatra, R. Lockey, N. Kolliputi;  
University Of South Florida, Tampa, FL.
- 213 Differential recruitment of CD49d+ Neutrophils by Toll-like Receptor Agonists**  
D. S. Cheung, E. J. Buell, D. A. Hunter, S. J. Zemple, M. H. Grayson;  
Medical College of Wisconsin, Milwaukee, WI.
- 215 Factors Associated with Daily Stress and Asthma Stress in Caregivers of Children with Asthma**  
C. L. Vibbert<sup>1</sup>, A. Butz<sup>2</sup>, M. Donithan<sup>2</sup>, M. E. Bollinger<sup>1</sup>;  
<sup>1</sup>University of Maryland, Baltimore, MD, <sup>2</sup>Johns Hopkins University, Baltimore, MD.
- 216 Increase in Food Protein consumed during Milk and Egg Open Food Challenges are not associated with increase in failures**  
S. A. Lowe<sup>1</sup>, J. E. Conner<sup>1</sup>, L. A. Crandall<sup>1</sup>, C. M. Lee<sup>1</sup>, M. B. Ho<sup>1</sup>, M. B. Feuling<sup>2</sup>, C. L. Sova<sup>2</sup>, M. Vasudev<sup>1</sup>;  
<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Children's Hospital of Wisconsin, Milwaukee, WI.
- 217 Churg-Strauss syndrome: The Clinical Features and Long-term Prognosis of 47 Patients**  
C. Lee<sup>1</sup>, B. Lee<sup>1</sup>, J. Lee<sup>2</sup>, D. Choi<sup>1</sup>;  
<sup>1</sup>Samsung medical center, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Center for Health Promotion, Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.
- 218 Food Allergy Educational Needs of Allergy Dietitians in the UK**  
C. Venter<sup>1</sup>, R. Meyer<sup>2</sup>, L. Reeves<sup>3</sup>;  
<sup>1</sup>The David Hide Asthma and Allergy Research Center, Isle of Wight, UNITED KINGDOM, <sup>2</sup>Great Ormond Street Hospital, London, UNITED KINGDOM, <sup>3</sup>Oxford Health NHS Foundation Trust, Oxford, UNITED KINGDOM.
- 219 Role of Preventive Anti-histamine Medications for Local Reactions with Conventional Aeroallergen Subcutaneous Immunotherapy (SCIT)**  
S. Golubski, T. Gobel, R. Gutta, L. Pien;  
cleveland clinic, cleveland, OH.
- 220 Response to State Epinephrine IM (epi IM) Dose vs. BMI and WAO Systemic Reaction Grading in the Incidence of Systemic Reactions (SRs) to Prick (P) and Intradermal (ID) Skin Tests**  
D. Shearer;  
Univ So. Fla, Tampa, FL.
- 221 Temporal Changes In Lung Function In A Mouse Worker Population**  
B. M. Thomas<sup>1</sup>, C. Aloe<sup>1</sup>, J. Curtin-Brosnan<sup>1</sup>, R. D. Peng<sup>2</sup>, P. A. Eggleston<sup>1</sup>, W. G. Shreffler<sup>3</sup>, K. A. Hagberg<sup>4</sup>, M. Krevans<sup>4</sup>, R. Korstanje<sup>4</sup>, E. C. Matsui<sup>1</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Massachusetts General Hospital, Boston, MA, <sup>4</sup>The Jackson Laboratory, Bar Harbor, ME.
- 222 Clinical Utility of Anergy Panel Testing in Conjunction with Purified Protein Derivative (PPD) Tuberculin Skin Testing (TST) for Detection of Latent Tuberculosis Infection (LTBI) in Pre-lung Transplant Patients**  
K. Caruso, R. Gutta, L. Pien;  
Cleveland Clinic, Cleveland, OH.
- 223 Development of Standards of Care for Immunoglobulin Replacement Therapy**  
C. M. Duff<sup>1</sup>, W. Blouin<sup>2</sup>, D. Sedlak<sup>3</sup>, I. D. F. Nurse Advisory Committee<sup>4</sup>;  
<sup>1</sup>University of South Florida, St. Petersburg, FL, <sup>2</sup>Miami Children's Hospital, Miami, FL, <sup>3</sup>Duke University Medical Center, Durham, NC, <sup>4</sup>Immune Deficiency Foundation, Townsend, MD.
- 224 The Newport News Healthy Homes Initiative: Targetting A Hard To Reach Low Income Asthmatic Population**  
J. C. Taylor-Fishwick, C. S. Kelly, C. Collins-Odoms;  
Eastern Virginia Medical School, Norfolk, VA.
- 225 Indoor Allergens in the Rocky Mountains: Dust Collection and Analysis in the Arid North**  
E. C. Weiler;  
University of Montana, Missoula, MT.
- 226 Effects of Asian Dust and Spherical Particles Exposure on Human Health and Allergic Symptom, Fukuoka, Japan**  
R. T. Kishikawa<sup>1</sup>, T. Imai<sup>2</sup>, T. Ichinose<sup>3</sup>, Y. Okuno<sup>4</sup>, K. Arashidani<sup>5</sup>, M. Nishikawa<sup>6</sup>, T. Shimoda<sup>1</sup>, T. Iwanaga<sup>1</sup>;

## Poster Session

### Allied Health Poster Session

2213

Session Time: Saturday, March 3, 2012,  
9:45 AM - 10:45 AM

- 214 Participant Survey Results From the Starting Hizentra Administration With Resources and Education (SHARE) Program**  
E. Murphy<sup>1</sup>, P. Riley<sup>1</sup>, A. Zampelli<sup>1</sup>, C. Duff<sup>2</sup>;  
<sup>1</sup>CSL Behring, LLC, King of Prussia, PA, <sup>2</sup>University of South Florida, Tampa, FL.

<sup>1</sup>The Fukuoka National Hospital, Fukuoka, JAPAN, <sup>2</sup>Medical Plaza Heiwadai Hospital, Chiba, JAPAN, <sup>3</sup>Oita University of Nursing and Health Science, Oita, JAPAN, <sup>4</sup>The Japanese Red Cross Kyushu International College, Fukuoka, JAPAN, <sup>5</sup>University of Occupational and Environmental Health, Fukuoka, JAPAN, <sup>6</sup>National Institute for Environmental Studies, Ibaraki, JAPAN.

**227 Recent Increase in Aeroallergen Indices in Texas Panhandle and Use of Nano Air Purifier to Alleviate Allergic Rhinitis and Asthma**

**N. GHOSH<sup>1</sup>, C. Saadeh<sup>2</sup>, V. Aguaiza<sup>1</sup>, M. Whiteside<sup>1</sup>, J. Chudasama<sup>3</sup>,**

<sup>1</sup>West Texas A&M University, Canyon, TX, <sup>2</sup>Allergy ARTS, Amarillo, TX, <sup>3</sup>Nano Air US LLC, Las Vegas, NV.

**228 Research Of The Allergenicity Evaluation System Of Recombinant Human Lactoferrin (rhLF) With BN Rats**

**C. Zhou<sup>1</sup>, N. Sun<sup>1</sup>, J. Wang<sup>1</sup>, H. Che<sup>1,2</sup>,**

<sup>1</sup>College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, CHINA, <sup>2</sup>The Supervision, Inspection and Testing Center of Genetically Modified Organisms, Ministry of Agriculture, Beijing, CHINA.

**229 Predictive Value Of Caregiver Report And Expert Assessment Of Home Mouse Allergen Levels**

**A. P. Taliaferro, J. Curtin-Brosnan, E. C. Matsui;**

Johns Hopkins University School of Medicine, Baltimore, MD.

## Oral Abstract Session

### Asthma Highlights

2601

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

**230 Elevated Cord Blood Soluble CD14 Levels Predict Wheezing in the First Year of Life**

**Y. Huang<sup>1</sup>, K. Yeh<sup>2</sup>, J. Huang<sup>2</sup>;**

<sup>1</sup>Chang Gung Memorial Hospital at Keelung, Keelung City, TAIWAN, <sup>2</sup>Chang Gung Memorial Hospital at Linkuo and Chang Gung University, Taoyuan, TAIWAN.

**231 Improvements In Quality Of Life Measures In A Structured Exercise Program For Persistent Asthma**

**S. M. Pollart, K. S. Elward, T. A. E. Platts-Mills;**

University of Virginia, Charlottesville, VA.

**232 Real-world Effectiveness Of Asthma Step-up Options: Matched Comparison Of Extrafine Hydrofluoroalkane-beclometasone AND Inhaled Corticosteroid / Long-Acting Beta-Agonist**

**D. B. Price<sup>1,2</sup>, R. Martin<sup>3</sup>, N. Barnes<sup>4</sup>, N. Roche<sup>5</sup>, A. J. Lee<sup>1</sup>, P. Dorinsky<sup>6</sup>, A. Burden<sup>2</sup>, J. von Ziegenweid<sup>2</sup>, A. Chisholm<sup>2</sup>, E. V. Hillyer<sup>2</sup>, G. Colice<sup>7</sup>;**

<sup>1</sup>University of Aberdeen, Aberdeen, UNITED KINGDOM, <sup>2</sup>Research in Real Life, Cambridge, UNITED KINGDOM, <sup>3</sup>National Jewish Health, Denver, CO, <sup>4</sup>London Chest Hospital, Barts and the London NHS Trust, London, UNITED KINGDOM, <sup>5</sup>Hopital de l'Hotel-Dieu, Paris, FRANCE, <sup>6</sup>Teva Pharmaceuticals, Horsham, PA, <sup>7</sup>Washington Hospital Center and George Washington University School of Medicine, Washington, DC.

**233 Alternaria Sensitization is Associated with Increased Airway Hyperresponsiveness and Sinusitis in Children with Severe Asthma**

**J. Shih, A. Fitzpatrick;**

Emory University, Atlanta, GA.

**234 Disconnect Between Sputum Neutrophilia and Indices of Mucosal Inflammation in Severe Asthma**

**J. R. Arron<sup>1</sup>, D. F. Choy<sup>1</sup>, S. Audousseau<sup>2</sup>, Q. Hamid<sup>2</sup>, J. M. Harris<sup>1</sup>, -. BOBCAT Study Group<sup>1</sup>;**

<sup>1</sup>Genentech, Inc., South San Francisco, CA, <sup>2</sup>McGill University, Montreal, QC, CANADA.

## Oral Abstract Session

### Immunogenetics

2602

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

**235 Co-associations Between IL10 Genetic Variants, IL 10 Production And Helminth Infection In A Tropical Population Of Brazil With High Prevalence Of Asthma**

**C. A. Figueiredo<sup>1,2</sup>, M. L. Barreto<sup>3</sup>, N. M. Alcantara-Neves<sup>4</sup>, P. J. Cooper<sup>5,6</sup>, L. C. Rodrigues<sup>7</sup>, A. A. Cruz<sup>8</sup>, L. C. Pontes-de-Carvalho<sup>9</sup>, C. Vergara<sup>1</sup>, N. Rafaels<sup>1</sup>, L. Gao<sup>1</sup>, C. Foster<sup>1</sup>, M. Campbell<sup>1</sup>, R. A. Mathias<sup>1</sup>, K. C. Barnes<sup>1</sup>;**

<sup>1</sup>Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD, <sup>2</sup>Instituto de Ciências da Saúde, Universidade Federal da Bahia, Salvador, BA, BRAZIL, <sup>3</sup>Instituto de Sade Coletiva, Universidade Federal de Bahia, Salvador, BA, BRAZIL, <sup>4</sup>Instituto de Ciencias da Saude, Universidade Federal da Bahia, Salvador, BA, BRAZIL, <sup>5</sup>Universidad San Francisco de Quito, Quito, ECUADOR, <sup>6</sup>Centre for Infection, St George's, University of London, London, UNITED KINGDOM, <sup>7</sup>London School of Hygiene and Tropical Medicine; London, United Kingdom, <sup>8</sup>ProAR Ncleo de Excelencia em Asma, Universidade Federal da Bahia, Salvador, BA, BRAZIL, <sup>9</sup>Centro de Pesquisas Gonalo Moniz, Fundao Oswaldo Cruz FIOCRUZ, Salvador, BA, BRAZIL.

**236 Glucocorticoid Receptor Translational Isoforms Contribute to Distinct Glucocorticoid Responses of Neutrophils and Eosinophils**

**J. Hsu, Y. Cao, I. K. Bender, P. C. Avila, N. Z. Lu;**  
Northwestern University, Chicago, IL.

**237 Epigenetic Biomarkers of Established Allergic Disease in Peripheral Blood Mononuclear Cells**

**M. L. North<sup>1</sup>, S. M. A. Neumann<sup>2</sup>, L. Lam<sup>2</sup>, L. M. Steacy<sup>3</sup>, J. Thiele<sup>4</sup>, M. S. Kobor<sup>5</sup>, A. K. Ellis<sup>6</sup>;**

<sup>1</sup>Department of Biomedical & Molecular Sciences and Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston, ON, CANADA, <sup>2</sup>Child & Family Research Institute and Centre for Molecular Medicine & Therapeutics, Vancouver, BC, CANADA, <sup>3</sup>Allergy Research Unit, Kingston General Hospital, Kingston, ON, CANADA, <sup>4</sup>Department of Biomedical & Molecular Sciences and Division of Allergy & Immunology, Department of Medicine, Queens University, Kingston, ON, CANADA, <sup>5</sup>Child & Family Research Institute and Centre for Molecular Medicine & Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, BC, CANADA, <sup>6</sup>Department of Biomedical & Molecular Sciences and Division of Allergy & Immunology, Department of Medicine, Queen's University, Allergy Research Unit, Kingston General Hospital, Kingston, ON, CANADA.

**238 Genetic Polymorphisms of Transforming Growth Factor-β Signaling Pathway and Kawasaki Disease in the Taiwanese population**

H. C. Kuo<sup>1</sup>, K. D. Yang<sup>1</sup>, W. C. Chang<sup>2</sup>;

<sup>1</sup>Kaohsiung Chang Gung Memorial Hospital, Taiwan, Kaohsiung, TAIWAN, <sup>2</sup>Department of Medical Genetics, College of Medicine, Kaohsiung Medical University, Taiwan, Kaohsiung, TAIWAN.

**239 The German Mouse Clinic (gmc): A Systemic Phenotyping Platform To Uncover New Models For Allergic Diseases**

J. A. Aguilar-Pimentel<sup>1,2</sup>, T. Adler<sup>3</sup>, V. Gailus-Durner<sup>4</sup>, H. Fuchs<sup>4</sup>, J. Guterth<sup>2</sup>, C. B. Schmidt-Weber<sup>2</sup>, M. Hrab de Angelis<sup>4</sup>, D. H. Busch<sup>3</sup>, M. Ollert<sup>1,2</sup>;

<sup>1</sup>Technische Universitaet Muenchen, Department of Dermatology and Allergy Biederstein, GERMANY, <sup>2</sup>Center of Allergy and Environment (ZAUM), Technische Universitaet Muenchen, GERMANY, <sup>3</sup>Technische Universitaet Muenchen, Institute for Medical Microbiology Immunology, GERMANY, <sup>4</sup>Helmholtz Zentrum Muenchen, GmbH, Institute of Experimental Genetics, Munich, GERMANY.

## Oral Abstract Session

### Healthy Homes - Do they make a difference in disease?

2603

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

**240 Exposure to Indoor Allergens in Urban Elementary Schools and Homes of Children with Asthma**

P. Permaul<sup>1</sup>, E. Hoffman<sup>2</sup>, C. Fu<sup>3</sup>, W. Sheehan<sup>4</sup>, S. Baxi<sup>4</sup>, J. Gaffin<sup>5</sup>, J. Lane<sup>6</sup>, A. Bailey<sup>3</sup>, D. Gold<sup>3</sup>, W. Phipatanakul<sup>4</sup>;

<sup>1</sup>Division of Pediatric Allergy and Immunology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Department of Biostatistics, Harvard School of Public Health, Boston, MA, <sup>3</sup>Channing Laboratory, Brigham and Women's Hospital, Boston, MA, <sup>4</sup>Division of Allergy and Immunology, Children's Hospital Boston, Boston, MA, <sup>5</sup>Division of Pulmonary, Children's Hospital Boston, Boston, MA, <sup>6</sup>Facilities Management, Boston, MA.

**241 Reduction in Dust Allergen Exposure through Healthy Homes Education**

F. Pacheco, M. G. Dhar, C. S. Barnes, C. Childrens Mercy Center for Environmental Health;  
Children's Mercy Hospital, Kansas City, MO.

**242 Neither Dust Mite nor Cat Allergen Exposure Is Associated with Lung Function or Asthma Morbidity in Sensitized Baltimore City Children**

S. K. Ahluwalia, P. Breyse, G. Diette, E. Matsui;  
Johns Hopkins University, Baltimore, MD.

**243 Among Middle-income Children In NYC, Neighborhood Reports Of Mouse Sightings Were Associated With Sensitization To Mouse**

M. S. Jackson-Browne, O. Olmedo, A. Divijan, I. F. Goldstein, L. Acosta, A. G. Rundle, R. B. Mellins, J. W. Quinn, F. P. Perera, R. L. Miller, J. S. Jacobson, M. S. Perzanowski;  
Columbia University, New York, NY.

**244 Indoor Airborne Spore Levels Before and After Healthy Homes Education and Remediation**

M. G. Dhar, F. Pacheco, C. Barnes, C. Childrens Mercy Center for Environmental Health;  
Children's Mercy Hospital, Kansas City, MO.

## Oral Abstract Session

### Food Allergy

2604

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

**245 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Egg Oral Immunotherapy in Children: An Analysis of Clinical Tolerance**

S. M. Jones<sup>1</sup>, A. W. Burks<sup>2</sup>, R. A. Wood<sup>3</sup>, D. M. Fleischer<sup>4</sup>, S. H. Sicherer<sup>2</sup>, R. W. Lindblad<sup>6</sup>, D. Stablein<sup>6</sup>, A. K. Henning<sup>6</sup>, B. P. Vickery<sup>2</sup>, A. H. Liu<sup>4</sup>, A. M. Scurlock<sup>1</sup>, W. G. Shreffler<sup>7</sup>, M. Plaut<sup>8</sup>, H. A. Sampson<sup>5</sup>;

<sup>1</sup>University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR, <sup>2</sup>Duke University Medical Center, Durham, NC, <sup>3</sup>Johns Hopkins University Medical Center, Baltimore, MD, <sup>4</sup>National Jewish Health, Denver, CO, <sup>5</sup>Mount Sinai School of Medicine, New York, NY, <sup>6</sup>The EMMES Corporation, Rockville, MD, <sup>7</sup>Massachusetts General Hospital, Harvard Medical School, Boston, MA, <sup>8</sup>National Institutes of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD.

**246 Peanut Challenge Outcomes Following Sublingual Immunotherapy (SLIT) Correlate With Increased Peanut-Specific Salivary IgA**

M. D. Kulis, K. Saba, E. H. Kim, J. A. Bird, N. Kamilaris, B. P. Vickery, H. Staats, A. W. Burks;

Duke University Medical Center, Durham, NC.

**247 Plasma from Subjects on Peanut Oral Immunotherapy (OIT) Suppresses *ex vivo* Basophil Activation in Peanut-Allergic Subjects**

C. Burk, M. Kulis, N. Kamilaris, S. Chin, A. W. Burks;  
Duke University Medical Center, Durham, NC.

**248 Sublingual Immunotherapy for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial (CoFAR)**

D. M. Fleischer<sup>1</sup>, R. A. Wood<sup>2</sup>, S. M. Jones<sup>3</sup>, S. H. Sicherer<sup>4</sup>, A. H. Liu<sup>1</sup>, D. Stablein<sup>5</sup>, A. Henning<sup>5</sup>, L. Mayer<sup>4</sup>, R. Lindblad<sup>5</sup>, H. A. Sampson<sup>4</sup>, A. W. Burks<sup>6</sup>;

<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>Johns Hopkins University Medical Center, Baltimore, MD, <sup>3</sup>University of Arkansas for Medical Sciences and Arkansas Childrens Hospital, Little Rock, AR, <sup>4</sup>Mount Sinai School of Medicine, New York, NY, <sup>5</sup>The EMMES Corporation, Rockville, MD, <sup>6</sup>Duke University Medical Center, Durham, NC.

**249 Development of Clinical Tolerance after Peanut OIT**

A. W. Burks<sup>1</sup>, B. P. Vickery<sup>1</sup>, A. M. Scurlock<sup>2</sup>, P. Steele<sup>1</sup>, J. Kamilaris<sup>1</sup>, A. M. Hiegel<sup>2</sup>, S. K. Carlisle<sup>2</sup>, T. T. Perry<sup>2</sup>, S. M. Jones<sup>2</sup>;

<sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR.

## Oral Abstract Session

### Determinants of Asthma Treatment Choices

2605

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

**250 Differences in Asthma Controller Medication Adherence by Age and Gender**

L. J. Hinyard<sup>1</sup>, C. Geremakis<sup>1</sup>, J. Temprano<sup>2</sup>;

<sup>1</sup>Saint Louis University Center for Outcomes Research, Saint Louis University, St. Louis, MO, <sup>2</sup>Division of Infectious Diseases, Allergy and Immunology, Section of Allergy and Immunology, Saint Louis University, St. Louis, MO.

- 251 **Survey of Asthma Management and Referral Preferences by Primary Care Pediatricians at a Pediatric Training Hospital**  
N. Farooqui<sup>1</sup>, D. Stukus<sup>1,2</sup>;  
<sup>1</sup>The Ohio State University, Columbus, OH, <sup>2</sup>Nationwide Children's Hospital, Columbus, OH.
- 252 **The Comparison of Asthma Control Judgment Based on Japanese Guidelines for Asthma, GINA, EPR3, and ACT**  
H. Nagase, N. Sugimoto, Y. Nakase, A. Kamiyama, H. Yoshihara, M. Kuramochi, H. Tashimo, H. Arai, N. Suzuki, M. Yamaguchi, K. Ohta;  
Teikyo University, Tokyo, JAPAN.
- 253 **Combined Corticosteroid Use in Patients with Asthma, Allergic Rhinitis, and Atopic Dermatitis**  
M. Lee<sup>1</sup>, S. Mithani<sup>2</sup>, J. Fagin<sup>2</sup>;  
<sup>1</sup>Cohen Children's Medical Center, New Hyde Park, NY, <sup>2</sup>North Shore LIJ, Division of Allergy and Immunology, Great Neck, NY.
- 254 **Depressive Symptoms in African American and Caucasian Women Participating in Telephone-Based Asthma Management Programs**  
G. Sanders<sup>1</sup>, M. Janevic<sup>1</sup>, L. Thomas<sup>1</sup>, T. Johnson<sup>1</sup>, N. M. Clark<sup>2</sup>;  
<sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Center for Managing Chronic Disease, University of Michigan, Ann Arbor, MI.

## Oral Abstract Session

### Rhinosinusitis Mechanisms and Management

2606

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

- 255 **Differential Regional Expression Of Innate Immune Antimicrobial Proteins In Sinonasal Mucosa**  
S. Seshadri<sup>1</sup>, M. Rosati<sup>1</sup>, D. C. Lin<sup>1</sup>, R. Carter<sup>1</sup>, J. Norton<sup>1</sup>, A. Kato<sup>1</sup>, L. Suh<sup>1</sup>, A. T. Peters<sup>1</sup>, R. Chandra<sup>2</sup>, K. E. Harris<sup>1</sup>, H. Chu<sup>3</sup>, D. B. Conley<sup>2</sup>, B. Tan<sup>2</sup>, L. C. Grammer<sup>1</sup>, R. C. Kern<sup>2</sup>, R. P. Schleimer<sup>1</sup>;  
<sup>1</sup>Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Department of Medicine, National Jewish Health, Denver, CO.
- 256 **STAT3 and NF- $\kappa$ B Regulate S100A7 Expression in Human Bronchial Epithelial Cells**  
K. E. Hulse<sup>1</sup>, R. Singh<sup>1</sup>, K. Chaung<sup>1</sup>, J. Norton<sup>1</sup>, K. Harris<sup>1</sup>, D. Conley<sup>2</sup>, R. Chandra<sup>2</sup>, R. Kern<sup>2</sup>, A. Peters<sup>1</sup>, L. Grammer<sup>1</sup>, B. Tan<sup>2</sup>, R. Carter<sup>1</sup>, S. Seshadri<sup>1</sup>, L. Suh<sup>1</sup>, A. Kato<sup>1</sup>, R. Schleimer<sup>1</sup>;  
<sup>1</sup>Northwestern University Department of Medicine, Chicago, IL, <sup>2</sup>Northwestern University Department of Otolaryngology, Chicago, IL.
- 257 **Clinical Characteristics of Patients with Chronic Rhinosinusitis and Specific Antibody Deficiency**  
S. Kashani<sup>1</sup>, L. C. Grammer<sup>2</sup>, R. P. Schleimer<sup>2</sup>, T. F. Carr<sup>3</sup>, A. T. Peters<sup>2</sup>;  
<sup>1</sup>Northwestern University, Evanston, IL, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>The University of Arizona College of Medicine, Tucson, AZ.
- 258 **Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And Asthma**

P. Gevaert, L. Calus, T. Van Zele, K. Blomme, N. De Ruyck, W. Bauters, P. Hellings, D. De Bacquer, G. Brusselle, P. Van Cauwenberge, C. Bachert;  
Ghent University, Ghent, BELGIUM.

- 259 **IL-21 is Increased in Nasal Polyposis and after Stimulation with Staphylococcus Aureus Enterotoxins**  
L. Calus<sup>1</sup>, I. Derycke<sup>1</sup>, N. De ruyck<sup>1</sup>, G. Holtappels<sup>1</sup>, M. Dullaers<sup>2</sup>, B. Lambrecht<sup>2</sup>, C. Bachert<sup>1</sup>, P. Gevaert<sup>1</sup>;  
<sup>1</sup>Upper airways research laboratory, Ghent, BELGIUM, <sup>2</sup>Laboratory of Immunoregulation and Mucosal Immunology, Ghent, BELGIUM.

## Oral Abstract Session

### Cytokines Initiating Allergic Responses

2607

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

- 260 **The Interaction Between Ara h 1 and TSLP Selectively Expands Skin-Homing Th2 Cells in Peanut-Sensitized Children**  
J. A. Wisniewski, M. D. Yu, S. P. Commins, J. A. Woodfolk;  
University of Virginia, Charlottesville, VA.
- 261 **Allergen Induces Dual Upregulation of TSLP Receptor on Circulating Basophils and Dendritic Cells in Atopic Dermatitis**  
R. Agrawal, P. W. Wright, J. A. Woodfolk;  
University of Virginia, Charlottesville, VA.
- 262 **IL-33 Mediates Both Innate and Adaptive Th2-type Responses Induced by Proteases in the Airway**  
K. Hara<sup>1,2</sup>, K. Iijima<sup>1</sup>, T. Kobayashi<sup>1</sup>, G. Kephart<sup>1</sup>, H. Kita<sup>1</sup>;  
<sup>1</sup>Mayo clinic, Rochester, MN, <sup>2</sup>Department of Medicine and Biological Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, JAPAN.
- 263 **Roles for IL-33 and TSLP in Chronic Eosinophilic Airway Inflammation Induced by Airborne Allergen Exposure**  
K. Iijima, T. Kobayashi, K. Hara, G. M. Kephart, H. Kita;  
Mayo Clinic, Rochester, MN.
- 264 **Role of Thymic Stromal Lymphopoietin (TSLP) in Chronic Rhinosinusitis**  
A. Kato<sup>1</sup>, J. A. Puposki<sup>1</sup>, D. R. Nagarkar<sup>1</sup>, B. K. Tan<sup>2</sup>, M. R. Co-meau<sup>3</sup>, A. L. Budelsky<sup>3</sup>, L. Suh<sup>1</sup>, J. Norton<sup>1</sup>, K. E. Harris<sup>1</sup>, A. T. Peters<sup>1</sup>, L. C. Grammer<sup>1</sup>, R. K. Chandra<sup>2</sup>, D. B. Conley<sup>2</sup>, R. C. Kern<sup>2</sup>, R. P. Schleimer<sup>1</sup>;  
<sup>1</sup>Allergy-Immunology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Department of Inflammation Research, Amgen Inc., Seattle, WA.

## Oral Abstract Session

### Drug Allergy

2608

Session Time: Saturday, March 3, 2012,  
2:00 PM - 3:15 PM

- 265 **Influenza Vaccine Administration in Egg Allergic Children**  
F. S. Khan<sup>1</sup>, F. S. Virant<sup>1,2</sup>, C. T. Furukawa<sup>1,2</sup>, L. C. Altman<sup>1,2</sup>, P. V. Williams<sup>1,2</sup>, M. S. Kennedy<sup>1,2</sup>, J. W. Becker<sup>1,3</sup>, M. V. Lasley<sup>1,2</sup>,

M. E. Weiss<sup>1,2</sup>, S. A. Tilles<sup>1,2</sup>, A. J. Tatum<sup>1,2</sup>, J. C. Walker<sup>1,2</sup>, T. N. Tran<sup>1,2</sup>, D. R. Naimi<sup>1,2</sup>, A. Y. Park<sup>1,2</sup>, N. J. Attaway<sup>1,2</sup>, J. D. Sprenger<sup>1,2</sup>, D. Frazier<sup>2</sup>, T. Chinn<sup>2</sup>, L. Higgins<sup>2</sup>;

<sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>Northwest Asthma and Allergy Center, Inc, Seattle, WA, <sup>3</sup>The Polyclinic, Seattle, WA.

**266 Experience With Carboplatin Desensitization: A Case Series**  
**A. Updegraff<sup>1</sup>, D. Bestul<sup>2</sup>, D. Doshi<sup>3</sup>;**

<sup>1</sup>William Beaumont Beaumont Hospital, Department of Internal Medicine and Pediatrics, Royal Oak, MI, <sup>2</sup>William Beaumont Beaumont Hospital, Department of Pharmacology, Royal Oak, MI, <sup>3</sup>William Beaumont Beaumont Hospital, Department of Internal Medicine and Pediatrics, Division of Allergy and Immunology, Oakland University William Beaumont School of Medicine, Royal Oak, MI.

**267 Nasal Inflammatory Mediators In Non-steroidal Anti-inflammatory Drugs (nsaids) Cross-intolerant Subjects After Lysine Nasal Challenge**

**I. Dona<sup>1</sup>, P. Campo<sup>1</sup>, M. Sanak<sup>2</sup>, J. Cornejo<sup>3</sup>, A. Correa<sup>1</sup>, N. Blanca-Lopez<sup>4</sup>, M. Salas<sup>1</sup>, M. Sanchez<sup>1</sup>, G. Canto<sup>4</sup>, M. Blanca<sup>1</sup>;**

<sup>1</sup>Allergy Department, Hospital Carlos Haya, Malaga, SPAIN, <sup>2</sup>Molecular Biology, Dept. of Medicine, UJ CM, Krakow, POLAND, <sup>3</sup>Allergy Laboratory, F. IMABIS, Malaga, SPAIN, <sup>4</sup>Allergy Department, Hospital Infanta Leonor, Madrid, SPAIN.

**268 Anaphylaxis as a Potential Cause of Death in Heroin Users**

**X. Zhou<sup>1</sup>, M. White<sup>1</sup>, L. Lau<sup>1</sup>, S. Williams<sup>1</sup>, A. C. Bateman<sup>2</sup>, E. Abu<sup>2</sup>, A. F. Walls<sup>1</sup>;**

<sup>1</sup>University of Southampton, Southampton, UNITED KINGDOM, <sup>2</sup>Southampton University Hospitals NHS Trust, Southampton, UNITED KINGDOM.

**269 Beta Blocker Pretreatment before Coronary CT Angiography does not Increase the Rate of Contrast Reactions**

**C. B. Lauter, G. L. Raff, K. M. Chinnaiyan, A. Abidov;**  
William Beaumont Hospital, Royal Oak, MI.

**G. Braunstahl<sup>1</sup>, R. Maykut<sup>2</sup>, M. Figliomeni<sup>3</sup>, C. Chen<sup>3</sup>, G. Peachey<sup>4</sup>;**

<sup>1</sup>St. Franciscus Gasthuis, Rotterdam, NETHERLANDS, <sup>2</sup>Novartis Pharma AG, Basel, SWITZERLAND, <sup>3</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, <sup>4</sup>Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, UNITED KINGDOM.

**274 Impact of Omalizumab on Emergency-Department Visits, Hospitalizations and Corticosteroid Use in Patients with Uncontrolled Asthma Using High-Dose Inhaled Corticosteroids**

**M. Lafeuille<sup>1</sup>, J. Dean<sup>1</sup>, J. Zhang<sup>2</sup>, M. S. Duh<sup>3</sup>, B. Gorsh<sup>2</sup>, P. Lefebvre<sup>1</sup>;**

<sup>1</sup>Groupe d'analyse, Ltee, Montreal, QC, CANADA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, <sup>3</sup>Analysis Group, Inc., Boston, MA.

**275 Characterization and Predictors of Asthma Exacerbations in Patients on Steps 4, 5 And 6 Therapy in the TENOR Cohort**

**W. Calhoun<sup>1</sup>, T. Haselkorn<sup>2</sup>, D. R. Mink<sup>3</sup>, D. P. Miller<sup>3</sup>, A. Dorenbaum<sup>4</sup>, R. Zeiger<sup>5</sup>;**

<sup>1</sup>University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Genentech, South San Francisco, CA, <sup>3</sup>ICON Late Phase & Outcomes Research, San Francisco, CA, <sup>4</sup>Genentech, Inc., South San Francisco, CA, <sup>5</sup>Kaiser Permanente Southern California, San Diego, CA.

**276 Predictive Factors for Therapeutic Response to Asthma Treatment with Montelukast or Fluticasone in a Randomized Controlled Trial with Asthmatic Smokers**

**D. Price<sup>1</sup>, L. Bjermer<sup>2</sup>, T. A. Popov<sup>3</sup>, S. Lu<sup>4</sup>, R. Petrovic<sup>4</sup>, K. Vandormael<sup>4</sup>, A. Mehta<sup>4</sup>, J. D. Strus<sup>4</sup>, P. G. Polos<sup>4</sup>, G. Philip<sup>4</sup>;**

<sup>1</sup>University of Aberdeen, Cambridge, UNITED KINGDOM, <sup>2</sup>Skane University Hospital, Lund, SWEDEN, <sup>3</sup>Alexander's University Hospital, Sofia, BULGARIA, <sup>4</sup>Merck Sharp & Dohme Corp., Whitehouse Station, NJ.

**278 Oral Corticosteroid Use Increases the Risk of Glucocorticoid-related Adverse Events in Asthmatics**

**J. L. Zazzali<sup>1</sup>, M. Broder<sup>2</sup>, E. Chang<sup>2</sup>;**

<sup>1</sup>Genentech, Inc., South San Francisco, CA, <sup>2</sup>Partnership for Health Analytic Research, Beverly Hills, CA.

**279 Onset and Duration of Action of Mometasone Inhalation Powder Measured by Impulse Oscillometry (IOS)**

**K. Badampudi, S. Spector;**

California Allergy & Asthma Medical Group, Los Angeles, CA.

**280 Association Between The STIP1 Polymorphism And The Response To Inhaled Steroid In Children With Asthma**

**J. Hong<sup>1</sup>, M. Kang<sup>2</sup>, H. Kim<sup>3</sup>, J. Seo<sup>3</sup>, Y. Kim<sup>2</sup>, J. Yu<sup>3</sup>, S. Hong<sup>3</sup>;**

<sup>1</sup>Cushing Academy, Ashburnham, MA, <sup>2</sup>Asan Institute for Life Science, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

**281 The Ability and Predictive Factors of Preschool Children to Use Swinghaler Device**

**P. Lertchanaruengrith, P. Rattanasukol, N. Suratannon, N. Voraphani, P. Chatchatee, J. Ngamphaiboon;**

Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND.

**282 Comparative Sensitivity of Various Indices in Evaluating Improvement in Mild Persistent Asthma**

**A. G. Ayars<sup>1</sup>, S. Potter-Perigo<sup>2</sup>, T. N. Wight<sup>2</sup>, S. A. Tilles<sup>3</sup>, L. C. Altman<sup>3</sup>;**

<sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>Benaroya Research Institute, Seattle, WA, <sup>3</sup>ASTHMA Inc, Seattle, WA.

**283 Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD): Phase 3 Efficacy and Safety Study**

**D. E. Doherty<sup>1</sup>, E. Kerwin<sup>2</sup>, D. P. Tashkin<sup>3</sup>, C. E. Matiz-Bueno<sup>4</sup>, T. Shekar<sup>5</sup>, S. Banerjee<sup>5</sup>, B. Knorr<sup>5</sup>, H. Staudinger<sup>5</sup>;**

SUNDAY

Poster Session

Asthma Therapeutics and Management

3201

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

**270 Impact on Anti-Endotoxin Immunity of Allergen Specific Immunotherapy and Probiotics in Asthma Patients**

**V. A. Beloglazov<sup>1</sup>, L. K. Znamenska<sup>1</sup>, Y. A. Bisyuk<sup>1</sup>, L. M. Dubuske<sup>2</sup>;**

<sup>1</sup>Crimea State Medical University, Simferopol, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.

**271 Use Of Omalizumab To Treat A Nine-year Old, With Steroid-dependent, Allergic Asthma, Adrenal Insufficiency And Vertebral Compression Fractures Due To Steroid-induced Severe Osteoporosis**

**S. Santucci<sup>1</sup>, A. Ring<sup>1</sup>, C. Rizk<sup>2</sup>, I. MacLuskey<sup>2</sup>, J. Karsh<sup>2</sup>, W. H. Yang<sup>2</sup>;**

<sup>1</sup>Yang Medicine, Ottawa, ON, CANADA, <sup>2</sup>University of Ottawa, Ottawa, ON, CANADA.

**272 Overturning The Conventional Notion Of Bronchial Asthma Treatment**

**Y. Shimoide;**

Yoshiteru Shimoide Clinic of Internal Medicine, Kagoshima City, JAPAN.

**273 Reductions In Oral Corticosteroid Use In Patients With Allergic (IgE-Mediated) Asthma Receiving Omalizumab**

- <sup>1</sup>Division of Pulmonary, Critical Care, and Sleep Medicine—University of Kentucky, Lexington, KY, <sup>2</sup>Clinical Research Institute of Southern Oregon, Medford, OR, <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>4</sup>Fundacion Salud Bosque, Bogota, COLOMBIA, <sup>5</sup>Merck Research Laboratories, Kenilworth, NJ.
- 284 Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in Patients With Mild to Moderate Asthma With and Without Fixed Airflow Obstruction**  
**B. E. Chipps<sup>1</sup>**, D. P. Tashkin<sup>2</sup>, T. Uryniak<sup>3</sup>, S. Zhao<sup>3</sup>, J. G. Zangrilli<sup>3</sup>;  
<sup>1</sup>Capital Allergy and Respiratory Dis. Ctr., Sacramento, CA, <sup>2</sup>University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>AstraZeneca LP, Wilmington, DE.
- 285 Clinical Pharmacokinetics and Tolerability of AZD3199, a New Inhaled Ultra Long-acting  $\beta_2$ -adrenoreceptor Agonist (uLABA) Bronchodilator**  
**P. Kuna<sup>1</sup>**, J. Rosenborg<sup>2</sup>, T. Bengtsson<sup>2</sup>, C. Jorup<sup>2</sup>, L. Bjermer<sup>3</sup>;  
<sup>1</sup>Barlicki University Hospital, Medical University of Lodz, Lodz, POLAND, <sup>2</sup>AstraZeneca R&D, Molndal, SWEDEN, <sup>3</sup>University Hospital, Lund, SWEDEN.
- 286 Long-term Cardiovascular Safety, as Evaluated by Electrocardiographic Monitoring, of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in African-American Patients With Moderate to Severe Asthma**  
**R. W. Brown<sup>1</sup>**, C. D. O'Brien<sup>2</sup>, U. J. Martin<sup>2</sup>, T. Uryniak<sup>2</sup>, K. L. Lampl<sup>2</sup>;  
<sup>1</sup>Children's Hospital of Michigan/University of Michigan School of Public Health, Ann Arbor, MI, <sup>2</sup>AstraZeneca LP, Wilmington, DE.
- 287 Efficacy of Budesonide/Formoterol Pressurized Metered-Dose Inhaler in Patients With Moderate to Severe Asthma With and Without Fixed Airflow Obstruction**  
**D. P. Tashkin<sup>1</sup>**, B. E. Chipps<sup>2</sup>, T. Uryniak<sup>3</sup>, S. Zhao<sup>3</sup>, J. G. Zangrilli<sup>3</sup>;  
<sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Capital Allergy and Respiratory Disease Center, Sacramento, CA, <sup>3</sup>AstraZeneca LP, Wilmington, DE.
- 288 Post-hoc Analysis Of Short-acting Beta<sub>2</sub>-agonist Efficacy In Baseline Corticosteroid Users And Non-corticosteroid Users Following Treatment With Levalbuterol Metered-dose Inhaler, Racemic Albuterol Or Placebo In Asthma Patients Ages 4-11 Years**  
**J. Walsh<sup>1</sup>**, D. Skoner<sup>2,3</sup>, W. Berger<sup>4</sup>, N. Wilson<sup>1</sup>;  
<sup>1</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA, <sup>2</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>3</sup>Drexel University College of Medicine, Philadelphia, PA, <sup>4</sup>Allergy and Asthma Associates, Mission Viejo, CA.
- 289 The Relationship between Sales Data for Asthmatic Drugs and Asthma Events**  
**A. Tanaka**, K. Sugiyama, H. Hirata, T. Kakuta, M. Watanabe, M. Tatewaki, A. Takeda, M. Arima, Y. Fukushima, T. Fukuda;  
Dokkyo Medical University, Tochigi, JAPAN.
- 290 Clinical Usefulness of Asthma Clinical Pathway for Management of Acute Asthmatic Children in Pediatric Emergency Department**  
**H. Kim**, Y. Chun, J. Yoon, J. Kim, J. Lee;  
The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.
- 291 Gastroesophageal Reflux Is Associated With More Severe Acute Respiratory Illness In Infants**  
**R. S. Valet**, T. Gebretsadik, K. N. Carroll, P. A. Minton, K. B. Woodward, Z. Liu, T. V. Hartert;  
Vanderbilt University School of Medicine, Nashville, TN.
- 292 Flavonoid-Rich Alcoholic Extract of Leaves of *Achyranthes Aspera* Reduces Inflammation in a Murine Model of Ova-Induced Asthma**  
**R. Kandasamy<sup>1</sup>**, G. R. Hellermann<sup>2</sup>, S. S. Mohapatra<sup>2,3</sup>, R. F. Lockey<sup>2,3</sup>;

<sup>1</sup>Anna University of Technology, Tiruchirappalli, INDIA, <sup>2</sup>Division of Allergy and Immunology-Joy McCann Culverhouse Airway Disease Center, Dept. of Internal Medicine and Nanomedicine Research Center, College of Medicine, Tampa, FL, <sup>3</sup>James A. Haley, VA Hospital, Tampa, FL.

- 293 The effect of vitamin D Status on Pediatric Asthma in a university hospital, Thailand**  
**W. Krotrakulchai**;  
Siriraj, bangkok, THAILAND.
- 294 History Of Asthma Maintenance Medication Use And Asthma Exacerbation Risk Factors Before Initiation Of Inhaled Corticosteroid/long-acting  $\beta$ -agonist (ICS/LABA) Combination Therapy For Asthma: Comparison Of Budesonide/formoterol (BFC) And Fluticasone/salmeterol (FCS) In A US Commercially Insured Population**  
**O. Tunceli<sup>1</sup>**, D. Kern<sup>1</sup>, S. Ramachandran<sup>2</sup>, N. Pethick<sup>2</sup>;  
<sup>1</sup>HealthCore, Wilmington, DE, <sup>2</sup>AstraZeneca, Wilmington, DE.
- 295 Positive Correlation Between Serum IL-5 and TNF-alpha Levels and Churg-Strauss Syndrome Activity in Patients Successfully Treated with Montelukast**  
**K. Lishchuk-Yakymovych<sup>1</sup>**, V. Chopryak<sup>1</sup>, R. Pukalyak<sup>1</sup>, L. M. DuBuske<sup>2</sup>;  
<sup>1</sup>Lviv National Medical University, Lviv, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.

## Poster Session

### Immunogenetics and Immunophenotyping

3202

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 296 Role of a Plasminogen Activator Inhibitor-1 4G/5G polymorphism in the development and clinical outcome of Idiopathic Sudden Sensorineural Hearing Loss**  
**J. Kim<sup>1</sup>**, H. Chen<sup>1</sup>, I. Kim<sup>1</sup>, C. Yokose<sup>1</sup>, C. Cai<sup>2</sup>, S. Palma<sup>3</sup>, M. Busi<sup>4</sup>, A. Martini<sup>4</sup>, T. J. Yoo<sup>2</sup>, S. H. Cho<sup>1</sup>;  
<sup>1</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>2</sup>University of Tennessee College of Medicine, Memphis, TN, <sup>3</sup>University of Modena, Modena, ITALY, <sup>4</sup>University of Ferrara, Ferrara, ITALY.
- 297 Interferon-Gamma Gene Polymorphism In Patients With Allergy**  
**O. O. Yanovich<sup>1</sup>**, L. V. Maslova<sup>1</sup>, L. P. Titov<sup>1</sup>, L. M. DuBuske<sup>2</sup>;  
<sup>1</sup>Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, <sup>2</sup>Immunology Research
- 298 Incidence of Immunodeficiency in Patients with 49-XXXXY Chromosomal Variation**  
**M. D. Keller<sup>1</sup>**, C. Samango-Sprouse<sup>2</sup>, T. Sadeghin<sup>3</sup>, J. S. Orange<sup>1</sup>;  
<sup>1</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>George Washington University of the Health Sciences, Washington, DC, <sup>3</sup>Neurodevelopmental Diagnostic Center for Young Children, Davidsonville, MD.
- 299 INTERLEUKIN 1 BETA +3953 C/T Gene Polymorphism In Patients With Asthma And Chronic Obstructive Pulmonary Disease In Venezuela**  
**N. E. Larocca**;  
Universidad Central de Venezuela, Caracas, VENEZUELA, BOLIVARIAN REPUBLIC OF.
- 300 Pregnancies in Women with Hereditary Angioedema due to Mutations in the F12 gene**  
**E. Aygoren-Pursun<sup>1</sup>**, I. Martinez Saguer<sup>1</sup>, G. Dewald<sup>2</sup>, E. Rucsic<sup>1</sup>, T. Klingebiel<sup>1</sup>, W. Kreuz<sup>1</sup>;

SUNDAY

- <sup>1</sup>University Hospital Frankfurt, Frankfurt, GERMANY, <sup>2</sup>Institute for Molecular and Preventive Medicine, Konigswinter, GERMANY.
- 301 Lack Of Associations Between Tnf- $\alpha$  Genetic Polymorphism -308g/a And Anti-tuberculosis Drug-induced Maculopapular Eruption**  
S. Kim<sup>1</sup>, S. Kim<sup>2</sup>, H. Yoon<sup>1</sup>, D. Shin<sup>1</sup>, S. Park<sup>1</sup>, Y. Kim<sup>3</sup>, J. Park<sup>3</sup>, Y. Jee<sup>3</sup>;  
<sup>1</sup>Hanyang University College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Eulji University School of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Dankook University College of Medicine, Cheonan, KOREA, REPUBLIC OF.
- 302 Reactivity Profile Of IgE, IgG1 And IgG4 To Dermatophagoides farinae Allergen Extract In Atopic And Non-atopic Patients Using Immunoproteomics Approach**  
E. A. Taketomi<sup>1</sup>, L. H. Ynoue<sup>1</sup>, J. S. Miranda<sup>1</sup>, K. C. Almeida<sup>1</sup>, J. P. Cunha-Junior<sup>1</sup>, C. P. Pirovani<sup>2</sup>, D. A. O. Silva<sup>1</sup>;  
<sup>1</sup>Federal University of Uberlandia, Uberlandia, BRAZIL, <sup>2</sup>State University of Santa Cruz, Ilheus, BRAZIL.
- 303 Blood Type Does Not Predict the Development of an IgE Response to Galactose-alpha-1,3-Galactose**  
N. D. Cresce, J. Posthumus, T. A. E. Platts-Mills, S. P. Commins; University of Virginia, Charlottesville, VA.
- 304 Classification of 26 Cases of Biopsy-proven Eosinophilic Myocarditis**  
R. I. Siles<sup>1</sup>, S. DaVeiga<sup>2</sup>, B. C. Schroer<sup>1</sup>, F. H. Hsieh<sup>1</sup>;  
<sup>1</sup>Cleveland Clinic Foundation, Cleveland, OH, <sup>2</sup>Children's Hospital of Philadelphia, Philadelphia, PA.
- 305 Basophils Autoinduced Degranulation (BAD) Test. A New Variant Of Basophils Activation Test (BAT) As Reliable In Vitro Tool For The Diagnosis Of Chronic Autoimmune Urticaria (CAU)**  
M. Caruso<sup>1</sup>, G. Tringali<sup>2</sup>, C. Russo<sup>1</sup>, R. Polosa<sup>1</sup>;  
<sup>1</sup>University of Catania, Catania, ITALY, <sup>2</sup>Istituto Ricerca Medica ed Ambientale (IRMA), Acireale (CT), ITALY.
- 306 Levels Of Inflammatory Cytokines And Chemokines In Bronchoalveolar Lavage Fluid In Patients With Idiopathic Interstitial Pneumonitis And Collagen Vascular Disease Associated Interstitial Pneumonitis**  
m. tatewaki;  
Dokkyo Medical University, Tochigi, JAPAN.
- 307 Terrelysin, a Potential Biomarker of Exposure to Aspergillus terreus**  
A. P. Nayak<sup>1,2</sup>, B. J. Green<sup>1</sup>, D. H. Beezhold<sup>1</sup>;  
<sup>1</sup>National Institute for Occupational Safety and Health, Morgantown, WV, <sup>2</sup>West Virginia University, Morgantown, WV.
- 308 Type III Hereditary Angioedema: First Description of a Mutation in Factor XII Gene and Clinical Features in a Brazilian Family**  
A. S. Moreno<sup>1</sup>, S. O. R. Valle<sup>2</sup>, A. T. Franca<sup>2</sup>, S. A. Levy<sup>2</sup>, D. Ponnard<sup>3</sup>, N. Monnier<sup>3</sup>, J. Lunardi<sup>3</sup>, L. Arruda<sup>1</sup>;  
<sup>1</sup>School of Medicine of Ribeirao Preto, Ribeirao Preto, BRAZIL, <sup>2</sup>Clementino Fraga Filho University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, BRAZIL, <sup>3</sup>Joseph-Fourier University of Grenoble, Grenoble, FRANCE.
- 309 Parasite-related IgE Antibodies, Including IgE to Galactose-alpha-1,3-galactose, in Sera from Virginia and Ecuador**  
H. R. James<sup>1</sup>, L. A. Kelly<sup>1</sup>, S. L. Pochan<sup>1</sup>, S. P. Commins<sup>1</sup>, L. J. Workman<sup>1</sup>, L. W. Nganga<sup>2</sup>, P. J. Cooper<sup>3,4</sup>, T. A. E. Platts-Mills<sup>1</sup>;  
<sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Futures Group International, Nairobi, KENYA, <sup>3</sup>Universidad San Francisco de Quito, Cumbay, ECUADOR, <sup>4</sup>Liverpool School of Tropical Medicine, Liverpool, UNITED KINGDOM.
- 310 Analysis Of 4,610 Patients With Elevated Serum Immunoglobulin E**  
R. Rokutanda, K. Yamaguchi, H. Shimizu, Y. Suyama, Y. Ohara, A. Takeda, M. Kishimoto, M. Okada;  
St.Luke's International Hospital, Tokyo, Japan, Tokyo, JAPAN.

- 311 Relationship Of Toll-like Receptors 2 And 4 Gene Polymorphisms With Elevated Production Of Specific Immunoglobulin E**  
I. P. Kaidashev<sup>1</sup>, O. V. Izmaylova<sup>1</sup>, N. L. Kutsenko<sup>1</sup>, O. A. Shlykova<sup>1</sup>, L. E. Vesnina<sup>1</sup>, L. M. DuBuske<sup>2</sup>;  
<sup>1</sup>Ukrainian Medical Stomatological Academy, Poltava, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.

## Poster Session

## Immune Deficiency

3203

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 312 B, T, and NK Cell Antigen Expression in Patients with Common Variable Immunodeficiency**  
S. A. Gierer<sup>1</sup>, M. Altrich<sup>2</sup>, C. Lutgen<sup>2</sup>, N. Torke<sup>2</sup>, J. D. Martinez<sup>1</sup>;  
<sup>1</sup>University of Kansas Medical Center, Kansas City, MO, <sup>2</sup>ViraCor-IBT Laboratories, Lee's Summit, MO.
- 313 Clinical and Molecular Characterization of Autosomal Recessive Hyper IgE Syndrome in Saudi Arabia**  
Z. Alsum<sup>1</sup>, A. Hawwari<sup>1</sup>, S. Al-Hifi<sup>1</sup>, E. Borrero<sup>1</sup>, H. Khalak<sup>1</sup>, N. Ades<sup>1</sup>, O. Alsmadi<sup>1</sup>, R. Arnaout<sup>1</sup>, A. Al-Ghoniaim<sup>1</sup>, S. Al-Muhsen<sup>1</sup>, H. Al-Dhekri<sup>1</sup>, B. Al-Saud<sup>1</sup>, H. Al-Mousa<sup>1,2</sup>;  
<sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA, <sup>2</sup>Alfaisal university, Riyadh, SAUDI ARABIA.
- 314 Safety, Tolerability, and Efficacy of Hizentra Over An Extended Period for the Treatment of Primary Immunodeficiency Disease**  
R. P. Nelson, Jr.<sup>1,2</sup>, I. Melamed<sup>3</sup>, M. R. Stein<sup>4</sup>, R. L. Wasserman<sup>5,6</sup>;  
<sup>1</sup>Melvin and Bren Simon Cancer Center, Indianapolis, IN, <sup>2</sup>Indiana University, Indianapolis, IN, <sup>3</sup>IMMUNOE International Research Centers, Centennial, CO, <sup>4</sup>Allergy Associates of the Palm Beaches, North Palm Beach, FL, <sup>5</sup>Allergy/Immunology Research Center of North Texas, Dallas, TX, <sup>6</sup>University of Texas Southwestern Medical School, Dallas, TX.
- 315 Clinical Characteristics of Adult Patients with Isolated Low IgG and Abnormal Response to Pneumovax**  
D. F. LaRosa, C. S. Patel;  
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
- 316 Clinical phenotypes and prognosis of patients with Common Variable Immunodeficiency (CVID) living in Rio de Janeiro, Brazil**  
A. J. Seba, N. P. M. Rubini, A. V. Capelo, E. M. da Silva, M. C. de Magalhaes, F. S. Sion, C. Morais-de-Sa;  
Federal University of Rio de Janeiro State, Rio de Janeiro, BRAZIL.
- 317 CD45 Deficiency Caused by Uniparental Disomy, a Novel Cause of Severe Combined Immunodeficiency**  
J. L. Roberts<sup>1</sup>, R. H. Buckley<sup>1</sup>, B. Luo<sup>2</sup>, J. Pei<sup>2</sup>, A. Lapidus<sup>2</sup>, S. Peri<sup>2</sup>, Q. Wei<sup>2</sup>, J. Shin<sup>1</sup>, R. E. Parrott<sup>1</sup>, R. Dunbrack<sup>2</sup>, J. R. Testa<sup>2</sup>, X. Zhong<sup>1</sup>, D. L. Wiest<sup>2</sup>;  
<sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>Fox Chase Cancer Center, Philadelphia, PA.
- 318 An Evaluation of Pneumococcal Titers in Patients receiving Ig replacement for Immunodeficiency**  
A. Shvarts<sup>1</sup>, M. Ballow<sup>2</sup>, A. YU<sup>1</sup>, H. Lehman<sup>1</sup>;  
<sup>1</sup>SUNY Buffalo, Buffalo, NY, <sup>2</sup>SUNY Buffalo, Buffalo, NY.
- 319 Admissions for Primary Immunodeficiency at San Lucas Hospital, Puerto Rico: A Pilot Project**  
B. K. Di Giorgi<sup>1</sup>, V. Velazquez<sup>2</sup>, S. Nazario<sup>3</sup>;



- <sup>1</sup>Universidad de Puerto Rico, Bayamon, PUERTO RICO, <sup>2</sup>Hospital Episcopal San Lucas/Ponce School of Medicine, Ponce, PR, <sup>3</sup>Universidad de Puerto Rico Medical Science Campus, Rio Piedras, PR.
- 320 Recombinant Human Hyaluronidase (rHuPH20) Facilitates Subcutaneous Infusion of Immunoglobulin, Increases Local Fluid Dispersion, and Reduces Induration in a Porcine Model**  
**D. W. Kang**, L. M. Jadin, T. A. Nekoroski, M. L. Zepeda; Halozyme Therapeutics Inc., San Diego, CA.
- 321 Correlation Between IgG, IgA, IgM and BMI or Race in a Large Pediatric Population**  
**A. Mehta**<sup>1,2</sup>, G. Ramirez<sup>3</sup>, G. Ye<sup>3</sup>, S. McGeary<sup>1,2</sup>, C. Chang<sup>1,2</sup>; <sup>1</sup>Alfred I duPont Children's Hospital, Wilmington, DE, <sup>2</sup>Thomas Jefferson University, Philadelphia, PA, <sup>3</sup>Nemours Children's Health System, Orlando, FL.
- 322 Cytokine Profile Shifts In Patients With Recurrent Herpes Simplex Of The Oral Mucosa And Lips**  
**G. N. Drannik**<sup>1</sup>, A. I. Kurchenko<sup>1</sup>, R. A. Rehuretska<sup>1</sup>, L. M. DuBuske<sup>2</sup>; <sup>1</sup>National Medical University, Kiev, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.
- 323 A Novel Severe Combined Immunodeficiency (SCID) Mutation in Three Mexican Siblings with additional de novo Duchenne Muscular Dystrophy (DMD) mutation**  
**S. K. Nicholas**, J. Chinen, C. Martinez, T. Lotze, A. M. Adesina, D. S. Fishman, R. A. Krance, I. C. Hanson; Baylor College of Medicine- Texas Children's Hospital, Houston, TX.
- 324 Serum Immunoglobulin Levels in Healthy Thai Infants and Children Aged 0-2 Years Determined by Nephelometry**  
**R. Sitcharungsri**<sup>1</sup>, J. Ananworanich<sup>2,3</sup>, A. Pornvoranunt<sup>4</sup>, T. Apornpong<sup>5</sup>, T. Bunupuradah<sup>5</sup>, K. Khupulsup<sup>4</sup>, P. Nouanthonng<sup>5</sup>, S. Vilaiyuk<sup>4</sup>, C. Phasomsap<sup>5</sup>, W. Kamchaisatian<sup>4</sup>, C. Pancharoen<sup>3</sup>, T. Puthanakit<sup>3</sup>, C. Sirivichayakul<sup>1</sup>, S. Benjaponpitak<sup>4</sup>; <sup>1</sup>Faculty of Tropical Medicine, Mahidol University, Bangkok, THAILAND, <sup>2</sup>SEARCH, HIV-NAT, The Thai Red Cross AIDS Research Center, Bangkok, THAILAND, <sup>3</sup>Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND, <sup>4</sup>Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND, <sup>5</sup>The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Center, Bangkok, THAILAND.
- 325 Role of IgM in Pulmonary Complications of Common Variable Immunodeficiency (CVID)**  
**P. J. Maglione**, C. Cunningham-Rundles; Mount Sinai Medical Center, New York, NY.
- 326 The Medical Awareness Concerning Primary Immunodeficiency Diseases (PID) in the City of Sao Paulo, Brazil**  
**E. O. Dantas**<sup>1</sup>, C. S. Aranda<sup>1</sup>, F. A. Nobre<sup>1</sup>, E. Felix<sup>1</sup>, K. Fahl<sup>2</sup>, J. T. L. Mazzucchelli<sup>1</sup>, D. L. Friedenbach<sup>3</sup>, V. Nudelman<sup>2</sup>, A. Condino-Neto<sup>4</sup>, L. H. Lin<sup>1</sup>, J. D. Chaves<sup>1</sup>, B. T. Costa-Carvalho<sup>1</sup>; <sup>1</sup>Federal University of Sao Paulo (UNIFESP), Sao Paulo, BRAZIL, <sup>2</sup>Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL, <sup>3</sup>Hospital do Servidor Publico Municipal, Sao Paulo, BRAZIL, <sup>4</sup>University of Sao Paulo, Sao Paulo, BRAZIL.
- 327 Vitamin D Levels and Respiratory Infections in Patients with Common Variable Immunodeficiency**  
**J. Zheng**<sup>1,2</sup>, K. Gundling<sup>2</sup>; <sup>1</sup>Kaiser Permanente Medical Group, Oakland, CA, <sup>2</sup>University of California, San Francisco, San Francisco, CA.
- 328 Prolonged Klebsiella Sepsis and Meningitis in a Five Week Old Infant with an IKBKG Gene Mutation (NEMO)**  
**S. S. Griffin**, T. P. Atkinson; University of Alabama at Birmingham, Birmingham, AL.
- 329 Common Variable Immunodeficiency Presenting with *Stenotrophomonas maltophilia* Pneumonia**  
**S. D. Dickson**<sup>1</sup>, K. H. Waibel<sup>2</sup>;

- <sup>1</sup>Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, Lackland AFB, TX, <sup>2</sup>Department of Medicine, San Antonio Military Medical Center, Fort Sam Houston, TX.
- 330 Combined T and B Cell Defects Presenting in a Previously Healthy Child After Splenectomy for Autoimmune Cytopenias**  
**C. Sokol**<sup>1</sup>, F. Bonilla<sup>2</sup>, M. R. Murali<sup>1</sup>, J. Walter<sup>1</sup>; <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Children's Hospital Boston, Boston, MA.
- 331 Griscelli Syndrome In A Newborn With Silver Hair And Seizures**  
**S. Min**, K. Zakarian, S. Yano, P. Huynh, MD, L. Scott; LAC+USC Medical Center, Los Angeles, CA.

## Poster Session

### Novel Allergens and Extracts: New Ways to Measure Sensitization

3204

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 332 High Resolution Crystal Structure of Peanut Allergen Ara H 5**  
**Y. Zhang**<sup>1,2</sup>, Y. Wang<sup>2</sup>; <sup>1</sup>US Dept of Agriculture, Albany, CA, <sup>2</sup>Illinois Institute of Technology, Chicago, IL.
- 333 Radial Immunodiffusion (RID) to Sandwich ELISA for the Quantitation of Fel d 1 and Amb a 1 in Cat and Short Ragweed Pollen Allergenic Extracts**  
**S. Huynh**, S. Menzies, T. Khurana, T. Lin, L. Yan, N. deVore, J. E. Slater, R. L. Rabin; FDA, Bethesda, MD.
- 334 Validation by Patch Testing of a Blood Test for Nickel Sensitization**  
**K. A. Pacheco**, L. Barker, L. Shirname-More, V. Nagabhusanam; National Jewish Health, Denver, CO.
- 335 Discordance Between Skin Prick Test and Aeroallergen Specific IgE in Children Under the Age of Four**  
**P. Parikh**<sup>1</sup>, D. Ferastraoraru<sup>2</sup>, R. Nizari<sup>2</sup>, Y. Pichardo<sup>2</sup>, M. Chin<sup>2</sup>, D. Serebrisky<sup>2</sup>, G. deVos<sup>1</sup>; <sup>1</sup>Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, NY, <sup>2</sup>Jacobi Medical Center, Bronx, NY, NY.
- 336 Allergen Specificity Of 3 Scfv Antibodies Developed For A Multiplex Assay Of *Blattella Germanica* Extract Potency**  
**T. Khurana**<sup>1</sup>, M. Collison<sup>1</sup>, F. Chew<sup>2</sup>, K. Jeong<sup>3</sup>, J. Slater<sup>1</sup>; <sup>1</sup>FDA, Bethesda, MD, <sup>2</sup>National University of Singapore, Singapore, SINGAPORE, <sup>3</sup>Institute of Tropical Medicine, Seoul, KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF.
- 337 IgE Against Bed Bug (*Cimex lectularius*) Allergens Are Common Among Adults Bitten By Bed Bugs**  
**J. B. Price**<sup>1</sup>, A. Divjan<sup>2</sup>, G. A. Freyer<sup>2</sup>, W. R. Montfort<sup>3</sup>, M. S. Perzanowski<sup>2</sup>; <sup>1</sup>Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, <sup>2</sup>Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, <sup>3</sup>Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ.
- 338 Assessment of Allergenicity of GMO Maize Pollen**  
**H. Steinman**; Food & Allergy Consulting & Testing Services, Milnerton, Cape Town, SOUTH AFRICA.
- 339 Clinical Usefulness Of Diagnosis By Molecular Components In Mite Allergy**

SUNDAY

**F. Rodriguez Fernandez**<sup>1</sup>, M. Lopez Hoyos<sup>2</sup>, P. Munoz Cacho<sup>3</sup>, C. Barbeito<sup>1</sup>, G. Perdomo Gutierrez<sup>1</sup>, A. Galan Nieto<sup>4</sup>, M. Arina Sanchez<sup>4</sup>;

<sup>1</sup>Hospital Marques de Valdecilla, Allergy Service, Santander, SPAIN, <sup>2</sup>Hospital Marques de Valdecilla, Immunology Service, Santander, SPAIN, <sup>3</sup>Servicio Contabro de Salud, Santander, SPAIN, <sup>4</sup>ALK-Abello, S.A., Madrid, SPAIN.

**350 Falsely Ascribing Changes In Disease Patterns To Climate Change**

**R. J. Green**, J. Cloete;

University of Pretoria, Pretoria, SOUTH AFRICA.

**351 A Recent Significant Increase in Ambrosia Pollen Abundance in Central Ukraine**

**O. Palamarchuk**<sup>1</sup>, V. Rodinkova<sup>1</sup>, L. M. DuBuske<sup>2</sup>;

<sup>1</sup>Vinnitsa National Pirogov Memorial Medical University, Vinnitsa, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.

## Poster Session

### Measuring Allergen Exposures

3205

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

**340 Development Of A System For Pollen Forecasting In Vinnitsa, Ukraine**

**V. Rodinkova**<sup>1</sup>, L. M. DuBuske<sup>2</sup>;

<sup>1</sup>Vinnitsa National Pirogov Memorial Medical University, Vinnitsa, UKRAINE, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.

**341 Airborne Exposures To Allergen And Particles With And Without Carpeting**

**B. Mitchell**, A. Southey, M. Fox, G. Hughes, T. Yeomans;

Airmid Healthgroup Ltd., Dublin, IRELAND.

**342 Mouse and Cockroach Exposure in Rural Arkansas Delta Region Homes**

**A. T. Coleman**<sup>1</sup>, M. Rettiganti<sup>1</sup>, S. Bai<sup>1,2</sup>, R. H. Brown<sup>1</sup>, T. T. Perry<sup>1</sup>;

<sup>1</sup>UAMS/Arkansas Children's Hospital, Little Rock, AR, <sup>2</sup>Ohio State, Columbus, OH.

**343 The Relationship Between Indoor Particulate Matter and Home Ventilation**

**A. L. Humphrey**, L. C. Gard, C. S. Barnes, C. E. Ciaccio;

Children's Mercy Hospital and Clinics, Kansas City, MO.

**344 The Effects Of Wind Conditions On Ragweed Counts**

**S. C. Argo**, C. S. Barnes, M. G. Dhar, J. M. Portnoy;

Children's Mercy Hospitals and Clinics/University of Missouri-Kansas City, Kansas City, MO.

**345 Is Red-Berry Juniper an Overlooked Fall Allergen in the Southwest?**

**E. Levetin**<sup>1</sup>, L. Bunderson<sup>1</sup>, P. Van de Water<sup>2</sup>, J. Luvall<sup>3</sup>;

<sup>1</sup>University of Tulsa, Tulsa, OK, <sup>2</sup>California State University - Fresno, Fresno, CA, <sup>3</sup>NASA Marshall Space Flight Center, Huntsville, AL.

**346 Trends In Kansas City Tree Pollen: A 15 Year Perspective**

**N. Raje**, C. S. Barnes, M. G. Dhar, J. M. Portnoy;

Children's Mercy Hospitals & Clinics/ University of Missouri-Kansas City, Kansas City, MO.

**347 Pilot Study on Inhalant Allergen filtration performance of newly developed intranasal filter**

**J. Lee**, J. Sohn, C. Hong, J. Park;

Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

**348 Collection and Detection of Airborne Cat Allergen, Fel d 1, with a Compact Ionic Capture Device**

**J. Gordon**;

Inspirotec Inc, Chicago, IL.

**349 When Is It Safe To Go Outside? Nighttime Juniper Pollen Concentrations In Texas, Oklahoma, And New Mexico**

**L. D. Bunderson**<sup>1</sup>, P. Van de Water<sup>2</sup>, J. Luvall<sup>3</sup>, E. Levetin<sup>1</sup>;

<sup>1</sup>The University of Tulsa, Tulsa, OK, <sup>2</sup>California State University, Fresno, Fresno, CA, <sup>3</sup>NASA, Huntsville, AL.

## Poster Session

### EGID/Immunologic GI Disorders

3206

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

**352 Identification Of Increased Oral Eosinophils In Patients With Eosinophilic Esophagitis (EE) Using Oral Rinse Analysis: Proof Of Concept**

**J. Ohayon**;

McMaster University, Hamilton, ON, CANADA.

**353 Fecal Eosinophil-derived Neurotoxin Is Significantly Elevated In Non-ige Dependent Gastrointestinal Allergies, Especially In Subtypes Showing Bloody Stool**

**H. Morita**<sup>1,2</sup>, I. Nomura<sup>1</sup>, T. Shoda<sup>1</sup>, H. Saito<sup>1</sup>, K. Matsumoto<sup>1</sup>;

<sup>1</sup>National Research Institute for Child Health and Development, Tokyo, JAPAN, <sup>2</sup>Department of Pediatrics, Keio University School of Medicine, Tokyo, JAPAN.

**354 Dynamics of Eosinophils in Non-IgE-mediated Gastrointestinal Food Allergies in Neonates and Infants, differences between 4 Clusters**

**I. Nomura**, H. Morita, T. Shoda, K. Arai, N. Ito, A. Nakazawa, Y.

Ohya, H. Saito, K. Matsumoto;

National Center for Child Health and Development, Tokyo, JAPAN.

**355 Our 3-year Experience with Patch Testing for Eosinophilic Esophagitis**

**C. S. Bauer**<sup>1</sup>, A. R. Lamba<sup>1</sup>, H. P. Zimmerman<sup>1</sup>, R. G. Hoffmann<sup>1</sup>, M. Dasgupta<sup>1</sup>, R. J. Noel<sup>1</sup>, M. B. Levy<sup>2</sup>, M. Vasudev<sup>1</sup>;

<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Assaf Harofe Medical Center, Tzrifin, ISRAEL.

**356 Food Extract Testing for Delayed-Type Hypersensitivity in Eosinophilic Esophagitis**

**D. M. Robertson**, J. L. Baldwin, M. J. Greenhawt;

University of Michigan, Ann Arbor, MI.

**357 Quantifying Allergic Sensitivities among Adults with Eosinophilic Esophagitis**

**E. A. Erwin**<sup>1</sup>, C. B. Cho<sup>2</sup>, P. U. Ogbogu<sup>2</sup>, L. Workman<sup>3</sup>, T. A. E. Platts-Mills<sup>3</sup>;

<sup>1</sup>Nationwide Children's Hospital, Columbus, OH, <sup>2</sup>The Ohio State University Medical Center, Columbus, OH, <sup>3</sup>University of Virginia Asthma and Allergic Diseases Center, Charlottesville, VA.

**358 Evaluation of Skin Testing to Aeroallergens and Foods in the Management of Adults with Eosinophilic Esophagitis and Response to Comprehensive Therapy**

**J. A. Tarbox**, M. J. Tang, K. L. McMullan, A. Kulczycki, Jr;

Washington University St. Louis, Saint Louis, MO.

**359 Clinical and Laboratory Characteristics of Adults with Eosinophilic Esophagitis**

**M. A. Slack**<sup>1</sup>, C. B. Cho<sup>1</sup>, R. Raveendran<sup>1</sup>, E. Erwin<sup>2</sup>, P. U. Ogbogu<sup>1</sup>;

SUNDAY

<sup>1</sup>Ohio State University Medical Center, Columbus, OH, <sup>2</sup>Nation-wide Children's Hospital, Columbus, OH.

- 360 Serum Free Light Chain Levels In Children Are Higher In Females Than In Males During Eosinophilic Esophagitis**  
C. Dupont<sup>1</sup>, K. Knipping<sup>2,3</sup>, P. Soulaïnes<sup>1</sup>, T. Groot Kormelink<sup>3</sup>, F. Redegeld<sup>3</sup>, L. M. J. Knippels<sup>2,3</sup>, J. Garssen<sup>2,3</sup>;  
<sup>1</sup>Hôpital Necker, Service d'Explorations Fonctionnelles Digestives Pédiatriques, Paris, FRANCE, <sup>2</sup>Danone Research Centre for Specialised Nutrition, Wageningen, NETHERLANDS, <sup>3</sup>Utrecht University, Division of Pharmacology, Utrecht, NETHERLANDS.
- 361 The Combination Of Skin Prick Testing And Atopy Patch Testing Can Successfully Guide A Food Elimination/reintroduction Diet In EE**  
S. M. Maggadottir<sup>1</sup>, J. M. Spergel<sup>2</sup>, A. Cianferoni<sup>1</sup>, T. Brown-Whitehorn<sup>1</sup>, M. M. Shuker<sup>1</sup>, C. Liacouras<sup>1</sup>;  
<sup>1</sup>Childrens Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA.
- 362 Biomarkers for Eosinophilic Esophagitis: A Systematic Review**  
N. Bhardwaj, G. Ghaffari;  
Penn State Milton S. Hershey Medical Center, Hershey, PA.
- 363 Histology Scoring System (HSS) is Superior to Peak Eosinophil Count (PEC) to Identify Treated vs Untreated Eosinophilic Esophagitis (EoE) Patients**  
M. H. Collins<sup>1</sup>, L. J. Martin<sup>1</sup>, E. S. Alexander<sup>1,2</sup>, S. Pentiu<sup>1</sup>, A. Ellison<sup>1</sup>, P. E. Putnam<sup>1</sup>, J. P. Franciosi<sup>1</sup>, J. P. Abonia<sup>1</sup>, M. E. Rothenberg<sup>1</sup>;  
<sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>University of Cincinnati College of Medicine, Cincinnati, OH.
- 364 The Potential Benefit of Immunotherapy in the Treatment of Eosinophilic Esophagitis in Adult Patients**  
S. Silverman, C. Bassett, E. Rothstein;  
New York University Langone Medical Center, New York, NY.
- 365 Predicting Esophageal Biopsy Eosinophil Counts from Presenting Symptoms in Patients with Suspected Eosinophilic Esophagitis**  
M. J. Greenhawt<sup>1</sup>, W. Rassbach<sup>2</sup>, M. Elkins<sup>2</sup>, J. K. Greenson<sup>1</sup>;  
<sup>1</sup>The University of Michigan Medical School, Ann Arbor, MI, <sup>2</sup>The University of Michigan Health System, Ann Arbor, MI.
- 366 Innate Immune Responses Differ In Patients With Food Protein Induced Enterocolitis Syndrome (fpies) Who Respond Well To The Restrictive Diet And Those Who Do Not**  
V. Rahimian, L. Geng, P. Kattouf, H. Jyonouchi;  
UMDNJ, Newark, NJ.
- 367 Remission of Refractory Aphthous Stomatitis of Celiac Disease with Etanercept**  
J. M. Litchfield<sup>1</sup>, H. Saleh<sup>1</sup>, C. Watkins<sup>2</sup>, S. Wilgenbusch<sup>2</sup>, G. Youngberg<sup>3</sup>, G. Krishnaswamy<sup>4</sup>;  
<sup>1</sup>East Tennessee State University Department of Internal Medicine, Johnson City, TN, <sup>2</sup>James H Quillen College of Medicine, Johnson City, TN, <sup>3</sup>East Tennessee State University Department of Pathology, Johnson City, TN, <sup>4</sup>East Tennessee State University Department of Allergy and Immunology, Johnson City, TN.
- 368 Comparison of Serum Cytokine, Chemokine, and Growth Factor Profiles in Crohn's Disease and Food Allergy in Children**  
J. Cohn, Y. Song, D. Dunkin, J. Wang, C. Ceballos, k. Hoffstadter-Thal, J. Ross, K. Benkov, X. Li;  
Mount Sinai School of Medicine, New York, NY.
- 369 The Role of Exhaled Nitric Oxide (FENO) in Eosinophilic Esophagitis: A Pilot Study to Evaluate the Correlation of Exhaled Nitric Oxide and Esophageal Eosinophils**  
S. D. Stanga, S. L. Page, C. Dinakar;  
Childrens Mercy Hospital, Kansas City, MO.
- 370 Eosinophilic Liver Involvement In Hypereosinophilic Syndrome: Clinico-pathologic Findings In Eight Patients**  
P. Khoury, N. Holland, T. Heller, D. E. Kleiner, A. D. Klion;  
National Institutes of Health, Bethesda, MD.

## Poster Session

### Drug Allergy

3207

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 371 Utility of a Website-based Database of Drug Allergy Case Reports and Desensitization Protocols**  
T. W. Pun<sup>1</sup>, Z. Abdurrahman<sup>2</sup>, R. Warrington<sup>1</sup>, A. Noyek<sup>3</sup>;  
<sup>1</sup>University of Manitoba, Winnipeg, MB, CANADA, <sup>2</sup>McMaster University, Hamilton, ON, CANADA, <sup>3</sup>University of Toronto, Toronto, ON, CANADA.
- 372 Outcomes Of Adult Provocation Tests In A Singapore Allergy Centre**  
M. Thalayasingam<sup>1</sup>, L. J. Davies<sup>2</sup>, G. Llanora<sup>1</sup>, I. Gerez<sup>1</sup>, H. Van Bever<sup>1,2</sup>, L. P. C. Shek<sup>1,2</sup>;  
<sup>1</sup>National University Hospital, Singapore, SINGAPORE, <sup>2</sup>National University of Singapore, Yong Loo Lin School of Medicine, Singapore, SINGAPORE.
- 373 Survey of Drug Allergy Testing, Challenge, and Desensitization Practice**  
J. H. Butterfield, C. Oslie;  
Mayo Clinic, Rochester, MN.
- 374 Analysis Of Adverse Drug Reactions In Children**  
G. M. Park<sup>1</sup>, J. H. Seo<sup>2</sup>, H. Y. Kim<sup>2</sup>, Y. W. Hwang<sup>3</sup>, Y. S. Na<sup>3</sup>, Y. C. Song<sup>3</sup>, J. H. Yu<sup>4</sup>, S. J. Hong<sup>2</sup>;  
<sup>1</sup>Childhood Asthma Atopy Center, Department of Pediatrics, Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Childhood Asthma Atopy Center, Research Center for Standardization of Allergic Diseases, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>4</sup>Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 375 A Survey of Current Physician Practice and Knowledge of Drug Allergy at a University Medical Center**  
J. Sturm, J. Temprano;  
Saint Louis University, St. Louis, MO.
- 376 Pediatric Patients with a History of Penicillin Allergy and a Positive Penicillin Skin Test May Not Be at an Increased Risk for Multiple Drug Allergies**  
V. A. Martin, M. A. Park;  
Mayo Clinic, Rochester, MN.
- 377 Multiple Drug Intolerance Syndrome: Prevalence, Clinical Characteristics, And Management**  
E. M. Macy<sup>1</sup>, N. J. Ho<sup>2</sup>;  
<sup>1</sup>SCPMG-Kaiser Permanente San Diego, San Diego, CA, <sup>2</sup>Kaiser Permanente Healthcare Program - Department of Research and Evaluation, Pasadena, CA.
- 378 Characterization of Multiple Antibiotic Allergies in Adult and Pediatric Patients**  
P. B. M. Jhaveri, B. VanNostrand, F. Ishmael;  
Penn State Hershey Medical Center, Hershey, PA.
- 379 Immediate Hypersensitivity To Quinolones: Drug Photodegradation Influences The Specific Basophil Activation**  
C. Mayorga<sup>1</sup>, A. Aranda<sup>1</sup>, I. Andreu<sup>2</sup>, M. I. Montaez<sup>1</sup>, A. Ariza<sup>1</sup>, I. Doa, PhD<sup>1</sup>, N. Blanca-Lopez<sup>3</sup>, E. Nuin<sup>2</sup>, M. A. Miranda<sup>2</sup>, M. Blanca<sup>4</sup>, M. J. Torres<sup>4</sup>;

SUNDAY

- <sup>1</sup>Fundacion IMABIS, Malaga, SPAIN, <sup>2</sup>Chemical Technology Institute, Valencia, SPAIN, <sup>3</sup>Infanta Leonor Hospital, Madrid, SPAIN, <sup>4</sup>Carlos Haya Hospital, Malaga, SPAIN.
- 380 Immunologic Evaluation of Quinolone Hypersensitivity**  
Y. NAM;  
IDepartment of Allergy & Clinical Immunology, Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF.
- 381 Allergy To Betalactams Is A Risk Factor For Anaphylaxis To Quinolones**  
M. J. Torres<sup>1</sup>, I. Dona<sup>1</sup>, I. Garcia<sup>1</sup>, F. Gomez<sup>1</sup>, M. Salas<sup>1</sup>, N. Blanca-Lopez<sup>2</sup>, M. D. Caamero<sup>1</sup>, G. Canto<sup>2</sup>, M. Blanca<sup>1</sup>;  
<sup>1</sup>Carlos Haya Hospital, Malaga, SPAIN, <sup>2</sup>Infanta Leonor Hospital, Madrid, SPAIN.
- 382 Skin Testing and Graded Challenges for Meropenem Hypersensitivity in Penicillin Allergic Subjects**  
P. A. Greenberger, P. Avila, A. Ditto, L. C. Grammer, K. McGrath, A. T. Peters, C. Saltoun;  
Northwestern Univ. Feinberg School of Medicine, Chicago, IL.
- 383 The Potential of Using ELISPOT to Diagnose Cephalosporin-induced Maculopapular Exanthems**  
J. Klaewongkram, B. Tanvarasethee, S. Buranapraditkun;  
Chulalongkorn University, Bangkok, THAILAND.
- 384 Epidemiology of Betalactams Hypersensitivity in a Drug Allergy Unit**  
J. J. LAGUNA, L. Sanchez-Morillas, P. Rojas, M. R. Gonzalez-Mendiola,;  
HOSPITAL CRUZ ROJA, MADRID, SPAIN.
- 385 Value Of Skin Testing Solely With Penicillin G In Children With a History Of Penicillin Allergy**  
M. Picard, A. Des Roches, P. Begin, J. Paradis, L. Paradis;  
CHU Sainte-Justine, Montreal, QC, CANADA.
- 386 Cross-Reactivity between Penicillins and Third-Generation Cephalosporins**  
E. Rodriguez, T. Nunez, R. Pineda, M. L. Baeza, P. Tornero, A. Prieto, M. de Barrio, R. Pelta, A. Alvarez-Perea;  
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.
- 387 Cephalosporin Allergy: Cross-reactivity To Penicillin In Pediatric Patients**  
E. K. Ham, M. Park;  
Mayo Clinic, Rochester, MN.
- 388 Safety and Effectiveness of Penicillin Allergy Evaluation in the Pre-Lung Transplant Patient Population**  
R. GUTTA, C. Radojicic;  
Cleveland Clinic, Cleveland, OH.
- 389 Prevalence of Penicillin Allergy and Adverse Outcomes in Geriatric Inpatients at a Tertiary Care Hospital**  
N. Baman, B. VanNostrand, F. Ishmael;  
Pennsylvania State University Milton S. Hershey Medical Center, Hershey, PA.
- 390 Carrier Molecules Displaying Dual Haptenic Presentation for in Vivo Testing to Determine IgE Antibody in Patients Allergic to Betalactams**  
M. I. Montanez<sup>1</sup>, A. J. Ruiz-Sanchez<sup>2</sup>, A. Ariza<sup>1</sup>, C. Mayorga<sup>1</sup>, E. Perez-Inestrosa<sup>2</sup>, J. L. Rodriguez-Bada<sup>1</sup>, M. D. Ruiz<sup>3</sup>, M. Blanca<sup>3</sup>, M. J. Torres<sup>3</sup>;  
<sup>1</sup>Research Laboratory, IMABIS Foundation-Carlos Haya Hospital, Malaga, SPAIN, <sup>2</sup>Organic Chemistry, Faculty of Science, University of Malaga, Malaga, SPAIN, <sup>3</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN.
- 391 Tlr Expression On Monocyte-derived Dendritic Cells From Patients With Allergy To Betalactams**  
M. J. Sanchez-Quintero;  
Fundacion IMABIS, Malaga, SPAIN.
- 392 Diagnosis in Hypersensitivity to Oxaliplatin**  
R. Madrigal-Burgaleta<sup>1</sup>, M. P. Berges-Gimeno<sup>1</sup>, D. Angel-Perreira<sup>1</sup>, G. V. Sanchez-Moreno<sup>1</sup>, L. Venemalm<sup>2</sup>, E. Alvarez-Cuesta<sup>1</sup>;  
<sup>1</sup>Ramon y Cajal University Hospital, Madrid, SPAIN, <sup>2</sup>Phadia AB, Uppsala, SWEDEN.
- 393 Use of Omalizumab to Achieve Successful Desensitization After Oxaliplatin Anaphylaxis**  
K. N. Cahill<sup>1,2</sup>, P. Harrison<sup>1</sup>, M. de Asis<sup>3</sup>, M. Castells<sup>1,2</sup>;  
<sup>1</sup>Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>Asthma and Allergy Consultants of Rockland/Bergan County, West Nyack, NY.
- 394 Hypersensitivity To Docetaxel: Retrospective Study And Desensitization Protocol**  
E. Syrigou, N. Makrilia, E. Kotteas, F. Psarros, K. N. Syrigos;  
Oncology Unit, 3rd Dept of Medicine, Sotiria General Hospital, Athens School of Medicine, Athens, GREECE.
- 395 Safety of Aspirin Desensitization in Patients with a Cardiac Indication for Aspirin**  
K. L. McMullan, H. J. Wedner;  
Washington University School of Medicine in St. Louis, St Louis, MO.
- 396 Value Of The Clinical History In The Diagnosis Of Nsaid Hypersensitivity Reactions Induced By Cross-intolerance**  
N. Blanca-Lopez<sup>1</sup>, I. Dona<sup>2</sup>, M. Torres<sup>2</sup>, P. Campo<sup>2</sup>, C. Rondon<sup>2</sup>, M. Salas<sup>2</sup>, I. Garcia<sup>2</sup>, G. Canto<sup>3</sup>, M. Blanca<sup>2</sup>;  
<sup>1</sup>Hospital Infanta Leonor, Madrid, SPAIN, <sup>2</sup>Hospital Carlos Haya, Malaga, SPAIN, <sup>3</sup>Hospital Infanta Leonor, Malaga, SPAIN.
- 397 Aspirin Allergy in a Community Teaching Hospital**  
D. E. Riestler, J. A. Jones, J. A. Saryan;  
Lahey Clinic, Burlington, MA.
- 398 Etoricoxib: A Probable Safe Alternative For NSAID Intolerant Patients In Asia**  
G. V. Llanora<sup>1</sup>, I. F. A. Gerez<sup>1</sup>, Y. K. Cheng<sup>2</sup>, L. P. C. Shek<sup>1,3</sup>;  
<sup>1</sup>National University Hospital, Singapore, SINGAPORE, <sup>2</sup>Gleneagles Hospital, Singapore, SINGAPORE, <sup>3</sup>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE.
- 399 Desensitization to Liposomal Amphotericin B after Anaphylactic Reaction**  
L. Dhindsa-Castanedo, M. Narra;  
Baylor College of Medicine, Houston, TX.
- 400 Anaphylactic Reaction After 6-methyl-prednisolone**  
A. Rosado, C. Vila, M. D. Alonso, E. G. Farias, M. Acosta, W. L. Almanzar, M. A. Tejedor;  
Hospital Universitario Fundacion Alcorcon, MADRID, SPAIN.
- 401 Two Cases Of Riluzole-induced Lung Injury In Patients With Amyotrophic Lateral Sclerosis**  
T. Kakuta, H. Hirata, K. Sugiyama, H. Koichi, T. Fukuda, Y. Fukushima;  
Dokkyo Medical University, Tochigi, JAPAN.
- 402 Using Human Single Chain Variable Fragment (scFv) Antibodies for Identification of Potential Allergens of Neurospora crassa**  
J. E. Slater<sup>1</sup>, T. Khurana<sup>1</sup>, M. Collison<sup>1</sup>, B. Haynes<sup>2</sup>, E. Cambareri<sup>2</sup>;  
<sup>1</sup>FDA/CBER/OVRR/DBPAP, Rockville, MD, <sup>2</sup>Neugenesis Corporation, Burlingame, CA.
- 403 Allergy to General Anesthetics: Evaluation of Patients Profile**  
C. Irani, C. Saade, C. Dagher;  
Hotel Dieu de France hospital, Beirut, LEBANON.
- 404 Retrospective Review of Adverse Reaction Profile of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers**  
T. L. Mertz, A. N. Peric, F. T. Ishmael;  
M.S. Hershey Penn State Medical Center, Hershey, PA.
- 405 Desensitization to Epoetin Alfa in a Patient with Anaphylaxis: a Case Report**  
C. J. Luna, N. Aziz, R. A. Rodby, M. C. Tobin;  
Rush University Medical Center, Chicago, IL.

- 406 Clinical Characteristics of Severe Cutaneous Adverse Reactions in a tertiary hospital in Korea**  
M. Yang, Y. Kim, M. Kim, J. Jung, T. Kim, H. Kang, H. Park, S. Cho;  
Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF
- 407 Hypersensitivity Reactions To Monoclonal Antibodies: Desensitization Approach**  
D. V. Prez Alzate, G. Marco, R. Pineda, P. Tornero, A. Prieto, M. Baeza, J. Zubeldia, T. Herrero;  
Hospital General Universitario Gregorio Marañon, Madrid, SPAIN.

## Poster Session

### Atopic Disease

3208

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 408 1. C1-INH: Test Use Evaluation On In-Patient Adults**  
V. Yee<sup>1</sup>, C. Lauter<sup>2,3</sup>;  
<sup>1</sup>Wayne State University School of Medicine, Detroit, MI, <sup>2</sup>William Beaumont Hospital, Royal Oak, MI, <sup>3</sup>Oakland University William Beaumont School of Medicine, Royal Oak, MI.
- 409 Distribution of Allergic Sensitization by ISAC Microarray**  
J. C. Thompson<sup>1</sup>, P. B. Williams<sup>2</sup>, G. F. Kroker<sup>1</sup>;  
<sup>1</sup>Allergy Associates of La Crosse, Onalaska, WI, <sup>2</sup>Mercy Hospitals and Clinics, Kansas City, MO.
- 410 Patterns of Intra-nasal Corticosteroid Use Among Individuals Diagnosed with Allergic Rhinitis: Evidence from a Large Claims Database**  
M. J. Lage<sup>1</sup>, G. N. Gross<sup>2</sup>, P. O. Buck<sup>3</sup>, M. Lepore<sup>3</sup>;  
<sup>1</sup>HealthMetrics Outcomes Research, Groton, CT, <sup>2</sup>Dallas Allergy and Asthma Center, Dallas, TX, <sup>3</sup>Teva North America Branded Pharmaceuticals, Inc., Horsham, PA.
- 411 Comparison Of Patient Adherence To Intra-nasal Corticosteroids By Pressurized Metered-dose Inhaler Versus Aqueous Formulations**  
M. Lepore<sup>1</sup>, D. Lang<sup>2</sup>, L. Cox<sup>3</sup>, C. S. Hankin<sup>4</sup>, Z. Wang<sup>4</sup>, A. Bronstone<sup>4</sup>, P. O. Buck<sup>1</sup>;  
<sup>1</sup>Teva North America Branded Pharmaceuticals, Inc., Horsham, PA, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, <sup>4</sup>BioMedEcon, Moss Beach, CA.
- 412 Evaluation of Coverage of Allergy Concepts in Electronic Health Records**  
A. Yu, M. Ballow, A. Shvarts, H. Lehman;  
Division of Allergy and Immunology, Women and Children's Hospital of Buffalo, SUNY-University at Buffalo, Buffalo, NY.
- 413 Blunted Emotional Availability In Mothers Who Have Food Allergy Children: an Analysis By "I Feel Pictures" Test**  
Y. Machino, M. Nagao, T. Fujisawa;  
Mie National Hospital, Tsu-City, JAPAN.
- 414 Does Allergen-Specific Immunotherapy Reduce the Risk, Reverse, and/or Mitigate Asthma in Children with Allergic Rhinitis? The Pediatric Improved Access to AllerGen-Specific Immunotherapy - Asthma Incidence Rates Among Medicaid Enrollees (Pediatric-IMAGINE-AIRE) Study, Funded by the Joint Council of Allergy, Asthma and Immunology**  
C. S. Hankin<sup>1</sup>, L. Cox<sup>2</sup>, A. Bronstone<sup>1</sup>, Z. Wang<sup>1</sup>;

- <sup>1</sup>BioMedEcon, Moss Beach, CA, <sup>2</sup>Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL.
- 415 Tolerability and Efficacy of 20% Subcutaneous Immune Globulin (ScIg) Delivered by Rapid Push**  
J. Y. Kim, J. Kuryan, V. R. Bonagura;  
North Shore-Long Island Jewish Health System, Great Neck, NY.
- 416 Reliability and Validity of the Phase V® Allergic Rhinitis Treatment Satisfaction and Preference Scale (Phase V® ARTSP) In Patients with Perennial Allergic Rhinitis (PAR)**  
R. R. Turner<sup>1</sup>, M. A. Testa<sup>2</sup>, J. F. Hayes<sup>1</sup>;  
<sup>1</sup>Phase V Technologies, Inc., Wellesley Hills, MA, <sup>2</sup>Harvard School of Public Health, Boston, MA.
- 417 Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%: Estimated Impact on Dosing Requirements and Cost of Therapy**  
R. Iyer, M. Luo, J. Li-McLeod;  
Baxter Healthcare Corp, Deerfield, IL.
- 418 Assessment of Actual Dose Adjustment in Patients Switching From Intravenous Immunoglobulin (IGIV) Therapy to IGSC 20%**  
M. Luo, R. Iyer, J. Li-McLeod;  
Baxter Healthcare Corp, Deerfield, IL.

## Poster Session

### Mechanisms of Allergic Rhinitis

3209

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 419 Gene-Environment Interaction between TLR4 Gene and Mold Exposure in Infancy on the Development of Allergic Rhinitis in School-Aged Children**  
H. Kim<sup>1,2</sup>, J. Seo<sup>1,2</sup>, S. Lee<sup>3,2</sup>, M. Kang<sup>4</sup>, J. Kwon<sup>5,2</sup>, B. Kim<sup>6,2</sup>, Y. Song<sup>7,2</sup>, Y. Kim<sup>4</sup>, S. Hong<sup>1,2</sup>;  
<sup>1</sup>Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Research Center for Standardization of Allergic Diseases, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, <sup>4</sup>Asan Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF, <sup>5</sup>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>6</sup>Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF, <sup>7</sup>Childhood Asthma Atopy Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 420 Development of an In Vitro Fluo-4 Calcium Assay for Assessing Selective TRPV1 Agonist Responses**  
B. P. Davis, U. Singh, L. Haar, K. W. Jones, J. A. Bernstein;  
University of Cincinnati, Cincinnati, OH.
- 421 Differential TRPV1 Activation Responses to Rhinoconjunctivitis Pharmacologic Agents Using an In Vitro Fluo-4 Calcium Assay**  
U. Singh, L. Haar, W. Jones, J. Bernstein;  
University of Cincinnati, Cincinnati, OH.
- 422 Specific Nasal Provocation Test With Predator Mites**  
R. GONZALEZ-PEREZ<sup>1</sup>, P. Poza-Guedes<sup>1</sup>, V. Matheu<sup>1</sup>, V. Iraola<sup>2</sup>, J. Iglesias-Souto<sup>1</sup>, I. Sanchez-Machin<sup>1</sup>;  
<sup>1</sup>Hospital del Torax-Ofra, Santa Cruz de Tenerife, SPAIN, <sup>2</sup>Laboratorios Leti, Madrid, SPAIN.

SUNDAY

- 423 Effects of Head-of-Bed Elevation in Supine Nasopharyngeal Reflux**  
D. R. Scott, R. A. Simon;  
Scripps Health, San Diego, CA.
- 424 Seasonal Local Allergic Rhinitis in Areas with High Exposure to Grass Pollen**  
F. de la Roca<sup>1</sup>, N. Blanca-Lopez<sup>2</sup>, C. Rondon<sup>3</sup>, R. Herrera<sup>4</sup>, J. L. Rodriguez-Bada<sup>4</sup>, G. Canto<sup>2</sup>, F. Feo Brito<sup>1</sup>, M. Blanca Gomez<sup>3</sup>;  
<sup>1</sup>Allergy Section, General Hospital, Ciudad Real, SPAIN, <sup>2</sup>Allergy Service, Infanta Leonor Hospital, Madrid, SPAIN, <sup>3</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, <sup>4</sup>Research Laboratory, Carlos Haya Hospital-Fundacin IMABIS, Malaga, SPAIN.
- 425 Evidence of Local Allergic Rhinitis in Areas with High and Permanent Aeroallergens Exposure**  
D. Cruz Niesvaara<sup>1</sup>, C. Rondon<sup>2</sup>, L. Almeida Quintana<sup>1</sup>, A. Correa<sup>3</sup>, R. Castillo Sainz<sup>1</sup>, L. Melendez<sup>3</sup>, T. Carrillo Diaz<sup>1</sup>, M. Blanca<sup>2</sup>;  
<sup>1</sup>Allergy Service, Dr. Negrin University Hospital, Gran Canaria, SPAIN, <sup>2</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, <sup>3</sup>Research Laboratory, Carlos Haya Hospital-Fundacion IMABIS, Malaga, SPAIN.
- 426 Anti-Allergic Effects of So-Cheong-Ryong-Tang, A Traditional Korean Herbal Medicine, in An Allergic Rhinitis Mouse Model**  
D. Kim, J. Mo, C. Rhee, C. Lee;  
Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF.
- 427 Clinical Validation of Controlled Grass Pollen Challenge in the Environmental Exposure Unit (EEU)**  
A. K. Ellis<sup>1</sup>, L. M. Steacy<sup>2</sup>, T. Walker<sup>2</sup>;  
<sup>1</sup>Queen's University, Kingston, ON, CANADA, <sup>2</sup>Kingston General Hospital, Kingston, ON, CANADA.
- 428 Does Presence of Nasal Congestion Influence Patient's Choice of Delivery Interface for Continuous Positive Airway Pressure Therapy?**  
P. Bajaj<sup>1</sup>, C. Sheerer<sup>2</sup>, A. Donato<sup>2</sup>;  
<sup>1</sup>Penn state Hershey Medical Centre, Hershey, PA, <sup>2</sup>The Reading Hospital and Medical Center, west Reading, PA.
- 429 Nasal Symptoms Induced By A Standardized Nasal Challenge Test With Aqueous *Phleum Pratense* Reflects Seasonal Nasal Symptoms In Grass Allergic Patients**  
K. Aasbjerg<sup>1</sup>, P. A. Wurtzen<sup>2</sup>, V. R. Vagtmann<sup>1</sup>, V. Backer<sup>1</sup>;  
<sup>1</sup>Bispebjerg Hospital, Copenhagen, DENMARK, <sup>2</sup>ALK-Abello, Hoersholm, DENMARK.
- 430 Using Objective Tools to Evaluate Pediatric Patients with Chronic Rhinitis**  
R. Raveendran<sup>1,2</sup>, E. Clough-Paabo<sup>2</sup>, L. Borish, MD<sup>3</sup>, E. Erwin<sup>2</sup>;  
<sup>1</sup>the Ohio State University Medical Center, Columbus, OH, <sup>2</sup>Nationwide Childrens Hospital, Columbus, OH, <sup>3</sup>University of Virginia, Charlottesville, VA.
- <sup>1</sup>DBV Technologies, Bagneux, FRANCE, <sup>2</sup>Hopital Necker, Paris, FRANCE.
- 432 *In Situ* Imaging Of Honeybee (*Apis Mellifera*) Venom Components From Immunotherapy Preparations**  
U. Seppala<sup>1</sup>, S. Francese<sup>2</sup>, S. Turilazzi<sup>3</sup>, G. Moneti<sup>3</sup>, M. Clench<sup>2</sup>, D. Barber<sup>4</sup>;  
<sup>1</sup>Global Research, ALK-Abello, Horsholm, DENMARK, <sup>2</sup>Sheffield Hallam University, Sheffield, UNITED KINGDOM, <sup>3</sup>CISM, University of Florence, Florence, ITALY, <sup>4</sup>Global Research, ALK-Abello, Madrid, SPAIN.
- 434 Protection from Oral Peanut-Induced Esophageal Lesions in Sensitized Mice treated by Epicutaneous Immunotherapy is Mediated by CD25+CD4+ Tregs**  
V. Dioszeghy<sup>1</sup>, L. Mondoulet<sup>1</sup>, V. Dhelft<sup>1</sup>, M. Ligouis<sup>1</sup>, E. Puteaux<sup>1</sup>, C. Dupont<sup>2</sup>, P. Benhamou<sup>1</sup>;  
<sup>1</sup>DBV-Technologies, Bagneux, FRANCE, <sup>2</sup>Universite Paris des cartes - Hopital Necker, Paris, FRANCE.
- 435 Bioavailability of IgG Administered by the Subcutaneous Route**  
M. Berger<sup>1</sup>, S. Jolles<sup>2</sup>, J. W. Sleasman<sup>3</sup>;  
<sup>1</sup>CSL Behring LLC, King of Prussia, PA, <sup>2</sup>University Hospital of Wales, Cardiff, UNITED KINGDOM, <sup>3</sup>University of South Florida, St. Petersburg, FL.
- 436 Sublingual Allergen Immunotherapy: Mode Of Action And Its Relationship With The Safely Profile**  
M. A. Calderon<sup>1</sup>, E. R. Simons<sup>2</sup>, H. Malling<sup>3</sup>, R. F. Lockey<sup>4</sup>, P. Moingeon<sup>2</sup>, P. Demoly<sup>6</sup>;  
<sup>1</sup>Section of Allergy and Clinical Immunology, Imperial College-NHLI, Royal Brompton, London, UNITED KINGDOM, <sup>2</sup>Department of Pediatrics & Child Health, Department of Immunology, University of Manitoba, Winnipeg, QC, CANADA, <sup>3</sup>Copenhagen University Hospital, Copenhagen, DENMARK, <sup>4</sup>Division of Allergy & Immunology, University of South Florida College of Medicine, Tampa, FL, <sup>5</sup>Stallergenes, Antony, FRANCE, <sup>6</sup>Allergy Division, Pneumology Department, INSERM U657, Hpital Arnaud de Ville-neuve, University Hospital of Montpellier, Montpellier, FRANCE.
- 437 Anti-Inflammatory Activity Of Sublingual Immunoglobulins (SLIG) In A Preclinical Model Of Allergic Asthma**  
T. BATARD;  
Stallergenes SA, Antony, FRANCE.
- 438 The Effect of Allergen Immunotherapy on Exhaled Nitric Oxide in Adult Subjects with Allergic Rhinitis and Asthma**  
A. S. Rohr<sup>1</sup>, B. Wong<sup>2</sup>, R. A. Panettieri, Jr.<sup>3</sup>, M. Columbo<sup>1</sup>;  
<sup>1</sup>Asthma, Allergy and Immunology Specialists, Bryn Mawr, PA, <sup>2</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, PA, <sup>3</sup>Pulmonary, Allergy and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, PA.
- 439 Inhibition Of Human IgE-Allergen Interaction By Antibodies Of Rabbits Immunized With Depigmented-polymerized Allergen Extracts**  
V. Iraola, M. T. Gallego, T. Aranda, M. A. Lopez-Matas, M. Morales, R. Saez, C. Marquez, J. R. Leonor, J. Carnes;  
Laboratorios LETI, S.L.U., Tres Cantos, SPAIN.
- 440 Immunological Changes During Subcutaneous And Sublingual Grass Pollen Immunotherapy**  
P. A. Wurtzen<sup>1</sup>, K. Aasbjerg<sup>2</sup>, G. Grauert<sup>1</sup>, G. K. Koed<sup>1</sup>, M. Holse<sup>1</sup>, V. Backer<sup>1</sup>, V. R. Vagtmann<sup>1</sup>;  
<sup>1</sup>ALK-Abello, Hoersholm, DENMARK, <sup>2</sup>Bispebjerg Hospital, Copenhagen, DENMARK.
- 441 Induced-Tolerogenic Dendritic Cells That Promote Tolerance And De Novo Differentiation Of Regulatory T Cells**  
R. A. Maldonado<sup>1,2</sup>, L. C. Perdomo<sup>2</sup>, F. Vascotto<sup>2</sup>, L. Francisco<sup>2</sup>, A. T. Bauquet<sup>3</sup>, V. K. Kuchroo<sup>3</sup>, A. H. Sharpe<sup>2</sup>, U. H. von Andrian<sup>2</sup>;  
<sup>1</sup>Selecta Biosciences Inc, Watertown, MA, <sup>2</sup>Harvard Medical School, Boston, MA, <sup>3</sup>Center for Neurologic Diseases and Brigham and Womens Hospital, Boston, MA.

## Poster Session

## Mechanisms of Immunotherapy

3210

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 431 In Mice Sensitized to Milk, Epicutaneous Immunotherapy Prevents Further Sensitization to Peanut or House Dust Mite**  
L. Mondoulet<sup>1</sup>, V. Dioszeghy<sup>1</sup>, E. Puteaux<sup>1</sup>, M. Ligouis<sup>1</sup>, V. Dhelft<sup>1</sup>, C. Dupont<sup>2</sup>, P. Benhamou<sup>1</sup>;

## Poster Session

### Eosinophils

3211

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 442 Modulation of Eosinophil Responsiveness to TSLP-Mediated Degranulation**  
E. B. Cook, J. L. Stahl, E. A. Schwantes, N. P. Barney, S. A. Mathur; University Wisconsin, Madison, WI.
- 443 Eosinophil Granular Proteins Specifically Major Basic Protein Damage Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus**  
M. Kato<sup>1</sup>, T. Ishioka<sup>2</sup>, H. Kita<sup>3</sup>, K. Kozawa<sup>2</sup>, Y. Hayashi<sup>4</sup>, H. Kimura<sup>5</sup>;  
<sup>1</sup>Department of Allergy and Immunology, Gunma Children's Medical Center, Shibukawa, Gunma, JAPAN, <sup>2</sup>Gunma Prefectural Institute of Public Health and Environmental Sciences, Maebashi, Gunma, JAPAN, <sup>3</sup>Department of Internal Medicine, Mayo Clinic, Rochester, MN, <sup>4</sup>Department of Hematology and Oncology, Gunma Children's Medical Center, Shibukawa, Gunma, JAPAN, <sup>5</sup>National Institute of Infectious Diseases, Musashimurayama, Tokyo, JAPAN.
- 444 Aspirin Activation of Eosinophils: Relevance to Aspirin-Exacerbated Respiratory Disease (AERD)**  
L. Borish, P. Huyett, L. Liu, J. A. Negri, S. Payne, J. W. Steinke; University of Virginia Practice, Charlottesville, VA.
- 445 Eosinophils Promote Epithelial To Mesenchymal Transition Of Bronchial Epithelial Cells**  
K. Hosoki<sup>1</sup>, A. Yasukawa<sup>2</sup>, M. Toda<sup>2</sup>, Y. Miyake<sup>2</sup>, D. B. Ruiz<sup>2</sup>, P. g. Bernabe<sup>2</sup>, T. Takagi<sup>3</sup>, R. Morooka<sup>3</sup>, M. Nagao<sup>1</sup>, C. N. DAlessandro-Gabazza<sup>2</sup>, O. Taguchi<sup>3</sup>, E. C. Gabazza<sup>2</sup>, T. Fujisawa<sup>1</sup>;  
<sup>1</sup>Mie National Hospital, Tsu, JAPAN, <sup>2</sup>Department of Immunology, Mie University School of Medicine, Tsu, JAPAN, <sup>3</sup>Department of Pulmonary and Critical Care Medicine, Mie University School of Medicine, Tsu, JAPAN.
- 446 Extracellular Release of Endogenous ATP Mediates Eosinophil Recognition of Fungal Products and Degranulation Response**  
T. Soma<sup>1,2</sup>, T. Kobayashi<sup>1,2</sup>, S. Seno<sup>2</sup>, H. Kita<sup>2</sup>;  
<sup>1</sup>Allergy Center, Saitama Medical University, Saitama, JAPAN, <sup>2</sup>Division of Allergic Diseases, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN.
- 447 Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression on Human Cell Lines and Hematologic Malignancies**  
A. N. Salicru<sup>1</sup>, H. Hermann<sup>2,3</sup>, S. Hudson<sup>1</sup>, J. Steinke<sup>4</sup>, L. Borish<sup>4</sup>, P. Valent<sup>2,3</sup>, B. S. Bochner<sup>1</sup>;  
<sup>1</sup>Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, AUSTRIA, <sup>3</sup>Ludwig Boltzmann Cluster Oncology, Vienna, AUSTRIA, <sup>4</sup>Asthma and Allergic Disease Center, Carter Center for Immunology Research, University of Virginia, Charlottesville, VA.
- 448 Cord Blood (CB) Eosinophil/Basophil (Eo/B) Progenitors Predict Respiratory Outcomes Until The Age Of Two**  
K. M. Weisse<sup>1,2</sup>, G. Herberth<sup>1</sup>, S. Roeder<sup>3</sup>, M. Borte<sup>4</sup>, D. Heroux<sup>2</sup>, J. A. Denburg<sup>2</sup>, I. Lehmann<sup>1</sup>;  
<sup>1</sup>Helmholtz-Centre for Environmental Research GmbH - UFZ, Department of Environmental Immunology, Leipzig, GERMANY, <sup>2</sup>McMaster University, Division of Clinical Immunology and Allergy, Hamilton, ON, CANADA, <sup>3</sup>Helmholtz-Centre for Environmental Research GmbH - UFZ, Core Facility Studies, Leipzig, GERMANY, <sup>4</sup>Childrens Hospital, Municipal Hospital St. Georg, Leipzig, GERMANY.

- 449 Mechanisms Of Tlr-mediated Cord Blood Cd34+ Progenitor Cell Eosinophil Differentiation: Signaling And Autocrine Pathways**  
P. Reece, A. J. Baatjes, M. M. Cyr, R. Sehmi, J. A. Denburg; McMaster, Hamilton, ON, CANADA.
- 450 Differential Effect of TGF-β1 and Eotaxin on Novel CLC3 Ion-Channel Variants in Human Peripheral Blood Eosinophils**  
R. Gaurav, D. K. Agrawal;  
Center for Clinical and Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, NE.
- 451 Identification of Suitable qPCR Reference Genes during IL-5 Induced Cord Blood Eosinophilopoiesis**  
J. Thiele, A. K. Ellis;  
Queen's University, Kingston, ON, CANADA.
- 452 Selective Glucocorticoid Receptor Modulator CpdA Overcomes GM-CSF-induced Resistance of Eosinophil to Glucocorticoid Treatment**  
K. Pazdrak<sup>1</sup>, Y. Moon<sup>2</sup>, C. Straub<sup>1</sup>, R. Maroto<sup>1</sup>, A. Kurosky<sup>1</sup>;  
<sup>1</sup>Univ. of TX Medical Branch, Galveston, TX, <sup>2</sup>University of Notre Dame, Notre Dame, IN.
- 453 Failure Of Hepoxilin A-3 To Chemoattract Eosinophils In An In-vitro Gradient Barrier System**  
S. A. Kubala, S. U. Patil, M. C. Radano, W. G. Shreffler, B. P. Hurlley;  
Massachusetts General Hospital, Boston, MA.
- 454 Peripheral Blood Eosinophils Are Not Activated By Highly Purified Recombinant High Mobility Group Box 1 (HMGB1) Protein**  
C. Straub, B. Xu, Z. Wu, T. Wood, A. Haag, K. Pazdrak, A. Kurosky;  
The University of Texas Medical Branch, Galveston, TX.
- 455 Membrane Cholesterol Removal from Human Eosinophils Disrupts Cholesterol Rich Membrane Microdomains Resulting in Down Regulated MAP Kinase Signaling but not JAK/STAT Signaling**  
M. E. Burnham, M. E. Bates, P. J. Bertics;  
University of Wisconsin School of Medicine and Public Health, Madison, WI.
- 456 Inhibition of Eosinophil Differentiation in vitro by a PPARγ Agonist**  
S. G. Smith, M. Hill, A. J. Baatjes, K. Howie, R. M. Watson, R. Sehmi, G. M. Gauvreau;  
McMaster University, Hamilton, ON, CANADA.

## Poster Session

### Mast Cells, Basophils and IgE

3212

Session Time: Sunday, March 4, 2012,  
9:45 AM - 10:45 AM

- 457 Mast Cell Phenotypes and Distribution in Nasal Polyps with Allergic Airway**  
E. E. Fouda<sup>1</sup>, S. Abdelgawad<sup>2</sup>, S. Said-Ahmed<sup>3</sup>, A. Ali<sup>4</sup>, E. Mohamed<sup>3</sup>;  
<sup>1</sup>Al-azhar university allergy & Immunology center, Cairo, EGYPT, <sup>2</sup>Faculty of medicine(girls),Al-azhar university, Cairo, EGYPT, <sup>3</sup>Faculty of medicine(Girls),Al-azhar university, Cairo, EGYPT, <sup>4</sup>Faculty of medicine,Al-azhar university, Cairo, EGYPT.
- 458 A Role for Mast Cell Chymase in Regulating Levels of Immunoglobulin E**

SUNDAY

- A. Fawzy**<sup>1,2</sup>, T. Iwanaga<sup>1</sup>, A. R. McEuen<sup>1</sup>, B. L. Nicholas<sup>1</sup>, A. Mo-chizuki<sup>1</sup>, J. W. Holloway<sup>1</sup>, A. F. Walls<sup>1</sup>;  
<sup>1</sup>University of Southampton, Southampton, UNITED KINGDOM, <sup>2</sup>National Research Center, Cairo, EGYPT.
- 459 Role of the Aryl-hydrocarbon Receptor (AhR)-ligand Axis in Mast Cells**  
**Y. Zhou**<sup>1</sup>, H. Tung<sup>1</sup>, Y. Tsai<sup>1,2</sup>, S. Hsu<sup>1</sup>, B. Plunkett<sup>1</sup>, B. M. Vonakis<sup>1</sup>, S. Huang<sup>1,3</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Kaohsiung Medical University, Kaohsiung, TAIWAN, <sup>3</sup>National Health Research Institutes, Miaoli, TAIWAN.
- 460 Abnormal Mast Cell Migration in the Wv/+ Piebald Mouse**  
**F. J. Lichtenberger**, N. Medic, A. Desai, G. Bandara, D. D. Metcalfe;  
National Institutes of Health, Bethesda, MD.
- 461 A Potential IL-33 Autocrine Loop in Mast Cells**  
**H. Tung**<sup>1</sup>, B. Plunkett<sup>1</sup>, S. Huang<sup>1,2</sup>, Y. Zhou<sup>1</sup>;  
<sup>1</sup>Johns Hopkins, Baltimore, MD, <sup>2</sup>National Health Research Institutes, Zhunan, TAIWAN.
- 462 Effects of the KIT K509I Extracellular Activating Mutation on Human Mast Cell Homeostasis**  
**Y. Bai**<sup>1</sup>, E. C. Chan<sup>1</sup>, A. S. Kirshenbaum<sup>1</sup>, E. R. Fischer<sup>2</sup>, O. Simakova<sup>3</sup>, I. Maric<sup>3</sup>, D. D. Metcalfe<sup>1</sup>, T. M. Wilson<sup>1</sup>;  
<sup>1</sup>Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, <sup>2</sup>Research Technologies Section, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, <sup>3</sup>Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD.
- 463 Functional Differences in Bronchoalveolar Lavage (BAL) Mast Cells (MCs) in Severe and Mild Asthma**  
**M. L. Fajt**<sup>1</sup>, J. B. Trudeau<sup>1</sup>, L. B. Schwartz<sup>2</sup>, S. E. Wenzel<sup>1</sup>;  
<sup>1</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Virginia Commonwealth University, Richmond, VA.
- 464 Mast Cell Trypsinase as a Stimulus for Upregulation of Adhesion Molecule Expression and Cytokine Release from Endothelial Cells**  
**M. E. Khedr**<sup>1</sup>, A. M. Abdelmotleb<sup>2</sup>, L. Lau<sup>2</sup>, M. Arno<sup>3</sup>, X. Zhou<sup>2</sup>, A. F. Walls<sup>2</sup>;  
<sup>1</sup>University of Southampton, Southampton, UNITED KINGDOM/Suez Canal University, Ismailia, EGYPT, <sup>2</sup>University of Southampton, Southampton, UNITED KINGDOM, <sup>3</sup>Genomics Centre, King's College, London, UNITED KINGDOM.
- 465 Effects Of Rupatadine On Platelet Activating Factor (PAF)-induced Human Mast Cell Degranulation Compared With Desloratadine And Levocetirizine**  
**R. Munoz-Cano**<sup>1</sup>, I. Torres-Atencio<sup>1</sup>, E. Ainsua<sup>2</sup>, M. Martin Andorra<sup>2</sup>, J. Sanchez-Lopez<sup>1</sup>, J. Bartra<sup>1</sup>, C. Picado<sup>1</sup>, A. Valero Santiago<sup>1</sup>;  
<sup>1</sup>Hospital Clinic. IDIBAPS., Barcelona, SPAIN, <sup>2</sup>Departament de Bioquímica. Universitat de Barcelona., Barcelona, SPAIN.
- 466 Obesity is Not Linked with Increased Whole-Body Mast Cell Burden in Children**  
**B. R. Ward**<sup>1</sup>, S. A. Arslanian<sup>2</sup>, E. Andreatta<sup>3</sup>, L. B. Schwartz<sup>1</sup>;  
<sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>3</sup>University of Verona, Verona, ITALY.
- 467 Human Basophil Activation Is Associated With Expression Of Co-stimulatory Molecules And Ige Dependent Antigen Capture**  
**S. U. Patil**<sup>1</sup>, A. Ma<sup>1</sup>, G. Lund<sup>2</sup>, K. Lund<sup>2</sup>, W. G. Shreffler<sup>1</sup>;  
<sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>ALK-Abello, Hørsholm, DENMARK.
- 468 Antigen-induced Anergy In Human Basophils Is Not Antigen Specific**  
**A. Ma**<sup>1</sup>, S. Patil<sup>1</sup>, G. Lund<sup>2</sup>, K. Lund<sup>2</sup>, W. G. Shreffler<sup>1</sup>;  
<sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>ALK-Abello, Hørsholm, DENMARK.
- 469 Anti-CD40 antibody or 8-oxo-dG reduces Migratin or Inactivation of Mast Cells via Chemokines and Foxp3+ Regulatory T Cells in Experimental Allergic Encephalomyelitis**  
**Y. Ahn**<sup>1</sup>, G. Hong<sup>2</sup>, Y. Lee<sup>2</sup>, J. Ro<sup>2</sup>;  
<sup>1</sup>Department of Pediatrics, Eulji University School of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Department of Pharmacology, Sungkyunkwan university of medicine, Suwon, KOREA, REPUBLIC OF.
- 470 IgE Expression on Murine Lung Conventional Dendritic Cells During a Paramyxoviral Infection**  
**B. J. Carroll**, E. Buell, D. Hunter, D. S. Cheung, M. H. Grayson;  
Medical College of Wisconsin, Milwaukee, WI.
- 471 Incidence of Clinical Cross-Reactivity Between Shrimp, Dust Mite, and Cockroach Allergy at an Inner City University-Based Outpatient Setting**  
**M. Kim**, R. Joks;  
SUNY Downstate University, Brooklyn, NY.
- 472 The Effect of Epigallocatechin Gallate on IgE Levels in HIV-1-Infected Subjects**  
**E. Leechawengwongs**, W. T. Shearer, C. L. Nance;  
Baylor College of Medicine, Houston, TX.
- 473 Determination of Mast Cell/Basophil Inhibitory Activities of Traditional Chinese Herbal Medicines**  
**I. Gluskin**, J. Harris, N. Yang, Y. Song, X. Li;  
MountSinai School of medicine, New York City, NY.
- 474 Maternal IgE Levels Are Associated With IgE Levels At Ages 10 And 18 In Girls But Not In Boys, Isle Of Wight Birth Cohort**  
**A. Sadeghnejad**<sup>1</sup>, W. Karmaus<sup>2</sup>, S. H. Arshad<sup>3</sup>;  
<sup>1</sup>Department of Medicine, Capital Health System, Trenton, NJ, <sup>2</sup>University of South Carolina, Columbia, SC, <sup>3</sup>The Asthma and Allergy Centre, Isle of Wight and University of Southampton, UNITED KINGDOM.
- 475 An Unusual Case of Mast Cell Activation Syndrome**  
**R. Patel**<sup>1</sup>, J. Celestin<sup>2</sup>, M. Frieri<sup>1</sup>;  
<sup>1</sup>Nassau University Medical Center, East Meadow, NY, <sup>2</sup>Albany Medical College, Albany, NY.
- 476 Effects of Omalizumab on Two Patients with Short Stature and Atopic Disease**  
**N. B. Richards**, S. McGeady, C. Chang, D. Doyle;  
Thomas Jefferson Hospital, Philadelphia, PA.

## Oral Abstract Session

### AHP: Oral Abstract Luncheon

3520

Session Time: Sunday, March 4, 2012,  
12:15 PM - 1:30 PM

- 477 Impact of Asthma Counseling by Pharmacist on Asthma Control and Medication Adherence in Asia**  
**T. Lim**<sup>1</sup>, S. Kowalski<sup>2</sup>, K. Tan<sup>3</sup>;  
<sup>1</sup>Department of Pharmacy, Singapore General Hospital, Singapore, SINGAPORE, <sup>2</sup>School of Pharmacy, University of South Australia, Adelaide, AUSTRALIA, <sup>3</sup>Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, SINGAPORE.
- 478 Prolonged Exposure to Sublingual Immunotherapy Improves Safety of Oral Immunotherapy**  
**S. Seopaul**<sup>1</sup>, C. A. Keet<sup>1</sup>, P. A. Frischmeyer-Guerrero<sup>1</sup>, A. Thyagarajan<sup>2</sup>, J. T. Schroeder<sup>1</sup>, R. Hamilton<sup>1</sup>, S. Boden<sup>2</sup>, P. Steele<sup>2</sup>, S. Driggers<sup>1</sup>, A. W. Burks<sup>2</sup>, R. A. Wood<sup>1</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>Duke University, Durham, NC.



- 479 Open Clinic-Based Peanut Food Challenges are a Viable and Safe Method of Evaluating Clinical Sensitivity and Tolerance**  
**J. E. Conner**<sup>1</sup>, S. A. Lowe<sup>1</sup>, L. A. Crandall<sup>1</sup>, M. B. Ho<sup>1</sup>, C. M. Lee<sup>1</sup>, M. Feuling<sup>2</sup>, C. Sova<sup>2</sup>, M. Vasudev<sup>1</sup>;  
<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Children's Hospital of Wisconsin, Milwaukee, WI.
- 480 Purposeful Exposure to Foods without Medical Recommendation in an Observational Study (COFAR)**  
**K. Mudd**<sup>1</sup>, J. Slinkard<sup>2</sup>, P. Mayfield<sup>3</sup>, L. Talarico<sup>4</sup>, J. Kamilaris<sup>5</sup>, S. H. Sicherer<sup>4</sup>;  
<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>National Jewish Health, Denver, CO, <sup>3</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>4</sup>Mount Sinai School of Medicine, New York, NY, <sup>5</sup>Duke University Medical Center, Durham, NC.
- 481 Rodent Sensitization Is Associated With Worse Lung Function In Urban Adults With Asthma**  
**M. C. Ong**, P. N. Breyse, G. B. Diette, B. M. Thomas, P. J. Lenehan, J. Curtin-Brosnan, E. C. Matsui;  
Johns Hopkins University, Baltimore, MD.
- 488 Ex Vivo Identification and Phenotyping of Allergen-Specific T Helper Cells In Human Peripheral Blood based on CD154 Expression**  
**K. A. Smith**<sup>1</sup>, R. S. Rashid<sup>2</sup>, A. J. Frew<sup>2</sup>, F. Kern<sup>1</sup>, M. D. Tarzi<sup>1</sup>;  
<sup>1</sup>Brighton and Sussex Medical School, Brighton, UNITED KINGDOM, <sup>2</sup>Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, UNITED KINGDOM.
- 489 Calculated Globulin (CG): A Viable Tool for the Identification of Patients with Potential Antibody Deficiency**  
**S. Jolles**, R. Borrell, M. Moody, C. Selwood, P. Williams, T. El-Shanawany;  
University Hospital of Wales, Cardiff, UNITED KINGDOM.
- 490 T<sub>H</sub>2A Cells As a Unique T<sub>H</sub>2 Cell Subset in Allergic Individuals: Steps Toward a T Cell Biomarker For Allergy**  
**E. R. G. Wambre**<sup>1</sup>, J. H. DeLong<sup>1</sup>, E. A. James<sup>1</sup>, D. Robinson<sup>2</sup>, W. W. Kwok<sup>1</sup>;  
<sup>1</sup>Benaroya Research Institute, Seattle, WA, <sup>2</sup>Virginia Mason Medical Center, Seattle, WA.
- 491 A Central B Cell Tolerance Defect In Group Ia CVID Patients**  
**N. Romberg**<sup>1</sup>, Y. Ng<sup>1</sup>, C. Cunningham-Rundles<sup>2</sup>, E. Meffre<sup>1</sup>;  
<sup>1</sup>Yale School of Medicine, New Haven, CT, <sup>2</sup>Mount Sinai Medical Center, New York, NY.

### Oral Abstract Session

#### Asthma Therapeutics: What's Below the Surface?

3601

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 482 Body Mass and Corticosteroid Response in Childhood Asthma**  
**R. A. Nunez**, L. P. Jackson, E. Goleva, D. Y. M. Leung, P. J. Hauk;  
National Jewish Health, Denver, CO.
- 483 Steroid Requirements and Immune Associations With Vitamin D Are Stronger In Children Than Adults With Asthma**  
**D. Y. Leung**, D. A. Searing, L. P. Jackson, B. N. Richers, E. Goleva;  
National Jewish Health, Denver, CO.
- 484 Ganoderic Acid C Isolated From *Ganoderma Lucidum* Suppress Lps-induced Macrophage Tnf- $\alpha$  Production By Down-regulating Mapk, Nf-kappab And Ap-1 Signaling Pathways**  
**C. Liu**, N. Yang, W. Folder, J. Cohn, R. Wang, X. Li;  
Pediatric Allergy & Immunology, The Mount Sinai School of Medicine, New York, NY.
- 485 Methoxyphenols Exhibit Anti-inflammatory Effects on Airway Epithelial Cells by Acting Post-transcriptionally**  
**F. T. Ishmael**<sup>1</sup>, K. R. Houser<sup>1</sup>, D. Johnson<sup>2</sup>;  
<sup>1</sup>The Pennsylvania State University, Hershey, PA, <sup>2</sup>State University of New York College at Geneseo, Geneseo, NY.
- 486 Asthma Control And Disordered Microbial Communities In The Lower Airways Of Patients With Poorly Controlled Asthma**  
**E. Goleva**<sup>1</sup>, J. K. Harris<sup>2</sup>, R. J. Martin<sup>1</sup>, A. Dakhama<sup>1</sup>, R. Alam<sup>1</sup>, E. W. Gelfand<sup>1</sup>, D. Y. M. Leung<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Colorado Denver, Denver, CO.

### Oral Abstract Session

#### Immunophenotyping

3602

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 487 TH IL-17 Immunophenotyping Reference for Children**  
**K. A. Gonzaga**, T. Dasu, J. M. Routes, J. W. Verbsky;  
Medical College of Wisconsin, Milwaukee, WI.

### Oral Abstract Session

#### Biological Dust Exposures and Atopic & Allergic Diseases

3603

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 492 Enhanced Organic Dust Induced Airway Inflammation in Protein Kinase C Epsilon Deficient Mice is Associated with Dysregulation of Nitric Oxide**  
**J. A. Poole**, A. Gleason, C. Bauer, W. W. West, D. J. Romberger, T. A. Wyatt;  
UNMC, Omaha, NE.
- 493 Cigarette Smoke Exposure and its Effect on Bronchial Responsiveness and Response to Fluticasone Propionate, Salmeterol and their Combination**  
**K. Sapkota**<sup>1</sup>, M. Sapkota<sup>2</sup>, R. G. Townley<sup>3</sup>;  
<sup>1</sup>Division of Asthma Allergy and Immunology and Department of pharmacology, Creighton University School of Medicine, Omaha, NE, <sup>2</sup>Department of pharmacology, Creighton University School of Medicine, Omaha, NE-68131, Omaha, NE, <sup>3</sup>Division of Asthma Allergy and Immunology Creighton University School of Medicine, Omaha, NE-68131, Omaha, NE.
- 494 The Prevalence of Asthma, Hay Fever and Allergic Sensitization in Amish Children**  
**M. Holbreich**<sup>1</sup>, J. Genuneit<sup>2</sup>, J. Weber<sup>3</sup>, C. Braun-Fahrlander<sup>4</sup>, E. von Mutius<sup>3</sup>;  
<sup>1</sup>Allergy and Asthma Consultants, Indianapolis, IN, <sup>2</sup>Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, GERMANY, <sup>3</sup>University Children's Hospital, Munich, GERMANY, <sup>4</sup>Swiss Tropical and Public Health Institute, Basel, SWITZERLAND.
- 495 Influence of Rural and Urban Dietary and Lifestyle Patterns in Atopic Diseases in a Colombian African-descent Population**  
**J. A. Marrugo**<sup>1</sup>, J. R. Urrego<sup>1</sup>, L. C. Fang<sup>1</sup>, C. A. Munoz<sup>1</sup>, L. C. Hernandez<sup>1</sup>, L. Lopez<sup>2</sup>;  
<sup>1</sup>University of Cartagena, Cartagena, COLOMBIA, <sup>2</sup>National University of Colombia, Bogota, COLOMBIA.

- 496 Vitamin E Reduces Airway Granulocyte Recruitment after Inhaled Endotoxin Challenge in Normal Volunteers**  
M. L. Hernandez<sup>1</sup>, N. E. Alexis<sup>1</sup>, J. C. Lay<sup>1</sup>, H. Zhou<sup>1</sup>, Q. Jiang<sup>2</sup>, D. B. Peden<sup>1</sup>;  
<sup>1</sup>UNC Chapel Hill, Chapel Hill, NC, <sup>2</sup>Purdue University, West Lafayette, IN.

## Oral Abstract Session

### Anaphylaxis

3604

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 497 Maternal Low Dose Peanut and Cholera Toxin Subunit B Induces Oral Tolerance Associated with An Increased Number of T Regulatory Cells**  
Y. SONG, H. Sampson, X. Li;  
Mount Sinai School of Medicine, New York, NY.
- 498 SHIP-1 Is Critical in Regulation of Severe Anaphylaxis**  
S. Oh, F. Wu, T. Zheng, Z. Zhu;  
Johns Hopkins Allergy and Asthma Center, Baltimore, MD.
- 499 Development of a Dendrimeric Structure containing ole e 1 and CpG to Modulate an Allergic Response in an Experimental Model**  
A. B. Blazquez<sup>1</sup>, A. Aranda<sup>1</sup>, A. Mascaraque<sup>2</sup>, M. Villalba<sup>3</sup>, M. J. Torres<sup>4</sup>, C. Mayorga<sup>1</sup>, J. Rojo<sup>2</sup>, M. Blanca<sup>5</sup>;  
<sup>1</sup>IMABIS Foundation-Carlos Haya Hospital, Malaga, SPAIN, <sup>2</sup>Instituto de Investigaciones Químicas, CSIC, Sevilla, SPAIN, <sup>3</sup>Departamento de Bioquímica y Biología Molecular I, Universidad Complutense, Madrid, SPAIN, <sup>4</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, <sup>5</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN.
- 500 Isolation and Identification of Compounds in *Rubia cordifolia* L. (Qian Cao) that Inhibit Human B cell IgE production**  
V. Chan, C. Liu, S. Uzun, N. Yang, X. Li;  
MountSinai School of medicine, New York City, NY.
- 501 Anaphylaxis in America - Results from a National Telephone Survey**  
J. Boyle<sup>1</sup>, C. A. Camargo<sup>2</sup>, P. Lieberman<sup>3</sup>, H. Sampson<sup>4</sup>, L. B. Schwartz<sup>5</sup>, F. E. R. Simons<sup>6</sup>, M. Zitt<sup>7</sup>, M. Wilkinson<sup>1</sup>, C. Collins<sup>8</sup>, M. Tringale<sup>8</sup>, R. Wood<sup>9</sup>;  
<sup>1</sup>Abt SRBI, Silver Spring, MD, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>University of Tennessee College of Medicine, Germantown, TN, <sup>4</sup>Mount Sinai School of Medicine, New York, NY, <sup>5</sup>Virginia Commonwealth University, Richmond, VA, <sup>6</sup>University of Manitoba, Winnipeg, MB, CANADA, <sup>7</sup>State University of NY Stony Brook, Stony Brook, NY, <sup>8</sup>Asthma and Allergy Foundation of America, Landover, MD, <sup>9</sup>Johns Hopkins University School of Medicine, Baltimore, MD.

## Oral Abstract Session

### Management of Food Allergies

3605

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 502 Food Allergy and Increased Asthma Morbidity in a School Inner-city Asthma Study**

- J. Friedlander<sup>1</sup>, W. Sheehan<sup>1</sup>, E. Hoffman<sup>2</sup>, C. Fu<sup>2</sup>, D. Gold<sup>3</sup>, W. Phipatanakul<sup>1</sup>;**  
<sup>1</sup>Children's Hospital Boston, Boston, MA, <sup>2</sup>Division of Respiratory Epidemiology, Channing Laboratory, Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Department of Biostatistics, Harvard School of Public Health, Boston, MA.

- 503 Outcome Rather Than the Type of Diagnostic Intervention Predicts Improvement in Health-Related Quality of Life Score Among Children With Food Allergy Between 0-12 Years**

L. Kirste<sup>1</sup>, T. K. Takaro<sup>1</sup>, B. Kuzeljevic<sup>2</sup>, T. Wong<sup>3</sup>, E. S. Chan<sup>3</sup>;

<sup>1</sup>Simon Fraser University, Burnaby, BC, CANADA, <sup>2</sup>Child and Family Research Institute, Vancouver, BC, CANADA, <sup>3</sup>Department of Pediatrics, Division of Allergy, University of British Columbia, Vancouver, BC, CANADA.

- 504 Bullying and Teasing In Children With Food Allergy: A Survey of Pediatric Patients In Urban Jackson, Mississippi Outpatient Allergy and Immunology Clinics**

A. E. Morris, A. B. Yates, G. D. Marshall, Jr.;

University of Mississippi Medical Center, Jackson, MS.

- 505 Novel Use of a Social Network for Families with Food Allergic Children**

T. T. Le<sup>1</sup>, S. V. Montandon<sup>1</sup>, T. C. Gaslin<sup>2</sup>;

<sup>1</sup>University of Louisville, Louisville, KY, <sup>2</sup>The Center for Courageous Kids, Scottsville, KY.

- 506 Food Allergy Attitudes and Beliefs among School Nurses in an Urban Public School District**

H. P. Sharma<sup>1</sup>, H. Robinson<sup>1</sup>, S. A. Twichell<sup>1</sup>, L. Hanks<sup>1</sup>, C. Nguyen<sup>1</sup>, E. Garrow<sup>2</sup>, M. L. Acebal<sup>2</sup>;

<sup>1</sup>Children's National Medical Center, Washington, DC, <sup>2</sup>Food Allergy and Anaphylaxis Network, Fairfax, VA.

## Oral Abstract Session

### Treatment of Allergic Rhinitis

3606

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 507 Comparing the Effect of Intranasal Fluticasone Furoate (FF) to Intraocular Olopatadine (OLO) on the Ocular Response to Nasal Allergen Challenge (NAC)**

M. DeTineo, H. Logothetis, M. Bashir, J. M. Pinto, F. M. Baroody, R. M. Naclerio;

University of Chicago, Chicago, IL.

- 508 Long-term Safety Study of MP29-02 (Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in Subjects with Chronic Allergic or Non-allergic Rhinitis**

W. E. Berger<sup>1</sup>, S. Shah<sup>2</sup>, W. Wheeler<sup>3</sup>, S. Bhatia<sup>4</sup>;

<sup>1</sup>Allergy & Asthma Associates, Mission Viejo, CA, <sup>2</sup>Allergy & Asthma Consultants of NJ-PA, Collegeville, PA, <sup>3</sup>Meda Pharmaceuticals, Somerset, NJ, <sup>4</sup>IRL-Synexus Clinical Research Centre, Mumbai, INDIA.

- 509 MP29-02 (Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate) in the Treatment of Ocular Symptoms of Seasonal Allergic Rhinitis (SAR)**

P. Ratner<sup>1</sup>, E. O. Meltzer<sup>2</sup>, W. Carr<sup>3</sup>, D. Ginsberg<sup>4</sup>;

<sup>1</sup>Sylvana Research Associates, San Antonio, TX, <sup>2</sup>Allergy & Asthma Medical Group & Research Center, San Diego, CA, <sup>3</sup>Allergy & Asthma Associates, Mission Viejo, CA, <sup>4</sup>Meda Pharmaceuticals, Somerset, NJ.

- 510 The Addition of Vitamin D (VitD) to an Intranasal Steroid (INS) Improves Control of Symptoms in Seasonal Allergic Rhinitis (SAR)**  
**F. M. Baroody**, J. Lane, S. Watanabe, M. DeTineo, J. Pinto, R. M. Naclerio;  
University of Chicago, Chicago, IL.
- 511 Ocular Safety of Fluticasone furoate Nasal Spray in Subjects with Perennial Allergic Rhinitis**  
**S. D. Miller**<sup>1</sup>, W. Wu<sup>2</sup>, L. Sutton<sup>2</sup>, L. Lee<sup>2</sup>;  
<sup>1</sup>Northeast Medical Research Associates, Dartmouth, MA, <sup>2</sup>Glaxo-SmithKline, Research Triangle Park, NC.

## Oral Abstract Session

### Regulation of Allergic Inflammation

3607

Session Time: Sunday, March 4, 2012,  
2:00 PM - 3:15 PM

- 512 Allergen Specific IL-10 Producing T-Regulatory Cells Are Up-regulated in Children Who Have Acquired Tolerance to Egg**  
**A. B. Fishbein**<sup>1</sup>, K. A. Erickson<sup>2</sup>, C. Szychliński<sup>1</sup>, M. J. Kwasny<sup>2</sup>, R. L. Fuleihan<sup>1</sup>, A. M. Singh<sup>1</sup>;  
<sup>1</sup>Northwestern University Children's Memorial Hospital, Chicago, IL, <sup>2</sup>Northwestern University, Chicago, IL.
- 513 IL-4, But Not IL-2, Induces Th2 Cells To Resist The IL-27 Counterregulation By Downregulating Stat1 Phosphorylation**  
**Z. Chen**<sup>1,2</sup>, S. Wang<sup>2</sup>, C. Bai<sup>1</sup>, R. Alam<sup>2</sup>, R. Katial<sup>2</sup>, H. Huang<sup>2</sup>;  
<sup>1</sup>Zhongshan Hospital, Shanghai, CHINA, <sup>2</sup>National Jewish Health, Denver, CO.
- 514 Increased Number of Regulatory T cells in Skin Draining Lymph Nodes Suppress Priming Towards New Antigens**  
**S. Mahapatra**<sup>1</sup>, E. Robinson<sup>2</sup>, C. Herrick<sup>2</sup>, M. Albrecht<sup>1</sup>, A. M. Dittrich<sup>1</sup>;  
<sup>1</sup>Hannover Medical School, Hannover, GERMANY, <sup>2</sup>Yale University School of Medicine, New Haven, CT.
- 515 IgE Cross-Linking Downregulates Expression of Glycolytic Genes in Human Plasmacytoid Dendritic Cells**  
**G. Bajwa**, F. Z. Chowdhury, J. D. Farrar, J. Sudderth, R. J. Deberardinis, M. A. Gill;  
UT Southwestern Medical Center at Dallas, Dallas, TX.
- 516 Increased Platelet Adherence to Leukocytes Results in Cysteinyl Leukotriene (cysLT) Overproduction in Aspirin Exacerbated Respiratory Disease (AERD)**  
**T. M. Laidlaw**<sup>1</sup>, M. S. Kidder<sup>1</sup>, N. Bhattacharyya<sup>1</sup>, G. L. Milne<sup>2</sup>, J. A. Boyce<sup>1</sup>;  
<sup>1</sup>Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Vanderbilt University Medical Center, Nashville, TN.
- 518 Meta-analysis of Transcriptome Data using Pathway-based Approach Reveals Biologically Relevant Asthma Genes**  
**T. M. Baye**, S. Amirsetty, G. Khurana Hershey;  
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- 519 Gene-Environment Interaction between CD14/TLR4 Polymorphisms and Use of Antibiotics in Infancy increases the Risk of Allergic Diseases**  
**K. Park**<sup>1</sup>, H. Lee<sup>1</sup>, J. Seo<sup>2</sup>, H. Kim<sup>2</sup>, M. Kang<sup>3</sup>, J. Kwon<sup>4</sup>, Y. Song<sup>2</sup>, B. Kim<sup>5</sup>, S. Lee<sup>6</sup>, S. Hong<sup>2</sup>;  
<sup>1</sup>Presbyterian Medical Center, Jeonju, KOREA, REPUBLIC OF, <sup>2</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Asan Institute for Life Sciences, University of Ulsan, Ulsan, KOREA, REPUBLIC OF, <sup>4</sup>Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF, <sup>5</sup>Inje University Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF, <sup>6</sup>Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF.
- 520 Exhaled Breath Condensate Formate Increases After Allergen Challenge In Human Atopic Asthmatics In Vivo**  
**R. Greenwald**<sup>1</sup>, A. Hoskins<sup>2</sup>, R. Dworski<sup>2</sup>;  
<sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>Vanderbilt University, Nashville, TN.
- 521 Characterization of Genetic Epidemiology for GWAS-identified Asthma Susceptibility Loci in Chinese by Next Generation Sequencing**  
**T. F. Leung**<sup>1</sup>, P. Law<sup>2</sup>, L. Y. Tse<sup>1</sup>, H. Y. Sy<sup>1</sup>, S. K. W. Tsui<sup>3</sup>;  
<sup>1</sup>Department of Pediatrics, The Chinese University of Hong Kong, Hong Kong, HONG KONG, <sup>2</sup>School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, HONG KONG, <sup>3</sup>School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, HONG KONG.

## Featured Poster Session

### ADT Featured Poster Session

3801

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 517 MiR150 Transgenic Mice Exhibit Altered T Cell Response, Cytokine Profile and Lung Inflammation**  
**J. Wang**, K. Li, G. Hellermann, S. Mohapatra, R. Lockey, S. Mohapatra;  
University of South Florida, Tampa, FL.

## Featured Poster Session

### BCI Featured Poster Session

3802

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 522 Simultaneous Detection of TRECs and KRECs in Newborn DNA Isolated From Dried Blood Spots (Guthrie Cards)**  
**V. R. Bonagura**<sup>1</sup>, J. DeVoti<sup>1</sup>, L. Massaro<sup>1</sup>, N. Sharif<sup>1</sup>, J. Isabelle<sup>2</sup>, M. Caggana<sup>2</sup>;  
<sup>1</sup>Feinstein Institute for Medical Research NS-LIJ Health System, Great Neck, NY, <sup>2</sup>NYS Department of Health Wadsworth Center, Albany, NY.
- 523 Different Effects Of ADA And PNP Deficiency On Thymocytes Development**  
**E. Grunebaum**, T. Papinazath, R. Somech, C. M. Roifman;  
Hospital for Sick Children, Toronto, ON, CANADA.
- 524 Pioglitazone (pio), A Peroxisome Proliferator-activated Receptor (ppar) $\gamma$  Agonist, Restores Efferocytosis Of Neutrophils In Chronic Granulomatous Disease (cgd) By Enhancing Oxidant Production And "Eat Me" Signaling**  
**R. Fernandez-Boyanapall**, S. Frasch, D. L. Bratton;  
National Jewish Health, Denver, CO.
- 525 Knockdown of Dock8 in Zebrafish Reveals a Role for Dock8 in Extra-Lymphoid Tissue Development**  
**W. Chan**, K. Dippole, S. Lin, T. Chatila;  
UCLA, Los Angeles, CA.
- 526 Elucidating the Role of IgM Memory B Cells in Common Variable Immunodeficiency**  
**J. H. Park**, C. Cunningham-Rundles;  
Mount Sinai Medical Center, New York, NY.

SUNDAY

## Featured Poster Session

## EORD Featured Poster Session

3803

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 527 **Specific Induction Of CD203c Expression In Blood Basophils Discriminates Between CF patients With Aspergillus Colonization And Those With CF-ABPA**  
Y. Gernez, C. Everson, E. Mitsunaga, C. Dunn, L. Herzenberg, R. Tirouvanziam, R. Moss;  
Stanford University, Stanford, CA.
- 528 **Inflammatory Gene Expression Differentiates With Airway Neutrophil Response To Ozone**  
R. Fry<sup>1</sup>, H. Zhou<sup>2</sup>, B. Zou<sup>2</sup>, J. Rager<sup>1</sup>, J. Brickey<sup>3</sup>, J. Ting<sup>4</sup>, D. Peden<sup>5</sup>, N. Alexis<sup>5</sup>;  
<sup>1</sup>Gillings School of Global Public Health, UNC Chapel Hill, Chapel Hill, NC, <sup>2</sup>Cnt for Env Med Asthma and Lung Biology, Chapel Hill, NC, <sup>3</sup>Dept of Microbiology and Immunology, Chapel Hill, NC, <sup>4</sup>Dept of Microbiology and Immunology, Lineberger Cancer Cntr., Chapel Hill, NC, <sup>5</sup>Cntr for Env Med Asthma and Lung Biology, Chapel Hill, NC.
- 529 **Functional Interaction of Cockroach Allergens and Mannose Receptor on Human Circulating Fibrocytes**  
Y. Tsai;  
School of Medicine, Johns Hopkins University, Baltimore, MD.
- 530 **Der p 2 Stimulate Inflammatory Responses from Lung Epithelial cells and Macrophages through the TLR2 and MAPK pathway**  
S. Tanyaratsrisakul<sup>1</sup>, O. Jirapongsananuruk<sup>2</sup>, W. R. Thomas<sup>3</sup>, S. Piboonpocanun<sup>4</sup>, D. R. Voelker<sup>1</sup>;  
<sup>1</sup>Department of Medicine, Program in Cell Biology, National Jewish Health, Denver, CO, <sup>2</sup>Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, THAILAND, <sup>3</sup>Center for Child Health Research, University of Western Australia, Perth, AUSTRALIA, <sup>4</sup>Institute of Molecular Biosciences, Mahidol University, Nakorn Pathom, THAILAND.
- 531 **Transient Receptor Potential Melastatin 8 Mediates Airway Inflammation Of Toluene-diisocyanate Induced Asthma**  
J. Kim<sup>1</sup>, E. Yang<sup>2</sup>, H. Jin<sup>2</sup>, Y. Nam<sup>2</sup>, E. Hwang<sup>2</sup>, G. Choi<sup>3</sup>, Y. Ye<sup>2</sup>, H. Park<sup>2</sup>;  
<sup>1</sup>Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, <sup>2</sup>Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF, <sup>3</sup>Kosin University Gaspel Hospital, Pusan, KOREA, REPUBLIC OF.

## Featured Poster Session

## FADDA Featured Poster Session

3804

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 532 **Comparison of Sublingual Immunotherapy (SLIT) versus Oral Immunotherapy (OIT) in the Treatment of Peanut Allergy**  
S. J. Chin<sup>1</sup>, E. H. Kim<sup>1</sup>, M. D. Kulis<sup>1</sup>, P. Varshney<sup>1</sup>, P. Steele<sup>1</sup>, J. Kamilaris<sup>1</sup>, A. Hiegel<sup>2</sup>, S. K. Carlisle<sup>2</sup>, A. M. Scurlock<sup>2</sup>, P. B.

Smith<sup>1</sup>, B. P. Vickery<sup>1</sup>, S. M. Jones<sup>2</sup>, A. W. Burks<sup>1</sup>;<sup>1</sup>Duke University Medical Center, Durham, NC, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR.

- 533 **Infants Who Develop Eczema at 12 Months Have a Deficient T Regulatory Cell Response to Microbial Stimuli at the Time of Birth**

I. Ismail;

Murdoch Childrens Research Institute, Melbourne, AUSTRALIA.

- 534 **Real-time Imaging Assessment of Blood Flow, Temperature and Skin Color on Patients with Cold-induced Urticaria: Correlation with Histamine and Tryptase Release**

H. D. Komarow<sup>1</sup>, J. Meyer<sup>2</sup>, A. M. Gorbach<sup>2</sup>, W. Liu<sup>2</sup>, N. Medic<sup>1</sup>, M. Young<sup>3</sup>, C. Nelson<sup>1</sup>, S. Arceo<sup>1</sup>, A. Desai<sup>1</sup>, D. D. Metcalfe<sup>1</sup>;<sup>1</sup>Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, <sup>2</sup>Infrared Imaging and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, <sup>3</sup>Clinical Research Directorate/CMRP, SAIC-Frederick, NCI Frederick, Frederick, MD.

- 535 **Vitamin D Insufficiency is Strongly Associated with Challenge-proven Infantile Food Allergy in the Healthnuts Population-based Study**

K. J. Allen<sup>1,2</sup>, J. J. Koplin<sup>1</sup>, P. E. Martin<sup>1</sup>, L. C. Gurrin<sup>3</sup>, M. L. K. Tang<sup>1,2</sup>, A. J. Lowe<sup>3</sup>, N. J. Osborne<sup>4</sup>, M. N. Robinson<sup>2</sup>, A. Ponsonby<sup>1</sup>, S. C. Dharmage<sup>3</sup>;<sup>1</sup>Murdoch Childrens Research Institute, Parkville, VICTORIA, AUSTRALIA, <sup>2</sup>Royal Children's Hospital, Parkville, AUSTRALIA, <sup>3</sup>University of Melbourne, Parkville, VICTORIA, AUSTRALIA, <sup>4</sup>European Centre for Environment and Human Health, Peninsula College of Medicine and Dentistry, University of Exeter, UNITED KINGDOM.

- 536 **Genetic Variants In Cep68 In Patients With Hypersensitivity Reactions To Nsaids**

J. A. Cornejo-Garcia<sup>1</sup>, M. C. Plaza-Seron<sup>1</sup>, C. Flores<sup>2</sup>, I. Dona<sup>3</sup>, N. Blanca-Lopez<sup>4</sup>, L. R. Jagemann<sup>1</sup>, J. J. Laguna<sup>5</sup>, J. Fernandez<sup>6</sup>, G. Canto<sup>4</sup>, M. Blanca<sup>3</sup>;<sup>1</sup>Laboratorio de Investigacion, Fundacion IMABIS, Malaga, SPAIN, <sup>2</sup>Unidad de Investigacion, Hospital Universitario N.S. de Candelaria, Tenerife, SPAIN, <sup>3</sup>Servicio de Alergologia, Hospital Carlos Haya, Malaga, SPAIN, <sup>4</sup>Servicio de Alergia, Hospital Infanta Leonor, Madrid, SPAIN, <sup>5</sup>Servicio de Alergia, Hospital Central de la Cruz Roja, Madrid, SPAIN, <sup>6</sup>Servicio de Alergia, Hospital de Elche, Elche, Alicante, SPAIN.

## Featured Poster Session

## HEDQ Featured Poster Session

3805

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 537 **A Speech Recognition (SR) Reminder System Improves Adherence to ICS Among Pediatric Asthma Patients**

P. J. Cvietusa<sup>1</sup>, D. J. Magid<sup>2</sup>, G. Goodrich<sup>2</sup>, N. Wagner<sup>2</sup>, R. Lowe<sup>1</sup>, H. Nuanes<sup>2</sup>, S. Shetterly<sup>2</sup>, C. Tacinas<sup>1</sup>, F. S. Wamboldt<sup>3</sup>, S. Xu<sup>2</sup>, B. G. Bender<sup>3</sup>;<sup>1</sup>Department of Asthma, Allergy and Immunology at Kaiser Permanente, Highlands Ranch, CO, <sup>2</sup>Institute For Health Research at Kaiser Permanente, Denver, CO, <sup>3</sup>Department of Pediatrics, National Jewish Health, Denver, CO.

SUNDAY

- 538 Short Message Service (SMS) For Asthma Management: A Pilot Study Utilizing Text Messaging To Promote Asthma Self-management**  
**D. A. Searing**, B. G. Bender;  
National Jewish Health, Denver, CO.
- 539 An Asthma Self-Management Intervention Can Improve Outcomes for Older Adults**  
**J. A. Ross**, N. M. Clark, A. Baptist;  
University of Michigan, Ann Arbor, MI.
- 540 Effects of Coping Skills Training in Low-Income Urban African-American Adolescents with Asthma**  
**B. F. Velsor-Friedrich**<sup>1</sup>, L. Militello<sup>2</sup>, M. Richards<sup>1</sup>;  
<sup>1</sup>Loyola University Chicago, Chicago, IL, <sup>2</sup>Arizona State University, Phoenix, AZ.
- 541 Associations Between Self-Reported Adherence to Asthma Anti-Inflammatory Therapy and Child/Parent Attitudes and Behaviors Regarding Disease Management**  
**A. G. Weinstein**<sup>1</sup>, J. Laurenceau<sup>2</sup>, J. Vok<sup>3</sup>;  
<sup>1</sup>Jefferson Medical College, Newark, DE, <sup>2</sup>University of Delaware, Newark, DE, <sup>3</sup>Asthma and Allergy Foundation of America, Landover, MD.

### Featured Poster Session

#### IRSOC Featured Poster Session

3806

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 542 Efficacy and Safety of a Novel Ragweed Allergy Immunotherapy Tablet (AIT) During Peak Season in North America**  
**P. Creticos**<sup>1</sup>, J. Maloney<sup>2</sup>, H. Nolte<sup>2</sup>, G. Berman<sup>3</sup>, A. Cheema<sup>4</sup>, A. Kaur<sup>5</sup>, J. Hebert<sup>6</sup>;  
<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>3</sup>Allergy & Asthma Specialists, Minneapolis, MN, <sup>4</sup>Alpha Medical Research, Mississauga, ON, CANADA, <sup>5</sup>Merck Research Laboratories, Kenilworth, NY, <sup>6</sup>Centre de Recherche Appliquee en Allergie de Quebec, Quebec, QC.
- 543 Efficacy and Tolerability of a Novel Ragweed Allergen Immunotherapy Tablet During Peak Season in North American and European Patients**  
**H. Nolte**<sup>1</sup>, J. Maloney<sup>1</sup>, D. Bernstein<sup>2</sup>, R. Berkowitz<sup>3</sup>, K. Nekam<sup>4</sup>, A. Kaur<sup>1</sup>, N. Liu<sup>1</sup>, K. Murphy<sup>5</sup>;  
<sup>1</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>2</sup>University of Cincinnati College of Medicine, Cincinnati, OH, <sup>3</sup>Rx Research, Woodstock, GA, <sup>4</sup>Hospital of the Hospitalier Brothers of St John of God, Budapest, HUNGARY, <sup>5</sup>Boys Town National Research Hospital, Boys Town, NE.
- 544 Timothy Grass Allergy Immunotherapy Tablets Reduce Nasal and Ocular Symptoms Associated With Allergic Rhinconjunctivitis During Grass Pollen Season in North American Children and Adults: 2 Randomized, Placebo-Controlled Trials**  
**D. Skoner**<sup>1</sup>, H. Nolte<sup>2</sup>, P. Creticos<sup>3</sup>, M. Blaiss<sup>4</sup>, J. Maloney<sup>2</sup>, H. Nelson<sup>5</sup>;  
<sup>1</sup>Drexel University College of Medicine, Philadelphia, PA, <sup>2</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4</sup>University of Tennessee Health Science Center, Memphis, TN, <sup>5</sup>National Jewish Medical & Research Center, Denver, CO.

- 545 Post-treatment, Long-term Clinical Efficacy Of A 300 IR Sublingual Tablet of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis**  
**H. Malling**<sup>1</sup>, A. Didier<sup>2</sup>, F. Horak<sup>3</sup>, M. Worm<sup>4</sup>, O. de Beaumont<sup>5</sup>, P. Rodriguez<sup>5</sup>, A. Montagut<sup>5</sup>, R. K. Zeldin<sup>5</sup>;  
<sup>1</sup>National University Hospital, Copenhagen, DENMARK, <sup>2</sup>Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, FRANCE, <sup>3</sup>Allergy Centre Vienna West, Dptm. - Institute for Allergy Research, Vienna, AUSTRIA, <sup>4</sup>Allergie-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, <sup>5</sup>Stallergenes, Antony, FRANCE.
- 546 Persistent Treatment Effect Achieved at One Year After 4 Doses of Fel d 1-Derived Peptide Immunotherapy in an Environmental Exposure Chamber (EEC) Model of Cat Allergy**  
**R. P. Hafner**<sup>1</sup>, J. Efthimiou<sup>1</sup>, A. Salapatek<sup>2</sup>, D. Patel<sup>2</sup>, M. Larche<sup>3</sup>;  
<sup>1</sup>Circassia Ltd., Oxford, UNITED KINGDOM, <sup>2</sup>Cetero Research, Mississauga, ON, CANADA, <sup>3</sup>McMaster University, Hamilton, ON, CANADA.

### Featured Poster Session

#### MAAI Featured Poster Session

3807

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 547 Eosinophil Derived LTC4 Acts Via CysLT2R to Promote Skin Thickening and Collagen Deposition in a Mouse Model of Allergic Skin Inflammation**  
**M. K. Oyoshi**<sup>1</sup>, R. He<sup>1</sup>, C. N. Lewis<sup>1</sup>, K. F. Austen<sup>2</sup>, Y. Kanaoka<sup>2</sup>, R. S. Geha<sup>1</sup>;  
<sup>1</sup>Children's Hospital Boston, Boston, MA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA.
- 548 Exposure to IL-1-Family Cytokines Regulates Differential Development of Antigen-Specific Th2 Cells and T Follicular Helper (Tfh) Cells in the Airway**  
**T. Kobayashi**, K. Iijima, H. Kita;  
Mayo Clinic Rochester, Rochester, MN.
- 549 Reduced Regulatory T Cells Due To Streptomycin Treatment Increases Mortality To Respiratory Viral Infection**  
**L. E. Camarda**, S. J. Zemple, M. A. Hayward, N. H. Salzman, M. H. Grayson;  
Medical College of Wisconsin, Milwaukee, WI.
- 550 Selective Deficiency Of Prostaglandin E<sub>2</sub> Uncovers A Dominant Effector Role For Thromboxane A<sub>2</sub> In Allergen-induced Pulmonary Inflammation And Vascular Remodeling**  
**T. Liu**<sup>1,2</sup>, C. Feng<sup>1,2</sup>, T. M. Laidlaw<sup>2,3</sup>, W. Xing<sup>1,2</sup>, S. Shen<sup>1,2</sup>, G. Milne<sup>4</sup>, J. A. Boyce<sup>2,3</sup>;  
<sup>1</sup>Department of Medicine, Harvard Medical School, Boston, MA, <sup>2</sup>Jeff and Penny Vinik Center for Allergic Disease Research, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Department of Medicine and Pediatrics, Harvard Medical School, Boston, MA, <sup>4</sup>Department of Pharmacology, Vanderbilt University, Nashville, TN.
- 551 Vitamin D Inhibits Monocyte/macrophage Pro-inflammatory Cytokine Production by Targeting Mitogen-Activated Protein Kinase Phosphatase-1**  
**Y. Zhang**<sup>1</sup>, D. Y. Leung<sup>1</sup>, B. N. Richers<sup>1</sup>, Y. Liu<sup>2</sup>, L. K. Remigio<sup>1</sup>, D. W. Riches<sup>1</sup>, E. Goleva<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>The Ohio State University College of Medicine, Columbus, OH.

SUNDAY

## Featured Poster Session

## Allied Health Featured Poster Session

3811

Session Time: Sunday, March 4, 2012,  
5:30 PM - 7:30 PM

- 552 Oral Food Challenge Tolerance Rates are higher in Patients with Asthma**  
C. M. Lee<sup>1</sup>, S. A. Lowe<sup>1</sup>, J. E. Conner<sup>1</sup>, L. A. Crandall<sup>1</sup>, M. B. Ho<sup>1</sup>, M. B. Feuling<sup>2</sup>, C. L. Sova<sup>2</sup>, M. Vasudev<sup>1</sup>;  
<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>Children's Hospital of Wisconsin, Milwaukee, WI.

## Poster Session

## Asthma Epidemiology and Environmental Influences

4201

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 553 Omalizumab Improves Patient-Reported Outcomes In Patients With Allergic (IgE-mediated) Asthma**  
W. H. Yang<sup>1</sup>, P. Georgiou<sup>2</sup>, J. Canvin<sup>2</sup>, C. Chen<sup>3</sup>, G. Peachey<sup>2</sup>;  
<sup>1</sup>Allergy & Asthma Research Centre, Ottawa, ON, CANADA, <sup>2</sup>Novartis Horsham Research Centre, Horsham, UNITED KINGDOM, <sup>3</sup>Novartis Pharmaceuticals, East Hanover, NJ.
- 554 Outcome Of Childhood Asthma Observational Follow-up Study In First 4 Years In Japan**  
A. Akasawa<sup>1</sup>, H. Watanabe<sup>2</sup>, K. Yoshida<sup>1</sup>, M. Furukawa<sup>1</sup>, T. Fujisawa<sup>3</sup>, M. Ebisawa<sup>4</sup>, H. Odajima<sup>5</sup>;  
<sup>1</sup>Tokyo Metropolitan Children's Medical Center, Tokyo, JAPAN, <sup>2</sup>Kanagawa Hospital, Kanagawa, JAPAN, <sup>3</sup>Mie Hospital, Mie, JAPAN, <sup>4</sup>Sagamihara Hospital, Kanagawa, JAPAN, <sup>5</sup>Fukuoka Hospital, Fukuoka, JAPAN.
- 555 The Predictors of Elderly Asthma Control**  
E. Hwang, Y. Nam, H. Jin, Y. Shin, Y. Ye, D. Nahm, H. Park;  
University School of Medicine, Suwon, KOREA, REPUBLIC OF.
- 556 Trend of Asthma Comorbidities of Sleep Apnea, Obesity, and Gastroesophageal Reflux - A 5-year Population Survey**  
K. Yeh<sup>1,2</sup>, C. Yu<sup>3</sup>, J. Horng<sup>3</sup>, J. Huang<sup>1,2</sup>;  
<sup>1</sup>Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, TAIWAN, <sup>2</sup>Chang Gung University, Taoyuan, TAIWAN, <sup>3</sup>Department of Computer Science and Information Engineering, National Central University, Taoyuan, TAIWAN.
- 557 International Study of Wheezing in Infants (EISL) - phase 3, São Paulo - SP, Brazil**  
C. S. Aranda<sup>1</sup>, E. O. Dantas<sup>1</sup>, J. A. Soares<sup>1</sup>, L. Fonzar<sup>1</sup>, A. C. Dela Bianca<sup>1</sup>, G. F. Wandalsen<sup>1</sup>, J. Mallo<sup>2</sup>, D. Sole<sup>1</sup>;  
<sup>1</sup>Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo, BRAZIL, <sup>2</sup>Universidade de Santiago, Santiago, CHILE.
- 558 Obesity Is Associated With Nocturnal And Exercise-related Symptoms, But Not Asthma Severity In Urban Children With Asthma**  
K. D. Lu<sup>1</sup>, G. B. Diette<sup>1</sup>, P. N. Breyse<sup>2</sup>, J. Curtin-Brosnan<sup>1</sup>, C. Aloe<sup>1</sup>, E. C. Matsui<sup>1</sup>;  
<sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.

- 559 Effect of Statins in Asthmatic Patients with Hyperlipidemia**  
S. C. Christiansen<sup>1,2</sup>, M. Schatz<sup>1</sup>, S. Yang<sup>1</sup>, W. Chen<sup>1</sup>, B. L. Zuraw<sup>2,3</sup>;  
<sup>1</sup>Southern California Kaiser Permanente Medical Grp, San Diego, CA, <sup>2</sup>University of California San Diego, La Jolla, CA, <sup>3</sup>San Diego VA Healthcare, San Diego, CA.
- 560 The Risk of Asthma in Late Preterm Infants**  
G. A. Matthews, B. D. Lahr, W. A. Carey, Y. J. Juhn;  
Mayo Clinic, Rochester, MN.
- 561 Impact Of Rhinitis On Asthma In Japanese School Children**  
Y. Adachi<sup>1</sup>, Y. Okabe<sup>1</sup>, T. Itazawa<sup>1</sup>, K. Yoshida<sup>2</sup>, Y. Ohya<sup>3</sup>, H. Odajima<sup>4</sup>, A. Akasawa<sup>2</sup>, T. Miyawaki<sup>1</sup>;  
<sup>1</sup>Department of Pediatrics, University of Toyama, Toyama, JAPAN, <sup>2</sup>Division of Allergy, Tokyo Metropolitan Children's Hospital, Tokyo, JAPAN, <sup>3</sup>Division of Allergy, National Center for Children Health and Development, Tokyo, JAPAN, <sup>4</sup>Department of Pediatrics, Fukuoka National Hospital, Fukuoka, JAPAN.
- 562 Asthma and Risk of Herpes Zoster in Children: A Population-Based Case-Control Study**  
B. Kim<sup>1,2</sup>, S. Mehra<sup>1</sup>, B. Yawn<sup>3</sup>, R. Tarrell<sup>4</sup>, B. Lahr<sup>4</sup>, Y. Juhn<sup>1</sup>;  
<sup>1</sup>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Department of Pediatrics, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung-si, KOREA, REPUBLIC OF, <sup>3</sup>Department of Research, Olmsted Medical Center, Rochester, MN, <sup>4</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
- 563 Strains of Rhinovirus Associated with Asthma in Costa Rican Children**  
P. W. Heymann<sup>1</sup>, D. Erdman<sup>2</sup>, M. Soto-Quiros<sup>3</sup>, L. Avila<sup>3</sup>, H. T. Carper<sup>1</sup>, D. D. Murphy<sup>1</sup>, T. A. E. Platts-Mills<sup>1</sup>, J. L. Kennedy<sup>1</sup>, J. W. Steinke<sup>1</sup>;  
<sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Center for Disease Control, Atlanta, GA, <sup>3</sup>Hospital Nacional de Ninos, San Jose, COSTA RICA.
- 564 Gene-environment Interaction Between Tlr4 +8959c/t Polymorphism And Bronchiolitis May Influence The Development Of Asthma In Preschool Children**  
Y. Jung<sup>1,2</sup>, H. Kim<sup>1,2</sup>, J. Seo<sup>1,2</sup>, J. Kwon<sup>2,3</sup>, B. Kim<sup>2,4</sup>, H. Kim<sup>2,5</sup>, S. Lee<sup>2,6</sup>, G. Jang<sup>2,7</sup>, D. Song<sup>2,8</sup>, W. Kim<sup>2,9</sup>, J. Shim<sup>2,10</sup>, M. Kang<sup>11</sup>, Y. Kim<sup>11</sup>, S. Hong<sup>1,2</sup>;  
<sup>1</sup>Childhood Asthma Atopy Center, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Research Center for Standardization of Allergic Diseases, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, <sup>4</sup>Department of Pediatrics, Inje University Hae-undae Paik Hospital, Busan, KOREA, REPUBLIC OF, <sup>5</sup>Department of Pediatrics, Inje University Sanggye Paik Hospital, Seoul, KOREA, REPUBLIC OF, <sup>6</sup>Department of Pediatrics, Hallym Sacred Heart Hospital, Hallym University College of Medicine, Anyang, KOREA, REPUBLIC OF, <sup>7</sup>Department of Pediatrics, National Health Insurance Corporation Ilsan Hospital, Il-san, KOREA, REPUBLIC OF, <sup>8</sup>Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>9</sup>Department of Pediatrics, Inje University Seoul Paik Hospital, Seoul, KOREA, REPUBLIC OF, <sup>10</sup>Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KOREA, REPUBLIC OF, <sup>11</sup>Asan Institute for Life Sciences, Asan Medical Center, Seoul, KOREA, REPUBLIC OF.
- 565 Adherence Estimator™ Scores and Relation to Asthma Control among Inner City Pediatric Patients**  
L. Yang, M. Kim, H. Lee, R. Joks;  
SUNY Downstate Medical Center, Brooklyn, NY.
- 566 Comparisons of Severe Asthma Characteristics from Two Pediatric Cohorts in the Severe Asthma Research Program (SARP)**  
S. B. Burke<sup>1</sup>, M. L. Fajt<sup>2</sup>, S. J. Aujla<sup>1</sup>, A. M. Fitzpatrick<sup>3</sup>, S. E.

MONDAY

- Wenzel<sup>2</sup>;  
<sup>1</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>2</sup>University of Pittsburgh Asthma Institute at UPMC and the University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>3</sup>Emory University Department of Pediatrics, Atlanta, GA.
- 567 Burden of Early Childhood Asthma in Children Born Preterm or With a History of Chronic Lung Disease**  
**S. Dorris**;  
Vanderbilt Medical Center, Nashville, TN.
- 568 Scuba Diving and Asthma: A 2011 Survey of AAAAI Members**  
**D. M. Lang<sup>1</sup>, F. Twarog<sup>2</sup>**;  
<sup>1</sup>Cleveland Clinic, Cleveland, OH, <sup>2</sup>Brigham and Women's Hospital, Concord, MA.
- 569 Environmental Factors and Pediatric Emergency Visits for Acute Bronchospasm**  
**V. VELAZQUEZ, B. DiGiorgi, N. Lopez, A. Pietri, J. Bracero**;  
Hospital Episcopal San Lucas, Ponce, PR.
- 570 Obstructive Sleep Apnea, Sinusitis, Gastroesophageal Reflux and Severe Asthma Exacerbations**  
**J. Temprano, C. Geremakis, L. Hinyard**;  
Saint Louis University, St. Louis, MO.
- 571 Follow-up of Wheezing in Preschool Children from São Paulo and Maceió, Brazil: International Study of Wheezing in Infants - phase 2**  
**A. C. C. Dela Bianca<sup>1</sup>, M. L. Medeiros<sup>2</sup>, G. F. Wandalsen<sup>1</sup>, F. J. Soares<sup>2</sup>, J. Mallol<sup>3</sup>, D. Sole<sup>1</sup>**;  
<sup>1</sup>Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo - SP, BRAZIL, <sup>2</sup>State University of Health Sciences (UNCISAL), Maceio - AL, BRAZIL, <sup>3</sup>Universidad do Chile, Santiago, CHILE.
- 572 Burden of Acute Pediatric Asthma Exacerbations in Gaborone, Botswana**  
**K. M. Best<sup>1</sup>, A. P. Steenhoff<sup>2,3</sup>, S. Barenbaum<sup>2</sup>, L. Mazhani<sup>4</sup>, S. Kung<sup>2,4</sup>**;  
<sup>1</sup>School of Nursing, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Botswana-UPenn Partnership, Gaborone, BOTSWANA, <sup>4</sup>School of Medicine, University of Botswana, Gaborone, BOTSWANA.
- 573 Evolving Prescription Trends in the Management of Childhood Wheeze in Singapore**  
**J. Soh<sup>1</sup>, S. Xu<sup>2</sup>, Z. Tan<sup>2</sup>, Z. Ng<sup>2</sup>, W. Hing<sup>3</sup>, T. Wu<sup>3</sup>, Y. Chan<sup>2</sup>, B. Lee<sup>1</sup>**;  
<sup>1</sup>National University Health Systems, Singapore, SINGAPORE, <sup>2</sup>Yong Loo Lin School of Medicine, National University of Singapore, Singapore, SINGAPORE, <sup>3</sup>Pharmacy, National University Health Systems, Singapore, Singapore, SINGAPORE.
- 574 Factors Related to Repeated Admission in Children with Asthma**  
**S. Choi<sup>1</sup>, Y. Rha<sup>2</sup>**;  
<sup>1</sup>Kyung Hee University Gangdong Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF.
- 575 Exercise-Induced Bronchoconstriction among Adolescent Athletes: A Survey of Symptoms, Prevalence, and Performance Anxiety**  
**J. C. Rabbat<sup>1</sup>, A. L. King<sup>2</sup>, J. R. Moy<sup>2</sup>, J. N. Moy<sup>1</sup>**;  
<sup>1</sup>Rush University Medical Center and John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, <sup>2</sup>Rush University Medical Center, Chicago, IL.
- 576 Hypovitaminosis D is Very Frequent but not Associated with Asthma Control in a Low-Income Pediatric Population Seen in an Allergy and Immunology Clinic**  
**F. Neagu**;  
Rush University Medical Center, Chicago, IL.
- 577 Age-Dependent Interaction Between Atopy and Eosinophils in Asthma**  
**S. J. Arbes, Jr<sup>1</sup>, A. Calatroni<sup>1</sup>, H. E. Mitchell<sup>1</sup>, P. J. Gergen<sup>2</sup>**;  
<sup>1</sup>Rho, Inc., Chapel Hill, NC, <sup>2</sup>NIAD/NIH, Bethesda, MD.
- 578 Multiple Weather Related Changes Are Perceived as Common Triggers in Inner City Asthma Patients**  
**E. E. Clarke, D. A. Khan**;  
University of Texas Southwestern Medical Center, Dallas, TX.
- 579 Zingiber Cassumunar Inhibits No Through The Suppression Of Nf-κB Pathway In Lps-stimulated Mouse Macrophages**  
**O. P. S. Poachanukoon**;  
Thammasat University, Pratum Tani, THAILAND.
- 580 Correlation of the Change of the Juniper Mini Quality of Life Questionnaire with Clinical Measurements in Asthma Patients from a Joint Commission Disease-Specific Practice**  
**D. Menillo, R. Shah, B. McGoey, M. Michelis**;  
Center for Allergy, Asthma & Immune Disorders, P.A, Hackensack, NJ.
- 581 Daily Stressors as Antecedents of Nocturnal Asthma in Children**  
**C. C. Horner, C. Dula, L. Bacharier, J. Garbutt, M. Krauss, R. Strunk**;  
Washington University School of Medicine, Saint Louis, MO.
- 582 Do Asthma Symptoms Lag Behind Cold Symptoms in a Viral Illness?**  
**D. McMahan, J. Gern, V. Rajamanickam**;  
UW Madison, Madison, WI.
- 583 Asthma Severity in Aspirin Exacerbated Respiratory Disease**  
**K. S. Farnam, D. D. Stevenson**;  
Scripps Clinic, San Diego, CA.

## Poster Session

### Immune Deficiency

4202

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 584 DiGeorge Syndrome Immune Reconstitution and CMV Elimination by Bone Marrow Transplant**  
**S. K. Chan<sup>1</sup>, R. Krance<sup>1</sup>, W. W. Stafford<sup>2</sup>, R. Lee<sup>3</sup>, D. K. Nguyen<sup>4</sup>, G. Harrison<sup>1</sup>, I. C. Hanson<sup>1</sup>**;  
<sup>1</sup>Texas Children's Hospital, Baylor College of Medicine, Houston, TX, <sup>2</sup>Driscoll Childrens Hospital, Corpus Christi, TX, <sup>3</sup>Texas Department of State Health Services, Austin, TX, <sup>4</sup>Houston Allergy Asthma Associates, Houston, TX.
- 585 Genetic Defects of Griscelli Syndrome Type 2 in Saudi Arabia**  
**H. Al-Mousa<sup>1,2</sup>, A. Al-Ghonaïm<sup>1</sup>, H. Al-Dhekri<sup>1</sup>, S. Al-Muhsen<sup>1</sup>, B. Al-Saud<sup>1</sup>, R. Arnaout<sup>1</sup>, N. Ades<sup>1</sup>, S. Alhisi<sup>1</sup>, A. Hawwan<sup>1</sup>**;  
<sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA, <sup>2</sup>Alfaisal university, Riyadh, SAUDI ARABIA.
- 586 Histone-3-lysine-4 (H3K4) Methylation Defects in an Adult Female Kabuki Syndrome Patient with Pan-Hypogammaglobinemia**  
**A. W. Lindsley<sup>1</sup>, J. Bernstein<sup>2</sup>, M. Wills-Karp<sup>1</sup>**;  
<sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>University of Cincinnati, College of Medicine, Division of Immunology Allergy & Rheumatology, Cincinnati, OH.
- 587 Development of Atopic Diseases in Patients with Primary Humoral Immunodeficiency**  
**A. M. Jongco<sup>1</sup>, L. Helfner<sup>2</sup>, J. Fagin<sup>1</sup>**;  
<sup>1</sup>Cohen Children's Medical Center of NY, Great Neck, NY, <sup>2</sup>North Shore-Long Island Jewish Health System, Manhasset, NY.

MONDAY

- 588 A Scoring System to Determine the Need for Immunoglobulin Therapy in Patients with Humoral Immune Defects**  
E. S. Resnick, S. Taylor-Black, S. Agarwal, C. Cunningham-Rundles;  
Mt. Sinai Medical Center, New York, NY.
- 589 Immune Abnormalities in Chronic Pain Syndrome (CPS) With Unknown Etiology**  
R. Khianey<sup>1</sup>, R. Shapiro<sup>2</sup>, L. Gang<sup>1</sup>, P. Kattouf<sup>1</sup>, H. Jyonouchi<sup>1</sup>;  
<sup>1</sup>University of Medicine and Dentistry of New Jersey - New Jersey Medical School, Newark, NJ, <sup>2</sup>Department of Physical Medicine - Columbia University, New York, NY.
- 590 IgM Deficiency: A Retrospective Chart Review of Clinical and Immunologic Features**  
N. A. Mazer, A. Rubinstein;  
Albert Einstein College of Medicine- Montefiore Medical Center, Bronx, NY.
- 591 Primary Immunodeficiency in Microcephalic Osteodysplastic Primordial Dwarfism Type I/III (MOPD I/III)**  
M. L. DeFelice, M. B. Bober, C. C. Chang, S. J. McGeady;  
Thomas Jefferson University/Alfred I. duPont Hospital for Children, Wilmington, DE.
- 592 Primary Immunodeficiency Presentations And 10 Warning Signs**  
M. L. Tierce, IV, E. Secord;  
Wayne State University/Children's Hospital of Michigan, Detroit, MI.
- 593 Prevalence of Malignancies in Various Primary Immune Deficiency States: A systematic review**  
D. M. George-Grandon, K. Osann, S. Gupta;  
UCI, Irvine, CA.
- 594 Phenotypic Comparison of B cells in Discordant Identical Twins with Common Variable Immunodeficiency and Recurrent Sino-Pulmonary Infection Patients**  
T. A. Hwangpo, E. Szymanska, C. R. Liu, M. G. Brand, E. E. Brown, H. Schroeder;  
University of Alabama at Birmingham, Birmingham, AL, AL.
- 595 Novel ZAP70 mutations causing Severe Combined Immunodeficiency Disease in Saudi Arabia**  
A. Hawwari<sup>1</sup>, O. Alsmadi<sup>1</sup>, H. Al-Dhekri<sup>1</sup>, A. Al-Ghonaium<sup>1</sup>, S. Al-Muhsen<sup>1</sup>, B. Al-Saud<sup>1</sup>, R. Arnaout<sup>1</sup>, H. Al-Mousa<sup>1,2</sup>;  
<sup>1</sup>King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA, <sup>2</sup>Alfaisal university, Riyadh, SAUDI ARABIA.
- 596 Primary Immunodeficiency Diseases; A 20 Years Experience in a Tertiary University Hospital at Ramathibodi**  
O. Luecha, W. Kamchaisatian, S. Vilaiyuk, W. Manuyakorn, C. Sasisakunporn, W. Teawsomboonkit, S. Benjaponpitak;  
Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND.
- 597 Is Common Variable Immune Deficiency Common In Cystic Fibrosis?**  
S. Jain<sup>1</sup>, R. Hopkins<sup>2</sup>, M. Kiernan<sup>2</sup>, J. M. El-Dahr<sup>3</sup>;  
<sup>1</sup>Tulane University School of Medicine, Section of Allergy and Clinical Immunology, New Orleans, LA, <sup>2</sup>Tulane University School of Medicine, Section of Pediatric Pulmonology, New Orleans, LA, <sup>3</sup>Tulane University School of Medicine, Section of Pediatric Allergy and Clinical Immunology, New Orleans, LA.
- 598 Phenotypic Variations in Patients with Profound Mannose Binding Lectin Deficiency**  
M. Rasheed<sup>1</sup>, E. Visconti<sup>2</sup>, J. Shliozberg<sup>1</sup>, A. Rubinstein<sup>1</sup>;  
<sup>1</sup>Albert Einstein - Montefiore Medical Center, Bronx, NY, <sup>2</sup>314 Seaview Avenue, Staten Island, NY.
- 599 C2 Deficiency Presenting as Pseudomonas Aeruginosa Bacteremia**  
S. Hasan, A. E. Hathaway, D. Q. Tran;  
University of Texas Health Science Center at Houston, Houston, TX.
- 600 Transient Hypereosinophilia and Markedly Elevated IgE as the Presenting Feature in DOCK8 (Dedicator of Cytokinesis 8) Deficiency**  
M. G. Gates, T. P. Atkinson;  
University of Alabama at Birmingham, Birmingham, AL.
- 601 Toll Like Receptor-3 (TLR3) Dysfunction in a Young Child with Recurrent Bacterial and Mucocutaneous HSV Infections**  
C. B. Cho<sup>1,2</sup>, D. W. Hauswirth<sup>2,1</sup>, P. J. Mustillo<sup>1</sup>;  
<sup>1</sup>Nationwide Children's Hospital, Columbus, OH, <sup>2</sup>The Ohio State University Medical Center, Columbus, OH.
- 602 Classical Pyoderma Gangrenosum Associated with Abnormal Neutrophil Oxidative Burst**  
J. M. Bellak, M. C. Bell, S. R. Durrani, R. K. Viswanathan, J. E. Gern, C. M. Seroogy;  
University of Wisconsin-Madison, Madison, WI.
- 603 Common Variable Immunodeficiency (CVID) Presenting as Severe, Refractory Gastritis and Autoimmune Enteropathy in an Adolescent Male**  
C. Kuo, M. Garcia-Lloret;  
UCLA, Los Angeles, CA.
- 604 Is It Hyper Ige Syndrome Or Something Else? A Patient With Chromosome 18q Deletion**  
M. R. Yasharpour, N. Cac, G. Venkat, S. Gupta, L. Yel;  
University of California, Irvine, CA.

## Poster Session

Dendritic Cells Pattern Recognition Receptors  
and Signaling

4203

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 605 Analysis of the Expression of Toll-like Receptors 2 and 4 in Keratinocytes of Patients with Extensive Dermatophytosis due Trichophyton rubrum**  
P. R. Criado, C. B. Oliveira, C. Vasconcellos, N. Y. S. Valente, M. N. Sotto, F. Guedes Luiz, W. Belda Junior;  
Post-graduation Program in Science of Health, Sao Paulo University, School of Medicine., Sao Paulo, BRAZIL.
- 606 Respiratory Syncytial Virus (RSV)-Infected Elderly Mice Exhibit Impaired Expression and Activation of Pattern Recognition Receptors (PRR)**  
T. M. Wong, S. S. Mohapatra;  
University of South Florida, Tampa, FL.
- 607 GRK3 Deficiency Enhances Parathyroid Hormone (PTH) Receptor Function On Bone Marrow Mesenchymal Stem Cells And May Enhance Hematopoiesis**  
M. W. McGinnis, R. G. Timoshchenko, D. S. Serafin, N. Case, J. Rubin, T. K. Tarrant;  
University of North Carolina, Chapel Hill, NC.
- 608 Cytokine Profiles of Human Myeloid Dendritic Cell Subsets in Response to RSV and TLR Agonists**  
M. R. Gupta, D. Kolli, R. P. Garofalo;  
UTMB, Galveston, TX.
- 609 Prostaglandin I<sub>2</sub> Receptor (IP) Signaling Inhibits Antigen Uptake but Induce the Ability of Migration on Immature Dendritic Cells**  
S. Toki<sup>1</sup>, K. Goleniewska<sup>1</sup>, G. A. FitzGerald<sup>2</sup>, R. S. Peebles, Jr.<sup>1</sup>;  
<sup>1</sup>Vanderbilt University, Nashville, TN, <sup>2</sup>University of Pennsylvania, Philadelphia, PA.

MONDAY



- 610 Inflammasome activates Alveolar Cell Permeability through Neuregulin-1-Human Epidermal Receptor-2 Signaling**  
V. Rajanbabu, B. Huynh, P. Tamarapu Parthasarathy, N. Kolliputi; Nanomedicine Research Center and Division of Allergy and Immunology, College of Medicine, University of South Florida, Tampa, FL.
- 611 Innate Interferons and Plasmacytoid Dendritic Cells constrain Th2 Cytokine Responses to Rhinoviruses: a Regulatory Mechanism with Relevance to Asthma**  
J. W. Upham<sup>1,2</sup>, M. L. Carroll<sup>1</sup>, J. G. Burel<sup>1</sup>, A. L. Pritchard<sup>1</sup>; <sup>1</sup>University of Queensland, Brisbane, AUSTRALIA, <sup>2</sup>Princess Alexandra Hospital, Brisbane, AUSTRALIA.
- 612 Remote Pulmonary Inflammation Following Renal Graft Engraftment In Rats**  
D. Ma, H. Huang, H. Zhao; Imperial College London, London, UNITED KINGDOM.
- 613 Respiratory Syncytial Virus (RSV) Nonstructural Protein 1 (NS1) Regulates Host Defense by Modulating LGP2**  
S. Boyapalle, T. Wong, S. Mohapatra, S. Mohapatra; University of South Florida, Tampa, FL.
- 614 Role of the NLRP3 Inflammasome in Vaccine Responses**  
S. Wilson, S. Cassel, F. Sutterwala; The University of Iowa Hospitals & Clinics, Iowa City, IA.
- 615 Soybean Isoflavones Inhibit DC-SIGN Signaling: Implications for Allergenicity of DC-SIGN Binding Food Allergens**  
M. Kamalakannan; Mount Sinai School of Medicine, New York, NY.
- 616 Th2 Cytokines Compromise The Function of TLR2 In Human Keratinocytes**  
I. KUO<sup>1,2</sup>, A. DeBenedetto<sup>1</sup>, T. Yoshida<sup>1</sup>, L. Y. McGirt<sup>3</sup>, D. Y. M. Leung<sup>4</sup>, L. A. Beck<sup>1</sup>; <sup>1</sup>Department of Dermatology, University Of Rochester Medical Center, Rochester, NY, <sup>2</sup>Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, <sup>3</sup>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4</sup>Department of Pediatrics, National Jewish Health, Denver, CO.
- 617 Type I And III IFN Expression Attenuated In Human Alternatively Activated Macrophages**  
A. El Fiky, R. Perreault, R. L. Rabin; FDA/CBER, Bethesda, MD.
- 618 Characterization Of Plasmacytoid Dendritic Cells From Blood Of Patients With Systemic Lupus Erythematosus**  
A. Y. Hancharou<sup>1</sup>, K. A. Chyzh<sup>2</sup>, L. P. Titov<sup>1</sup>, N. F. Soroka<sup>2</sup>, L. M. DuBuske<sup>3</sup>; <sup>1</sup>Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, <sup>2</sup>Belarusian State Medical University, Minsk, BELARUS, <sup>3</sup>Immunology Research Institute of New England, Gardner, MA.
- Miller; Vanderbilt University, Nashville, TN.
- 621 Seasonal Asthma Exacerbation and Viral Association in a Pediatric Population Receiving ICS ± LABA Therapy**  
C. M. Prazma<sup>1</sup>, B. A. Prillaman<sup>1</sup>, J. E. Gern<sup>2</sup>, D. A. Stempel<sup>1</sup>; <sup>1</sup>GlaxoSmithKline, Durham, NC, <sup>2</sup>University of Wisconsin-Madison, Madison, WI.
- 622 LDH/Caspase Ratio in Nasal-Wash Fluid as a Marker of Disease Severity in Bronchiolitis**  
R. Mehta<sup>1</sup>, K. Patel<sup>2</sup>, A. Jewell<sup>2</sup>, K. Jennings<sup>3</sup>, M. Scheffler<sup>4</sup>, L. Aideyan<sup>2</sup>, R. Garofalo<sup>1</sup>, P. Piedra<sup>4,2</sup>; <sup>1</sup>Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, <sup>2</sup>Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, <sup>3</sup>Department of Preventative Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, <sup>4</sup>Department of Pediatrics, Baylor College of Medicine, Houston, TX.
- 623 Asthma and Risk of Community-Associated Blood Stream Infection Due to *Staphylococcus aureus*: A Population-Based Case-Control Study**  
J. Lee<sup>1,2</sup>, H. Yang<sup>3,2</sup>, W. Atrouni<sup>4</sup>, L. Baddour<sup>5</sup>, B. Yawn<sup>6</sup>, Y. Juhn<sup>2</sup>; <sup>1</sup>Department of Pediatrics, Samsung Changwon Hospital, Changwon-si, KOREA, REPUBLIC OF, <sup>2</sup>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, <sup>3</sup>Department of Pediatrics, Soonchunhyang University Hospital, Seoul, KOREA, REPUBLIC OF, <sup>4</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Kansas Medical Center, Kansas, KS, <sup>5</sup>Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, <sup>6</sup>Department of Research, Olmsted Medical Center, Rochester, MN.
- 624 Air Pollution And Environmental Tobacco Smoking During Infancy May Increase The Risk Of Bronchiolitis**  
B. Kim<sup>1</sup>, H. Kim<sup>2</sup>, S. Lee<sup>3</sup>, J. Kwon<sup>4</sup>, J. Seo<sup>5</sup>, H. Kim<sup>5</sup>, J. Yu<sup>5</sup>, S. Hong<sup>5</sup>; <sup>1</sup>Inje University Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF, <sup>2</sup>Inje University Sanggye Paik Hospital, Busan, KOREA, REPUBLIC OF, <sup>3</sup>Hallym University Medical Center, Seoul, KOREA, REPUBLIC OF, <sup>4</sup>Seoul National University Bundang Hospital, Seoul, KOREA, REPUBLIC OF, <sup>5</sup>Asan Medical Center, Seoul, KOREA, REPUBLIC OF.
- 625 Asthma and Severity of Blood Stream Infection Caused by *Escherichia coli*: A Population-Based Study**  
H. J. Yang<sup>1,2</sup>, J. Lee<sup>3</sup>, L. M. Baddour<sup>4</sup>, M. N. Al-Hasan<sup>5</sup>, B. P. Yawn<sup>6</sup>, J. Juhn<sup>2</sup>; <sup>1</sup>Soonchunhyang Univ Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, <sup>3</sup>Samsung Changwon Hospital, SungKyunKwan University, Changwon, KOREA, REPUBLIC OF, <sup>4</sup>Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, MN, <sup>5</sup>Department of Medicine, Division of Infectious Diseases, University of Kentucky Medical Center, Lexington, KY, <sup>6</sup>Department of Research, Olmsted Medical Center, Rochester, MN.

## Poster Session

### Infections and Allergic Disease

4204

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 619 Live But Not Heat-Killed *Staphylococcus aureus* Induce Production Of TSLP And IL-33 In Skin Fibroblasts From Both Healthy Children And Those With Atopic Dermatitis**  
S. Tan, J. L. Pennock, P. D. Arkwright; University of Manchester, Manchester, UNITED KINGDOM.
- 620 Human Rhinovirus Species Vary By Season And Diagnosis In 21-year Prospective Pediatric Cohort**  
J. E. (Linder) Jackson, D. Kraft, K. M. Edwards, J. V. Williams, E.

## Poster Session

### Epidemiology of Sensitization, Asthma and Occupational Asthma

4205

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 626 The Role of Seasonal Grass Pollen on Childhood Asthma Emergency Department Presentations**

MONDAY

- B. Erbas**<sup>1</sup>, M. Akram<sup>2</sup>, S. Dharmage<sup>3</sup>, R. Tham<sup>4</sup>, M. Dennekamp<sup>5</sup>, E. Newbigin<sup>3</sup>, P. Taylor<sup>6</sup>, M. Tang<sup>7</sup>, M. J. Abramson<sup>2</sup>;  
<sup>1</sup>La Trobe University, Melbourne, AUSTRALIA, <sup>2</sup>Monash University, Melbourne, AUSTRALIA, <sup>3</sup>The University of Melbourne, Melbourne, AUSTRALIA, <sup>4</sup>Monash University, Bendigo, AUSTRALIA, <sup>5</sup>Monash Melbourne, AUSTRALIA, <sup>6</sup>Deakin University, Melbourne, AUSTRALIA, <sup>7</sup>The Royal Children's Hospital, Melbourne, AUSTRALIA.
- 627 Bronchial Asthma in urban Malagasy Children: The VAVANY-Study**  
**P. T. Wolff**<sup>1</sup>, L. Arison<sup>2</sup>, A. Rahasamiakatra<sup>2</sup>, F. Raserisaona<sup>2</sup>, B. Niggemann<sup>3</sup>;  
<sup>1</sup>Pediatric Practice, Pfullendorf, GERMANY, <sup>2</sup>Clinique MM 24/24 Mpitsabo Mikambana, Antananarivo, MADAGASCAR, <sup>3</sup>German Red Cross Hospital Westend, Berlin, GERMANY.
- 628 Triclosan, a Common Ingredient in Household Products, is Associated With Allergic Sensitization**  
**J. H. Savage**, E. C. Matsui, R. A. Wood, C. A. Keet;  
Johns Hopkins Hospital, Baltimore, MD.
- 629 Microarray Analysis of IgE Reactivity in Patients with Asthma and/or Rhinitis Allergic to Cockroach and Mites: Clinical Application**  
**G. A. Bardini**<sup>1</sup>, A. S. Moreno<sup>1</sup>, A. C. A. F. Santos<sup>1</sup>, K. S. Santos<sup>2</sup>, L. Arruda<sup>1</sup>;  
<sup>1</sup>School of Medicine of Ribeirao Preto, Ribeirao Preto, BRAZIL, <sup>2</sup>School of Medicine - University of Sao Paulo, Sao Paulo, BRAZIL.
- 630 Association Between Asthma-related Emergency Department Visits, And Tree Pollen Concentrations In The Bronx, 2001 - 2008**  
**J. Toh**<sup>1</sup>, S. Jariwala<sup>1</sup>, D. Rosenstreich<sup>1</sup>, K. Zou<sup>2</sup>;  
<sup>1</sup>Albert Einstein School of Medicine, New York, NY, <sup>2</sup>Southern Methodist University, Dallas, TX.
- 631 Specific IgE to Mite, Shrimp and Blo t 13 allergens in an Allergic Population From the Caribbean**  
**L. Puerta**<sup>1</sup>, J. I. Tudela<sup>2</sup>, M. Munera<sup>1</sup>, B. Cases<sup>2</sup>, S. Lafosse-Marin<sup>3</sup>, E. Fernandez-Caldas<sup>2</sup>, L. Caraballo<sup>1</sup>;  
<sup>1</sup>Institute for Immunological Research, University of Cartagena, Cartagena, COLOMBIA, <sup>2</sup>Inmunotek, Madrid, SPAIN, <sup>3</sup>Cabinet de Allergologie, Fort de France, MARTINIQUE.
- 632 What causes Asthma and Allergy in School-going Children in Jaipur?**  
**R. S. Rao**, V. Singh, S. Singh;  
SMS Medical college & hospital, Jaipur, INDIA.
- 633 Aeroallergen Sensitivities In A Cohort of Patients Residing In Vietnam**  
**T. Nguyen**<sup>1</sup>, N. Ngoc Dung<sup>1</sup>, Q. Nguyen<sup>2</sup>, T. Craig<sup>3</sup>;  
<sup>1</sup>ENT Hospital, Ho Chi Minh City, VIET NAM, <sup>2</sup>Penn State, 500 University Dr, PA, <sup>3</sup>Penn State, Hershey, PA.
- 634 Serum Cytokine Profiles In Trimellitic Anhydride Exposed Factory Workers**  
**D. Ghosh**, J. Bernstein;  
University of Cincinnati College of Medicine, Cincinnati, OH.
- 635 Dug-Well Lung**  
**S. Singh**, B. B. Sharma, V. Singh, R. S. Rao;  
SMS Medical college & hospital, Jaipur, INDIA.
- 636 Sensitization to Storage Mites, Wheat and Yeast Allergens in Cuban Bakers**  
**M. Alvarez-Castello**<sup>1</sup>, Y. Leyva<sup>1</sup>, R. L. Castro-Alamarales<sup>2</sup>, A. Labrada<sup>2</sup>, V. R. Meli<sup>3</sup>, H. Barata<sup>3</sup>;  
<sup>1</sup>Calixto Garcia University Hospital, Havana, CUBA, <sup>2</sup>National Center of Bioproducts, Havana, CUBA, <sup>3</sup>Diater Laboratorios, Buenos Aires, ARGENTINA.
- 637 Sensitization To Multiple Woods Caused By An Ige-mediated Mechanism**  
**A. Aranda**<sup>1</sup>, P. Campo<sup>2</sup>, A. Palacin<sup>3</sup>, M. Montanez<sup>1</sup>, R. Herrera<sup>2</sup>, G. Campos<sup>2</sup>, A. Diaz-Perales<sup>3</sup>, M. Blanca<sup>2</sup>;  
<sup>1</sup>Allergy Laboratory, Fundacion IMABIS, Malaga, SPAIN, <sup>2</sup>Allergy

Department, Carlos Haya Hospital, Malaga, SPAIN, <sup>3</sup>Biotechnology Dept, Politechnic University, Madrid, SPAIN.

- 638 A National Review of Tobacco Smoking Among Females and Males in Turkey**  
**G. E. EROGLU**;  
Bezmialem Vakif University, Istanbul, Turkey.

## Poster Session

### Food Allergy II

4206

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 639 Retrospective Analysis of Shellfish Allergy, Atopy, and Radiocontrast Media Reactions**  
**P. Chopra**, I. Randhawa, W. B. Klaustermeyer, S. Lee;  
VA Greater Los Angeles Healthcare System/UCLA, Los Angeles, CA.
- 640 Initial Allergic Reactions to Fish and Shellfish in Children: Clinical Characteristics and Treatment**  
**A. Hassaine**<sup>1</sup>, A. Clarke<sup>2,3</sup>, R. Alizadehfar<sup>1</sup>, L. Joseph<sup>3,4</sup>, G. Shand<sup>3</sup>, M. Ben-Shoshan<sup>1</sup>;  
<sup>1</sup>Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, QC, CANADA, <sup>2</sup>Division of Allergy and Clinical Immunology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, <sup>3</sup>Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, <sup>4</sup>Departments of Epidemiology and Biostatistics, McGill University, Montreal, QC, CANADA.
- 641 Crustacean Allergy: A New Allergen Inside Cephalothorax?**  
**N. Cancelliere**, D. Guillen, S. Olalde, O. Caldern, T. Caballero, A. Fiandor, S. Quirse;  
Hospital La Paz, Spain, SPAIN.
- 642 Delayed Gastrointestinal Symptoms after Ingesting Shrimp in the Absence of IgE Sensitization**  
**R. Firszt**, K. Sebastien, G. J. Gleich, L. A. Wagner;  
University of Utah, Salt Lake City, UT.
- 643 Clinical Characteristics of Prawn Allergy in an Asian Population**  
**I. F. A. Gerez**<sup>1</sup>, G. Llanora<sup>1</sup>, G. C. Yap<sup>2</sup>, Y. K. Cheng<sup>3</sup>, B. Y. Thong<sup>4</sup>, C. Y. Tang<sup>4</sup>, H. P. S. Van Bever<sup>2</sup>, L. P. C. Shek<sup>2</sup>, M. A. Curotto de Lafaille<sup>5</sup>, B. W. Lee<sup>2</sup>;  
<sup>1</sup>National University Health System, University Children's Medical Institute, Department of Paediatrics, Singapore, SINGAPORE, <sup>2</sup>National University Singapore, Yong Loo Lin School of Medicine, Department of Paediatrics, Singapore, SINGAPORE, <sup>3</sup>Gleneagles Medical Center, Singapore, SINGAPORE, <sup>4</sup>Tan Tock Seng Hospital, Department of Rheumatology, Allergy and Immunology, Singapore, SINGAPORE, <sup>5</sup>Singapore Immunology Network, Singapore, SINGAPORE.
- 644 Assessment of Fish Products Containing Krill for Shrimp Allergic Cross-Reactivity**  
**J. G. Black**, S. B. Lehrer, L. Jensen, L. G. Wild;  
Tulane Medical Center, New Orleans, LA.
- 645 Exclusive Sensitization to Striped Catfish (*Pangasianodon hypophthalmus*) and Closely Related Fish Species**  
**G. Seszak-Greinecker**<sup>1</sup>, N. Balic<sup>2</sup>, W. Hemmer<sup>1</sup>, I. Swoboda<sup>2</sup>;  
<sup>1</sup>Floridsdorf Allergy Center, Vienna, AUSTRIA, <sup>2</sup>Department of

MONDAY

- Pathophysiology and Allergy Research, Medical University Vienna, Vienna, AUSTRIA.
- 646 A Retrospective Database Study of US Children in the Emergency Department or Hospital with Food-induced Anaphylaxis: Concordance with Recommended Post-Discharge Care**  
**P. B. Landsman-Blumberg**<sup>1</sup>, W. Wei<sup>2</sup>, D. Douglas<sup>3</sup>, D. Smith<sup>1</sup>, C. A. Camargo<sup>4</sup>;  
<sup>1</sup>Thomson Reuters, Washington, DC, <sup>2</sup>Sanofi-aventis, Bridgewater, NJ, <sup>3</sup>Valley Hospital, Ridgewood, NJ, <sup>4</sup>Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MD.
- 647 Experiencing a First Allergic Reaction to Food: A Qualitative Study of Parent And Caregiver Perspectives**  
**Z. Abdurrahman**<sup>1</sup>, M. Kastner<sup>2</sup>, C. Wurman<sup>3</sup>, L. Harada<sup>4</sup>, L. Bantock<sup>4</sup>, S. Wasserman<sup>1</sup>;  
<sup>1</sup>McMaster University, Hamilton, ON, CANADA, <sup>2</sup>Li Ka Shing Knowledge Institute of St. Michaels Hospital, Toronto, ON, CANADA, <sup>3</sup>University of Western Ontario, London, ON, CANADA, <sup>4</sup>Anaphylaxis Canada, Toronto, ON, CANADA.
- 648 Relative Severity and Treatment Response to Peanut and Tree Nut Allergic Reactions in a Self-Report Registry**  
**M. Ramesh**, H. A. Sampson, S. H. Sicherer;  
Mt. Sinai School of Medicine, New York, NY.
- 649 Epinephrine Auto-injector Use In Children At Risk Of Food-induced Anaphylaxis: Is It Used Appropriately?**  
**K. Mukaida**<sup>1,2</sup>, T. Kusunoki<sup>2</sup>, N. Mito<sup>2</sup>, A. Hayashi<sup>2</sup>, I. Hiejima<sup>2</sup>, F. Nozaki<sup>2</sup>, R. Kawakita<sup>2</sup>, K. Saito<sup>2</sup>, T. Kumada<sup>2</sup>, T. Miyajima<sup>2</sup>, T. Fujii<sup>2</sup>;  
<sup>1</sup>Kumiko Allergy Clinic, Kyoto, JAPAN, <sup>2</sup>Shiga Medical Center for Children, Shiga, JAPAN.
- 650 Mothers of Food Allergic Children Over-Report Food Allergy in Themselves**  
**M. Makhija**<sup>1</sup>, L. Arguelles<sup>2</sup>, C. Szychlinski<sup>1</sup>, R. G. Robison<sup>1</sup>, D. Caruso<sup>1,3</sup>, R. Kumar<sup>1</sup>, X. Wang<sup>4</sup>, J. Pongratic<sup>1</sup>;  
<sup>1</sup>Children's Memorial Hospital, Chicago, IL, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital and Children's Memorial Research Center, Chicago, IL, <sup>4</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 651 Identification of Peanuts and Tree nuts by Guardians of Nut-Allergic Children**  
**L. Kao**<sup>1</sup>, P. S. Bhangoo<sup>2</sup>, J. A. Bird<sup>1</sup>;  
<sup>1</sup>UT Southwestern, Dallas, TX, <sup>2</sup>Children's Medical Center, Dallas, TX.
- 652 The High Rate Of Cow'S Milk Sensitization In Asian Children Is Associated With The Amount Of Cow'S Milk Ingestion**  
**P. Vatanasurkitt**, N. Saengsawang, N. Suratannon, N. Voraphani, P. Chatchatee, J. Ngamphaiboon;  
Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, THAILAND.
- 653 Prenatal Exposure to Nut Allergens and Risk of Childhood Nut Sensitization**  
**J. T. Hsu**<sup>1</sup>, S. A. Missmer<sup>2</sup>, M. C. Young<sup>1</sup>, K. F. Berry<sup>2</sup>, F. J. Twarog<sup>1</sup>, I. Borras<sup>1</sup>, M. D. Hornstein<sup>2</sup>, L. C. Schneider<sup>1</sup>;  
<sup>1</sup>Children's Hospital Boston, Boston, MA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA.
- 654 Maternal Dietary Intake and Subsequent Allergy Development**  
**K. E. C. Grimshaw**<sup>1</sup>, E. M. Oliver<sup>1</sup>, T. Kemp<sup>2</sup>, E. N. C. Mills<sup>3</sup>, K. Beyer<sup>4</sup>, K. Foote<sup>2</sup>, G. Roberts<sup>1</sup>;  
<sup>1</sup>Academic Unit of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UNITED KINGDOM, <sup>2</sup>Department of Paediatric and Child Health, Royal Hampshire County Hospital, Winchester, UNITED KINGDOM, <sup>3</sup>Institute of Food Research, Norwich, UNITED KINGDOM,
- <sup>4</sup>Department of Paediatric Pneumology and Immunology, Charit University Medical Centre, Berlin, GERMANY.
- 655 Maternal Cow's Milk Avoidance During Lactation Suppresses IgA Levels in Breast Milk and Serum IgG Levels in Infants**  
**K. M. Jarvinen**, M. S. Seppo, A. James, A. Tsuang, M. C. Berin, H. A. Sampson;  
Mount Sinai School of Medicine, New York, NY.
- 656 Detection Of Peanut Allergens In Breast Milk**  
**K. Rose**<sup>1</sup>, H. Cheng<sup>2</sup>, S. A. Jortani<sup>1</sup>, S. J. Maleki<sup>2</sup>;  
<sup>1</sup>University of Louisville, Louisville, KY, <sup>2</sup>U.S. Department of Agriculture-ARS, New Orleans, LA.
- 657 Filaggrin Mutations are Associated with an Increased Risk of Infantile Food Allergy and Sensitization**  
**T. Tan**<sup>1,2</sup>, J. A. Ellis<sup>1,3</sup>, J. J. Koplin<sup>1</sup>, P. E. Martin<sup>1,2</sup>, T. D. Dang<sup>1,2</sup>, M. C. Matheson<sup>4</sup>, S. Dharmage<sup>1,4</sup>, A. Lowe<sup>1,4</sup>, M. Tang<sup>1,5</sup>, M. Robinson<sup>5</sup>, A. Ponsonby<sup>1</sup>, N. Osborne<sup>6</sup>, D. Hill<sup>1</sup>, K. J. Allen<sup>1,5</sup>;  
<sup>1</sup>Murdoch Childrens Research Institute, Melbourne, AUSTRALIA, <sup>2</sup>Department of Paediatrics, University of Melbourne, Melbourne, AUSTRALIA, <sup>3</sup>Department of Physiology, University of Melbourne, Melbourne, AUSTRALIA, <sup>4</sup>Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Melbourne, AUSTRALIA, <sup>5</sup>Department of Allergy and Immunology, Royal Children's Hospital, Melbourne, AUSTRALIA, <sup>6</sup>European Centre for Environment and Human Health, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UNITED KINGDOM.
- 658 The Skin Is A Potent Site Of Allergic Sensitization To Multiple Food Allergens**  
**D. Dunkin**, K. Jarvinen, W. Wang, H. Sampson, L. Mayer, C. Berin;  
The Mount Sinai School of Medicine, New York, NY.
- 659 High Molecular Weight Glutenin, Tri a 26, Is An Important Allergen Component In Children With Immediate Allergy To Wheat**  
**C. Eriksson**<sup>1</sup>, M. Lundberg<sup>2</sup>, A. Tanka<sup>3</sup>, H. Takahashi<sup>4</sup>, E. Morita<sup>4</sup>, K. Ito<sup>5</sup>;  
<sup>1</sup>Thermo Fisher Scientific, ImmunoDiagnostics, R&D, Uppsala, SWEDEN, <sup>2</sup>Thermo Fisher Scientific, ImmunoDiagnostics, Uppsala, SWEDEN, <sup>3</sup>Thermo Fisher Scientific, ImmunoDiagnostics, Tokyo, JAPAN, <sup>4</sup>Department of Dermatology, Shimane University, Izumo, JAPAN, <sup>5</sup>Aichi Childrens Health and Medical Center, Obu, JAPAN.
- 660 The Difference of Allergic Reactions Compared between BN Rats and Wistar Rats on Oral Exposure to Ovalbumin**  
**N. Sun**<sup>1</sup>, C. Zhou<sup>1</sup>, Q. K. Pu<sup>2</sup>, J. Wang<sup>1</sup>, H. L. Che<sup>1,3</sup>;  
<sup>1</sup>College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, CHINA, <sup>2</sup>College of Engineering, China Agricultural University, Beijing, CHINA, <sup>3</sup>The Supervision, Inspection and Testing Center of Genetically Modified Organisms, Ministry of Agriculture, Beijing, CHINA.
- 661 Desensitization Of Hen'S Egg Sensitized Mice As A Result Of Dietary (therapeutic) Intervention With A Specific Mixture Of Non-digestible Oligosaccharides**  
**A. Hogenkamp**<sup>1</sup>, S. de Kivit<sup>1</sup>, L. M. J. Knippels<sup>1,2</sup>, J. Garssen<sup>1,2</sup>, B. C. A. M. van Esch<sup>1,2</sup>;  
<sup>1</sup>Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, NETHERLANDS, <sup>2</sup>Danone Research-Centre for Specialised Nutrition, Wageningen, NETHERLANDS.
- 662 A Mixture Of Non-digestible Oligosaccharides Enhances The Tolerizing Capacity Of A Partial Whey Hydrolysate In A Mouse Model For Cow'S Milk Allergy**  
**B. C. A. M. van Esch**<sup>1,2</sup>, S. de kivit<sup>1</sup>, G. A. Hofman<sup>1</sup>, L. E. M. Willemssen<sup>1</sup>, J. Garssen<sup>1,2</sup>, L. M. J. Knippels<sup>1,2</sup>;

<sup>1</sup>Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, NETHERLANDS, <sup>2</sup>Danone Research-Centre for Specialised Nutrition, Wageningen, NETHERLANDS.

**663 A Bioassay For Assessing Dose-Response Relationships In A Food Allergic Mouse Model**

**E. K. Kwegyir-Afful**<sup>1,2</sup>, O. T. Foye<sup>3</sup>, K. Williams<sup>3</sup>, S. Luccioli<sup>1</sup>;  
<sup>1</sup>Office of Food Additive Safety, CFSAN, FDA, College Park, MD, <sup>2</sup>Office of the Commissioner, Office of Science and Innovation, Silver Spring, MD, <sup>3</sup>Office of Applied Research and Safety Assessment, CFSAN, FDA, Beltsville, MD.

**664 Peanut plus Cholera Toxin Subunit B in vitro Effects on Induction of IL-10 in Human Peripheral Blood Mononuclear Cells from Subjects with Peanut Allergy**

**A. Tang**, Y. Song, J. Wang, J. Ross, X. Li;  
Mount Sinai School of Medicine, New York, NY.

**665 Nasal Immunization with Peanut Antigen and The Cationic Peptide Adjuvant Mastoparan 7 Induces Serum Humoral Immunity That Protects Peanut Allergic Mice Against Systemic Anaphylaxis**

**B. T. Johnson**, M. Kulis, S. N. Abraham, A. W. Burks, H. F. Staats;  
Duke University, Durham, NC.

**666 In vitro Digestion and Characterization of Proteins and Digestion-Resistant Peptides of Pecan**

**J. Spirc**<sup>1</sup>, A. Knuls<sup>2</sup>, J. Nordlee<sup>1</sup>, S. Taylor<sup>1</sup>, J. Baumert<sup>1</sup>;  
<sup>1</sup>University of Nebraska-Lincoln, Lincoln, NE, <sup>2</sup>University Medical Center Utrecht, Utrecht, NETHERLANDS.

**667 Modified Peanut Extracts are Hypoallergenic in Mediator Release Assay**

**R. Bencharitwong**<sup>1</sup>, H. P. van der Kleij<sup>2</sup>, S. J. Koppleman<sup>2</sup>, A. H. Nowak-Wegrzyn<sup>1</sup>;  
<sup>1</sup>Mt. Sinai School of Medicine, New York, NY, <sup>2</sup>Hal Allergy BV, Leiden, NETHERLANDS.

**668 Recombinant Ara H 6 Expressed In Pichia Pastoris Preserves Effector Function And Is Useful To Assess Mutations**

**Y. Zhuang**, S. Durrani, K. Otsu, S. C. Dreskin, X. Chen;  
University of Colorado Denver, Aurora, CO.

**669 Identification of Maillard reaction induced chemical modifications on Ara h 1**

**C. P. Mattison**, C. C. Grimm, W. A. Desormeaux, S. Ruan, S. J. Maleki;  
USDA-ARS-SRRC, New Orleans, LA.

**670 Interest Of Specific Ige Measurement For Galactose-alpha-1,3-galactose In Unexplained Recurrent Urticaria With Angioedema, Predominantly Nocturnal : About 6 Cases**

**J. Renaudin**<sup>1</sup>, S. Jacquenet<sup>2</sup>, C. Metz-Favre<sup>3</sup>, E. Baudouin<sup>1</sup>, F. Engel<sup>3</sup>, F. de Blay<sup>3</sup>, D. Moneret-Vautrin<sup>1</sup>;  
<sup>1</sup>Department of Allergology, J Monnet Hospital, Epinal, FRANCE, <sup>2</sup>Genclis SAS, Vandoeuvre les Nancy, FRANCE, <sup>3</sup>Department of Pneumology, University Hospital, Strasbourg, FRANCE.

**671 In the Pork-Cat Syndrome, Allergic Reactions to Pork Reflect IgE Antibodies to Cat Albumin that Cross-reacts with Other Albumins**

**J. Posthumus**<sup>1</sup>, L. J. Workman<sup>1</sup>, H. R. James<sup>1</sup>, S. L. Pochan<sup>1</sup>, C. J. Lane<sup>2</sup>, D. C. McBride<sup>3</sup>, S. S. Eapen<sup>3</sup>, L. A. Matos<sup>3</sup>, S. P. Commins<sup>1</sup>, T. A. E. Platts-Mills<sup>1</sup>;  
<sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Allergy Partners of Lynchburg, Lynchburg, VA, <sup>3</sup>Asthma and Allergy Center, Lynchburg, VA.

**672 A Successful Project Giving Special Foods For Food Allergy From the United States To Children With Food Allergy In The Area Affected By The Great East Japan Earthquake**

**K. Miura**<sup>1</sup>, K. Mita<sup>2</sup>, T. Yanai<sup>2</sup>, R. Eto<sup>3</sup>, T. Eto<sup>3</sup>;  
<sup>1</sup>Miyagi Children's Hospital, Sendai, JAPAN, <sup>2</sup>Volunteer, Sendai, JAPAN, <sup>3</sup>Volunteer, Flemington, NJ.

## Poster Session

### Anaphylaxis

4207

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

**673 Knowledge and Management of Anaphylaxis in Primary Care Settings in Argentina**

**L. R. F. Arduso**<sup>1</sup>, M. Carignani<sup>1</sup>, L. Sanchez<sup>1</sup>, J. L. Molinas<sup>2</sup>, M. Arduso<sup>2</sup>, M. Gonzalez Broin<sup>3</sup>, H. Neffen<sup>3</sup>;  
<sup>1</sup>Hospital Provincial del Centenario, Rosario, ARGENTINA, <sup>2</sup>Facultad de Ciencias Medicas, Universidad Nacional de Rosario, Rosario, ARGENTINA, <sup>3</sup>Centro de Alergia e Inmunologia, Santa Fe, ARGENTINA.

**674 Knowledge, Attitudes and Behaviors of Internal Medicine Residents Regarding Anaphylaxis Diagnosis and Management**

**R. J. Sporter**<sup>1</sup>, A. M. Jongco<sup>2</sup>, S. J. Schuval<sup>3</sup>, M. A. Cavuoto<sup>2</sup>;  
<sup>1</sup>Department of Medicine, North Shore Long Island Jewish Health System, New Hyde Park, NY, <sup>2</sup>Division of Allergy and Immunology, Department of Pediatrics, North Shore Long Island Jewish Health System, Great Neck, NY, <sup>3</sup>Division of Allergy and Immunology, Department of Pediatrics, Stony Brook University Medical Center, Stony Brook, NY.

**675 Anaphylaxis Training Courses For Pharmacists In Australia And Nz**

**S. Vale**, R. Mullins, J. Smith, R. Loh;  
Australasian Society of Clinical Immunology and Allergy, Sydney, AUSTRALIA.

**676 Anaphylaxis Management Training, Legislation And Epinephrine Autoinjector Provision In The School And Childcare Sectors**

**R. K. S. Loh**<sup>1</sup>, S. Vale<sup>2</sup>;  
<sup>1</sup>Princess Margaret Hospital, Subiaco, AUSTRALIA, <sup>2</sup>Anaphylaxis Australia, Perth, AUSTRALIA.

**677 AAAAI Anaphylaxis Wallet Card: A Practical Anaphylaxis Education Tool for Time-Challenged Healthcare Professionals**

**V. P. Hernandez-Trujillo**<sup>1</sup>, F. E. R. Simons<sup>2</sup>;  
<sup>1</sup>Miami Children's Hospital, Miami, FL, <sup>2</sup>University of Manitoba, Winnipeg, MB, CANADA.

**678 Epinephrine 0.3 mg Bioavailability Following a Single Injection with a Novel Epinephrine Auto-injector, e-cue™, in Healthy Adults, with Reference to a Single Injection using EpiPen® 0.3 mg**

**E. S. Edwards**<sup>1</sup>, R. Gunn<sup>1</sup>, E. F. Simons<sup>2</sup>, K. Carr<sup>3</sup>, V. M. Chinchilli<sup>4</sup>, G. Painter<sup>5</sup>, R. Goldwater<sup>6</sup>;  
<sup>1</sup>Intelliject Inc., Richmond, VA, <sup>2</sup>University of Manitoba, Winnipeg, MB, CANADA, <sup>3</sup>RRD International, Rockville, MD, <sup>4</sup>Penn State Hershey College of Medicine, Hershey, PA, <sup>5</sup>Chimerix Inc., Durham, NC, <sup>6</sup>PAREXEL International, Baltimore, MD.

**679 At What Age Should Children and Teenagers Be Able To Recognize Anaphylaxis and Self-Inject Epinephrine?**

**E. Simons**<sup>1</sup>, S. H. Sicherer<sup>2</sup>, F. E. R. Simons<sup>3</sup>;  
<sup>1</sup>Hospital for Sick Children, CHES, Toronto, ON, CANADA, <sup>2</sup>Mount Sinai School of Medicine, New York, NY, <sup>3</sup>University of Manitoba, Winnipeg, MB, CANADA.

**680 Comparing Activation and Recoil Forces Generated by Epinephrine Autoinjectors and their Training Devices**

**R. C. Jacobsen**<sup>1</sup>, T. M. Guess<sup>2</sup>, A. W. Burks<sup>3</sup>;  
<sup>1</sup>University of Missouri-Kansas City School of Medicine/Truman Medical Center, Kansas City, MO, <sup>2</sup>University of Missouri-Kansas City Department of Mechanical Engineering, Kansas City, MO, <sup>3</sup>Duke University Medical Center, Durham, NC.

- 681 Outdated Epinephrine Autoinjectors: Ejection Volume Integrity And Epinephrine Content And Dose**  
K. J. Simons<sup>1</sup>, O. M. Rachid<sup>1</sup>, M. A. Rawas-Qalaji<sup>2</sup>, M. Wein<sup>3</sup>, F. E. R. Simons<sup>1</sup>;  
<sup>1</sup>University of Manitoba, Winnipeg, MB, CANADA, <sup>2</sup>Nova Southeastern University, Fort Lauderdale, FL, <sup>3</sup>Florida State University, Tallahassee, FL.
- 682 Perioperative Anaphylaxis: Clinical Features of 51 Patients**  
L. S. Garro, A. T. Rodrigues, M. R. Ribeiro, M. V. Aun, J. Kalil, A. A. Motta, P. Giavina-Bianchi;  
FMUSP, Sao Paulo, BRAZIL.
- 683 Intraoperative Anaphylaxis In A Pediatric Patient Induced By Thrombin Gel Administration**  
E. Khoriaty, R. Rachid;  
Children's Hospital Boston, Boston, MA.
- 684 Kounis Syndrome: Paradoxical Vasoconstriction of a Coronary Artery During an Angiography Contrast-Induced Anaphylactoid Reaction**  
M. N. Le, A. Canady, S. K. Zimmerman, S. Gierer, M. Earnest;  
The University of Kansas Medical Center, Kansas City, KS.
- 685 Ropivacaine Anaphylaxis Necessitating Emergent Tracheostomy After Open Reduction Internal Fixation Of Left Tibial Fracture Confirmed Through Percutaneous Testing, Intradermal Testing and Subcutaneous Challenge**  
J. D. Martinez, M. N. Le, D. J. Stechschulte;  
The University of Kansas Medical Center, Kansas City, KS.
- 686 Is Severity Of Drug Induced Anaphylaxis Dependent Of Its Etiology?**  
M. V. Aun, A. T. Rodrigues, M. R. Ribeiro, L. S. Garro, J. Kalil, A. A. Motta, P. Giavina-Bianchi;  
FMUSP, Sao Paulo, BRAZIL.
- 687 Risk of Anaphylaxis in Narcotic Drug Addicts Being Treated for Drug Rehabilitation**  
U. Maurer<sup>1</sup>, R. Jarisch<sup>2</sup>, A. Pollesbck<sup>3</sup>, W. Hemmer<sup>2</sup>, F. Wantke<sup>2</sup>, B. Spitzer<sup>3</sup>;  
<sup>1</sup>University of applied sciences, Wiener Neustadt, AUSTRIA, <sup>2</sup>Floridsdorf Allergy Center, Vienna, AUSTRIA, <sup>3</sup>Landesklinikum, Mauer-Amstetten, AUSTRIA.
- 688 A Comparison of Tryptase Levels in Patients with Septic vs. Cardiogenic Shock**  
D. R. Sun<sup>1</sup>, J. R. Dye<sup>1</sup>, C. Xu<sup>2</sup>, A. Abbate<sup>1</sup>, L. B. Schwartz<sup>1</sup>;  
<sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Kaiser Permanente, Oakland, CA.
- 689 Baseline Serum Tryptase Levels in Patients who Suffered Anaphylaxis**  
P. Martinez, G. Marco, D. Perez, M. Tomas, A. Prieto, J. Navarro, J. J. Rodriguez, M. L. Baeza, A. Alvarez-Perea;  
Hospital General Universitario Gregorio Maranon, Madrid, SPAIN.
- 690 Latitude Gradient of Anaphylaxis in Chile: A Potential Role of Vitamin D Status**  
R. Hoyos-Bachilloglu, P. S. Morales, J. Cerda, E. Talesnik, C. Mendez, G. Gonzalez, A. Borzutzky;  
Pontificia Universidad Catolica de Chile, Santiago, CHILE.
- 691 Aspirin Administration Effect On Food-Dependent Exercise Induced Anaphylaxis**  
C. Motomura;  
Fukuoka National Hospital, Fukuoka, JAPAN.
- 692 Does Concomitant Chronic Pulmonary Disease Increase the Severity of an Anaphylactic Episode?**  
Z. D. Mulla<sup>1</sup>, F. E. R. Simons<sup>2</sup>;  
<sup>1</sup>Texas Tech University Health Sciences Center, El Paso, TX, <sup>2</sup>University of Manitoba Faculty of Medicine, Winnipeg, MB, CANADA.
- 693 Food-dependent Exercise-induced Anaphylaxis (fdeia) And Sensitization To Omega-5-gliadin**  
D. Guillen<sup>1</sup>, C. Gomez-Traseira<sup>1</sup>, R. Cabanas<sup>1</sup>, N. Prior<sup>1</sup>, S. Quirce<sup>1,2</sup>, T. Caballero<sup>1</sup>;  
<sup>1</sup>Hospital Universitario La Paz, Madrid, SPAIN, <sup>2</sup>Spanish network of centers for biomedical research on respiratory diseases (Ci-beRes), Madrid, SPAIN.
- 694 From 2000-2008, Statewide Hospital Admission Rates for Allergic Reaction Increased More Rapidly in the Northeast United States When Compared to Other Regions of the United States**  
R. C. Van Winkle<sup>1,2</sup>, J. Hossain<sup>1</sup>, C. C. Chang<sup>1,2</sup>, S. J. McGeady<sup>1,2</sup>;  
<sup>1</sup>A.I. duPont Hospital for Children, Wilmington, DE, <sup>2</sup>Thomas Jefferson University, Philadelphia, PA.
- 695 Comparison between Allergists and Non-allergists on Issues Related to Food-induced Anaphylaxis**  
M. Desjardins<sup>1</sup>, A. Clarke<sup>2</sup>, R. Alizadehfar<sup>1</sup>, D. Grenier<sup>3</sup>, H. Eisman<sup>4</sup>, S. Carr<sup>5</sup>, T. Vander Leek<sup>5</sup>, L. Teperman<sup>6</sup>, N. Higgins<sup>7</sup>, L. Joseph<sup>8</sup>, G. Shand<sup>7</sup>, M. Ben-Shoshan<sup>1</sup>;  
<sup>1</sup>Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Center, Montreal, QC, CANADA, <sup>2</sup>Division of Allergy and Clinical Immunology & Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, <sup>3</sup>Canadian Pediatric Society, Ottawa, ON, CANADA, <sup>4</sup>Montreal Children's Hospital, Emergency Department, McGill University Health Center, Montreal, QC, CANADA, <sup>5</sup>Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, University of Alberta, Edmonton, AB, CANADA, <sup>6</sup>Society of Rural Physician of Canada, Shawville, QC, CANADA, <sup>7</sup>Department of Epidemiology, McGill University Health Center, Montreal, QC, CANADA, <sup>8</sup>Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, CANADA.
- 696 Translating Science Into Meaningful Strategies That Improve Quality Of Life In Food Allergy : An Investigation Of Defined Thresholds And Risk Stratification In Consumers, Clinicians And Food Producers**  
A. DunnGalvin<sup>1</sup>, J. O. B. Hourihane<sup>1</sup>, S. Taylor<sup>2</sup>;  
<sup>1</sup>University College Cork, Cork, IRELAND, <sup>2</sup>University College Cork, Cork, NE.
- 697 Chemical and biological characterization of Food Allergy Herbal Formula 2 (FAHF-2) product consistency and potency**  
N. Yang, C. Bautista, I. Gluskin, H. Sampson, X. Li;  
MountSinai School of medicine, New York City, NY.
- 698 Comparison of Systemic Absorption of Epinephrine Delivered Intranasally (5 mg) vs Intramuscularly (0.3 mg) Using Liquid Chromatography with Tandem Mass Spectrophotometry (LC-MS/MS)**  
R. Pensrichon;  
Siriraj Hospital, Bangkok, THAILAND.
- 699 Ribavirin Desensitization in Chronic Hepatitis C Infection**  
O. Tokor;  
Hadassah Medical Center, Jerusalem, ISRAEL.
- 700 Identification of Structural Determinants Supporting The Absence of IgE Cross-Reactivity Between Caprine and Bovine  $\beta$ -Caseins In Patients Allergic to Goat's Milk But Tolerant To Cow's Milk**  
S. Hazebrouck<sup>1</sup>, S. Ah-Leung<sup>1</sup>, E. Paty<sup>2</sup>, E. Bidat<sup>3</sup>, M. F. Drumare<sup>1</sup>, S. Tilleul<sup>1</sup>, K. Adel-Patient<sup>1</sup>, J. M. Wal<sup>1</sup>, H. Bernard<sup>1</sup>;  
<sup>1</sup>Laboratoire d'Immuno-Allergie Alimentaire INRA, Gif sur Yvette, FRANCE, <sup>2</sup>Hopital Necker Enfants Malades, Paris, FRANCE, <sup>3</sup>Hopital Ambroise Pare, Boulogne-Billancourt, FRANCE.
- 701 Anaphylactic Reaction To Intravenous Administration Of Folinic Acid: A Case Report**  
K. N. Syrigos<sup>1,2</sup>, E. Syrigou<sup>1</sup>, S. Hotchkiss<sup>2</sup>, M. Gambaccini<sup>2</sup>, K. Kaley<sup>2</sup>, M. W. Saif<sup>3</sup>;

<sup>1</sup>Oncology Unit, 3rd Dept of Medicine, Sotiria General Hospital, Athens School of Medicine, Athens, GREECE, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>Columbia University College of Physicians and Surgeons and Pancreas Center, New York Presbyterian Hospital, New York, NY.

**702 Desensitization Protocol In A Patient With Immediate Hypersensitivity To Apomorphine**

**A. Foncubierta Fernandez<sup>1</sup>**, D. Gutierrez Fernandez<sup>2</sup>, R. Espinosa Rosso<sup>2</sup>, J. Anguita Carazo<sup>3</sup>, S. Fernandez Melendez<sup>4</sup>, A. Miranda Paez<sup>4</sup>;

<sup>1</sup>Joaquin Pece Health Center, San Fernando, SPAIN, <sup>2</sup>Hospital Universitario Puerta del Mar, Cadiz, SPAIN, <sup>3</sup>Complejo Hospitalario de Jaen, Jaen, SPAIN, <sup>4</sup>Hospital Universitario Carlos Haya, Malaga, SPAIN.

**703 Anaphylaxis related to Laronidase: Case report**

**A. M. Martins**, C. Aranda, M. Malozzi, E. O. Dantas, L. F. Ensina, D. Sole;

Universidade Federal de Sao Paulo, Sao Paulo, BRAZIL.

## Poster Session

### Provider Knowledge and Training

4208

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

**704 Effectiveness of an Educational Intensive Course on Allergy and Immunology Clinical and Diagnostic Procedures**

**M. J. Dorsey**, A. Elizalde, E. E. Perez, P. Sriaroon, D. Nguyen, R. F. Lockey, J. W. Sleasman;  
University of South Florida, St Petersburg, FL.

**705 Pharmacists And Knowledge Of Asthma: Survey Of 120 Pharmacists, Comparison Between 1999 And 2009**

**F. de Blay<sup>1</sup>**, M. Meunier-Spitz<sup>1</sup>, H. Lefevre<sup>2</sup>, P. Rebotier<sup>1</sup>, A. Bihler<sup>1</sup>, C. Heitz<sup>3</sup>;

<sup>1</sup>Allergy Division University Hospital, Strasbourg, FRANCE, <sup>2</sup>Department of Medical Information, University Hospital, Strasbourg, FRANCE, <sup>3</sup>Faculty of Pharmacy, University, Strasbourg, FRANCE.

**706 Food Allergy Knowledge among School Nurses in an Urban Public School District**

**H. Robinson<sup>1</sup>**, S. Twichell<sup>1</sup>, L. Hanks<sup>1</sup>, C. Nguyen<sup>1</sup>, E. Garrow<sup>2</sup>, M. L. Acebal<sup>2</sup>, H. P. Sharma<sup>1</sup>;

<sup>1</sup>Children's National Medical Center, Washington, DC, <sup>2</sup>Food Allergy and Anaphylaxis Network, Fairfax, VA.

**707 Allergy Training and Immunotherapy in Latin America: How Survey-Results Lead to a Regional Overview**

**D. E. S. Larenas Linnemann<sup>1</sup>**, M. Gomez<sup>2</sup>, G. Passalacqua<sup>3</sup>, S. N. Gonzalez Diaz<sup>4</sup>, V. H. Croce<sup>5</sup>, G. W. Canonica<sup>6</sup>, C. Baena Cagnani<sup>5</sup>;

<sup>1</sup>Hospital Medica Sur, Mexico, MEXICO, <sup>2</sup>Centro Investigacion Medicina Respiratoria (CIMER-UCC), Salta, ARGENTINA, <sup>3</sup>Allergy & Respiratory Diseases (DIMI), Universit Degli Studi Di Genova, Genoa, ITALY, <sup>4</sup>Latin American Society of Allergy, Asthma & Immunology, Monterrey, MEXICO, <sup>5</sup>Centro Investigacion Medicina Respiratoria (CIMER-UCC), Cordoba, ARGENTINA, <sup>6</sup>Allergy & Respiratory Diseases (DIMI), Universita Degli Studi Di Genova, Genoa, ITALY.

**708 Pharmacists' Understanding of Patient Education on Inhalers**

**J. JEONG<sup>1</sup>**, C. Park<sup>2</sup>;

<sup>1</sup>Ilsan Paik Hospital, Goyang, KOREA, REPUBLIC OF, <sup>2</sup>Haeundae Paik Hospital, Busan, KOREA, REPUBLIC OF.

## Poster Session

### Treatment of Allergic Rhinitis/Conjunctivitis

4209

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

**709 A Scintigraphy Study Evaluating The Nasal Deposition And Retention Of Ciclesonide Hydrofluoroalkane Nasal Aerosol And Mometasone Furoate Aqueous Nasal Spray In Patients With Perennial Allergic Rhinitis**

**J. Karafilidis**, B. Wang;  
Sunovion Pharmaceuticals, Marlborough, MA.

**710 Effective Nasal Symptom Relief and Improvement in Health-Related Quality of Life in Subjects with Perennial Allergic Rhinitis Following 6-Week Once-Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol**

**W. Carr<sup>1</sup>**, E. O. Meltzer<sup>2</sup>, A. Finn<sup>3</sup>, P. M. Dorinsky<sup>4</sup>, L. Kelley<sup>4</sup>, S. A. Dunbar<sup>4</sup>, S. K. Tantry<sup>4</sup>;

<sup>1</sup>Allergy and Asthma Associates of Southern California Medical Group, Mission Viejo, CA, <sup>2</sup>Allergy and Asthma Medical Group & Research Center, San Diego, CA, <sup>3</sup>National Allergy, Asthma & Urticaria Centers of Charleston, Charleston, SC, <sup>4</sup>Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

**711 Once-Daily Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg/d) Is Not Associated With Hypothalamic-Pituitary-Adrenal Axis Suppression in Adolescent Subjects With Perennial Allergic Rhinitis**

**F. C. Hampel<sup>1</sup>**, P. H. Ratner<sup>2</sup>, S. D. Miller<sup>3</sup>, A. Melchior<sup>4</sup>, S. A. Dunbar<sup>4</sup>, S. K. Tantry<sup>4</sup>, P. M. Dorinsky<sup>4</sup>;

<sup>1</sup>Central Texas Health Research, New Braunfels, TX, <sup>2</sup>Sylvana Research Associates, San Antonio, TX, <sup>3</sup>Northeast Medical Research Associates, Dartmouth, MA, <sup>4</sup>Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

**712 Once Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol Is Safe and Effective in Children (6-11 Years of Age) With Seasonal Allergic Rhinitis**

**N. Segall<sup>1</sup>**, L. Mansfield<sup>2</sup>, N. Amar<sup>3</sup>, P. M. Dorinsky<sup>4</sup>, L. Kelley<sup>4</sup>, Y. Ding<sup>4</sup>, S. K. Tantry<sup>4</sup>;

<sup>1</sup>Georgia Allergy & Respiratory, Atlanta, GA, <sup>2</sup>Allergy, Immunology & Asthma, El Paso, TX, <sup>3</sup>Allergy Asthma Research Institute, Waco, TX, <sup>4</sup>Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

**713 Long-Term (52-Week) Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg Once Daily) Is Safe and Effective in Adult and Adolescent Subjects With Perennial Allergic Rhinitis**

**A. S. Nayak<sup>1</sup>**, C. P. Andrews<sup>2</sup>, D. I. Bernstein<sup>3</sup>, P. M. Dorinsky<sup>4</sup>, A. Tankelevich<sup>4</sup>, Y. Ding<sup>4</sup>, S. K. Tantry<sup>4</sup>;

<sup>1</sup>Sneeze, Wheeze & Itch Associates, LLC, Normal, IL, <sup>2</sup>Diagnostics Research Group, San Antonio, TX, <sup>3</sup>Bernstein Clinical Research Center, Cincinnati, OH, <sup>4</sup>Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

**714 Once-Daily Treatment With Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol (320 mcg/d) Provides Substantial Nasal Symptom Relief in Subjects With Perennial Allergic Rhinitis**

**B. M. Prenner<sup>1</sup>**, S. Weinstein<sup>2</sup>, W. Pleskow<sup>3</sup>, A. Tankelevich<sup>4</sup>, Y. Ding<sup>4</sup>, S. K. Tantry<sup>4</sup>, P. M. Dorinsky<sup>4</sup>;

<sup>1</sup>Allergy Associates Medical Group, Inc., San Diego, CA, <sup>2</sup>Allergy & Asthma Specialists Medical Group, Huntington Beach, CA, <sup>3</sup>Warren W. Pleskow, MD, Encinitas, CA, <sup>4</sup>Teva Branded Pharmaceutical Products R&D, Inc., Horsham, PA.

MONDAY

- 715 Use of *In Vivo* Confocal Microscopy to Assess Allergic Inflammation following Conjunctival Allergen Challenge**  
E. Angjeli, K. J. Lane, M. Contractor, P. Gomes, M. B. Abelson; Ora, Inc, Andover, MA.
- 716 Dry Eye Syndrome in an Allergy Practice and Effect of Cyclosporine Treatment**  
R. Tharackal Ravindran<sup>1</sup>, S. Breitbart<sup>2</sup>, L. Bielory<sup>3</sup>;  
<sup>1</sup>Overlook Hospital, Summit, NJ, <sup>2</sup>Englewood Hospital and Medical Center, Englewood, NJ, <sup>3</sup>Rutgers University, New Brunswick, NJ.
- 717 Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5% Improves Morning (AM) Ocular Redness Scores in a Placebo-Controlled Environmental Study of Seasonal Allergic Rhinoconjunctivitis (SAR)**  
J. I. Williams, J. A. Gow, M. Munoz, T. McNamara;  
ISTA Pharmaceuticals, Irvine, CA.
- 718 Comparison of Environmental and Allergen-Challenge based Assessments of Allergic Conjunctivitis Treatment using an Antihistamine-Steroid Combination Therapy**  
P. Gomes<sup>1</sup>, M. B. Abelson<sup>1,2</sup>;  
<sup>1</sup>Ora, Inc, Andover, MA, <sup>2</sup>Harvard Medical School, Schepens Eye Research Institute, Boston, MA.
- 719 Lower Symptom Severity Scores in Cetirizine-Treated Patients with Moderate/Severe Seasonal Allergic Rhinitis**  
E. R. Urdaneta<sup>1</sup>, M. K. Patel<sup>1</sup>, P. A. Przygoda<sup>1</sup>, K. B. Franklin<sup>1</sup>, P. Du<sup>2</sup>, M. Wu<sup>3</sup>;  
<sup>1</sup>McNeil Consumer Healthcare, Fort Washington, PA, <sup>2</sup>Johnson & Johnson Consumer Products China, Shanghai, CHINA, <sup>3</sup>Johnson & Johnson Consumer Products US, Morris Plains, NJ.
- 720 Satisfaction With And Preference For Ciclesonide Hydrofluoroalkane Nasal Aerosol Or Mometasone Furoate Nasal Aqueous Spray In Patients With Perennial Allergic Rhinitis: Results From A Validation Study**  
E. O. Meltzer<sup>1</sup>, P. H. Ratner<sup>2</sup>, M. Testa<sup>3</sup>, R. Turner<sup>4</sup>, W. Spalding<sup>5</sup>, J. Karafilidis<sup>5</sup>;  
<sup>1</sup>Allergy & Asthma Medical Group & Research Center, San Diego, CA, <sup>2</sup>Sylvana Research Associates, San Antonio, TX, <sup>3</sup>Harvard School of Public Health, Boston, MA, <sup>4</sup>Phase V Technologies, Wellesley Hills, MA, <sup>5</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA.
- 721 Lower Symptom Severity Scores in Cetirizine-Treated Patients with Moderate-Severe Perennial Allergic Rhinitis**  
M. K. Patel<sup>1</sup>, E. R. Urdaneta<sup>1</sup>, P. A. Przygoda<sup>1</sup>, K. B. Franklin<sup>1</sup>, P. Du<sup>2</sup>, M. Wu<sup>3</sup>;  
<sup>1</sup>McNeil Consumer Healthcare, Fort Washington, PA, <sup>2</sup>Johnson & Johnson Consumer Products China, Shanghai, CHINA, <sup>3</sup>Johnson & Johnson Consumer Products US, Morris Plains, NJ.
- 722 A 26-week, Open-label Extension Study Evaluating The Long-term Safety And Tolerability Of Ciclesonide Hydrofluoroalkane Nasal Aerosol In Patients With Perennial Allergic Rhinitis**  
W. Storms<sup>1</sup>, G. Gross<sup>2</sup>, S. Spector<sup>3</sup>, H. Huang<sup>4</sup>, S. Y. Desai<sup>4</sup>;  
<sup>1</sup>Storm Clinical Research Institute, Colorado Springs, CO, <sup>2</sup>Pharmaceutical Research & Consulting, Inc., Dallas, TX, <sup>3</sup>California Allergy & Asthma Medical Group, Los Angeles, CA, <sup>4</sup>Sunovion Pharmaceuticals Inc., Marlborough, MA.
- 723 Loteprednol Etabonate Ophthalmic Suspension, 0.2% Is As Safe as Olopatadine Hydrochloride Ophthalmic Solution, 0.1% With Superior Relief of Signs and Symptoms In The Treatment of Seasonal Allergic Conjunctivitis**  
A. Elion-Mboussa<sup>1</sup>, L. Gong<sup>2</sup>, L. Roy<sup>3</sup>, B. Zhu<sup>4</sup>, H. DeCory<sup>1</sup>, E. Chu<sup>3</sup>;  
<sup>1</sup>Bausch & Lomb Incorporated, Rochester, NY, <sup>2</sup>Eye, Nose & Throat Hospital of Fudan University, Shanghai, CHINA, <sup>3</sup>Bausch & Lomb (S) Pte Ltd., Singapore, SINGAPORE, <sup>4</sup>Shandong Bausch & Lomb Freda Pharmaceutical Co.,Ltd., Shanghai, CHINA.

- 724 Comparison of Health Outcomes of Patients with Allergic Rhinitis Receiving Pressurized Metered-Dose Inhaler Versus Aqueous Intranasal Corticosteroid Formulations**  
P. O. Buck<sup>1</sup>, L. Cox<sup>2</sup>, D. Lang<sup>3</sup>, C. S. Hankin<sup>4</sup>, Z. Wang<sup>4</sup>, A. Bronstone<sup>4</sup>, M. Lepore<sup>1</sup>;  
<sup>1</sup>Teva North America Branded Pharmaceuticals, Inc., Horsham, PA, <sup>2</sup>Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, <sup>3</sup>Cleveland Clinic, Cleveland, OH, <sup>4</sup>BioMedE-con, Moss Beach, CA.

## Poster Session

### Immunotherapy Outcomes

4210

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 725 Allergen Immunotherapy: More Stuttering than Finishing**  
K. M. Payne, R. J. M. Engler, R. L. McCoy, M. R. Nelson;  
Walter Reed National Military Medical Center, Bethesda, MD.
- 726 Efficacy of Sublingual Immunotherapy In a Typical American Practice**  
J. G. Sanchez, R. Garcia-Ibanez;  
The AllergiGroup, Tampa, FL.
- 727 Incidence of Respiratory Tract Infections in Clinical Trials of Intravenous and Subcutaneous Immunoglobulin**  
J. S. Baggish<sup>1</sup>, M. Bexon<sup>2</sup>, M. Rojavin<sup>1</sup>, O. Zenker<sup>3</sup>, M. Berger<sup>1</sup>;  
<sup>1</sup>CSL Behring LLC, King of Prussia, PA, <sup>2</sup>CSL Behring AG, Berne, SWITZERLAND, <sup>3</sup>CSL Behring GmbH, Marburg, GERMANY.
- 728 Hints to Increase Therapeutic Benefits by Initiating Conventional Allergen Immunotherapy As Soon As Possible Regardless of Age**  
H. Nagaya;  
Kugayama Institute of Clinical Allergy and Allergy Clinic, TOKYO, JAPAN.
- 729 Integrated Database of Eight Prospective IgG Studies in Primary Immunodeficiency: New Tool for Pooled Analysis**  
M. A. Rojavin<sup>1</sup>, M. Bexon<sup>2</sup>, M. Praus<sup>3</sup>, C. Miede<sup>3</sup>, O. Zenker<sup>4</sup>;  
<sup>1</sup>CSL Behring LLC, King of Prussia, PA, <sup>2</sup>CSL Behring AG, Bern, SWITZERLAND, <sup>3</sup>Accovion GmbH, Marburg, GERMANY, <sup>4</sup>CSL Behring GmbH, Marburg, GERMANY.
- 730 Increased Frequency of Infections at the End of the IVIG Dosing Cycle: Effect Characterization from Three Phase III Studies**  
M. Bexon<sup>1</sup>, J. S. Baggish<sup>2</sup>, M. Rojavin<sup>2</sup>, M. Berger<sup>2</sup>, O. Zenker<sup>3</sup>;  
<sup>1</sup>CSL Behring AG, Berne, SWITZERLAND, <sup>2</sup>CSL Behring LLC, King of Prussia, PA, <sup>3</sup>CSL Behring GmbH, Marburg, GERMANY.
- 731 Evaluation of the Relationship between Injection Site Reaction Rate and SCIG Doses in Patients with Primary Immunodeficiencies**  
O. Zenker<sup>1</sup>, M. Rojavin<sup>2</sup>, J. Baggish<sup>2</sup>, M. Bexon<sup>3</sup>;  
<sup>1</sup>CSL Behring GmbH, Marburg, GERMANY, <sup>2</sup>CSL Behring LLC, King of Prussia, PA, <sup>3</sup>CSL Behring AG, Berne, SWITZERLAND.
- 732 Multiple-allergen And Single-allergen Immunotherapy Strategies In Polysensitized Patients: Looking At The Published Evidence**  
P. Demoly<sup>1</sup>, L. Cox<sup>2</sup>, T. B. Casale<sup>3</sup>, P. Moingeon<sup>4</sup>, M. A. Calderon<sup>5</sup>;  
<sup>1</sup>Allergy Division, Pneumology Department, INSERM U657, Hpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, FRANCE, <sup>2</sup>Department of Medicine, Nova Southeastern University, Davie, FL, <sup>3</sup>Division of Allergy and Immunology,

MONDAY

- Department of Medicine, Creighton University, Omaha, NE, <sup>4</sup>Stalergenes, Antony, FRANCE, <sup>5</sup>Section of Allergy and Clinical Immunology, Imperial College-NHLI, Royal Brompton Hospital, London, UNITED KINGDOM.
- 733 Adverse Reactions To Subcutaneous Allergen Immunotherapy Following Thunderstorms**  
**J. C. Turbyville;**  
Ireland Army Community Hospital, Fort Knox, KY.
- 734 Modifying Target Doses and Premedication Protocols Results in Less Systemic Reactions to Aeroallergen Rush Immunotherapy (RIT)**  
**M. L. Alvares,** D. Min, K. Hilton, T. Walton, D. A. Khan;  
UT Southwestern, Dallas, TX.
- 735 Systemic Reactions to Allergen Immunotherapy in a Community Practice**  
**D. Gadde<sup>1</sup>,** P. Creticos<sup>2</sup>, D. Beakes<sup>3</sup>, L. Wu<sup>3</sup>, B. Joseph<sup>3</sup>, K. Fouche<sup>3</sup>, J. Gadde<sup>3</sup>;  
<sup>1</sup>George Washington, Washington, DC, DC, <sup>2</sup>Creticos Research Group, Annapolis, MD, <sup>3</sup>Allergy and Asthma Specialists of Greater Washington, Warrenton, VA.
- 736 Allergen Immunotherapy Administration Errors: Assessing The Reporting Measure**  
**S. Patel,** K. L. Rossow, P. LaCanne, K. Poe, J. T. C. Li, M. A. Rank;  
Mayo Clinic, Rochester, MN.
- 737 Relationship Between Ragweed Specific IgE and Acute Allergic Events During Ragweed Rush Immunotherapy (RIT)**  
**P. S. Jonsson-Razdan<sup>1</sup>,** J. Stokes<sup>1</sup>, P. D. Turner<sup>1</sup>, R. Walters<sup>1</sup>, W. W. Busse<sup>2</sup>, J. N. Kline<sup>3</sup>, Z. K. Ballas<sup>3</sup>, T. B. Casale<sup>1</sup>;  
<sup>1</sup>Creighton University Medical Center, Omaha, NE, <sup>2</sup>University of Wisconsin, Madison, WI, <sup>3</sup>University of Iowa, Iowa City, IA.
- 742 A Non-redundant Role of ERK1 in Th2 Cell Differentiation, Survival and Development of Asthma**  
**R. Alam<sup>1</sup>,** N. Goplen<sup>1</sup>, Z. Karim<sup>1</sup>, L. Guo<sup>1</sup>, Y. Zhuang<sup>1</sup>, H. Huang<sup>1</sup>, M. M. Gorska<sup>1</sup>, E. Gelfand<sup>1</sup>, G. Pages<sup>2</sup>, J. Pouyssegur<sup>2</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Nice Sophia Antipolis, Nice, FRANCE.
- 743 Ex Vivo Characterization of the Epitope-Specific T Cell Response to Alternaria**  
**J. H. DeLong<sup>1</sup>,** E. Wambre<sup>1</sup>, R. LaFond<sup>1</sup>, N. Torres-Chinn<sup>1</sup>, E. A. James<sup>1</sup>, D. Robinson<sup>2</sup>, W. W. Kwok<sup>1</sup>;  
<sup>1</sup>Benaroya Research Institute, Seattle, WA, <sup>2</sup>Virginia Mason Medical Center, Seattle, WA.
- 744 Th2 Profile of Stimulated PBMC from Atopic Patients is Enhanced by C. Pneumoniae and is Switched to Th1 by Lactobacillus GG**  
**D. Erstein,** R. Joks, H. Durkin, S. Kohlhoff;  
SUNY Downstate Medical Center, Brooklyn, NY.
- 745 Control Of T-regulatory Cells By Stat6 During Allergic Lung Inflammation**  
**N. Dorsey<sup>1</sup>,** S. Chapoval<sup>1</sup>, E. Smith<sup>1</sup>, J. Skupsky<sup>1</sup>, D. Scott<sup>1,2</sup>, A. Keegan<sup>1</sup>;  
<sup>1</sup>University of Maryland Baltimore School of Medicine, Baltimore, MD, <sup>2</sup>Uniformed Services University, Bethesda, MD.

## Poster Session

## Poster Session

## T Cells

4211

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 738 Vaccination Of Mice With Plasmid DNA Encoding Der p 2 And Blo t 5 Induced a CD4 T Cell Response To Allergen Proteins**  
**K. H. S. Wong,** G. M. Grotenbreg, D. M. Kemeny;  
National University of Singapore, Singapore, SINGAPORE.
- 739 Effects of Nasal Allergen Challenge on T cell signature in Peripheral Blood in Patients with Severe Seasonal Allergic Rhinitis**  
**M. H. Shamji,** V. Bellido, G. Scadding, J. A. Leyhadi, M. Calderon, A. Togias, N. Tcho, M. Plaut, L. Turka, D. Phippard, S. Durham;  
Imperial College London, South Kensington, UNITED KINGDOM.
- 740 Involvement Of Polycyclic Aromatic Hydrocarbons In Th2/Th17 Polarization In Allergic Diseases**  
**C. Ple<sup>1</sup>,** Y. Fan<sup>1</sup>, H. Vorng<sup>1</sup>, I. Azzaoui<sup>1</sup>, S. Ait Yahia<sup>1</sup>, G. Lazenc<sup>2</sup>, B. Wallaert<sup>1,3</sup>, A. Tscopoulos<sup>1,3</sup>;  
<sup>1</sup>Pulmonary Immunity-CIIL, Lille, FRANCE, <sup>2</sup>INSERM U844, Montpellier, FRANCE, <sup>3</sup>Clinique des Maladies Respiratoires et Centre Hospitalier Régional et Universitaire de Lille, Lille, FRANCE.
- 741 IL-4 Controls The Phenotypic Conversion Of Effector Memory CD8<sup>+</sup> T Cells To IL-13-Producing Cells That Enhance Allergen-Induced Airway Hyperresponsiveness And Inflammation**  
**Y. Jia,** K. Takeda, J. Han, A. Joetham, J. J. Lucas, E. W. Gelfand;  
National Jewish Health, Denver, CO.

## Cytokines and Chemokines

4212

Session Time: Monday, March 5, 2012,  
9:45 AM - 10:45 AM

- 746 Exposure to Airborne Allergens Induces Rapid Extracellular Release of Stored IL-1b from Airway Epithelial Cells**  
**H. Kouzaki<sup>1,2</sup>,** K. Iijima<sup>2</sup>, T. Kobayashi<sup>2</sup>, S. OGrady<sup>3</sup>, H. Kita<sup>2,4</sup>;  
<sup>1</sup>Otorhinolaryngology, Shiga University of Medical Science, Otsu, Shiga, JAPAN, <sup>2</sup>Division of Allergic Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN, <sup>3</sup>Departments of Integrated Biology and Physiology and Animal Science, University of Minnesota, St. Paul, MN, <sup>4</sup>Department of Immunology, Mayo Clinic, Rochester, MN.
- 747 Changes in Serum Vascular Endothelial Growth Factor and Interleukin-5 in Atopic Children With Mycoplasma Pneumonia**  
**J. Oh,** J. Kim, Y. Jeong, H. Lee;  
Hanyang University Guri Hospital, Kyunggi-do, KOREA, REPUBLIC OF.
- 748 Serum TSLP and IL-33 Levels are Lower in Young Children Raised on Farms**  
**M. C. Bell,** K. A. Grindle, C. J. Tisler, R. F. Lemanske, Jr., J. E. Gern;  
University of Wisconsin Hospital and Clinics, Madison, WI.
- 749 Endotoxin Challenge Increases Production of IL-1β in the Peripheral Blood but not in Sputum of Allergic Asthmatics**  
**A. R. Auerbach,** W. Wu, D. Peden, M. Hernandez;  
UNC Hospitals, Durham, NC.
- 750 Cysteine Proteases Induce Production and Extracellular Release of IL-33 in Airway Epithelial Cells**  
**S. Seno<sup>1,2</sup>,** K. Iijima<sup>1</sup>, S. M. O'Grady<sup>3</sup>, H. Kita<sup>1</sup>;  
<sup>1</sup>Mayo Clinic, Rochester, MN, <sup>2</sup>Department of Otorhinolaryngology, Shiga University of Medical Science, Otsu, JAPAN, <sup>3</sup>Departments of Integrated Biology and Physiology and Animal Science, University of Minnesota, St. Paul, MN.



**751 Novel Analysis Methods for Longitudinal Cytokine Response Data in a Birth Cohort Study**

C. M. Visness<sup>1</sup>, K. F. Jaffee<sup>1</sup>, A. Calatroni<sup>1</sup>, R. A. Wood<sup>2</sup>, P. J. Gergen<sup>3</sup>, J. E. Gern<sup>4</sup>;

<sup>1</sup>Rho Federal Systems Division, Inc., Chapel Hill, NC, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Division of Allergy, Immunology, and Transplantation, National Institutes of Health, Bethesda, MD, <sup>4</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI.

**752 IL-17A-mediated STAT6 Independent Mucus Production in Mice**

M. G. Boswell<sup>1</sup>, D. C. Newcomb<sup>1</sup>, K. Goleniewska<sup>1</sup>, S. Reiss<sup>1</sup>, K. B. Adler<sup>2</sup>, R. S. Peebles, Jr<sup>1</sup>;

<sup>1</sup>Vanderbilt University Medical School, Nashville, TN, <sup>2</sup>North Carolina State University, Nashville, TN.

**753 The Effect of TNF- alpha on Glucocorticoid Receptor Translocation**

I. A. Etuk, L. Kaphalia, W. J. Calhoun;  
The University of Texas Medical Branch, Galveston, TX.

**754 Bacterial PAMP Induced Cytokine Profiles in Children from a Boston-area Birth Cohort**

J. E. Sordillo<sup>1</sup>, T. Webb<sup>1</sup>, E. Hoffman<sup>2</sup>, R. Kelly<sup>1</sup>, P. Wallace<sup>3</sup>, M. Rickert<sup>3</sup>, T. A. Platts-Mills<sup>4</sup>, D. R. Gold<sup>1</sup>;

<sup>1</sup>Channing Laboratory, Boston, MA, <sup>2</sup>Harvard School of Public Health, Boston, MA, <sup>3</sup>Roswell Park Cancer Institute, Buffalo, NY, <sup>4</sup>University of Virginia, Charlottesville, VA.

**755 Reduced Cord Blood IFN-γ and IL-10 are Associated with Reduced Lung Function at School Age**

S. R. Durrani, R. F. Lemanske, V. Rajamanickam, R. E. Gangnon, J. E. Gern, D. J. Jackson;

University of Wisconsin School of Medicine and Public Health, Madison, WI.

**756 Asthmatics Infected with Rhinovirus (RV) Demonstrate Up-regulation of IL-15**

J. L. Kennedy, J. W. Steinke, D. Murphy, H. Carper, A. P. Stallings, T. A. E. Platts-Mills, L. Borish, P. W. Heymann;

University of Virginia, Charlottesville, VA.

**Oral Abstract Session**

**Update in Asthma Therapeutics and Monitoring**

4601

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

**757 Early Non-Respiratory Symptom Patterns Precede Loss of Asthma Control in Children**

L. Newton<sup>1</sup>, Y. Osei-Akosa<sup>2</sup>, R. Strunk<sup>3</sup>, M. Krauss<sup>3</sup>, L. Bacharier<sup>3</sup>, J. Garbutt<sup>3</sup>, K. Rivera-Spoljaric<sup>3</sup>;

<sup>1</sup>Cleveland Clinic, Cleveland, OH, <sup>2</sup>Washington University in St. Louis, St. Louis, MO, <sup>3</sup>Washington University School of Medicine, St. Louis, MO.

**758 Adverse Reaction Preparedness for Allergen Immunotherapy in the Primary Care Setting**

V. Reddy, P. Jhaveri, T. J. Craig;

Division of Pulmonary, Allergy, and Critical Care Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA.

**759 Clinical Efficacy and Safety of Combined Mometasone Furoate and Formoterol in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)**

E. Kerwin<sup>1</sup>, D. P. Tashkin<sup>2</sup>, C. E. Matiz-Bueno<sup>3</sup>, D. E. Doherty<sup>4</sup>, T.

Shekar<sup>5</sup>, S. Banerjee<sup>5</sup>, B. Knorr<sup>5</sup>, H. Staudinger<sup>5</sup>;

<sup>1</sup>Clinical Research Institute of Southern Oregon, Medford, OR,

<sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA,

<sup>3</sup>Fundacion Salud Bosque, Bogota, COLOMBIA, <sup>4</sup>University of Kentucky, Lexington, KY, <sup>5</sup>Merck Research Laboratories, Kenilworth, NJ.

**760 ASHMI (Antiasthma Simplified Herbal Medicine Intervention) is a Potent Inhibitor of Interferon-α Production from Human Dendritic Cells by Increasing Pro-inflammatory Cytokines**

J. R. Tversky;

The Mount Sinai School of Medicine, New York, NY.

**761 Efficacy and Safety of AMG 853 in Asthma: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study**

W. W. Busse<sup>1</sup>, S. E. Wenzel<sup>2</sup>, E. O. Meltzer<sup>3</sup>, E. M. Kerwin<sup>4</sup>, M. C. Liu<sup>5</sup>, N. Zhang<sup>6</sup>, Y. Chon<sup>7</sup>, J. Lin<sup>6</sup>, S. Lin<sup>6</sup>;

<sup>1</sup>University of Wisconsin, Madison, WI, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Allergy and Asthma Medical Group and Research Center, San Diego, CA, <sup>4</sup>Clinical Research Institute of Southern Oregon, PC, Medford, OR, <sup>5</sup>Johns Hopkins Asthma and Allergy Center, Baltimore, MD, <sup>6</sup>Amgen Inc., Thousand Oaks, CA, <sup>7</sup>Amgen, Inc., Thousand Oaks, CA.

**Oral Abstract Session**

**Immunoglobulin and Biological Therapy**

4602

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

**762 The Sialylated Fraction Of IVIg Suppresses Th2-driven Airway Inflammation Via The Induction Of Tolerogenic Dendritic Cells**

A. Massoud<sup>1</sup>, A. Ablona<sup>1</sup>, C. Piccirillo<sup>2</sup>, W. Mourad<sup>3</sup>, B. Mazer<sup>1</sup>;

<sup>1</sup>McGill University / Meakins Christie Laboratories, Montreal, QC, CANADA, <sup>2</sup>McGill University / Dept. of Immunology, Montreal, QC, CANADA, <sup>3</sup>Universit de Montral / L'Hpital Saint-Luc, Montreal, QC, CANADA.

**763 The Effect of Anti-IL-5 Therapy on Esophageal Mastocytosis in Pediatric Eosinophilic Esophagitis**

I. M. Otani, M. Bhagat, R. O. Newbury, R. Dohil, D. H. Broide, S. S. Aceves;

University of California, San Diego, La Jolla, CA.

**764 Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PID)**

I. Melamed<sup>1</sup>, R. L. Wasserman<sup>2</sup>, M. Stein<sup>3</sup>, J. Puck<sup>4</sup>, S. Gupta<sup>5</sup>, W. Engl<sup>6</sup>, H. Leibl<sup>6</sup>, D. Gelmont<sup>7</sup>, R. I. Schiff, on behalf of IGSC 10% rHuPH20 Study Group<sup>7</sup>;

<sup>1</sup>Allergy Associates of the Palm Beaches, North Palm Beach, FL, <sup>2</sup>Dallas Allergy Immunology, Dallas, TX, <sup>3</sup>IMMUNOe, Centennial, CO, <sup>4</sup>University of California, San Francisco, CA, <sup>5</sup>University of California, Irvine, CA, <sup>6</sup>Baxter BioScience, Vienna, AUSTRIA, <sup>7</sup>Baxter BioScience, Westlake Village, CA.

**765 A Scoring System to Guide Decisions on Immunoglobulin Replacement Treatment in Hypogammaglobulinemia**

S. Agarwal, C. Cunningham-Rundles;

Mount Sinai School of Medicine, New York, NY.

**766 Long-term Safety And Efficacy Of Mepolizumab For The Treatment Of Hypereosinophilic Syndrome**

A. D. Klion<sup>1</sup>, F. E. Roufosse<sup>2</sup>, J. Kahn<sup>3</sup>, G. J. Gleich<sup>4</sup>, L. B. Schwartz<sup>5</sup>, A. Singh<sup>6</sup>, L. J. Rosenwasser<sup>7</sup>, J. Denburg<sup>8</sup>, J. Ring<sup>9</sup>,

**MONDAY**

M. E. Rothenberg<sup>10</sup>, J. Sheikh<sup>11</sup>, A. E. Haig<sup>12</sup>, S. Mallett<sup>13</sup>, D. Templeton<sup>14</sup>, H. Ortega<sup>14</sup>;

<sup>1</sup>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, <sup>2</sup>Universite Libre Bruxelles, Brussels, BELGIUM, <sup>3</sup>Hopital Foch, Suresnes, FRANCE, <sup>4</sup>University of Utah School of Medicine, Salt Lake City, UT, <sup>5</sup>Virginia Commonwealth University, Richmond, VA, <sup>6</sup>Royal North Shore Hospital, Sydney, AUSTRALIA, <sup>7</sup>Children's Mercy Hospital, Kansas City, MO, <sup>8</sup>Cancer Care Nova Scotia, Halifax, NS, CANADA, <sup>9</sup>Technische Universitat Munchen, Munich, GERMANY, <sup>10</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>11</sup>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, <sup>12</sup>GlaxoSmithKline, King of Prussia, PA, <sup>13</sup>GlaxoSmithKline, Middlesex, UNITED KINGDOM, <sup>14</sup>GlaxoSmithKline, Research Triangle Park, NC.

## Oral Abstract Session

### The Effect of Pollution on Allergic Disease

4603

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

- 767 Postnatal Ozone Exposure Enhances House Dust Mite Induced Airway Hyperresponsiveness Without Increasing Inflammation**  
**K. Gabehart**, K. A. Correll, J. Yang, M. L. Collins, J. E. Loader, C. W. White, A. Dakhama;  
National Jewish Health, Denver, CO.
- 768 Frequent Allergy Symptoms Among Children Living Near The World Trade Center Associated With Elevated Peripheral Airways Resistance**  
**Y. Chen**<sup>1</sup>, K. Pan<sup>1</sup>, Y. Yan<sup>2</sup>, T. Khaimchayev<sup>1</sup>, Y. Aronova<sup>1</sup>, K. Savary<sup>1</sup>, J. Chen<sup>3</sup>, A. M. Szema<sup>1</sup>;  
<sup>1</sup>Stony Brook University Department of Medicine, Stony Brook, NY, <sup>2</sup>Stony Brook University Department Preventative Medicine, Stony Brook, NY, <sup>3</sup>Stony Brook University Department of Preventative Medicine, Stony Brook, NY.
- 769 Annual New York City Trends Of Ambient Fine Particulate Matter, Black Carbon And Ambient Metals Implicated In Airway Disease**  
**F. L. Kuang**<sup>1</sup>, K. H. Jung<sup>2</sup>, B. Yan<sup>3</sup>, S. N. Chillrud<sup>3</sup>, R. L. Miller<sup>2,4</sup>;  
<sup>1</sup>Internal Medicine Residency, Department of Medicine, College of Physicians and Surgeons, Columbia University, PH8E 630 W. 168th St., New York, NY, <sup>2</sup>Division of Pulmonary, Allergy and Critical Care of Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, PH8E 630 W. 168th St., New York, NY, <sup>3</sup>Lamont-Doherty Earth Observatory, Columbia University, 61 Rt. 9W, Palisades, NY, <sup>4</sup>Mailman School of Public Health, Department of Environmental Health Sciences, Columbia University, 722 W. 168 St., New York, NY.
- 770 Relationship Between Environmental Phenols And Aeroallergen And Food Allergies In The US: Results From The National Health And Nutrition Examination Survey 2005-2006**  
**N. Vernon**, E. Jerschow, S. Jariwala, G. de Vos, D. Rosenstreich;  
Montefiore Medical Center, Bronx, NY.
- 771 Distance From A Heavily Trafficked Highway Is Implicated In The Presence Of Allergic Rhinoconjunctivitis And Asthma In Adults**  
**M. Vastardi**<sup>1</sup>, I. Katayeva<sup>2</sup>, D. Puebla-Neira<sup>2</sup>, R. Joks<sup>1</sup>;  
<sup>1</sup>SUNY Downstate Medical Center, Brooklyn, NY, <sup>2</sup>Lutheran Medical Center, Brooklyn, NY.

## Oral Abstract Session

### Genetic and Other Mechanisms of Atopic & Skin Diseases

4604

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

- 772 Effect of Th2 and Th17 Cytokines on Human Epidermal Tight Junctions**  
**A. De Benedetto**<sup>1</sup>, T. Yoshida<sup>1</sup>, I. Kuo<sup>1</sup>, S. N. Georas<sup>1</sup>, A. Ivanov<sup>1</sup>, D. Y. Leung<sup>2</sup>, L. A. Beck<sup>1</sup>;  
<sup>1</sup>University of Rochester, Rochester, NY, <sup>2</sup>National Jewish Health, Denver, CO.
- 773 The Association Between HLA B7 Alleles and Human Atopic Dermatitis Complicated by Eczema Herpeticum**  
**R. A. Mathias**<sup>1</sup>, N. Rafaels<sup>1</sup>, C. Vergara<sup>1</sup>, M. Boguniewicz<sup>2</sup>, T. Hata<sup>3</sup>, L. Schneider<sup>4</sup>, J. M. Hanifin<sup>5</sup>, R. L. Gallo<sup>3</sup>, T. H. Beaty<sup>6</sup>, L. A. Beck<sup>7</sup>, K. C. Barnes<sup>1</sup>, D. Y. Leung<sup>2</sup>;  
<sup>1</sup>Johns Hopkins University, Baltimore, MD, <sup>2</sup>National Jewish Health, Denver, CO, <sup>3</sup>UCSD Medical Center, San Diego, CA, <sup>4</sup>Children's Hospital Boston, Boston, MA, <sup>5</sup>Oregon Health & Science University, Portland, OR, <sup>6</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>7</sup>University of Rochester Medical Center, Rochester, NY.
- 774 C3a Receptor (C3aR) is Important for Viral Containment in Mice Inoculated with Vaccinia Virus (VV) at Sites of Allergic Skin Inflammation**  
**L. Kumar**, R. S. Geha;  
Division of Immunology, Children's Hospital, Boston and Department of Pediatrics, Harvard Medical School, Boston, MA.
- 775 Staphylococcus Aureus Alpha-Toxin Augments Viral Load In Keratinocytes**  
**L. Bin**<sup>1</sup>, E. Goleva<sup>1</sup>, J. Streib<sup>1</sup>, C. Hall<sup>1</sup>, P. M. Schlievert<sup>2</sup>, D. Y. Leung<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>The University of Iowa, Iowa City, IA.
- 776 Genetic Variants Associated with Asthma and Related Phenotypes are Also Risk Factors for Food Allergy**  
**C. Vergara**<sup>1</sup>, N. Rafaels<sup>1</sup>, L. Gao<sup>1</sup>, C. Foster<sup>1</sup>, M. Campbell<sup>1</sup>, J. Potee<sup>1</sup>, R. Lewis<sup>1</sup>, T. H. Beaty<sup>2</sup>, S. Jones<sup>3</sup>, A. W. Burks<sup>4</sup>, S. Sicherer<sup>5</sup>, R. A. Wood<sup>6</sup>, D. Stablein<sup>6</sup>, L. A. Beck<sup>7</sup>, H. A. Sampson<sup>8</sup>, A. H. Liu<sup>8</sup>, D. Y. Leung<sup>7,8</sup>, R. A. Mathias<sup>1,9</sup>, K. C. Barnes<sup>1</sup>;  
<sup>1</sup>Division of Allergy and Clinical Immunology, Department of Medicine, The Johns Hopkins University, Baltimore, MD, <sup>2</sup>Department of Epidemiology, Bloomberg School of Public Health, JHU, Baltimore, MD, <sup>3</sup>University of Arkansas for Medical Sciences, Little Rock, AR, <sup>4</sup>Duke University Medical Center, Durham, NC, <sup>5</sup>Mount Sinai School of Medicine, New York, NY, <sup>6</sup>The EMMES Corporation, Rockville, MD, <sup>7</sup>Department of Dermatology, University of Rochester Medical Center, Rochester, NY, <sup>8</sup>Department of Pediatrics, National Jewish Health, Denver, CO, <sup>9</sup>Division of General Internal Medicine, Department of Medicine, The Johns Hopkins University, Baltimore, MD.

## Oral Abstract Session

### New Insights Into Allergy and Asthma Assessment

4605

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

- 777 Reliability, Validity, and Responsiveness of the Asthma Control Questionnaire among Pediatric Patients**

**J. M. Nguyen<sup>1</sup>, J. Holbrook<sup>2</sup>, C. Bime<sup>1</sup>, W. G. Teague<sup>3</sup>, R. A. Wise** for the American Lung Association-ACRC.<sup>1</sup>;

<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>University of Virginia Children's Hospital, Charlottesville, VA.

**778 A Retrospective Analysis of Anti-Allergy Drug Efficacy tested in an Environmental Exposure Chamber (EEC) Model compared to that observed in the Traditional Allergy Field Trials demonstrates the clinical relevance of allergen exposure models**

**A. Salapatek, N. Camuso, A. Amhed, V. Nelson;** Cetero Research, Mississauga, ON, CANADA.

**779 Online Allergy Surveys - is There an App For That? A Quantitative and Qualitative Study of Allergic Rhinitis Patients During a Pollen Season**

**D. A. Dalan;**

Allergy and Asthma Care Center, Fargo, ND.

**780 A Personalized Care Platform: Incorporating Structured Data In Allergy Clinical Care**

**J. Meng<sup>1</sup>, C. Barnes<sup>2</sup>, C. Ciaccio<sup>1</sup>, J. Portnoy<sup>2</sup>, K. Kelly<sup>2</sup>, G. A. Salzman<sup>3</sup>, T. Carver<sup>4</sup>, P. Dowling<sup>2</sup>, B. Jones<sup>2</sup>, M. Amado<sup>2</sup>, C. Miller<sup>2</sup>, K. Kennedy<sup>2</sup>, L. J. Rosenwasser<sup>1</sup>;**

<sup>1</sup>Pediatric Immunology Research, Division of Allergy Clinics, the Children's Mercy Hospital, Kansas City, MO, <sup>2</sup>Division of Allergy Clinics, the Children's Mercy Hospital, Kansas City, MO, <sup>3</sup>Respiratory and Critical Care Medicine, UMKC School of Medicine, Kansas City, MO, <sup>4</sup>Division of Pediatric Pulmonary and Respiratory Care, Children's Mercy Hospital, Kansas City, MO.

**781 The First Phase of Instrument Development: The Conventional and Alternative Management (CAM) for Asthma Questionnaire**

**M. George<sup>1</sup>, C. Rand<sup>2</sup>, J. A. Shea<sup>3</sup>;**

<sup>1</sup>University of Pennsylvania School of Nursing, Philadelphia, PA, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>University of Pennsylvania School of Medicine, Philadelphia, PA.

## Oral Abstract Session

### Mechanisms of Rhinitis

4606

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

**782 Local Allergic Rhinitis is Highly Prevalent in a Population Attended for the Evaluation of Rhinitis**

**C. Rodon Segovia<sup>1</sup>, P. Campo Mozo<sup>1</sup>, L. Galindo Reyes<sup>2</sup>, G. Campos<sup>1</sup>, J. L. Rodriguez-Bada<sup>2</sup>, C. De Leyva<sup>1</sup>, M. J. Torres Jaen<sup>1</sup>, M. Blanca Gomez<sup>1</sup>;**

<sup>1</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN, <sup>2</sup>Research Laboratory, Carlos Haya Hospital-Fundacin IMABIS, Malaga, SPAIN.

**783 Interleukin-35 Suppresses Allergen-specific Th2 Response in Patients with Grass pollen induced Seasonal Allergic Rhinitis**

**D. Achkova, F. W. Chung, J. A. Leyhadi, G. W. Scadding, J. Charlesworth, D. Phippard, S. Durham, M. H. Shamji;** Imperial College London, South Kensington, UNITED KINGDOM.

**784 Effects of Repetitive Allergen Challenge on Expression of TGF- $\beta$ , Activin -A and Its Receptor ALK4 in Nasal Mucosa of Allergic Rhinitis**

**H. Wu, N. Orban, M. Jacobson, D. Lee, S. R. Durham;** Imperial College London, NHLI, London, UNITED KINGDOM.

**785 Basophils In Peripheral Blood can be Sensitized in Local Allergic Rhinitis**

**E. Gomez<sup>1</sup>, C. Rondon<sup>2</sup>, P. Campo<sup>2</sup>, L. Galindo Reyes<sup>1</sup>, J. A. Huer-tas<sup>2</sup>, L. Melendez<sup>1</sup>, J. Garcia Campos<sup>2</sup>, M. J. Torres<sup>2</sup>, M. Blanca<sup>2</sup>;** <sup>1</sup>Research Laboratory, Carlos Haya Hospital-Fundacion IMABIS, Malaga, SPAIN, <sup>2</sup>Allergy Service, Carlos Haya Hospital, Malaga, SPAIN.

**786 Evaluation of Thymic Stromal Lymphopoietin (TSLP) and its Receptor in Adults with Allergic Rhinitis Following Controlled Allergen Challenge in the Environmental Exposure Unit (EEU)**

**T. Batool<sup>1</sup>, J. Thiele<sup>2</sup>, A. K. Ellis<sup>2</sup>;**

<sup>1</sup>McMaster University, Hamilton, ON, CANADA, <sup>2</sup>Queen's University, Kingston, ON, CANADA.

## Oral Abstract Session

### Myeloid Cells in Allergic Inflammation

4607

Session Time: Monday, March 5, 2012,  
2:00 PM - 3:15 PM

**787 Group V sPLA2 is Required in Alternative Activated Macrophages for the Development of Allergic Pulmonary Inflammation**

**S. Ohta, G. Giannattasio, W. Xing, J. A. Boyce, B. Balestrieri;** Brigham and Women's Hospital / Harvard Medical School, Boston, MA.

**788 Thioredoxin is Positively Associated with Eosinophils in Induced Sputum from Patients with Asthma**

**J. M. Hartman, A. Hastie, W. C. Moore, B. Rector, S. P. Peters, E. R. Bleecker, M. S. Dykewicz;** NHLBI Severe Asthma Research Program, Wake Forest University School of Medicine, Winston-Salem, NC.

**789 Histamine is Necessary for IL-4-driven Eosinophilic Allergic Responses**

**J. A. Swartzendruber, A. J. Byrne, P. J. Bryce;** Northwestern University, Chicago, IL.

**790 Hypoxia Regulates Activation/Inhibitory Receptors on Eosinophils**

**A. H. Nissim Ben Efraim<sup>1</sup>, L. Karra<sup>1</sup>, Y. Minai-Fleminger<sup>1</sup>, R. Elia-shar<sup>2</sup>, F. Levi-Schaffer<sup>1</sup>;** <sup>1</sup>The Hebrew University of Jerusalem, Jerusalem, ISRAEL, <sup>2</sup>Department of Otolaryngology/Head and Neck Surgery, Hadassah Hebrew University Medical Center, Jerusalem, ISRAEL.

**791 Mechanisms Involved In IL-5 Enhancement Of Siglec-8-induced Eosinophil Apoptosis: Role For Reactive Oxygen Species (ROS)-enhanced MEK/ERK Activation**

**G. Kano<sup>1</sup>, B. Bochner<sup>2</sup>, N. Zimmermann<sup>1</sup>;**

<sup>1</sup>Cincinnati children's Hospital, Cincinnati, OH, <sup>2</sup>Johns Hopkins Asthma and Allergy Center, Baltimore, MD.

## Poster Session

### Critical Asthma Issues

5201

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

**792 The Effect of Aerobic Exercise on Asthma-related Responses in Adults**

MONDAY

- A. Boyd, K. Estell, M. Dransfield, L. M. Schwiebert;  
University of Alabama Birmingham, Birmingham, AL.
- 793 The Effects Of Asthma On REM-related Sleep-disordered Breathing In Children With Obstructive Sleep Apnea (OSA)**  
M. J. Gutierrez<sup>1</sup>, C. L. Nino<sup>2</sup>, G. Graff<sup>3</sup>, G. Nino<sup>3,4</sup>;  
<sup>1</sup>Division of Pulmonary, Allergy and Critical Care Medicine, Pennsylvania State University College of Medicine, Hershey, PA, <sup>2</sup>Department of Electronics Engineering, Javeriana University, Bogota, COLOMBIA, <sup>3</sup>Division of Pediatric Pulmonary Medicine, Pennsylvania State University College of Medicine, Hershey, PA, <sup>4</sup>Penn State Sleep Research and Treatment Center, Pennsylvania State University College of Medicine, Hershey, PA.
- 794 Positive Bronchial Responses To *D. Pteronyssinus* In Subjects With Confirmed Local Allergic Rhinitis**  
P. Campo<sup>1</sup>, C. Mayorga<sup>2</sup>, C. Rondon<sup>1</sup>, L. Galindo<sup>1</sup>, R. Garcia<sup>1</sup>, J. Garcia-Campos<sup>1</sup>, L. Melendez<sup>2</sup>, J. Rodriguez-Bada<sup>2</sup>, M. Blanca<sup>1</sup>;  
<sup>1</sup>Allergy Department, Hospital Carlos Haya, Malaga, SPAIN, <sup>2</sup>Allergy Laboratory, F. IMABIS, Malaga, SPAIN.
- 795 Relationships Between Airway Hyperresponsiveness to Methacholine, Blood Eosinophil Markers and FeNO in Asthmatic Children**  
Y. Yoo<sup>1,2</sup>, S. Bauer<sup>1</sup>, K. S. La<sup>1</sup>, H. S. Seo<sup>1</sup>, S. C. Seo<sup>2</sup>, D. J. Song<sup>1,2</sup>, J. T. Choung<sup>1,2</sup>;  
<sup>1</sup>Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Environmental Health Center, Korea University Anam Hospital, Seoul, KOREA, REPUBLIC OF.
- 796 Comparison of Respiratory Impedance Data Measured by the MostGraph and Master Screen IOS in Adults with Bronchial Asthma**  
T. Shimoda<sup>1</sup>, Y. Obase<sup>2</sup>, M. Imaoka<sup>1</sup>, R. Kishikawa<sup>1</sup>, T. Iwanaga<sup>1</sup>;  
<sup>1</sup>Fukuoka National Hospital, Fukuoka, JAPAN, <sup>2</sup>Kawasaki Medical School, Kurashiki, JAPAN.
- 797 Maternal Diet during Pregnancy and Wheeze and Eczema in Infants; the Japanese Birth Cohort (T-CHILD) Study**  
M. Narita<sup>1</sup>, D. Qiu<sup>2</sup>, M. Hamaguchi<sup>1</sup>, M. Doi<sup>1</sup>, M. Futamura<sup>1</sup>, N. Sakamoto<sup>2</sup>, H. Saito<sup>3</sup>, Y. Ohya<sup>1</sup>;  
<sup>1</sup>Division of Allergy, National Center for Child Health and Development, Tokyo, JAPAN, <sup>2</sup>Division of Epidemiology, Research Institute, National Center for Child Health and Development, Tokyo, JAPAN, <sup>3</sup>Research Institute, National Center for Child Health & Development, Tokyo, JAPAN.
- 798 The Elevation Of Th2 cytokines In Airway with Rsv Infection Is High Risk For Recurrent Wheeze In Young Children**  
H. MURAI<sup>1,2</sup>, A. Terada<sup>3,2</sup>, S. Shimizu<sup>1</sup>, M. Asai<sup>4</sup>, M. Mizuno<sup>4</sup>, N. Kamioka<sup>1</sup>, H. Togari<sup>2</sup>;  
<sup>1</sup>Nagoya-city West medical center, Nagoya-city, Aichi, JAPAN, <sup>2</sup>Nagoya city University, Nagoya-city, Aichi, JAPAN, <sup>3</sup>Terada Kid's allergy clinic, Nagoya-city, Aichi, JAPAN, <sup>4</sup>Daido Hospital, Nagoya-city, Aichi, JAPAN.
- 799 Unmet Awareness of Allergic Asthma**  
T. M. Nsouli<sup>1</sup>, C. D. Schluckebier<sup>2</sup>, E. J. McSorley-Gerard<sup>2</sup>, C. M. Davis<sup>2</sup>, S. T. Nsouli<sup>2</sup>, S. T. Nsouli<sup>2</sup>;  
<sup>1</sup>Georgetown University, Washington, DC, <sup>2</sup>Burke Allergy and Asthma Treatment Center, Burke, VA.
- Loops to Modulate the Inflammatory Axis in Arthritis**  
M. Goldberg, O. Nadiv, N. Kovalchuk, G. Agar, Y. Beer, Y. Katz;  
Assaf Harofeh Medical Center, Zerifin, ISRAEL.
- 801 A Review of Churg-Strauss Syndrome in Childhood at the Cleveland Clinic**  
S. Gendelman, S. Spalding;  
Cleveland Clinic, Cleveland, OH.
- 802 Suppression of Delayed Type Hypersensitivity by Fullerene Derivatives**  
A. A. Babakhin<sup>1</sup>, S. M. Andreev<sup>1</sup>, E. N. Bashkatova<sup>1</sup>, M. R. Khaitov<sup>1</sup>, L. M. DuBuske<sup>2</sup>;  
<sup>1</sup>Institute of Immunology, Moscow, RUSSIAN FEDERATION, <sup>2</sup>Immunology Research Institute of New England, Gardner, MA.
- 803 Immunologic Phenotype Of GRK3-null Mice At Baseline And In Inflammatory Disease**  
R. G. Timoshchenko<sup>1</sup>, L. R. Rothlein<sup>1</sup>, M. W. McGinnis<sup>1</sup>, O. Foreman<sup>2</sup>, D. Esserman<sup>1</sup>, D. M. Lee<sup>3</sup>, D. D. Patel<sup>3</sup>, D. P. Siderovski<sup>1</sup>, T. K. Tarrant<sup>1</sup>;  
<sup>1</sup>University of North Carolina, Chapel Hill, NC, <sup>2</sup>The Jackson Laboratory, Bar Harbor, ME, <sup>3</sup>Novartis Institutes, Basel, SWITZERLAND.
- 804 Cytokine Status In Patients With Systemic Lupus Erythematosus**  
K. A. Chyzh<sup>1</sup>, A. Y. Hancharou<sup>2</sup>, T. A. Ryabzeva<sup>1</sup>, L. P. Titov<sup>2</sup>, N. F. Soroka<sup>1</sup>, L. M. DuBuske<sup>3</sup>;  
<sup>1</sup>Belarusian State Medical University, Minsk, BELARUS, <sup>2</sup>Research Institute for Epidemiology and Microbiology, Minsk, BELARUS, <sup>3</sup>Immunology Research Institute of New England, Gardner, MA.
- 805 Exhaled nitric oxide a biomarker for activity of Systemic Lupus Erythematosus in children**  
R. Karanicolas, S. Kumar, G. Henry, S. Kimble, J. Moallem;  
SUNY at Downstate, Brooklyn, NY.
- 806 Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome: Evaluation of Patients in San Diego, California**  
L. Broderick, D. Carvalho, A. Magit, W. Jiang, M. Bothwell, D. Kearns, S. Pransky, H. M. Hoffman;  
University of California, San Diego, San Diego, CA.
- 807 Clinical Features And Prognostic Factors Of Churg-strauss Syndrome**  
M. Kim<sup>1,2</sup>, S. Lee<sup>1,2</sup>, W. Song<sup>1,2</sup>, S. Lee<sup>1,2</sup>, H. Kang<sup>1,2</sup>, S. Kim<sup>1,2</sup>, S. Cho<sup>1,2</sup>, K. Min<sup>1,2</sup>, Y. Kim<sup>1,2</sup>;  
<sup>1</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, KOREA, REPUBLIC OF.
- 808 B Cell Reconstitution Following Rituximab in Autoimmune Disorders**  
P. D. Patel, A. Rubinstein;  
Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY.
- 809 Effects Of Short-chain Galacto- And Long-chain Fructo-oligosaccharides On Systemic And Local Immune Status During Pregnancy**  
J. Garssen<sup>1,2</sup>, A. Hogenkamp<sup>1</sup>, N. van Vlies<sup>1</sup>, S. Thijssen<sup>1</sup>, G. M. Dingjan<sup>1</sup>, K. Knipping<sup>1,2</sup>, L. Knippels<sup>1,2</sup>;  
<sup>1</sup>Pharmacology, Utrecht Institute for Pharmaceutical science, Faculty of Science, Utrecht University, Utrecht, NETHERLANDS, <sup>2</sup>Danone Research-Centre for Specialised Nutrition, Wageningen, NETHERLANDS.
- 810 Eosinophil And Interleukin-5 In Urine Of Patients With Systemic Lupus Erythematosus**  
V. S. F. Sales<sup>1</sup>, M. J. P. Vilar<sup>1</sup>, L. K. P. Arruda<sup>2</sup>, L. B. F. C. Souza<sup>1</sup>, A. L. S. B. Faria<sup>3</sup>, S. D. V. Medeiros<sup>1</sup>, T. N. S. Brito<sup>1</sup>;  
<sup>1</sup>Federal University of Rio Grande do Norte, Natal, BRAZIL,

## Poster Session

## Autoimmunity and Other Topics

5202

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 800 Specific Expression of Cytokine Receptor-like Factor-1 and IL-27p28 in Fibroblast-Like Synoviocytes: Potential Feedback**

<sup>2</sup>University of So Paulo (FMRP-USP), Ribeiro Preto, BRAZIL,  
<sup>3</sup>University of Uberaba, Uberaba, BRAZIL.

- 811 Immunologic and Rheumatologic Diseases Temporally Associated with *Mycoplasma pneumoniae* Infection in Children**  
**P. S. Morales**, M. Iruretagoyena, E. Talesnik, M. Lizama, A. Borzutzky;  
Pontificia Universidad Catolica de Chile, Santiago, CHILE.
- 812 Varied Manifestations and Treatment of Pediatric Wegener's Granulomatosis**  
**M. R. Shams**<sup>1</sup>, R. Kado<sup>1</sup>, N. Seth<sup>1</sup>, J. M. El-Dahr<sup>2</sup>;  
<sup>1</sup>Tulane University School of Medicine, New Orleans, LA, <sup>2</sup>Tulane University School of Medicine, Section of Pediatric Allergy and Clinical Immunology, New Orleans, LA.
- 813 Chronic Urticaria as Possible Manifestation of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)**  
**S. Huebner**, M. Nelson, B. Martinez;  
Walter Reed National Military Medical Center, Bethesda, MD.

## Poster Session

### Mechanisms of Allergy, HIV

5203

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 814 Therapeutic Effects Of Recombinant *Salmonella Typhimurium* Expressing Ccl22 mirna On Atopic Dermatitis**  
**W. Yoon**<sup>1</sup>, B. Kang<sup>1</sup>, Y. Park<sup>1</sup>, Y. Chae<sup>2</sup>, J. Choung<sup>3</sup>, Y. Yoo<sup>4</sup>;  
<sup>1</sup>Department of Life Science and Biotechnology, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Department of Pathology, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>3</sup>Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF, <sup>4</sup>Department of Pediatrics, College of Medicine, Korea University, Seoul, KOREA, REPUBLIC OF.
- 815 Development of an Airway Epithelium In Vitro Model System**  
**D. Papazian**<sup>1,2</sup>, M. Arge<sup>2</sup>, T. Chhoden<sup>2</sup>, T. Vorup-Jensen<sup>3</sup>, C. Nielsen<sup>4</sup>, K. Skjoed<sup>2</sup>, K. Lund<sup>1</sup>, P. A. Wurtzen<sup>1</sup>, S. Hansen<sup>2</sup>;  
<sup>1</sup>Pharmacology, Horsholm, DENMARK, <sup>2</sup>Molecular Medicine, Odense, DENMARK, <sup>3</sup>Medical Microbiology & Immunology, rhus, DENMARK, <sup>4</sup>Inflammation Research, Copenhagen, DENMARK.
- 816 Interleukin- 4 Induces Bronchial Epithelial Cells Barrier Dysfunction**  
**B. Saatian**, N. Meednu, F. Rezaee, L. Beck, S. N. Georas;  
University of Rochester Medical Center, Rochester, NY.
- 817 Mutants of the Major Cockroach Allergen, Bla g 2, Modulate T Cell Responses in Cockroach-Allergic Subjects**  
**P. W. Wright**<sup>1</sup>, J. Glesner<sup>2</sup>, M. Chapman<sup>2</sup>, A. Pomes<sup>2</sup>, J. Woodfolk<sup>1</sup>;  
<sup>1</sup>University of Virginia, Charlottesville, VA, <sup>2</sup>Indoor Biotechnologies Inc., Charlottesville, VA.
- 818 IgG Fc Receptor Activity *in vivo* is Under Complement Control**  
**E. Y. Wu**, H. Jiang, G. Hester, M. M. Frank;  
Duke University Medical Center, Durham, NC.
- 819 Effects of Vitamin D Deficiency on Inner City Children and Adolescents with HIV**  
**P. Poowuttikul**, E. Secord;  
Children's Hospital of Michigan, Wayne State University, Detroit, MI.

## Poster Session

### Urticaria and Angioedema

5204

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 820 Efficacy of Icatibant in Non-Laryngeal Attacks of Type I and II Hereditary Angioedema: Integrated Results from Three Phase III Trials**  
**H. Farkas**<sup>1</sup>, M. Riedl<sup>2</sup>;  
<sup>1</sup>Semmelweis University, Budapest, HUNGARY, <sup>2</sup>UCLA - David Geffen School of Medicine, Los Angeles, CA.
- 821 Efficacy of Icatibant in Laryngeal Attacks of Type I and II Hereditary Angioedema (HAE): A Pooled Analysis of Three Phase III Trials**  
**W. Lumry**<sup>1</sup>, B. Ritchie<sup>2</sup>, M. Baş<sup>3</sup>;  
<sup>1</sup>Allergy and Asthma Research Associates Research Center, Dallas, TX, <sup>2</sup>University of Alberta, Edmonton, AB, CANADA, <sup>3</sup>Technische Universität München, Munich, GERMANY.
- 822 Efficacy of Icatibant is Consistent by Attack Frequency and Baseline Severity in the Treatment of Type I and II Hereditary Angioedema (HAE) Attacks**  
**A. Reshef**<sup>1</sup>, R. Levy<sup>2</sup>, T. Craig<sup>3</sup>;  
<sup>1</sup>Sheba Medical Center, Tel-Aviv, ISRAEL, <sup>2</sup>Family Allergy and Asthma Center, Atlanta, GA, <sup>3</sup>Penn State University, Hershey, PA.
- 823 Efficacy of Icatibant for Cutaneous and Abdominal Attacks of Type I and II Hereditary Angioedema: A Pooled Analysis of Three Phase III trials**  
**A. Malbran**<sup>1</sup>, H. H. Li<sup>2</sup>;  
<sup>1</sup>Hospital Britnico de Buenos Aires, Buenos Aires, ARGENTINA, <sup>2</sup>Institute for Asthma and Allergy, Chevy Chase, MD.
- 824 Icatibant in Patients with Acquired Angioedema Who Did Not Respond to pdCIINH**  
**A. Zanichelli**<sup>1</sup>, M. Bova<sup>2</sup>, A. Coerezza<sup>3</sup>, A. Petraroli<sup>2</sup>, M. Trigiani<sup>2</sup>, M. Cicardi<sup>1</sup>;  
<sup>1</sup>Universit degli Studi di Milano, Milano, ITALY, <sup>2</sup>Universit degli Studi di Napoli Federico II, Napoli, ITALY, <sup>3</sup>Fondazione Don Carlo Gnocchi ONLUS, Milano, ITALY.
- 825 Rates of Rebound or Relapse Among Acute Attacks of Hereditary Angioedema Treated with Ecallantide in Open-Label, Repeat-Treatment Study**  
**H. H. Li**<sup>1</sup>, J. A. Bernstein<sup>2</sup>, D. F. Soteres<sup>3</sup>, M. Riedl<sup>4</sup>, W. R. Lumry<sup>5</sup>, T. J. Craig<sup>6</sup>, A. J. MacGinnitie<sup>7</sup>, R. Iarrobino<sup>8</sup>, Y. Chyung<sup>8</sup>, E. P. Shea<sup>8</sup>, W. E. Pullman<sup>8</sup>;  
<sup>1</sup>Institute for Asthma and Allergy, Wheaton, MD, <sup>2</sup>University of Cincinnati, Cincinnati, OH, <sup>3</sup>Asthma & Allergy Associates, PC, Colorado Springs, CO, <sup>4</sup>UCLA - David Geffen School of Medicine, Los Angeles, CA, <sup>5</sup>AARA Research Center, Dallas, TX, <sup>6</sup>Pennsylvania State University, Hershey, PA, <sup>7</sup>Children's Hospital Boston, Boston, MA, <sup>8</sup>Dyax Corp., Cambridge, MA.
- 826 Ecallantide Reverses Laryngeal Hereditary Angioedema Attacks: Experience from the EDEMA Clinical Development Program**  
**A. L. Sheffer**<sup>1</sup>, A. J. MacGinnitie<sup>2</sup>, M. Campion<sup>3</sup>, L. E. Stolz<sup>4</sup>, W. E. Pullman<sup>4</sup>;  
<sup>1</sup>Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Children's Hospital Boston, Boston, MA, <sup>3</sup>Independent Statistical Consultant, Newton, MA, <sup>4</sup>Dyax Corp., Cambridge, MA.
- 827 Hypersensitivity Reactions to Ecallantide: an Update of the Clinical Trial Experience and Post-Market Surveillance for Treatment of Attacks of Hereditary Angioedema**

- T. J. Craig**<sup>1</sup>, M. Riedl<sup>2</sup>, H. H. Li<sup>3</sup>, J. A. Bernstein<sup>4</sup>, A. J. MacGinnitie<sup>5</sup>, D. F. Soteres<sup>6</sup>, W. R. Lumry<sup>7</sup>, W. E. Pullman<sup>8</sup>;  
<sup>1</sup>Penn State University, Hershey, PA, <sup>2</sup>UCLA - David Geffen School of Medicine, Los Angeles, CA, <sup>3</sup>Institute for Asthma & Allergy, Wheaton, MD, <sup>4</sup>University of Cincinnati, Cincinnati, OH, <sup>5</sup>Children's Hospital Boston, Boston, MA, <sup>6</sup>Asthma and Allergy Associates, PC, Colorado Springs, CO, <sup>7</sup>AARA Research Center, Dallas, TX, <sup>8</sup>Dyax Corp., Cambridge, MA.
- 828 Prompt Reversal of Airway Obstruction Secondary to Angiotensin Converting Enzyme Inhibitor (ACEI) Induced Angioedema by Ecallantide: A Case Report**  
**J. R. Cohn**<sup>1,2</sup>, C. McDaniel<sup>2</sup>, N. Richards<sup>2</sup>, C. Au<sup>2</sup>, M. Baram<sup>2</sup>;  
<sup>1</sup>Asthma, Allergy and Pulmonary Associates, Philadelphia, PA, <sup>2</sup>Thomas Jefferson University & Hospitals, Philadelphia, PA.
- 829 Efficacy and Safety of Ecallantide Treatment for HAE Attacks in Patients Treated with Both Ecallantide and Placebo**  
**W. R. Lumry**<sup>1</sup>, H. H. Li<sup>2</sup>, A. J. MacGinnitie<sup>3</sup>, J. A. Bernstein<sup>4</sup>, D. F. Soteres<sup>5</sup>, M. Riedl<sup>6</sup>, T. J. Craig<sup>7</sup>, M. Campion<sup>8</sup>, W. E. Pullman<sup>9</sup>;  
<sup>1</sup>AARA Research Center, Dallas, TX, <sup>2</sup>Institute for Asthma & Allergy, Wheaton, MD, <sup>3</sup>Children's Hospital Boston, Boston, MA, <sup>4</sup>University of Cincinnati, Cincinnati, OH, <sup>5</sup>Asthma & Allergy Associates, PC, Colorado Springs, CO, <sup>6</sup>UCLA - David Geffen School of Medicine, Los Angeles, CA, <sup>7</sup>Pennsylvania State University, Hershey, PA, <sup>8</sup>Independent Statistical Consultant, Newton, MA, <sup>9</sup>Dyax Corp., Cambridge, MA.
- 830 Absence of Inhibitory Anti-C1 Esterase-Inhibitor Antibody Formation in Subjects Treated With C1 Esterase-Inhibitor Concentrate (Berinert®) for Successive Hereditary Angioedema Attacks**  
**D. S. Hurewitz**<sup>1</sup>, J. A. Bernstein<sup>2</sup>, A. K. Bewtra<sup>3</sup>, U. Kalina<sup>4</sup>, T. Machnig<sup>4</sup>, T. J. Craig<sup>5</sup>;  
<sup>1</sup>Allergy Clinic of Tulsa, Tulsa, OK, <sup>2</sup>University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH, <sup>3</sup>Creighton University School of Medicine, Omaha, NE, <sup>4</sup>CSL Behring, Marburg, GERMANY, <sup>5</sup>Penn State University, Hershey, PA.
- 831 Effect of Time to Treatment on Treatment Response With C1 Esterase-Inhibitor Concentrate (Berinert®) for Acute Hereditary Angioedema Attacks**  
**J. A. Bernstein**<sup>1</sup>, D. S. Hurewitz<sup>2</sup>, A. K. Bewtra<sup>3</sup>, T. Machnig<sup>4</sup>, H. Keinecke<sup>5</sup>, T. J. Craig<sup>6</sup>;  
<sup>1</sup>University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH, <sup>2</sup>Allergy Clinic of Tulsa, Tulsa, OK, <sup>3</sup>Creighton University School of Medicine, Omaha, NE, <sup>4</sup>CSL Behring GmbH, Marburg, GERMANY, <sup>5</sup>Accovion GmbH, Marburg, GERMANY, <sup>6</sup>Penn State University, Hershey, PA.
- 832 Management of paediatric patients with Hereditary Angioedema (HAE)- A retrospective evaluation of 120 patients from 91 families**  
**I. Martinez-Saguer**, E. Aygoeren-Puersuen, E. Rusicke, T. Klingebiel, W. Kreuz;  
J.-W. Goethe University Hospital Frankfurt, Germany, Frankfurt, GERMANY.
- 833 Efficacy of Recombinant Human C1 Inhibitor Treatment for Abdominal Attacks of Hereditary Angioedema**  
**D. Suez**<sup>1</sup>, D. Moldovan<sup>2</sup>, J. W. Baker<sup>3</sup>, S. Kivity<sup>4</sup>, A. Relan<sup>5</sup>, A. Reshef<sup>6</sup>, R. Levy<sup>7</sup>;  
<sup>1</sup>Allergy, Asthma and Immunology Clinical RA, Irving, TX, <sup>2</sup>University of Medicine and Pharmacy, Mures County Hospital, Tirgu Mures, ROMANIA, <sup>3</sup>Baker Allergy, Asthma and Dermatology Research Center, Lake Oswego, OR, <sup>4</sup>Tel Aviv Medical Center, Tel-Aviv, ISRAEL, <sup>5</sup>Pharming Technologies BV, Leiden, NETHERLANDS, <sup>6</sup>Immunology & Angioedema Center, Sheba Medical Center, Tel Hashomer, ISRAEL, <sup>7</sup>Family Allergy and Asthma Center, Atlanta, GA.
- 834 Angioedema Hospitalization Trends and Characteristics in the US: 2000-2009**  
**R. Y. Lin**<sup>1</sup>, R. J. Levine<sup>2</sup>;  
<sup>1</sup>New York Downtown Hospital, New York, NY, <sup>2</sup>New York Medical College, Valhalla, NY.
- 835 Icatibant Duration of Action During Bradykinin Challenge**  
**K. Leach**<sup>1</sup>, B. Rosenkranz<sup>2</sup>, B. J. Bloom<sup>1</sup>, T. G. McCauley<sup>1</sup>;  
<sup>1</sup>Shire HGT, Lexington, MA, <sup>2</sup>University of Stellenbosch, Tygerberg, SOUTH AFRICA.
- 836 Review of the Long-Term Safety of a Human Pasteurized C1 Inhibitor Concentrate**  
**K. Bork**<sup>1</sup>, G. Korgor<sup>2</sup>, W. Kreuz<sup>3</sup>;  
<sup>1</sup>Department of Dermatology, University of Mainz, Mainz, GERMANY, <sup>2</sup>CSL Behring, Marburg, GERMANY, <sup>3</sup>Center of Pediatrics, University of Frankfurt, Frankfurt, GERMANY.
- 837 Association of C1 Esterase-Inhibitor Functional Activity and Treatment Response With C1 Esterase-Inhibitor Concentrate (Berinert®) for Acute Attacks of Hereditary Angioedema**  
**A. K. Bewtra**<sup>1</sup>, D. S. Hurewitz<sup>2</sup>, J. A. Bernstein<sup>3</sup>, T. Machnig<sup>4</sup>, H. Keinecke<sup>5</sup>, T. J. Craig<sup>6</sup>;  
<sup>1</sup>Creighton University School of Medicine, Omaha, NE, <sup>2</sup>Allergy Clinic of Tulsa, Tulsa, OK, <sup>3</sup>University of Cincinnati Medical Center and Bernstein Clinical Research Center, Cincinnati, OH, <sup>4</sup>CSL Behring, Marburg, GERMANY, <sup>5</sup>Accovion GmbH, Marburg, GERMANY, <sup>6</sup>Penn State University, Hershey, PA.
- 838 High Doses of C1 Esterase Inhibitor as Treatment for a Patient with Exacerbating Hereditary Angioedema During Pregnancy**  
**W. Chan**<sup>1</sup>, N. Berlin<sup>1</sup>, G. Sussman<sup>1,2</sup>;  
<sup>1</sup>Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA, <sup>2</sup>University of Toronto, Toronto, ON, CANADA.
- 839 Self Intravenous (IV) Administration of C1-INH Concentrate for Hereditary Angioedema: A Retrospective Analysis of Patient Outcomes**  
**R. S. Shapiro**;  
Midwest Immunology Clinic, Plymouth, MN.
- 840 Gaining Weight And Losing Appetite! ; A Case Of Recurrent Diffuse Angioedema, Weight Gain and Peripheral Eosinophilia Without Visceral Organ Damage**  
**B. Q. Khan**, G. D. Marshall;  
University of Mississippi Medical Center, Jackson, MS.
- 841 Auto-antibodies in Chronic Idiopathic Urticaria (CIU) and Non-urticarial Systemic Autoimmune Disorders**  
**S. A. Stutes**<sup>1</sup>, C. B. Cho<sup>1</sup>, M. Altrich<sup>2</sup>, S. P. Ardoin<sup>1</sup>, P. U. Ogbogu<sup>1</sup>;  
<sup>1</sup>The Ohio State University Medical Center, Columbus, OH, <sup>2</sup>ViraCor-IBT Laboratories, Lee's Summit, MO.
- 842 Autoimmune Profiling in Chronic Idiopathic Urticaria – Is there Utility or Futility?**  
**R. K. Viswanathan**<sup>1,2</sup>, M. J. Biagtan<sup>2</sup>, S. K. Mathur<sup>1,2</sup>;  
<sup>1</sup>Univ of Wisconsin Hosp & Clinics, Madison, WI, <sup>2</sup>William S Middleton Veterans Hospital, Madison, WI.
- 843 Prevalence Of Papular Urticaria By Flea Bite And Associated Factors In Children Of 1-6 Years Old In Bogotá D.c.**  
**P. E. Chaparro**;  
Universidad del Valle, Bogota, COLOMBIA.
- 844 Efficacy of Hydroxychloroquine in the Treatment of 19 Patients with Antihistamine-refractory Chronic Urticaria**  
**R. M. Pongonis**, J. M. Fahrenholz;  
Vanderbilt University, Nashville, TN.
- 845 Metabolic Syndrome In Patients With Chronic Urticaria**  
**Y. Ye**, H. Jin, E. Hwang, Y. Nam, J. Kim, Y. Shin, H. Park;  
Ajou University School of Medicine, Suwon, KOREA, REPUBLIC OF.
- 846 The Urticaria Severity Score May Serve As An Early Clinical Indicator In Monitoring Patients With Chronic Urticaria**  
**D. E. Ferastraoraru**<sup>1</sup>, S. Jariwala<sup>2</sup>, E. Lobell<sup>2</sup>, P. Parikh<sup>2</sup>, P. Walters<sup>3</sup>, M. Altrich<sup>3</sup>, G. Hudes<sup>2</sup>, D. Rosenstreich<sup>2</sup>;  
<sup>1</sup>Albert Einstein College of Medicine / Jacobi Medical Center, Bronx, NY, <sup>2</sup>Montefiore Medical Center/ Division of Allergy-Immunology, Bronx, NY, <sup>3</sup>ViraCor-IBT Laboratories, Lee's Summit, MO.

- 847 Omalizumab (Xolair) in the Treatment of Severe Refractory Chronic Urticaria (SRCIU)**  
M. Giruparajah<sup>1</sup>, N. Berlin<sup>1</sup>, S. Maclachlan<sup>1</sup>, G. Sussman<sup>1,2</sup>;  
<sup>1</sup>Gordon Sussman Clinical Research Inc., Toronto, ON, CANADA, <sup>2</sup>University of Toronto, Toronto, ON, CANADA.
- 848 Treating Chronic Urticaria With Omalizumab - Our Experience In An Immunology Department**  
A. C. Costa, P. M. Silva, J. G. Dias, A. Mendes, E. Pedro, M. P. Barbosa;  
Hospital de Santa Maria EPE, CHLN, Lisboa, PORTUGAL.
- 849 Neutrophil Predominant Urticaria: A Systematic Review of Patients Undergoing Skin Biopsy in an Allergy Practice**  
S. H. Axelrod<sup>1</sup>, M. Punsoni<sup>1</sup>, B. Arendash<sup>1</sup>, B. Kim<sup>1</sup>, M. Feuerman<sup>1</sup>, M. Jacobson<sup>2</sup>, L. Fonacier<sup>1</sup>;  
<sup>1</sup>Winthrop University Hospital, Mineola, NY, <sup>2</sup>DermPath Diagnostics, Port Chester, NY.
- 850 Mutations in the Factor XII Gene in Solitary Cases of Recurrent Angioedema with Normal C1 Inhibitor Induced or Worsened by Oral Contraceptives or Hormonal Replacement Therapy**  
C. Stanger<sup>1</sup>, K. Wulf<sup>2</sup>, J. Hardt<sup>3</sup>, G. Witzke<sup>1</sup>, K. Bork<sup>1</sup>;  
<sup>1</sup>Department of Dermatology, University of Mainz, Mainz, GERMANY, <sup>2</sup>Institute of Human Genetics, University of Greifswald, Greifswald, GERMANY, <sup>3</sup>Department of Medical Psychology and Medical Sociology, University of Mainz, Mainz, GERMANY.
- 851 Effect of Topical Minocycline on Immediate and Late Phase Allergic Skin Responses**  
G. Dapul-Hidalgo, R. Joks;  
SUNY Downstate Medical Center, Brooklyn, NY.
- 852 Vaccination-induced Severe Bullous Eruption in a Child with Diffuse Cutaneous Mastocytosis**  
L. G. Bankova<sup>1</sup>, J. E. Walter<sup>2</sup>, S. R. Iyengar<sup>2</sup>, M. E. Lorenzo<sup>3</sup>, J. L. Hornick<sup>4</sup>, M. C. Castells<sup>1</sup>;  
<sup>1</sup>Department of Rheumatology, Allergy and Immunology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, <sup>2</sup>Division of Allergy, Immunology and Pulmonology, MassGeneral Hospital for Children, Harvard Medical School, Boston, MA, <sup>3</sup>Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, <sup>4</sup>Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, Boston, MA.
- 853 Drug Rash Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Association with Vancomycin**  
J. McNeil-Glassford, Y. Yilmaz Demirdag;  
West Virginia University School of Medicine, Morgantown, WV.
- 854 Is It Contact Dermatitis Or Something More Serious?**  
B. Dyer, L. Wild;  
Tulane University, New Orleans, LA.
- 855 Gabapentin for the Treatment of Neurogenic Pruritis**  
J. Hajjar, D. Sun, L. B. Schwartz;  
VCU, Richmond, VA.
- S. J. Ramey<sup>1</sup>, S. Bozeman<sup>2</sup>, J. T. Ramey<sup>1</sup>, R. L. Franck<sup>3</sup>, A. T. Vu<sup>4</sup>, R. F. Lockey<sup>3</sup>, J. E. Walsh<sup>1</sup>;**  
<sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>University of Mississippi Medical Center, Jackson, MS, <sup>3</sup>University of South Florida, Tampa, FL, <sup>4</sup>Orlando Department of Veterans Affairs Medical Center, Orlando, FL.
- 857 Use To The Recombinant Species-Specific In The Diagnosis Of Hymenoptera Venom Allergy**  
P. F. Jara, MD<sup>1</sup>, E. Hernandez, MD<sup>2</sup>, M. Fernandez, MD<sup>2</sup>, J. Sastre, PD<sup>2</sup>;  
<sup>1</sup>Fundaci3n Jimenez Diaz, Madrid, Spain, <sup>2</sup>Fundacion Jimenez Diaz, Madrid, Spain.
- 858 Possible Association Between Elevated Basal Serum Trypsin Levels and Systemic Reactions To Stings From Blood-Feeding Insects**  
W. Hemmer<sup>1</sup>, B. Zahel<sup>2</sup>, R. Jarisch<sup>1</sup>;  
<sup>1</sup>Floridsdorf Allergy Center, Vienna, AUSTRIA, <sup>2</sup>Dept. of Dermatology, General Hospital Linz, Linz, AUSTRIA.
- 859 Measurement Of Hymenoptera Venom Specific Ige By The Immulite 3gallergy In Subjects With Negative Or Positive Results By Immunocap**  
M. Watanabe, H. Hirata, Y. Hayashi, Y. Fukushima, T. Fukuda, K. Sugiyama;  
Respiratory medicine and clinical immunology, Tochigi, JAPAN.
- 860 Reported Ant Re-sting Reaction in Thai Children with Ant Anaphylaxis Receiving Immunotherapy**  
P. Puranitee, S. Vilaiyuk, W. Kamchaisatian, W. Manuyakorn, W. Teawsomboonkit, C. Sasisakunporn, S. Benjaponpitak;  
Division of Pediatric Allergy/Immunology/Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND.
- 861 Venom Allergy In Systemic Mastocytosis**  
S. Sridhara, C. Weiler, J. Butterfield;  
Mayo clinic, Rochester, MN.
- 862 Growth Characteristics Of Children Aged 2-17 Years With Food Allergy**  
K. Robbins, C. A. Keet, R. A. Wood;  
Johns Hopkins School of Medicine, Baltimore, MD.
- 863 Feeding Difficulties and Food Allergy**  
M. E. Groetch<sup>1</sup>, A. Tran<sup>2</sup>, J. Wang<sup>1</sup>;  
<sup>1</sup>Mount Sinai School Medicine, New York, NY, <sup>2</sup>University of Cincinnati College of Medicine, Cincinnati, OH.
- 864 Children's Food Allergies (FA): Development of the Food Allergy Adaptation and Management Scale (FAMAS)**  
M. D. Klinnert<sup>1,2</sup>, D. Atkins<sup>1,2</sup>, D. Fleischer<sup>1,2</sup>, E. L. McQuaid<sup>3</sup>, J. Robinson<sup>1,2</sup>, J. O. Hourihane<sup>4</sup>, S. Cohen<sup>1</sup>, H. Franssen<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Colorado School of Medicine, Aurora, CO, <sup>3</sup>Brown School of Medicine, Providence, RI, <sup>4</sup>University College, Cork, IRELAND.
- 865 Relationship of Asthma and Food Allergy In An Urban Pediatric Population**  
H. Mehta;  
The Mount Sinai School of Medicine, New York, NY.
- 866 Food Allergy is an Independent Risk Factor for Decreased Lung Function in Children**  
A. M. Singh<sup>1</sup>, R. Kumar<sup>1</sup>, L. M. Arguelles<sup>1</sup>, D. Caruso<sup>1</sup>, X. Wang<sup>2</sup>, J. A. Pongratic<sup>1</sup>;  
<sup>1</sup>Northwestern Feinberg School of Medicine, Chicago, IL, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
- 867 Diagnosis of childhood food allergy in the United States**  
R. S. Gupta<sup>1,2</sup>, C. H. Lau<sup>1</sup>, E. E. Springston<sup>2</sup>, B. Smith<sup>3,4</sup>, M. R. Warrier<sup>5</sup>, J. Pongratic<sup>1</sup>, J. Holl<sup>2</sup>;  
<sup>1</sup>Children's Memorial Hospital, Chicago, IL, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Edward Hines Jr. VA Hospital, Hines, IL, <sup>4</sup>Loyola University, Maywood, IL, <sup>5</sup>Allergy, Asthma, and Sinus Care, St. Louis, MO.

## Poster Session

### Insect Hypersensitivity, Food Epidemiology, Food Allergens

5205

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 856 Ability of Medical Students and Allergists to Correctly Identify Flying Hymenoptera Species**

TUESDAY

- 868 Prevalence of IgE-mediated Food Allergy in Korean schoolchildren: A Population-based Study**  
**K. Ahn;**  
Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.
- 869 Increase In Prevalence Of Food Allergy On The National And State Level In The National Survey Of Children's Health**  
**K. A. DeMuth, C. McCracken;**  
Emory University, Atlanta, GA.
- 870 Prevalence Of Food Allergy In Urban Children**  
**S. A. Taylor-Black, J. Wang;**  
Mount Sinai School of Medicine, New York, NY.
- 871 The Development of Atopic Dermatitis according to Age of Onset and the Association with Prenatal and Early Life Exposures**  
**C. Roduit<sup>1</sup>, R. Frei<sup>2</sup>, C. Braun-Fahrlander<sup>3</sup>, R. Lauener<sup>4</sup>;**  
<sup>1</sup>University of Zurich, Zurich, SWITZERLAND, <sup>2</sup>Swiss Institute of Allergy and Asthma Research, Davos, SWITZERLAND, <sup>3</sup>Swiss Tropical and Public Health Institute, University of Basel, Basel, SWITZERLAND, <sup>4</sup>Children's Allergy and Asthma Hospital, Hochgebirgsklinik, Davos, SWITZERLAND.
- 872 Do Factors Known to Alter Infant Microbial Exposures Alter the Risk of Food Allergy and Eczema in a Population-based Infant Study?**  
**J. J. Koplin<sup>1</sup>, P. E. Martin<sup>1</sup>, M. L. K. Tang<sup>1,2</sup>, L. C. Gurrin<sup>3</sup>, A. J. Lowe<sup>3</sup>, N. J. Osborne<sup>4</sup>, M. N. Robinson<sup>2</sup>, A. Ponsonby<sup>1</sup>, S. C. Dharmage<sup>3</sup>, K. J. Allen<sup>1,2</sup>;**  
<sup>1</sup>Murdoch Childrens Research Institute, Parkville, VICTORIA, AUSTRALIA, <sup>2</sup>Royal Children's Hospital, Parkville, AUSTRALIA, <sup>3</sup>University of Melbourne, Parkville, VICTORIA, AUSTRALIA, <sup>4</sup>European Centre for Environment and Human Health, Peninsula College of Medicine and Dentistry, University of Exeter, UNITED KINGDOM.
- 873 Goji Berries, a Novel Potent Allergenic Source with High Cross-Reactivity with Other Fruits**  
**M. A. Lopez-Matas<sup>1</sup>, J. Carnes<sup>1</sup>, C. H. de Larramendi<sup>2</sup>, A. Ferrer<sup>3</sup>, A. J. Huertas<sup>4</sup>, J. A. Pagan<sup>5</sup>, L. A. Navarro<sup>6</sup>, J. L. Garcia-Abujeta<sup>2</sup>, M. Pena<sup>3</sup>, S. Vicario<sup>2</sup>;**  
<sup>1</sup>Laboratorios LETI, S.L., Tres Cantos (Madrid), SPAIN, <sup>2</sup>Hospital Marina Baixa, Villajoyosa (Alicante), SPAIN, <sup>3</sup>Hospital Vega Baja, Orihuela (Alicante), SPAIN, <sup>4</sup>Hospital Santa Mara del Rosell, Cartagena (Murcia), SPAIN, <sup>5</sup>Hospital Virgen de la Arrixaca, Murcia, SPAIN, <sup>6</sup>Centro de especialidades El Espaoleto, Jativa (Valencia), SPAIN.
- 874 State Health Departments' Misinformation on Shellfish Allergy and use of KI in the Aftermath of Fukushima**  
**S. Teuber;**  
University of California, Davis, Davis, CA.
- 875 In-silico Assessment of Potential Allergenicity of Transgenes Used For The Development of Genetically Modified Food Crops**  
**A. Mishra<sup>1</sup>, S. N. Gaur<sup>2</sup>, N. Arora<sup>1</sup>;**  
<sup>1</sup>Institute of Genomics and Integrative Biology, Delhi, INDIA, <sup>2</sup>Val-labhbhai Patel Chest Institute, Delhi, INDIA.
- 876 Similar IgE Binding to Soybean Proteins from a Genetically Modified Soybean Line, a Near-Isogenic Line and Three Other Non-GM Soybean Lines Using 10 Sera from Soybean Allergic Subjects**  
**R. Panda<sup>1</sup>, A. Capt<sup>2</sup>, C. Herouet-Guicheney<sup>2</sup>, R. E. Goodman<sup>1</sup>;**  
<sup>1</sup>University of Nebraska Lincoln, Food Allergy Research and Resource Program, Lincoln, NE, <sup>2</sup>Bayer S.A.S., Bayer CropScience, Regulatory Science, Sophia-Antipolis, FRANCE.
- 877 Identification And Analysis Of The IgE Binding By Parvalbumin And Other Potential Allergens In Different Fish And Frog Species**  
**P. Lee<sup>1</sup>, J. A. Nordlee<sup>1</sup>, S. J. Koppelman<sup>2</sup>, J. L. Baumert<sup>1</sup>, S. L. Taylor<sup>1</sup>;**  
<sup>1</sup>University of Nebraska, Lincoln, NE, <sup>2</sup>University of Nebraska, De-Bilt, NETHERLANDS.
- 878 Monoclonal Antibodies for Defining Conformational Epitopes in Ara h 2 and Ara h 6**  
**J. Glesner<sup>1</sup>, S. Wuenschmann<sup>1</sup>, A. Koid<sup>1</sup>, G. A. Mueller<sup>2</sup>, L. C. Pedersen<sup>2</sup>, M. D. Chapman<sup>1</sup>, A. Pomes<sup>1</sup>;**  
<sup>1</sup>INDOOR Biotechnologies, Inc., Charlottesville, VA, <sup>2</sup>National Institute of Environmental Health Sciences, Research Triangle Park, NC.
- 879 Similar Repeated Sequences May account For Cross-Reactions Caused By Many Different Nuts**  
**S. J. Maleki<sup>1</sup>, S. S. Teuber<sup>2</sup>, C. H. Schein<sup>3</sup>;**  
<sup>1</sup>US Dept. of Agriculture, New Orleans, LA, <sup>2</sup>University of California, Davis, School of Medicine, Davis, CA, <sup>3</sup>University of Texas Medical Branch, Galveston, TX.
- 880 Effect of High Pressure on Peanut Allergens in Presence of Polyphenol Oxidase and Caffeic Acid**  
**S. Chung<sup>1</sup>, M. Houska<sup>2</sup>, S. Reed<sup>1</sup>;**  
<sup>1</sup>USDA, Southern Regional Research Center, New Orleans, LA, <sup>2</sup>Food Research Institute, Prague, CZECH REPUBLIC.
- 881 A Combination of Boiling and Frying, but not Pressure or Temperature, Decreases Soluble Peanut Allergens but Does not Generate Hypoallergenic Peanuts**  
**S. S. Comstock<sup>1</sup>, S. S. Teuber<sup>2</sup>;**  
<sup>1</sup>University of Illinois, Urbana, IL, <sup>2</sup>University of California, Davis, CA.
- 882 Milk Is The Predominant Undeclared Allergen In Us Food Product Recalls**  
**I. Malyukova, S. M. Gendel, S. Luccioli;**  
Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, Food and Drug Administration, College Park, MD.
- 883 Life-threatening Allergic Reactions To Foods In Adult Patients From Spain**  
**A. Enriquez-Matas, A. Jimenez, C. Fernandez, B. Cabanillas, R. Mielgo, J. Crespo, J. Rodriguez;**  
Hospital Universitario 12 de Octubre, Madrid, SPAIN.
- 884 Overall Prevalence Of Self-reported Food Allergy In Canada**  
**L. Soller<sup>1</sup>, M. Ben-Shoshan<sup>1</sup>, D. W. Harrington<sup>2</sup>, J. Fraga-pane<sup>1</sup>, L. Joseph<sup>1</sup>, Y. St-Pierre<sup>1</sup>, S. B. Godefroy<sup>3</sup>, S. La Vieille<sup>3</sup>, S. J. Elliott<sup>4</sup>, A. E. Clarke<sup>1</sup>;**  
<sup>1</sup>McGill University, Montreal, QC, CANADA, <sup>2</sup>University of Toronto, Toronto, ON, CANADA, <sup>3</sup>Health Canada, Ottawa, ON, CANADA, <sup>4</sup>University of Waterloo, Waterloo, ON, CANADA.
- 885 Prevalence of Common Food Allergies in Canada: Targeting Specific Demographic Groups across Canada**  
**M. Ben-Shoshan<sup>1</sup>, M. Knoll<sup>2</sup>, L. Soller<sup>2</sup>, D. Harrington<sup>3</sup>, J. Fraga-pane<sup>2</sup>, L. Joseph<sup>2,4</sup>, Y. St. Pierre<sup>2</sup>, S. La Vieille<sup>5</sup>, S. Elliott<sup>6</sup>, A. Clarke<sup>2,7</sup>;**  
<sup>1</sup>McGill University Montreal Children Hospital, Montreal, QC, CANADA, <sup>2</sup>Division of Clinical Epidemiology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA, <sup>3</sup>School of Geography and Earth Sciences, McMaster University, Hamilton, Ontario, Canada, Hamilton, ON, CANADA, <sup>4</sup>Departments of Epidemiology and Biostatistics, McGill University, Montreal, QC, CANADA, <sup>5</sup>Food Directorate, Health Canada, Ottawa, Ontario, Canada, Ottawa, ON, CANADA, <sup>6</sup>Applied Health Sciences, University of Waterloo, Ontario, Canada, Waterloo, ON, CANADA, <sup>7</sup>Division of Allergy and Clinical Immunology, Department of Medicine, McGill University Health Center, Montreal, QC, CANADA.
- 886 Low Level Specific IgE Sensitization in Parents of Food Allergic Children**  
**R. G. Robison<sup>1</sup>, M. Makhija<sup>1</sup>, L. M. Arguelles<sup>2</sup>, D. M. Caruso<sup>3</sup>, C. Szychlinski<sup>1</sup>, R. Kumar<sup>1</sup>, X. Wang<sup>4</sup>, J. Pongracic<sup>1</sup>;**  
<sup>1</sup>Children's Memorial Hospital, Chicago, IL, <sup>2</sup>Northwestern University Feinberg School of Medicine, Chicago, IL, <sup>3</sup>Mary Ann and J. Milburn Smith Child Health Research Program, Children's Memorial Hospital, Childrens Memorial Research Center, Chicago, IL, <sup>4</sup>John's Hopkins Bloomberg School of Public Health, Baltimore, MD.



- 887 Increasing The Accuracy Of Peanut Allergy Diagnosis Using Ara H2**  
T. D. Dang<sup>1,2</sup>, S. Choo<sup>3</sup>, P. V. Licciardi<sup>1,2</sup>, J. J. Koplin<sup>1,2</sup>, P. E. Martin<sup>1,2</sup>, T. Tan<sup>1,2</sup>, L. C. Gurrin<sup>4,1</sup>, D. Tey<sup>1,3</sup>, M. Robinson<sup>1,3</sup>, S. Dharmage<sup>1,4</sup>, M. Tang<sup>1,3</sup>, K. J. Allen for the Healthnuts study<sup>1,3</sup>;  
<sup>1</sup>Murdoch Childrens Research Institute, Melbourne, AUSTRALIA, <sup>2</sup>Department of Paediatrics, University of Melbourne, Melbourne, AUSTRALIA, <sup>3</sup>Department of Allergy & Immunology, Royal Childrens Hospital, Melbourne, AUSTRALIA, <sup>4</sup>School of Population Health, University of Melbourne, Melbourne, AUSTRALIA.
- 888 Peanut Allergen (Ara h 2) in Settled Dust Samples of Inner-City Schools and Homes of Children with Asthma**  
W. J. Sheehan<sup>1</sup>, E. B. Hoffman<sup>2</sup>, J. L. Friedlander<sup>1</sup>, D. R. Gold<sup>3</sup>, W. Phipatanakul<sup>1</sup>;  
<sup>1</sup>Children's Hospital Boston; Harvard Medical School, Boston, MA, <sup>2</sup>Department of Biostatistics, Harvard School of Public Health, Boston, MA, <sup>3</sup>Division of Respiratory Epidemiology, Channing Laboratory, Brigham and Womens Hospital; Harvard Medical School, Boston, MA.
- 889 Peanut Protein Contamination in Peanut Hulls/Shells Used in Compost and Other Lawn Service Applications**  
T. Stelk, D. West, J. L. Baumert, S. L. Taylor;  
University of Nebraska, Lincoln, NE.
- 890 In Vitro Assessment of the Allergenicity of Novel H1N1 Influenza Vaccine Produced in Dog Kidney Cells in Subjects with Dog Allergy**  
S. Leonard<sup>1</sup>, R. Bencharitiwong<sup>1</sup>, T. Tsai<sup>2</sup>, A. Nowak-Wegrzyn<sup>1</sup>;  
<sup>1</sup>Mt. Sinai School of Medicine, New York, NY, <sup>2</sup>Novartis Vaccines, Cambridge, MA.
- 891 Amoxicillin-induced Aseptic Meningitis with Neutrophil Prevalence**  
J. Leung, M. Wilson;  
Massachusetts General Hospital, Boston, MA.
- 892 The Impact of Parasite Infection Associated With Hyper-IgE on Tolerance of Aspirin and Desensitization**  
N. V. Dinh<sup>1</sup>, C. C. Hieu<sup>1</sup>, N. V. Doan<sup>1</sup>, S. van Nunen<sup>2</sup>, T. Craig<sup>3</sup>;  
<sup>1</sup>Allergy Department, Hanoi Medical University, Hanoi, VIETNAM, <sup>2</sup>Department of Allergy, Royal North Shore Hospital and Sydney Medical School- Northern, University of Sydney, Sydney, AUSTRALIA, <sup>3</sup>Penn State University, Hershey, PA.

## Poster Session

### Epidemiology of Rhinitis

5206

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 893 Prevalence and Co-morbidities of Ocular Allergy in Adolescents**  
M. Geraldini, N. A. Rosario, H. J. Chong Neto, C. A. Riedi, G. GEA;  
Federal University of Parana, Curitiba, BRAZIL.
- 894 The High Prevalence Of Allergic Rhinoconjunctivitis And Correlation With Cedar And Cypress Pollen Counts In Japanese Schoolchildren**  
K. Yoshida<sup>1</sup>, M. Furukawa<sup>1</sup>, Y. Adachi<sup>2</sup>, H. Odajima<sup>3</sup>, Y. Ohya<sup>4</sup>, A. Akasawa<sup>1</sup>;  
<sup>1</sup>Tokyo Metropolitan Children's Medical Center, Tokyo, JAPAN, <sup>2</sup>University of Toyama, Toyama, JAPAN, <sup>3</sup>Fukuoka National Hospital, Fukuoka, JAPAN, <sup>4</sup>National Center for Child Health and Development, Tokyo, JAPAN.

- 895 Allergic Rhinitis Symptoms in Infancy: Prevalence, Clinical Characteristics and Treatment**  
H. J. Chong Neto, N. A. Rosario, F. C. Silva, L. F. M. Bojarski, E. A. Grasselli, C. S. Rosario, F. H. Chong, B. A. Rosario;  
Federal University of Parana, Curitiba, BRAZIL.
- 896 How Commonly Does Symptom Severity Vary by Season in Nonallergic Rhinitis?**  
S. A. Samant, S. Patel, J. B. Hagan, M. A. Rank;  
Mayo Clinic, Rochester, MN.
- 897 Exhaled NO May Predict Development of Allergic Rhinitis in Children**  
Y. Rha<sup>1</sup>, H. Ko<sup>1</sup>, S. Choi<sup>2</sup>;  
<sup>1</sup>Kyung Hee University Hospital, Seoul, KOREA, REPUBLIC OF, <sup>2</sup>Kyung Hee University Gandong Hospital, Seoul, KOREA, REPUBLIC OF.
- 898 Higher Levels of Perceived Stress Lead To More Allergy Symptoms**  
A. M. Patterson<sup>1,2</sup>, V. O. Yildiz<sup>1</sup>, W. B. Malarkey<sup>1</sup>;  
<sup>1</sup>The Ohio State University, Columbus, OH, <sup>2</sup>Nationwide Children's, Columbus, OH.
- 899 Impact Of Allergic Rhinitis On Physical Activity In Children**  
M. Sugimoto<sup>1</sup>, M. Nagao<sup>1</sup>, K. Hosoki<sup>1</sup>, K. Togashi<sup>2</sup>, T. Fujisawa<sup>1</sup>;  
<sup>1</sup>Mie National Hospital, Tsu, JAPAN, <sup>2</sup>Mie University, Tsu, JAPAN.

## Poster Session

### Allergenic products: Diagnostics and Standardization

5207

Session Time: Tuesday, March 6, 2012,  
9:45 AM - 10:45 AM

- 900 To Bee or Not to Bee - Bee Pollen Sensitive**  
P. Hemmers, Z. Li, J. Santilli;  
St. Vincent's Medical Center, Bridgeport, CT.
- 901 Are Pseudopods On Skin Prick Testing Reproducible?**  
M. Serota, J. Portnoy, Z. Jacobs;  
Children's Mercy Hospital, Kansas City, MO.
- 902 Optimal Concentration Of *Dermatophagoides Pteronyssinus* allergen Extract (Dp) For Skin Prick Testing (SPT) In Thai Population With Allergic Rhinitis (AR)**  
P. Prottsan<sup>1,2</sup>, C. Bunnag<sup>1,3</sup>, P. Tantilipikorn<sup>1,3</sup>, T. Suwanwech<sup>1,3</sup>, N. Visitsunthorn<sup>1,2</sup>, O. Jirapongsananuruk<sup>1,2</sup>, P. Pacharn<sup>1,2</sup>, P. Vichayanond<sup>1,2</sup>;  
<sup>1</sup>Siriraj Hospital, Bangkok, THAILAND, <sup>2</sup>Department of Pediatrics, Faculty of Medicine, Bangkok, THAILAND, <sup>3</sup>Department of Otorhinolaryngology, Faculty of Medicine, Bangkok, THAILAND.
- 903 Histamine Skin Prick Test (SPT) Titration Following Antihistamine Administration: Wheal Comparison of Histamine Strength Using Different Devices**  
G. Plunkett, J. Young, R. Erskine, S. Young;  
ALK-Abello, Inc., Round Rock, TX.
- 904 Evaluation of Fungal Sensitivity in the Greater New Orleans Area**  
K. Z. Dhanani<sup>1</sup>, J. G. Black<sup>1</sup>, H. Weaver<sup>2</sup>, J. C. Carlson<sup>1</sup>, W. E. Davis<sup>2</sup>;  
<sup>1</sup>Tulane Medical Center, New Orleans, LA, <sup>2</sup>Ochsner Clinic Foundation, New Orleans, LA.

TUESDAY

- 905 Comparison of Skin Prick Testing and ImmunoCAP Testing in the Diagnosis of Cat Allergy**  
B. D. Robertson, MD, K. K. McKinney, J. W. Cole, M. R. Nelson, S. M. Gada, S. S. Laubach;  
Walter Reed National Military Medical Center Bethesda, Bethesda, MD.
- 906 Photoaging Attenuates Skin Test Response to Histamine but not Morphine**  
M. J. King, D. J. Fitzhugh, S. E. Phillips, R. F. Lockey;  
University of South Florida, Tampa, FL.
- 907 Relative Prick and Intradermal Skin Test Reactivities of Non-Standardized *Alternaria alternata* Extracts from Two U.S. Manufacturers**  
M. H. Moss<sup>1</sup>, J. A. Bardelas<sup>2</sup>;  
<sup>1</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI, <sup>2</sup>Allergy and Asthma Center of NC, High Point, NC.
- 908 Comparison Of The IgE Interaction In Depigmented-polymerized And Native Allergen Extracts By Surface Plasmon Resonance Biosensor Analysis**  
J. Carnes<sup>1</sup>, M. T. Gallego<sup>1</sup>, M. Taulas<sup>2</sup>, M. A. Lopez-Matas<sup>1</sup>, M. Morales<sup>1</sup>, R. Saez<sup>1</sup>, J. R. Leonor<sup>1</sup>, C. Marquez<sup>1</sup>, T. Aranda<sup>1</sup>, V. Iraola<sup>1</sup>;  
<sup>1</sup>Laboratorios LETI, S.L.U., Tres Cantos, SPAIN, <sup>2</sup>University of Barcelona, Barcelona, SPAIN.
- 909 Relationship Between The Levels Of Total Serum Ige And Skin Reactivity In Patients With Allergic Rhinitis (ar)**  
D. Aguilar;  
Juarez Hospital Centre, Mexico City, MEXICO.

### Oral Abstract Session

#### Novel Mechanisms in Asthma Therapeutics

5601

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

- 910 Suppression of Allergic Airway Inflammation by Low Dose, Intranasally Administered Der p 1 Derived Peptides, in a Murine Model of House Dust Mite Allergy**  
D. M. Moldaver<sup>1</sup>, M. S. Bharhani<sup>1</sup>, J. Wattie<sup>1</sup>, R. P. Hafner<sup>2</sup>, M. Inman<sup>1</sup>, M. Larche<sup>1</sup>;  
<sup>1</sup>McMaster University, Hamilton, ON, CANADA, <sup>2</sup>Circassia Ltd., Oxford, UNITED KINGDOM.
- 911 A Comparison of the Local and Systemic Effects of AZD3199, an Inhaled Ultra-long-acting  $\beta_2$ -adrenoceptor Agonist (uLABA), With Formoterol in Patients With Asthma**  
L. Bjermer<sup>1</sup>, T. Bengtsson<sup>2</sup>, C. Jorup<sup>2</sup>;  
<sup>1</sup>Skane University Hospital, Lund, SWEDEN, <sup>2</sup>AstraZeneca R&D, Molndal, SWEDEN.
- 912 Selective Blockade of Pulmonary Epithelial Stat3 for the Treatment of Asthma**  
S. De Golovine, A. Kim, D. Tweardy;  
Baylor College of Medicine, Houston, TX.
- 913 Maternal Ashmi Therapy Reduces Offspring Susceptibility To Developing Airway Inflammation In A Murine Model**  
K. D. Srivastava, H. A. Sampson, X. Li;  
The Mount Sinai School of Medicine, New York, NY.
- 914 Myeloid Derived Suppressor Cells Attenuate Murine Allergic Airway Inflammation**  
Q. Guan, S. Moreno, C. Weiss, Q. Gefei, A. Halayko, R. Warrington, Z. Peng;  
University of Manitoba, Winnipeg, MB, CANADA.

### Oral Abstract Session

#### Cellular Mechanisms of Allergy

5602

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

- 915 Expression of the Regulatory Protein Caveolin-1 is reduced in Asthma**  
S. N. Bains<sup>1</sup>, C. Atkinson<sup>1</sup>, E. Tourkina<sup>1</sup>, H. W. Chu<sup>2</sup>, R. Martin<sup>2</sup>, E. C. Riemer<sup>1</sup>, A. P. Kaplan<sup>1</sup>, S. Hoffman<sup>1</sup>;  
<sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>National Jewish Health and the University of Colorado Health Sciences Center, Denver, CO.
- 916 Mechanical Skin Injury Induces TLR4/MyD88 Dependent IL-23 Expression In Epidermal Keratinocytes**  
J. Yoon;  
Childrens hospital boston, Boston, MA.
- 917 Human Dendritic Cells Stimulated with a Novel Peanut Protein Express High Levels of RALDH2 and Induce RA-Sensitive Genes in Naïve T Cells**  
B. Ruiter<sup>1</sup>, G. Grishina<sup>2</sup>, C. F. den Hartog Jager<sup>3</sup>, E. F. Knol<sup>3</sup>, P. Ozias-Akins<sup>4</sup>, H. A. Sampson<sup>2</sup>, W. G. Shreffler<sup>1</sup>;  
<sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Mount Sinai School of Medicine, New York, NY, <sup>3</sup>University Medical Center Utrecht, Utrecht, NETHERLANDS, <sup>4</sup>University of Georgia, Tifton, GA.
- 918 Interaction With Myd88-dependent CD8-CD11c+ Cells Mediates Rapid Induction Of Antigen-specific IgE-suppressive Gamma Delta T Cells**  
y. huang<sup>1</sup>, M. K. MacCleod<sup>1</sup>, A. S. McKee<sup>1</sup>, M. K. Aydintug<sup>1</sup>, C. V. Jacobzick<sup>1</sup>, R. M. Kedl<sup>1</sup>, D. Sun<sup>2</sup>, R. L. O'Brien<sup>1</sup>, W. K. Born<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA.
- 919 Combined Blockade Of The Histamine H1 and H4 Receptor Suppresses Peanut-Induced Diarrhea And Intestinal Inflammation By Regulating Dendritic Cell Function**  
M. Wang<sup>1</sup>, J. Domenico<sup>1</sup>, G. Kirchenbaum<sup>2</sup>, S. K. Oda<sup>2</sup>, Y. Shin<sup>1</sup>, J. Han<sup>1</sup>, E. W. Gelfand<sup>1</sup>;  
<sup>1</sup>National Jewish Health, Denver, CO, <sup>2</sup>University of Colorado Denver and National Jewish Health, Denver, CO.

### Oral Abstract Session

#### Viral Bronchiolitis and Asthma in Children

5603

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

- 920 Upregulation Of Glucocorticoids Beta Receptors In Severe Rsv Bronchiolitis In Infants**  
P. V. Diaz<sup>1</sup>, R. Mammani<sup>1</sup>, R. A. Pinto<sup>1</sup>, A. A. Gaggero<sup>1</sup>, M. R. Bono<sup>2</sup>, J. Guerrero<sup>1</sup>, A. Goecke<sup>1</sup>;  
<sup>1</sup>Faculty of Medicine, University of Chile, Santiago, CHILE, <sup>2</sup>Faculty of Science, University of Chile, Santiago, CHILE.
- 921 Sequence Analysis of a Cloned Human Rhinovirus Designed For Use in Human Inoculation Studies**  
K. Nakagome<sup>1</sup>, Y. A. Bochkov<sup>1</sup>, W. Lee<sup>1</sup>, S. B. Liggett<sup>2</sup>, G. Crisafi<sup>1</sup>, J. E. Gern<sup>1</sup>;  
<sup>1</sup>University of Wisconsin School of Medicine and Public Health, Madison, WI, <sup>2</sup>University of Maryland School of Medicine, Baltimore, MD.
- 922 Risk of Childhood Asthma Following Infant Bronchiolitis During RSV Season**

**K. M. James**<sup>1</sup>, T. Gebretsadik<sup>1</sup>, G. J. Escobar<sup>2</sup>, P. Wu<sup>1</sup>, K. N. Carroll<sup>1</sup>, S. X. Li<sup>2</sup>, E. M. Walsh<sup>2</sup>, E. F. Mitchel<sup>1</sup>, C. Sloan<sup>1</sup>, T. V. Hartert<sup>1</sup>;  
<sup>1</sup>Vanderbilt University School of Medicine, Nashville, TN, <sup>2</sup>Kaiser Permanente Division of Research, Oakland, CA.

**923 Clinical Factors and Response to Albuterol in Wheezing Infants with Bronchiolitis & Respiratory Failure**

**C. L. Carroll**, K. Sala, A. R. Zucker, C. M. Schramm;  
Connecticut Children's Medical Center, Hartford, CT.

**924 Bacterial Detection In The Fall Is Associated With Increased Viral Respiratory Infections**

**K. M. Kloepfer**, R. F. Vrtis, T. E. Pappas, T. Kang, W. Lee, M. D. Evans, R. E. Gangnon, R. F. Lemanske, J. E. Gern;  
University of Wisconsin Madison, Madison, WI.

## Oral Abstract Session

### Mechanisms of EGID

5604

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

**925 Proton-sensing Receptor GPR65 Regulates Allergic Gastrointestinal Eosinophilia**

**X. Zhu**, E. Mose, S. Hogan, N. Zimmermann;  
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

**926 Twin Shared Environment Increases Risk of Eosinophilic Esophagitis in Families**

**E. S. Alexander**<sup>1,2</sup>, L. J. Martin<sup>1,3</sup>, J. P. Abonia<sup>1,4</sup>, M. H. Collins<sup>1,5</sup>, P. A. Succop<sup>1</sup>, A. J. Greenler<sup>4</sup>, E. S. Dellon<sup>6</sup>, J. G. Demain<sup>7</sup>, J. P. Franciosi<sup>1,8</sup>, G. T. Furuta<sup>9</sup>, L. E. Gurian<sup>10</sup>, R. J. Hopp<sup>11</sup>, A. Kaul<sup>1,8</sup>, K. Nadeau<sup>12,13</sup>, R. J. Noel<sup>14,15</sup>, P. E. Putnam<sup>1,8</sup>, K. F. von Tiehl<sup>1,4</sup>, M. D. Eby<sup>4</sup>, H. Foote<sup>4</sup>, A. C. Ellison<sup>4</sup>, M. E. Rothenberg<sup>1,16</sup>;

<sup>1</sup>University of Cincinnati College of Medicine, Cincinnati, OH, <sup>2</sup>Cincinnati Children's Hospital Medical Center Division of Biostatistics and Epidemiology, Cincinnati, OH, <sup>3</sup>Cincinnati Children's Hospital Medical Center Division of Human Genetics, Cincinnati, OH, <sup>4</sup>Cincinnati Children's Hospital Medical Center, Division of Allergy & Immunology, Cincinnati, OH, <sup>5</sup>Cincinnati Children's Hospital Medical Center, Division of Pathology, Cincinnati, OH, <sup>6</sup>University of North Carolina School of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, Chapel Hill, NC, <sup>7</sup>Director, Allergy, Asthma & Immunology Center of Alaska, Anchorage, AK, <sup>8</sup>Cincinnati Children's Hospital Medical Center, Division of Gastroenterology, Hepatology & Nutrition, Cincinnati, OH, <sup>9</sup>Children's Hospital Colorado, Division of Gastroenterology, Aurora, CO, <sup>10</sup>Cox Health, Springfield, MO, <sup>11</sup>Creighton University, Omaha, NE, <sup>12</sup>Stanford Medical School, Stanford, CA, <sup>13</sup>Stanford Medical Center & Lucille Packard Children's Hospital, Division of Allergy & Immunology, Stanford, CA, <sup>14</sup>Children's Hospital of Wisconsin, Milwaukee, WI, <sup>15</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>16</sup>Cincinnati Children's Hospital Medical Center, Director, Division of Allergy & Immunology, Cincinnati, OH.

**927 Interleukin (il)-15 Overexpression In The Esophagus Promotes IgE Associated Experimental EoE**

**P. Rajavelu**, M. Rayapudi, S. Narayanan, A. Mishra;  
Cincinnati Children's Hospital and Medical Center, Cincinnati, OH.

**928 Increased CD3+CD69+ T-Cells and CD40+ Eosinophils in the Esophageal Tissue of Eosinophilic Esophagitis**

**M. Le-Carlson**, S. Seki, K. Cox, K. Nadeau;  
Stanford University Medical Center, Palo Alto, CA.

**929 Dietary Therapy and Topical Corticosteroids Can Reverse Esophageal Fibrosis in Patients with Eosinophilic Esophagitis**

**J. Lieberman**, R. Morotti, O. Yerhov, M. Chehade;  
Mount Sinai School of Medicine, New York, NY.

## Oral Abstract Session

### Treatment of Immunodeficiency and Angioedema

5605

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

**930 Preferences for Immunoglobulin Treatment Administration Attributes by Patients and Parents**

**A. Mohamed**<sup>1</sup>, V. Kilambi<sup>1</sup>, M. Luo<sup>2</sup>, J. Li-McLeod<sup>2</sup>;  
<sup>1</sup>RTI Health Solutions, Research Triangle Park, NC, <sup>2</sup>Baxter Healthcare Corp, Deerfield, IL.

**931 Financial Impact of Late Diagnosis of Severe Combined Immunodeficiency: Why It is Fiscally Sound for States to Invest in the Implementation of Newborn Screening**

**C. Kubiak**, J. Sleasman, E. Perez, M. Dorsey;  
University of South Florida/All Children's Hospital, St. Petersburg, FL.

**932 Tolerability of Subcutaneous Immunoglobulin (SCIG) in Patients Receiving Antiplatelet (AP) and Anticoagulant (AC) Therapy**

**J. Kuryan**<sup>1</sup>, S. Galowitz<sup>2</sup>, B. Kaplan<sup>1</sup>;  
<sup>1</sup>Division of Allergy & Immunology, North Shore-Long Island Jewish Health System, Great Neck, NY, <sup>2</sup>Cohen Children's Medical Center of New York, New Hyde Park, NY.

**933 Discrepancies Between Guidelines and International Practice in the Treatment of Hereditary Angioedema: Results from a World Allergy Organization Survey of Physicians**

**M. C. Dispenza**, T. J. Craig;  
Penn State University College of Medicine, Hershey, PA.

**934 Cost of Treating Hereditary Angioedema with Newly Available Medications in Five Different Settings**

**A. Bhasin**<sup>1</sup>, M. Lunn<sup>1</sup>, K. Olivieri<sup>2</sup>, T. Craig<sup>1</sup>;  
<sup>1</sup>Penn State University College of Medicine, Hershey, PA, <sup>2</sup>BioRX, Cincinnati, OH.

## Oral Abstract Session

### Immunotherapy

5606

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

**935 How Molecular Diagnosis Can Change Allergen-specific Immunotherapy Prescription In A Complex Area Of Pollen Sensitization (madrid, Spain)**

**M. Landivar Encalada**, V. Andregnette Roscigno, M. Ruiz Garcia, E. Hernandez Garcia De La Barrera, J. Sastre Dominguez;  
Fundacion Jimenez Diaz, Madrid, Spain.

**936 Bispecific Antibody-induced Allergen-specific Regulatory T cells (Tregs) Suppress Der-P-1-induced Airway Inflammation**

**B. S. Prabhakar**<sup>1</sup>, A. S. Nayak<sup>2</sup>, P. Bhattacharya<sup>1</sup>, N. A. Nayak<sup>2</sup>;  
<sup>1</sup>College of Medicine, University of Illinois, Chicago, IL, <sup>2</sup>Sneeze, Wheeze and Itch Associates, Normal, IL.

**937 Long-term Safety Of A 300IR Sublingual Tablet Of 5-grass-pollen Allergen Extract In Adults With Grass-pollen-induced Allergic Rhinoconjunctivitis**

**A. Didier**<sup>1</sup>, M. Worm<sup>2</sup>, F. Horak<sup>3</sup>, H. Malling<sup>4</sup>, A. Montagut<sup>5</sup>, R. K. Zeldin<sup>5</sup>;  
<sup>1</sup>Ranguel-Larrey Hospital, Respiratory Diseases Department, Toulouse, FRANCE, <sup>2</sup>Allergie-Centrum-Charit, Klinik fr Dermatologie, Venerologie und Allergologie, Berlin, GERMANY, <sup>3</sup>Allergy Centre

TUESDAY

Vienna West, Vienna, AUSTRIA, <sup>4</sup>National University Hospital, Copenhagen, DENMARK, <sup>5</sup>Stallergenes, Antony, FRANCE.

**938 Ragweed Allergy Immunotherapy Tablet Reduces Nasal and Ocular Symptoms of Allergic Rhinoconjunctivitis Over the Peak Ragweed Pollen Season in North America**

**G. Berman**<sup>1</sup>, H. Nolte<sup>2</sup>, J. Maloney<sup>2</sup>, P. Creticos<sup>3</sup>, A. Cheema<sup>4</sup>, A. Kaur<sup>2</sup>, J. Hebert<sup>5</sup>;

<sup>1</sup>Minneapolis Allergy & Asthma Specialists, Minneapolis, MN, <sup>2</sup>Merck Research Laboratories, Kenilworth, NJ, <sup>3</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>4</sup>Alpha Medical Research, Mississauga, ON, CANADA, <sup>5</sup>Centre de Recherche Appliquee en Allergie de Quebec, Quebec, QC, CANADA.

## Oral Abstract Session

### Mechanism of Allergic Sensitization

5607

Session Time: Tuesday, March 6, 2012,  
2:00 PM - 3:15 PM

**939 Age-related Differences in Antigen Sensitization and the Allergic Airway Responses in Acute and Resolved Viral Respiratory Infection**

**J. Birmingham**, K. Srivastava, X. Li, P. Busse;  
Mount Sinai School of Medicine, New York, NY.

**940 Diesel Exhaust Particles Induce Cysteine Oxidation and S-Glutathionylation in House Dust Mite Induced Murine Asthma**

**G. B. Lee**<sup>1</sup>, E. B. Brandt<sup>2</sup>, A. M. Gibson<sup>2</sup>, T. D. Le Cras<sup>2</sup>, L. S. Brown<sup>3</sup>, A. M. Fitzpatrick<sup>3</sup>, G. K. Khurana Hershey<sup>2</sup>;

<sup>1</sup>University of Louisville School of Medicine, Louisville, KY, <sup>2</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>3</sup>Emory University School of Medicine, Atlanta, GA.

**941 The Gut Mucosa Microenvironment Affects Allergic Sensitization vs tolerance to Food proteins**

**K. Adel-Patient**, H. Bernard, S. Wavrin, S. Ah-Leung, J. Wal;  
INRA, Gif-sur-Yvette, FRANCE.

**942 Rhinovirus Matures Dendritic Cells (DCs) and Primes Them for Antigen Presentation**

**J. W. Steinke**, J. A. Woodfolk, R. Agrawal, L. Liu, T. Braciale, L. Borish;

Asthma and Allergic Diseases Center, Charlottesville, VA.

**943 Leukocyte Ig-like Receptor LILRB4 (LILRB4) Downregulates Key Events in the Migration of Antigen (Ag)-bearing Lung Dendritic Cells in Th2 Inflammation**

**L. B. Fanning**, C. C. Buckley, W. Xing, R. G. Breslow, H. R. Katz;  
Div. of Rheumatology, Immunology and Allergy, Brigham and Womens Hospital and Dept. of Medicine, Harvard Medical School, Boston, MA.

**TUESDAY**